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Summary 
 
The Rho family of small GTPases act as molecular switches in the cell and are involved in 
signalling pathways implicated in cytoskeletal organisation. To mediate their effects, they 
interact with downstream effectors. The protein kinase C-related kinase (PRK) family of 
serine/threonine kinases consists of three members, PRK1, PRK2 and PRK3, all of which are 
Rho family effectors. PRKs have three N-terminal Homology Region 1 (HR1) domains, HR1a, 
HR1b and HR1c. These are predicted antiparallel coiled coils which interact with the Rho 
proteins. While HR1a and HR1b domains have been studied in vitro, very little is known 
about the HR1c domain. This project aims to provide much-needed biochemical, biophysical 
and structural understanding of HR1 domains. 
The secondary structure and stability of PRK1 and PRK3 HR1 domains is outlined, followed 
by the identification of some HR1 domains as oligomerisation domains of their respective 
PRK. Analysis of the oligomeric state of the single, di- and tri-domains indicates that the 
three HR1 domains are not independent in solution. The NMR solution structure of the PRK1 
HR1c domain is solved, highlighting the differences between this domain and other HR1 
domains. The structure is then used as a tool to delineate the interactions between the 
three PRK1 HR1 domains. A model is created which summarises intra- and inter-molecular 
HR1 interactions. GTPase-HR1 interactions then expand the model by linking the HR1 
oligomerisation to GTPase binding. New GTPase interactions with PRK1 and PRK3 HR1 
domains are also identified, highlighting our limited knowledge about the PRKs and the 
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Chapter 1 Introduction 
 
1.1 The Ras superfamily 
 
The Ras superfamily of small GTPases or G proteins consists of over 160 proteins which are 
often described as “molecular switches” of signalling pathways, based on their ability to 
exist in two states. G proteins bind to either guanosine diphosphate (GDP) or guanosine 
triphosphate (GTP). They can also hydrolyse GTP and it is this activity which classifies them 
as switches, as effectors only interact with the GTP-bound state, i.e. in a nucleotide-
dependent manner. While the molecular switch mechanism is universally shared across the 
Ras superfamily, the range of cellular processes which are governed by this is astonishingly 
diverse. These processes include gene expression, vesicular trafficking, cytoskeletal 
organisation and nuclear import and export, amongst others. 
The Ras superfamily can be divided into five distinct families on the basis of structural and 
functional similarities. These are the Ras, Rho (Ras homology), Rab, Arf and Ran families 
(reviewed in Wenneburg et al., 2005). The proteins in this family all share a core G domain 
which is ~20 kDa in size (reviewed in Bourne et al., 1991) and typically binds GDP and GTP 
with pM affinities. The cycling from the GDP- to the GTP-bound state and vice-versa 
depends on a number of regulator proteins (Figure 1.1). Guanine nucleotide exchange 
factors (GEFs) catalyse the exchange of GDP for GTP, activating the GTPase. Conversely, 
GTPase activating proteins (GAPs) stimulate the intrinsic hydrolysis activity of the GTPase to 
switch it off, thereby terminating its ability to interact with downstream effectors. Guanine 
nucleotide dissociation inhibitors (GDIs) provide an additional layer of regulation for the Rho 
and Rab families by extracting the GDP-bound GTPases from membranes and sequestering 






















1.1.1 The G domain 
 
The G domain comprises 5 α-helices and 6 β-sheets which are linked by hydrophobic loops 
and are arranged in a Rossmann fold with a hydrophobic core (Bourne et al., 1991) (Figure 
1.2A). The G domain is conserved in thousands of proteins across all five kingdoms of life 
(reviewed in Wittinghofer & Vetter, 2011). Five conserved sequence motifs (Table 1.1), 
termed G1-G5, are part of the core G domain and are important for nucleotide binding and 
hydrolysis. Figure 1.2B summarises the key contacts between G1-G5 and the nucleotide 
Figure 1.1 G proteins act as molecular switches in signalling pathways. Schematic of the molecular switch 
mechanism of G proteins. G proteins bind GDP in their inactive state and GTP in their active state. GEFs 
catalyse nucleotide exchange of GDP for GTP. In their active state G proteins can interact with downstream 
effectors and hence activate cellular signalling pathways. A GAP interacts with the active G protein and 
stimulates the rate of hydrolysis of GTP to GDP. Pi is subsequently released and the G proteins revert to 
their inactive state. A GDI may also negatively regulate some G proteins by removing them from the 
membrane when they are in their GDP-bound state. GEF (Guanine nucleotide exchange factor), GAP 
(GTPase activating protein), GDI (Guanine nucleotide dissociation inhibitor). Representative structures 
used: RhoA·GDP (PDB:1FTN), RhoA·GTPγS (PDB:1A2B), RhoA/AKAP13 RhoGEF (PDB:4D0N, RhoA/p50 
RhoGAP (PDB:1TX4), RhoA/PRK1 (PDB:1CXZ), RhoA/RhoGDI-1 (PDB:5FR1). 
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(using the residues of H-Ras as the example) while Figure 1.3A illustrates the conserved 
motifs on the structure of H-Ras. 
G1-G4 are strongly conserved within the Ras superfamily while G5 shows weak conservation 
and in some cases it may be completely absent. G1-G3 are also weakly conserved in proteins 
which bind to ATP in lieu of GTP as they are mostly involved in contacts with the ribose 
sugar and the phosphate groups of the nucleotide, and G1 and G3 resemble Walker motifs 
found in other nucleotide-binding proteins (Walker et al., 1982). G4 and G5 instead contact 
the guanine ring thereby conferring nucleotide selectivity to the G domain. The switch 
regions are strongly conserved within each of the five families of the Ras superfamily but 
less conserved between separate families. 








G1 (also known as P-loop or phosphate-binding loop) contains Gly(15) (H-Ras numbering) 
and Lys(16) residues which hydrogen bond to the β- and γ-phosphates. In addition the 
Ser(17)/Thr residue contributes to the coordination of the Mg2+ ion which offsets the 
negative charges of the nucleotide phosphates to allow binding. 
G2/Switch 1 is part of β2 and the loop before it and contains two important residues; a 
Val(29) which hydrogen bonds to the ribose and an invariant Thr(35) which hydrogen bonds 
to the deprotonated hydroxyl group of the γ-phosphate (this hydrogen bond is broken 
during GTP hydrolysis). The side-chain hydroxyl group also stabilises the Mg2+ ion. 
G3 is in part of β3 and the loop that follows and contains a critical Asp residue that 
hydrogen bonds to a water molecule which is in turn coordinated by the Mg2+ ion. G3 also 
overlaps with switch 2; a glycine residue forms a hydrogen-bond to the GTP γ-phosphate  
  
Table 1.1 The G1-G5 conserved sequence motifs. The sequence of each motif is listed in the table. X for 



























Figure 1.2 The G domain. (A) Topology of the G domain. The α-helices are represented by blue cylinders 
and the β-sheets are represented by green arrows. Dark blue loops connect the α-helices and the β-sheets 
from N- to C-terminus. Conserved motifs are highlighted; G1 in purple, G2/Switch 1 in yellow, G3/Switch 2 
in red, G4 in orange and G5 in magenta. (B) Interactions between the G domain and the GTP nucleotide. 
Key residues involved in the contact were derived from the structure of H-Ras (PDB:5P21). The contacts 
are described in Bourne et al., 1991 and Wittinghofer & Vetter, 2011. The residues are colour-coded in the 




and is therefore, unsurprisingly, invariant. The hydrophilic residue (Gln61 in H-Ras) is 
involved in GTP hydrolysis. The direct contact of G2/switch 1 and G3/switch 2 with the γ-
phosphates confers the ability to sense the nucleotide state and different conformations are 
adopted as a result, turning the GTPase into a molecular switch. 
G4 is in β5 and in part of the loop before α4 and comprises a stretch of four hydrophobic 
residues followed by an Asn/Thr and other polar or charged residues and has a key role in 
nucleotide specificity. The Asn/Thr has a role in stabilising Val14 of G1 while Lys117 also 
stabilises a G1 residue, Gly13. The Asp hydrogen bonds to the guanine ring, providing 
nucleotide specificity. 
G5 is found in the loop after β6. It contains an Ala which forms an important hydrogen bond 
to the carbonyl of the guanine ring, an interaction which serves a dual role; specificity to 
guanine nucleotides and steric exclusion of adenine nucleotides. 
 
1.1.2 The switch regions 
 
The switch regions have an intrinsic flexibility which allows their structure and dynamics to 
be altered depending on the nucleotide which is bound by the GTPase. Figure 1.3B uses 
RhoA·GDP and RhoA·GTPγS structures to highlight this. It is this feature which makes 
effectors bind to GTPases only in a GTP-dependent manner and therefore defines the 
GTPases as molecular switches. GTP hydrolysis causes the Thr in G2/Switch 1 (and the 
adjacent Tyr at -3) to lose contact with the nucleotide and the switch thus rotates away 
from the nucleotide, inducing a conformational change. The same phenomenon occurs with 
the Gly in G3/Switch 2. The Thr and Gly contacts with the γ-phosphate are often 
simplistically described to be in a ‘tense state’ which is lost when GTP is hydrolysed; the so-
called ‘loaded spring model’ (reviewed in Wittinghofer & Vetter, 2011). This is the basis for 
how effectors can interact with GTPases in a nucleotide-dependent manner and thus 
transmit signals downstream in signalling pathways. 
The inherent flexibility of the switch regions on the μs-ms time scale has been described by 
NMR relaxation studies (Ito et al., 1997). This flexibility of the switches makes it difficult to 
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structurally characterise the conformational changes they undergo by NMR or 
crystallography. For example, peaks for switch II of the small GTPase RheB cannot be seen in 
NMR spectra as a result of the extensive line broadening which occurs (Schwarten et al., 
2007). This is indicative of the switches adopting multiple conformations (Karassek et al., 
2010), a property often described as ‘regional polysterism’ of the GTPases (Ito et al., 1997). 
This is further supported by 31P NMR which has used the phosphates of the nucleotide to 
detect switch conformations that have not been detected in crystal structures (Geyer et al., 
1996). Importantly, effectors can stabilise a single conformation, e.g. the switches of H-Ras 
are stabilised by binding of its effector, Raf (Ito et al., 1997), suggesting that effectors and 






























Figure 1.3 Structural features of the G domain. (A) The crystal structure of H-Ras·GMPPNP (4L9W) is 
shown in cyan. Conserved regions are highlighted as follows - G1 in purple, G2/switch 1 in yellow, 
G3/switch 2 in red, G4 in orange and G5 in magenta. The Mg2+ ion appears as a purple sphere. The 
GMPPNP nucleotide is also labelled. (B) Structural comparison of inactive and active conformations of a 
GTPase using RhoA·GDP (PDB:1FTN) and RhoA·GTPγS (PDB:1A2B) as examples. RhoA·GDP is coloured grey 
and RhoA·GTPγS is coloured cyan. Switch 1 is coloured navy (GDP) or yellow (GTPγS). Switch 2 is coloured 







GTPases hold on to GDP very tightly and therefore require the help of guanine nucleotide 
exchange factors (GEFs) to catalyse exchange of GDP for GTP and activate the GTPase 
(reviewed in Bos et al., 2007; Cherfils & Zeghouf, 2013). GEFs act by reducing the affinity of 
the GTPase for GDP in a two-step mechanism which firstly involves binding to the GTPase, 
and secondly GTP/GDP exchange. The GEF contacts the GDP-bound GTPase at first in a low 
affinity complex which becomes a high affinity one when GDP dissociates and the GTPase is 
nucleotide-free. GTP, at ten times higher the cellular concentration of GDP, then binds to 
the GTPase and causes the GEF to dissociate. 
GEFs of different families are structurally unrelated but they all adopt the same mechanism 
of nucleotide exchange. In particular, all GEFs interact with Switch 1, luring it away from the 
nucleotide and they also interact with Switch 2, stabilising in this way the nucleotide-free 
GTPase. Many GEFs also make use of a conserved Asp/Glu residue which is thought to 
electrostatically repel the nucleotide away from the GTPase, while several others use the 
conserved Lys in G1/P-loop to form a salt bridge with an Asp/Glu residue of either the GEF 
or Switch 2 of the GTPase itself, stabilising the nucleotide-free GTPase (reviewed in Cherfils 
& Zeghouf, 2013). 
Rho family GTPases are activated by two major GEF families. The first family comprises Dbl 
homology (DH)-containing GEFs. In addition to the DH domain, these proteins always 
contain a pleckstrin homology (PH) domain. Worthylake et al. (2000) solved the structure of 
the first DH/PH GEF, that of Tiam1 in complex with Rac1 (Figure 1.4A). The DH domain is a 
helical bundle with a ‘long chair’ shape (Worthylake et al., 2000; reviewed in Cherfils & 
Zeghouf, 2013). The PH domain is connected to the DH domain by a hinge region and as a 
result can move around. This may explain why it can promote, inhibit or exist independently 
of the nucleotide exchange, although in vitro the DH domain is sufficient for catalysis (Liu et 
al., 1998). In the case of Tiam1, the PH domain is thought to push the DH domain into a 
particular orientation that favours its interaction with Rac1 (Baumeister et al., 2006). 
Regardless, key structural features are conserved between DH/PH GEFs, as indicated by the 
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direct comparison of Rac1/Tiam1 and the recently solved structure of RhoA/AKAP13 (Abdul 
Azeez et al., 2014) (Figure 1.4B). 
The second major Rho GEF family are the DOCK proteins which have a Dock Homology 
Region 1 (DHR1) domain which recruits them to membranes and a DHR2 domain which 
confers Rac1- and Cdc42-subfamily-specific GEF activity (reviewed in Côté et al., 2007). 
DOCK GEFs characteristically utilise a hydrophobic valine to push the Mg2+ ion out of the 
nucleotide binding site, thereby catalysing nucleotide release. 
Differences in some residues may explain the specificity of GEFs for some GTPases. For 
example, Vav proteins (DH/PH GEFs) specifically interact with conserved Asp and Glu 
residues of RhoA and Rac1 (in β2 and β3) to recognise the GTPase and subsequently interact 
with a conserved lysine (in β5) to catalyse the nucleotide exchange (Movilla et al., 2001; 
reviewed in Snyder et al., 2002). 
GEFs are themselves regulated in several ways, e.g. phosphorylation of the Vav proteins by 
Src kinases augments their catalytic activity towards RhoA and Rac1 (Crespo et al., 1997). 
Autoinhibitory, intramolecular interactions between DH domains and SH3 domains have 
also been reported in the Rac1 GEF, Asef (Murayama et al., 2007). This regulation of GEFs is 
of utmost importance, as GEFs should only be activated when the appropriate upstream 































Figure 1.4 Structure and function of GEFs. (A) The structure of the Tiam1 (PDB:1FOE) is shown in complex 
with Rac1. Rac1 is in cyan, switch 1 in yellow, switch 2 in red, the DH domain of the GEF in green, the PH 
domain of the GEF in purple. (B) Structural conservation between the GEFs to allow nucleotide exchange. 
The structures of Rac1/Tiam1 and RhoA/AKAP13 (PDB:4D0N) are shown here as examples. The conserved 







GTPase Activating Proteins (GAPs) are also regulators of GTPases. In contrast to 
heterotrimeric G proteins which hydrolyse GTP quickly, small GTPases exhibit very slow 
intrinsic GTP hydrolysis rates which are only of 10-4-10-5 s-1 in magnitude. GAPs stimulate 
this intrinsic hydrolysis by 105 (Lancaster et al., 1994; Lamarche & Hall, 1994), therefore 
accelerating the return to the inactive, GDP-bound state of the GTPase, which swiftly 
switches off downstream signalling pathways. While the GAPs of the different families show 
poor structural conservation (reviewed in Cherfils & Zeghouf, 2013), many GAPs function by 
inserting an arginine ‘finger’ into the active site of the GTPases. This has a number of roles. 
Firstly, the arginine side-chain positions and coordinates the Gln in Switch 2, which in turn 
coordinates and activates a water molecule for nucleophilic attack, and secondly it offsets 
the build-up of negative charge from the β- and γ-phosphates, stabilising the transition state 
and leading to catalysis. This arginine ‘finger’ mimics the intramolecular arginine which 
catalyses hydrolysis in heterotrimeric G proteins, making them have much higher intrinsic 
hydrolysis rates than small GTPases. Rittinger et al. (1997) provided the first structure of a 
RhoGAP, that of the p50 RhoGAP (Figure 1.5A). Figure 1.5B highlights the key components 
of GAP-catalysed hydrolysis. GAPs can provide completely different hydrolysis rate 
accelerations even within one family of GTPases, as indicated by a study on RhoGAPs (Amin 
et al., 2016). Furthermore, specificity of GAPs for particular GTPases may be dependent on 
other protein-protein interaction domains which are part of RhoGAP domain-containing 
proteins. GAPs are regulated in a number of ways including intramolecular, autoinhibitory 
interactions in the case of the RhoGAP β2-chimerin or by membrane curvature in the case of 
the RhoGAP GRAF or ArfGAP1 (reviewed in Cherfils & Zeghouf, 2013). GAPs and GEFs may 
also form regulatory complexes to act on distinct GTPases, which may be another way in 
which the activity of both of these regulators is regulated (reviewed in Hodge & Ridley, 
2016). 
 
Without GAPs, the intrinsic rate of hydrolysis is usually faster than the intrinsic rate of 
nucleotide exchange. This results in a pool of inactive, GDP-bound GTPases which are only 
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activated in response to upstream signals. Recently however, differences in intrinsic GTP 
hydrolysis and intrinsic nucleotide exchange rates have been described between members 
of the Rho family (Jaiswal et al., 2012). This is an example of a shifted paradigm, in which 
previously thought “canonical” GTPases have features which set them apart from the well-
studied members of the family. For example, within the Rho family, RhoD, RhoF, Wrch1 and 
Wrch2 are considered fast cycling GTPases with high rates of intrinsic nucleotide exchange 
and low rate of intrinsic nucleotide hydrolysis. Rnd1-3, RhoH and the RhoBTBs on the other 
hand cannot hydrolyse GTP at all (Jaiswal et al., 2012; reviewed in Aspenström et al., 2007). 
These ‘atypical’ GTPases are therefore subject to different layers of regulatory mechanisms, 
e.g. at the level of expression. These properties have been linked to variations of residues 
12, 59 and 61 (Ras numbering) but the residues adjacent to these are conserved making it 

































Figure 1.5 Structure and function of GAPs. (A) Structure of RhoA in complex with p50 RhoGAP (PDB:1TX4). 
RhoA is coloured in cyan, switch 1 in yellow, switch 2 in red and p50 RhoGAP in purple. The Mg2+ ion 
appears as a purple sphere. The GMPPNP nucleotide is also labelled. (B) Zoomed view of the catalytic site. 
The ‘arginine finger’ Arg85 side-chain inserts into the active site and stabilises negative charges during the 
transition state. Gln63 coordinates and activates the water molecule (in brick red) for nucleophilic attack. 
The AlF4







Guanine nucleotide dissociation inhibitors (GDIs) are additional regulators of the G protein 
cycle which were first discovered on the basis of their ability to inhibit dissociation of GDP 
from the GTPase (Fukumoto et al., 1990; Sasaki et al., 1990; Araki et al., 1990). GDIs specific 
to the Rho and Rab GTPases have been discovered with a total of 3 isoforms per GTPase 
family. They recognise and bind to the prenyl group of lipid-modified GTPases in their GDP-
bound form. They then sequester GTPases in the cytosol which abrogates their ability to 
interact with downstream effectors. 
RhoGDIs have two domains, an N-terminal α-helical bundle that contacts the switches of the 
Rho GTPase and a C-terminal β-sandwich domain that binds the lipid moiety of the GTPase. 
Figure 1.6 shows the structure of Rac1 in complex with RhoGDI-1 (Grizot et al., 2001). It is 
speculated that the interaction of the GDI with the GTPase is stepwise; first the switch 
regions are recognised by the N-terminal domain, which becomes more structured upon 
binding to the GTPase (Gosser et al., 1997); this then facilitates binding of the lipid group 
and thus the subsequent extraction from the membrane (Nomanbhoy et al., 1999). Binding 
of RhoGDIs to the GTP-bound form of Rho GTPases has been reported (Forget et al., 2002), 
however the significance of this is not well understood. It is also speculated that RhoGDIs 
may maintain a pool of Rho·GTP in the cytosol (reviewed in Cherfils & Zeghouf, 2013). 
Structural differences between the 3 RhoGDI isoforms may also define their differential 
preference for Rho GTPases. For example, the unique N-terminal amphipathic helix of 
RhoGDI-3 has been reported to be indispensable for binding to RhoG (Brunet et al., 2002). 
Similar to RhoGDIs, RabGDIs also have two distinct domains to bind the GTPase and the 
geranylgeranyl group. However these domains are structurally dissimilar to those of 
RhoGDIs (Pylypenko et al., 2006). This may explain the ability of RabGDIs to only bind to 
Rab·GDP (Wu et al., 2007), in contrast to RhoGDIs which can bind to Rho GTPases loaded 
with either GDP or GTP. While classical GDIs have not been discovered for the Ras and Arf 
families, phosphodiesterase δ (PDEδ) can bind to farnesyl groups of GTPases with a β-
sandwich domain that resembles that of RhoGDIs (Hanzal-Bayer et al., 2002). PDEδ however 
lacks a GTPase-interacting motif. 
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Binding of the GDIs to GTPases leads to the steric occlusion of GEFs and GAPs which ensures 
that nucleotide exchange and hydrolysis are prevented. This ensures the fidelity of the 
molecular switch mechanism, which needs to be tightly controlled. GDIs are regulated in 
several ways including phosphorylation, e.g. protein kinase C phosphorylates RhoA to 
reduce its affinity for RhoGDI, while protein kinases A and G phosphorylate RhoA to stabilise 
this interaction (Dovas et al., 2010; Rolli-Derkinderen et al., 2005; reviewed in Cherfils & 
Zeghouf, 2013). The effect of these phosphorylation events cannot be rationalised based on 
structures of Rho GTPases in complex with GDIs; phosphorylation may be inducing allosteric 
effects in the GTPase. SUMOylation can also regulate GDIs as indicated by SUMOylated 




























Figure 1.6 Structure of Rac1 in complex with RhoGDI-1. Rac1 is shown in cyan and RhoGDI-1 in dark green. 
Switch 1 (yellow), switch 2 (red), GDP, Mg2+ (purple sphere) and the geranylgeranyl group of Rac1 (black) 





Effectors are molecules which interact with GTPases in a GTP-dependent manner. Binding of 
the effector to the GTPase often leads to the activation of the effector which can then 
mediate cellular signals in downstream pathways. It is possible for more than one effector 
to interact with each GTPase, effectively implicating GTPases in a plethora of signalling 
pathways and cellular effects. Each of the 5 families of GTPases within the Ras superfamily 
can be assigned to a particular cellular effect that is mediated through its effectors; Ras 
proteins control cell growth and differentiation, Rho proteins control cytoskeletal 
reorganisation, Rab and Arf proteins are involved in vesicular transport and Ran, the only 
member of its family, controls nuclear import and export. 
Dissecting signalling pathways and understanding the role of GTPase/effector interactions 
remained a challenging task until the advent of structural studies. The first structure of a 
GTPase in complex with an effector was Rap1A (a Ras family GTPase) in complex with Raf 
(Nassar et al., 1995). Since then, ~70 structures of GTPase/effector complexes have been 
solved, indicating that there are three main groups of structural motifs which effectors 
contain that bind to the GTPase, and particularly to switch 1, switch 2, the interswitch 
region (consisting of parts of α1 and β1) and β3. The largest group of effectors is that which 
interacts with GTPases using a pair of α-helices. The effectors in this group can be sub-
divided into six classes based on the orientation of the helices with respect to each other 
and the GTPase switch regions; these classes comprise four anti-parallel coiled coil classes 
and two parallel coiled coil classes (reviewed in Mott & Owen, 2015). The second group is 
that which uses intermolecular β-sheet formation for the interaction, while the third and 
smallest group is that of effectors using a PH domain to bind to the GTPase. Structures show 
that PH domains all use different interfaces and secondary structure elements to interact 
with different GTPases (reviewed in Mott & Owen, 2015), illustrating that GTPase/effector 
interactions are far from predictable but instead are an enigma. 
Despite the large number of known effectors, it is likely that there are many effectors which 
have not yet been identified. This is highlighted by the less well-studied GTPases for which 
only a few effectors have been identified. Lack of conserved binding motifs across the 
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different families makes their identification difficult. Recent studies however have identified 
some new interactions (Paul et al., 2017) but also highlight the tremendous lack of our 
understanding of which signalling pathways are governed by which GTPases. 
Effectors may be activated directly by the GTPase, e.g. the GTPase relieves effector 
autoinhibition by inducing a conformational change, or may be activated by being localised 
to the correct cellular compartment by the GTPase. An example of direct activation by a 
GTPase is that of the PAK1 kinase which forms inactive homodimers that are dissociated 
upon activation by Rac1 and Cdc42 (Parrini et al., 2002). 
 
1.1.7 Post-translational modifications 
 
Ras, Rho and Rab GTPases are prenylated at their C-terminus by the mevalonate pathway. 
Ras family proteins are modified with the addition of a farnesyl group (Schafer et al., 1989; 
Casey et al., 1989). However, while K-Ras is only farnesylated, H-Ras can also be 
palmitoylated. Rho family proteins are often modified with a geranylgeranyl group 
(Katayama et al., 1991), although RhoD, TCL, TC10, Rnd1, Rnd2 and Rnd3 are exclusively 
farnesylated (Roberts et al., 2008; Foster et al., 1996). Rab proteins are also 
geranylgeranylated (Horiuchi et al., 1991) and this is often a double geranylgeranylation on 
two C-terminal cysteines (Seabra et al., 1992). In contrast, Arf proteins are myristoylated at 
the new N-terminus following the removal of the N-terminal methionine (Lodge et al., 
1994). Ran is not modified at all, which allows it to move freely in and out of the nucleus. 
Figure 1.7A illustrates the different lipids that can be added to GTPases. 
Prenylation of Ras, Rho and Rab GTPases is catalysed by either one of two prenyl 
transferases, farnesyl transferase (FTase) or geranylgeranyl transferase (GGTase) (Figure 
1.7B). These recognise a C-terminal motif known as the CAAX box (C=cysteine, A=aliphatic, 
X=any). The specificity for FTase or GGTase is determined by the X residue, which is the last 
residue in the protein. The prenyl transferases add the lipid group to the cysteine of the 
CAAX box.  Subsequently, the AAX sequence is cleaved by Ras-converting CAAX 
endopeptidase 1 (RCE1) which is followed by the methylesterification of the cysteine by 
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isoprenylcysteine carboxymethyltransferase (ICMT). Palmitoylation is catalysed by 
palmitoyltransferase enzymes, e.g. H-Ras is palmitoylated by a heterodimeric complex 
consisting of the ZDHHC9 and GCP16 proteins (Swarthout et al., 2005). 
Prenylation has several effects on GTPases. Firstly, it is important for the correct cellular 
localisation of the GTPase, targeting the GTPase to the right membrane where it can 
interact with the correct regulators and effectors (Roberts et al., 2008; Taguchi & Misaki, 
2011). A study using an inhibitor specific to GGTase demonstrated that this is enough to 
prevent the activation of RhoA and as a result cause the disruption of the actin cytoskeleton 
(Khwaja et al., 2006). Secondly, the prenyl group is recognised directly by the GDIs, allowing 
them to extract GTPases from the cell membranes. Thirdly, it has been shown to have an 
effect on GEF and GAP activity (Pechlivanis et al., 2007; Moskwa et al., 2005). The affinity of 
GTPases for their effectors is often determined using soluble proteins; however it is likely 
that the anchored GTPases bind differently to effectors in the context of a lipid bilayer. 
Furthermore, while prenylation does not appear to have a structural effect on GTPases such 
as Ras (Güldenhaupt et al., 2008), it may induce structural changes in other GTPases. For 
example, NMR studies have shown that the myristoyl group of Arf6 folds back to interact 
with hydrophobic residues in the N-terminal domain of the protein (Gizachew & Oswald, 
2006). The GTPases may also associate with the membrane at different orientations which 
may dictate how they interact with downstream effectors (reviewed in Prakash & Gorfe, 
2017). The significance of prenylation is highlighted by RCE1 and ICMT knockout mice which 
show abnormal development (reviewed in Wang & Casey, 2016). RhoB remains an 
interesting case, as it can be farnesylated or geranylgeranylated, states which are linked to 
RhoB’s tumour promoting or tumour suppressing roles, respectively (Du & Prendergast, 
1999). The identity of the prenyl group is therefore sufficient, at least in the case of RhoB, to 
determine the function of the protein (by determining its localisation, i.e. plasma membrane 
or endosome). 
Small GTPases are also subject to other types of post-translational modification, including 
phosphorylation, SUMOylation and ubiquitylation (reviewed in Hodge & Ridley, 2016). For 
example, phosphorylation of Tyr64 and Ser71 of Rac1 (both in switch 2) by Src and PKB, 
respectively, leads to stabilisation of the GDP-bound state of the GTPase with consequential 
effects on the actin cytoskeleton (Chang et al., 2011; Kwon et al., 2000). In contrast, 
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phosphorylation of Thr108 leads to nuclear translocation (Tong et al., 2013). Therefore 


























Figure 1.7 Prenylation of GTPases. (A) Post-translational modifications of GTPases by lipids. (B) 
Mevalonate pathway for the farnesylation or geranylgeranylation of Ras, Rho and Rab GTPases. 
Geranylgeranylation is shown as an example. CAAX (C=cysteine, A=aliphatic, X=any) represents the 
conserved four-amino acid motif at the C-terminus of GTPases. FTase for farnesyltransferase, GGTase for 






1.1.8 Structural similarities and differences between the 5 families 
 
The members of the 5 families within the Ras superfamily all share the core G domain. 
However, there are also distinct structural elements which are unique to each of the Rho, 
Arf and Ran families (Figure 1.8). Rho GTPases have a 13-residue α-helix located between α4 
and β5 of the G domain (Hirshberg et al., 1997). This Rho insert does not contact any 
regulators or effectors of Rho GTPases but it has been shown to be necessary for cellular 
transformation (Wu et al., 1998; Zong et al., 2001) and it has also been reported to have a 
different conformation when a GDI is bound (Abramovitz et al., 2012). Arf GTPases have an 
N-terminal α-helix which is involved in membrane binding (Goldberg, 1998). When Arf 
proteins bind to GTP, there is a conformational change involving the antiparallel β-sheet 
(known as the ‘interswitch toggle’) which causes the N-terminal helix to be displaced and 
interact with the membrane (Amor et al., 1994; Pasqualato et al., 2002). On the other hand, 
the C-terminal extension of Ran serves to define the GDP-bound state with its deletion 
affecting the switch regions and leading to a constitutively active protein (Nilsson et al., 
2002). Specifically, GTP/GDP exchange makes the C-terminal helix no longer able to bind to 
Ran, allowing it to interact with its effectors (Scheffzek et al., 1995). 
While the majority of the GTPases in the Ras superfamily share sequence and structural 
similarity and are regulated in similar ways, they are involved in a multitude of cellular 
processes. This diversity, an amalgamation of the effects of subtle structural and regulatory 
differences, differential binding to effectors and localisation, makes them fascinating to 































Figure 1.8 The 5 families of the Ras superfamily. Representative structures of a member of each of the 
families are used to highlight the overall fold as well as any unique structural elements. (A) H-Ras·GDP of 
the Ras family (PDB:4L9S) (B) RhoA·GDP of the Rho family (PDB:1FTN) (C) Rab14·GDP of the Rab family 
(PDB:1Z0F) (D) Arf6·GDP of the Arf family (PDB:1E0S) (E) Ran·GDP (PDB:3GJ0). GTPases are in cyan and any 







1.2 The Rho family 
 
1.2.1 Implications in several signalling pathways and cellular localisation 
 
The Rho family consists of 23 members which can be divided into sub-families based on 
their evolutionary similarity (Figure 1.9). RhoA, Rac1 and Cdc42 are the three archetypes of 
the family and their regulators, effectors and physiological roles have been well-
characterised. Out of the remaining 20 Rho GTPases, some have not been characterised 
substantially however it is known that there is a diverse range of PTMs, localisation, effector 
binding and cellular functions of the Rho GTPases (reviewed in Vega & Ridley, 2007). 
Rho GTPases couple changes in the extracellular environment to changes in intracellular 
signal transduction pathways. Similar to the diverse range of functions across the Ras 
superfamily, a surprising diversity in function is also observed amongst the Rho family 
GTPases. This is true even for members within a specific subfamily. For example, the Rho 
subfamily members RhoA, RhoB and RhoC share 84% sequence similarity. Regulators and 
some effectors are shared amongst these three GTPases, as are some key biological 
functions, e.g. all three Rho subfamily GTPases induce stress fibre formation. Despite this, 
differential roles have been observed for these three proteins, e.g. RhoA is involved in 
cytokinesis while RhoB regulates endosomal transport, suggesting that they are not 
redundant. This may be partly due to the different cellular compartments in which they can 
be found. In particular, RhoA and RhoC localise to the plasma membrane, while RhoB 
localises to the endosomes. RhoA and RhoC share 91% sequence identity and they are more 
similar to each other than to RhoB, yet the effects they have on cell morphology are distinct 
(Vega et al., 2011). This is thought to be a result of them acting through different effectors. 
Further differences in function are thought to arise from the distinct cellular localisation of 
these GTPases which is partly dependent on their specific lipid modification. For instance, 
RhoA, RhoC, Rac1 and Cdc42 are localised to the cell membrane, while RhoD and RhoB are 
localised to early and late endosomes, respectively. This localisation is often coupled to the 
corresponding localisation of the effectors, e.g. PRK1 and mDia1 localise to the endosomes 












Figure 1.9 Phylogenetic tree of the Rho family GTPases. The different subfamilies are highlighted. The 
unrooted phylogenetic tree was constructed on phylogeny.fr as described in Dereeper et al. (2008). 
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1.2.2 The three key players 
 
Each of the three key players is responsible for inducing distinctive effects on the cell 
cytoskeleton. RhoA controls the rearrangement of existing actin and myosin filaments to 
form stress fibres (Ridley & Hall, 1992), whereas Rac1 and Cdc42 cause the de novo 
polymerisation of actin, leading to formation of cell protrusions known as lamellipodia and 
filopodia, respectively (Ridley et al., 1992; Nobes & Hall, 1995; Kozma et al., 1995). These 
effects are governed by effectors which are specific to these GTPases (see section 1.3). The 
cellular structures regulated by the three archetypal Rho GTPases are essential for cell 
migration (Figure 1.10) (reviewed in Zegers & Friedl, 2014; Ridley, 2015). The three 
archetypal Rho GTPases are also involved in the regulation of the cell cycle in yeast (Olson et 
al., 1995) and control of vesicular trafficking (reviewing in Symons & Rusk, 2003).  
 
1.2.3 Role in disease 
 
The Rho family is implicated in many diseases and notably in cancer. Originally RhoGEFs 
were discovered as oncogenes, and Rho GTPases were thought to only be deregulated via 
the RhoGEFs (reviewed in Porter et al., 2016). Recently however, several Rho family 
mutations have been identified in various cancers, e.g. fast-cycling P29S Rac1 in melanoma 
(reviewed in Haga & Ridley, 2016; Bustelo, 2018) and while Rho proteins are often described 
as drivers of metastasis, some proteins like RhoB may have a tumour suppressing role in 
addition to a tumourigenic one (Ju & Gilkes, 2018). Understanding the structure, function 
and regulation of Rho GTPases, their regulators and their effectors is key for designing 






























Figure 1.10 Cytoskeletal structures controlled by Rho GTPases. RhoA controls the formation of stress 
fibres, Rac1 controls the formation of lamellipodia and Cdc42 controls the formation of filopodia. The 
concerted contraction of stress fibres and polarised formation of cell protrustions allow the cell to migrate. 
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1.3 Rho family effectors 
 
Rho family GTPases have an abundance of effectors. Over 70 effectors have been identified 
for each of the archetypal RhoA, Rac1 and Cdc42 GTPases (Iden & Collard, 2008). However 
our knowledge and understanding of Rho family effectors still remains nebulous, particularly 
for less well-characterised Rho GTPases. A recent mass spectrometry study identified 
several novel effectors even for canonical GTPases (Paul et al., 2017), highlighting the 
missing pieces in the Rho family signalling puzzle. Effectors can be grouped into different 
categories by means of how they interact with the Rho GTPases (reviewed in Hakoshima et 
al., 2003; Mott & Owen, 2015). The physiological roles of the key effector families of RhoA, 
Rac1 and Cdc42 will be briefly described below, as well as any structural features involving 
their interaction with Rho GTPases. 
 
1.3.1 Rac1 and Cdc42 effectors 
 
1.3.1.1 CRIB motif effectors 
Rac1 has been implicated in lamellipodia formation (McCarty et al., 2005) through its 
interaction with its effector IRSp53 (Miki et al., 2000) and focal contact turnover through its 
interaction with p21-activated kinase (PAK) (Vidal et al., 2002; Delorme-Walker et al., 2011). 
In contrast, Cdc42 is involved in filopodia formation, partly by activating Neuronal Wiskott-
Aldrich Syndrome protein (N-WASP) which signals to the Arp2/3 actin filament nucleation 
complex (Rohatgi et al., 2000). 
These effectors interact with Rac1 and Cdc42 via a CRIB (Cdc42, Rac interactive binding) 
motif. The CRIB motifs of the WASP and ACK effectors are unstructured when free in 
solution and become structured when they interact with Cdc42 and Rac1, forming anti-
parallel intermolecular β-sheets (Figure 1.11B). This type of interaction has been seen with 
Ras binding to its effector Raf, however while in that case the interaction is driven by 
electrostatic contacts, CRIB motif effectors also make a series of hydrophobic contacts with 
the GTPase. An additional difference is that these CRIB motifs adopt an extended 
28 
 
conformation, making additional contacts with switch 2 that are absent in the Ras-Raf 
complex. 
 
1.3.1.2 HR1 effectors 
The Transducer of Cdc42-dependent actin assembly protein 1 (TOCA1) and the closely-
related proteins CIP4 and FBP17 are effectors of Cdc42 which are involved in actin 
polymerisation. They interact with active Cdc42 via their HR1 domain which shows 
sequence and structural homology to the PRK HR1 domains, and they also have an SH3 
domain and an F-BAR domain (Ho et al., 2004; Watson et al., 2016). 
The HR1 domains of this family interact with Cdc42 with low μM affinities, in contrast to PRK 
HR1 domains which have nM affinities for GTPases. Differences in the inter-helical loop may 
explain this weaker binding. The transient protein-protein interactions of the TOCA1 family 
are thought to be critical for the recruitment of N-WASP in an ‘effector handover’ that 
facilitates actin polymerisation (Watson et al., 2016). 
 
1.3.1.3 IQGAP 
IQGAPs (IQGAP1 and IQGAP2) interact with Rho GTPases via their GAP-like domain, which 
cannot stimulate GTP hydrolysis by the GTPase as it lacks the key arginine finger (Kurella et 
al., 2009). The other domains of IQGAP implicate it in several cellular processes, including 
actin cytoskeletal reorganisation, calmodulin signalling, E-cadherin-mediated adhesion and a 
role as a scaffold for components of the MAPK pathway (reviewed in Watanabe et al., 
2015). 
IQGAP is an effector of both Rac1 and Cdc42 and mutational analysis has revealed that 
these G proteins use overlapping but not identical interaction interfaces (Owen et al., 2008). 
Furthermore, Cdc42 was shown to bind more tightly to an extended GAP-like domain than 
to the isolated GAP domain (Owen et al., 2008). Interestingly, Cdc42, but not Rac1, binds to 
this additional site in IQGAP resulting in the stabilisation of IQGAP dimers (LeCour Jr. et al., 
2016). This highlights key differences on the effects that different GTPases may have on the 






























Figure 1.11 Rho GTPase/effector complex structures. The effectors are categorised based on the fold of 
the effector which interacts with the switch regions of the GTPase. (A) α-helical effectors include 
RhoA/ROCK1 (PDB:1S1C) and RhoC/mDia1 (PDB:1Z2C). (B) The CRIB effectors of Rac1 and Cdc42. Shown 






1.3.2 RhoA effectors 
 
























Figure 1.12 Summary of the key effectors of RhoA. The diagram summarises the main types of receptors 
which activate GEFs, leading to the activation of RhoA. RhoA then binds to the Rho-binding domain of 
several downstream effectors which can be grouped into different classes based on sequence and 
structural homology. These effectors control distinct cellular functions. 
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1.3.2.1 The diaphanous proteins 
The diaphanous proteins, or mDia (mammalian homolog of Drosophila diaphanous) proteins 
are Rho effectors which contain formin-homology domains in addition to a Rho-binding 
domain (RBD). They are involved in the formation of actomyosin bundles such as stress 
fibres and the contractile ring (reviewed in Narumiya et al., 2009; Thumkeo et al., 2013). 
mDia1 also co-localises to endosomes with RhoB, where it promotes the formation of an 
actin coat around endosomes (Fernandez-Borja et al., 2005). 
The RBD of mDia1 consists of several α-helices, but only two are prominently used in the 
interaction (Rose et al., 2005) (Figure 1.11A). The structure of mDia1 with RhoC includes a 
series of hydrophobic and salt-bridge interactions between these helices and the two 
switches. Interestingly, mDia1 has a stabilising helix which helps the two main helices 
contact the switches but also makes minor contacts with RhoC. The RhoC insert also makes 
additional contacts with residues in a different domain of mDia1, which contains armadillo 
repeats. 
 
1.3.2.2 The ROCK proteins 
Rho-associated coiled coil kinase (ROCK) refers to two proteins, ROCK1 and ROCK2, which 
are RhoA effectors. ROCK is a serine/threonine kinase which phosphorylates the myosin 
light chain, leading to myosin-dependent actin cross-linking. ROCK also phosphorylates LIM-
kinase, which in turn phosphorylates and inactivates the actin depolymerising factor, cofilin. 
Both of these events are important in the formation of actin structures such as stress fibres 
and it is unsurprising that ROCK is important in the assembly of the actomyosin ring during 
cytokinesis (reviewed in Narumiya et al., 2009). ROCK is also thought to be critical for the 
invasion of cancer cells (Itoh et al., 1999) while it has also been linked to apoptosis through 
its activation by caspase-3 (Sebbagh et al., 2001). 
ROCK1 homodimerises through its very long α-helical Rho-binding domain to form a parallel 
coiled coil which interacts with the switch regions of RhoA (Dvorsky et al., 2004) (Figure 
1.11A). This type of interaction is akin to those of other helical effectors interacting with the 
switch regions with parallel helices (reviewed in Mott & Owen, 2015). While all but one of 
the RhoA residues involved in the interaction are conserved in Rac1 and Cdc42, ROCK1 is an 
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exclusive effector of RhoA. This is thought to be due to a Glu residue which forms a salt 
bridge with a Lys of ROCK1. This Glu is an Asp in Rac1 and Cdc42 and may therefore be too 
short for the salt bridge to successfully form. Such subtle differences may be all that is 
needed for effectors to be specific to a particular GTPase, making it hard to predict 
specificity. 
 
1.3.2.3 Citron kinase 
Citron kinase (CIK) is a serine/threonine kinase which was first identified as a Rho effector 
involved in cytokinesis (reviewed in Thumkeo et al., 2013; D’Avino, 2017). In addition to the 
kinase domain (which is absent from its neurone-specific isoform), CIK also contains two 
coiled-coil domains amongst others. The second coiled coil domain contains the RhoA-
binding site, but the structure of this domain in complex with RhoA has not been 
determined. 
RhoA in complex with CIK is part of the midbody complex of proteins which forms during 
cytokinesis. In particular, CIK is thought to serve as the link between the actomyosin 
contractile ring and the central spindle. In addition to its structural role, CIK is involved in a 
cross-regulation with Aurora B kinase. Phosphorylation of Aurora B kinase by CIK inactivates 
the former. Binding of RhoA is thought to prevent the inactivation of the Aurora B kinase 
which is required for the eventual disassembly of the contractile ring. In this sense, CIK 
appears to act as more of a regulator than an effector. Failure of cytokinesis as a result of 
CIK mutations is thought to cause microcephaly in both rodents and humans. 
 
1.3.2.4 The Rhotekins and the Rhophilins 
Rhophilin and Rhotekin are scaffold proteins which were identified on the basis of their Rho 
binding domain (RBD) which is an HR1 domain that is homologous to the HR1 domain of 
PRK1 (Watanabe et al., 1996; Reid et al., 1996). The physiological roles of the Rhophilins and 
the Rhotekins are poorly understood, although Rhophilin has primarily been linked to RhoA-
dependent suppression of actin fibres while Rhotekin has been implicated in synapse 
regulation in neurones and outgrowth of axons (reviewed in Thumkeo et al., 2013). 
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The Rhotekins (Rhotekin1 and Rhotekin2) have an N-terminal HR1 domain which has ~41% 
sequence identity to the HR1a domain of PRK1 and also contain a PH domain that is 
speculated to bind to lipids in the plasma membrane (reviewed in Ito et al., 2018). The 
Rhotekin HR1 binds to RhoA with a higher affinity than PRK1 HR1a does (Blumenstein & 
Ahmadian, 2004), yet the reasons for this, whether structural or sequence-driven, have not 
been explored. In contrast, the Rhophilins (Rhophilin1 and Rhophilin2) contain BRO1 and 
PDZ protein-protein interaction domains in addition to their N-terminal HR1 domain. The 
affinity of the Rhophilin HR1 for RhoA has not been investigated to date. 
 
1.3.2.5 The PRKs 
The Protein Kinase C-related kinase (PRK) family consists of three members, PRK1, PRK2 and 
PRK3. PRK1 was the first identified effector of RhoA (Watanabe et al., 1996). The HR1 
domains function as the RBD of the PRKs (Flynn et al., 1998; Owen et al., 2003, Modha et al., 













The PRK family of serine/threonine kinases consists of three members, PRK1 (also PKN, 
PKN1 and PKNα), PRK2 (also PKN2, PKNγ) and PRK3 (also PKN3, PKNβ). PRK1 was first 
identified from a human hippocampus cDNA library (Mukai and Ono, 1994) and was shown 
to have a catalytic domain related to that of the protein kinase C superfamily. It is found on 
chromosome 19 (Bartsch et al., 1998). PRK2 (chromosome 1) and PRK3 (chromosome 9) 
were later identified as members of the same family due to their sequence similarity to 
PRK1 (Palmer et al., 1995; Oishi et al., 1999). PRK2 and PRK3 show 87% and 70% 
conservation to PRK1, respectively. 
 
1.4.2 Domain arrangement 
 
The domain arrangement of the PRKs is illustrated in the schematic in Figure 1.13. 
 
1.4.2.1 The N-terminal HR1 domains 
PRKs have three N-terminal HR1 domains, HR1a, HR1b and HR1c. They are predicted 
antiparallel coiled coils of approximately 10 kDa and together they form the regulatory 
region of the PRKs. The HR1 domains are also effector domains of Rho GTPases, with RhoA 
being the first GTPase identified as an interacting partner of PRK1, specifically interacting 
with HR1a (Watanabe et al., 1996; Flynn et al., 1998). Binding to Rho GTPases is how HR1 


























1.4.2.2 The C2-like domain 
PRKs have a C2-like domain which shows weak homology to the C2 domains of other PKC 
proteins. C2 domains comprise 8 anti-parallel β-sheets which form a β-sandwich that binds 
to membrane phospholipids in a Ca2+-dependent manner. They are therefore critical for the 
recruitment of proteins to the plasma membrane (reviewed in Corbalán-García & Gómez-
Fernández, 2010). The C2-like domains of PRK are insensitive to Ca2+ but bind lipids to 
activate the PRKs (see sections 1.4.3 and 1.4.4). 
Figure 1.13 Domain structure of PRK proteins. The family has three members, PRK1, PRK2 and PRK3. Each 
carries 3 tandem N-terminal HR1 domains, a C2-like domain which is thought to target them to the 
membrane and a catalytic kinase domain which belongs to the PKC superfamily. In addition, PRK2 and 
PRK3 have one and two proline-rich regions, respectively. Solved structures of these domains, or an 
equivalent structure from another family isoform in the case of the C2-like domain are seen above the 
schematic; PRK1 HR1a (PDB:1CXZ), PRK1 HR1b (PDB:2RMK), C2-like domain from PKC (PDB:2UZP) and 
PRK1 catalytic domain (PDB:4OTD). No structure exists of an HR1c domain. 
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1.4.2.3 Proline-rich regions 
Quilliam et al. (1996) identified a proline-rich region in PRK2 and showed that it can interact 
with the middle SH3 domain of the NCK adaptor protein and also more weakly with the SH3 
domain of phospholipase Cγ. The PRK2 amino acid motif DLEPEPPPAPPRASSL fits the 
consensus X2EX2PPX2PXRX2SX which associates with the NCK SH3 domain. This proline-rich 
region is absent in PRK1. In contrast, PRK3 has two proline-rich regions, both of which fit the 
same consensus as the PRK2 motif and are also involved in SH3 domain-mediated protein-
protein interactions (Shibata et al., 2001; Oishi et al., 1999; see section 1.4.5.9). 
 
1.4.2.4 Kinase domain 
The PRKs are members of the AGC kinase family, which includes the master protein kinases 
(PK) PKA, PKB, PKC and PKG amongst others. In particular, the PRKs have a C-terminal 
catalytic domain which belongs to the protein kinase C superfamily. In addition to the 
sequence homology of their catalytic domain, AGC kinases share three conserved features; 
firstly, a C-terminal extension of the catalytic domain which contains a hydrophobic motif 
(HM) that usually includes a phosphorylation site, secondly, a PDK1-interacting fragment 
(PIF) that binds to the activating loop kinase, PDK1, and thirdly, a turn motif (TM) (C-
terminal to the catalytic domain) (reviewed in Pearce et al., 2010; Arencibia et al., 2013). 
Phosphorylated HM motifs recruit activating kinases like PDK1 and can interact with the PIF 
motif of either PDK1 or of their own molecule, forming an intramolecular interaction which 
allosterically activates the kinase (reviewed in Leroux et al., 2018). PRKs have a 
phosphomimic residue at the HM phosphorylation site, so they are not regulated by 
phosphorylation of their HM. Phosphorylation of the TM has been reported to increase the 
affinity of the PRK2 C-terminal extension for the kinase domain to enhance activation 
(Dettori et al., 2009). 
The crystal structure of the PRK1 kinase domain has been solved to 2.0 Å by molecular 
replacement to PKCθ (Chamberlain et al., 2014). The structure resembles AGC kinases with 
an N-lobe and C-lobe. Similar to other AGC kinases, e.g. PKA, the C-terminal extension of the 
PRK1 kinase domain encircles the catalytic domain and forms an active site tether, with 
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Phe910 docking into the active site of the kinase domain. This may provide the structural 




PRKs can be activated in several ways (Figure 1.14). PRK1 is the best-characterised of the 
PRK isoforms and it is assumed that PRK2 and PRK3 share at least some of its mechanisms of 
activation. Activated RhoA binds and activates PRK1 (Amano et al., 1996; Lu & Settleman, 
1999). Both PRK1 and PRK2 require an intact C-terminus for maximum activation by RhoA 
(Lim et al., 2006; Lim et al., 2008). Activation by RhoA is further supported by the Drosophila 
PRK which is activated by RhoA and Rac1 (Lu & Settleman, 1999). RhoC has also been linked 
to increased PRK3 activity (Unsal-Kacmaz et al., 2012). 
PRK1 can also be activated by phosphorylation of its activation loop by phosphoinositide-
dependent protein kinase-1 (PDK1) (Dong et al., 2000). This interaction was identified by a 
yeast two-hybrid screen using mouse PDK1 as bait against a cDNA library generated from 
HeLa cell mRNAs as prey. A co-immunoprecipitation from CHO cells confirmed this 
interaction. Deletion mutants further narrowed the interaction to be between the PDK1 and 
PRK1 catalytic domains, while phosphopeptide analysis identified several PRK1 Ser and Thr 
residues which were phosphorylated, primarily Thr774 (in activation loop). This 
phosphorylation was later confirmed in CHO/IR cells and shown to activate PRK1 activity, 
thereby confirming PDK1 as an in vivo activating kinase of PRK1. Additionally, PRK1 has to be 
in complex with RhoA for this activation (Flynn et al., 2000). PRK2 has also been shown to be 
activated by PDK1 (Balendran et al., 2000), and sequence analysis of PRK3 suggests that this 
third isoform of the family is regulated in an analogous manner. Specifically, mutation of the 
phosphoacceptor residue (in activation loop) in PRK2 has been shown to abrogate its 
activation, as did mutation of the TM phosphoacceptor residue, demonstrating that dual 
phosphorylation is required for activation (Lim et al., 2008). The TM of PRK3 must also be 
phosphorylated for activation (Unsal-Kacmaz et al., 2012). 
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PRK1 and PRK2 can also be activated by proteolysis, such as by caspase-3 during apoptosis 























Figure 1.14 Activation of PRKs and downstream cellular effects. Blue arrows indicate PRK activation. The 
red arrow indicates PRK autoinhibition. Green arrows indicate key PRK cellular activities. PDK1 




PRK1 has also been shown to be activated by phosphatidylinositol 4,5-bisphosphate (PIP2) 
and phosphatidylinositol 3,4,5-triphosphate (PIP3) in vitro (Palmer et al., 1995). Finally, PRK1 
can be activated by arachidonic acid (Mukai et al., 1994), and the last 4 C-terminal residues 
appear to be required for this activation (Lim et al., 2005). Arachidonic acid is thought to 
remove the autoinhibition exhibited by a region of PRK1 and PRK2 which overlaps with the 
C2-like domain (Yoshinaga et al., 1999). Arachidonic acid also activates PRK3; however 
activation of both PRK2 and PRK3 by arachidonic acid is less than that of PRK1 (Yu et al., 
1997; Oishi et al., 1999). The activation is associated with an increase in 
autophosphorylation. In addition to arachidonic acid, PRKs are activated by additional lipids 
which include linoleic acid, oleic acid, linolenic acid as well as cardiolipin which leads to 
greater increase in PRK2 than PRK1 phosphorylation (Morrice et al., 1994; Kitagawa et al., 
1995; Peng et al., 1996; Yu et al., 1997; Mukai & Ono, 2006). Furthermore, the C-terminus of 
PRK2 may prevent activation by cardiolipin (Lim et al., 2008). A kinetic study has recently 
confirmed that the PRKs show distinct lipid activation and that the mechanisms of activation 
may differ as indicated by arachidonic acid increasing the kcat of PRK1 and PRK2 but 
decreasing the Km of PRK3 (Falk et al., 2014). Differential activation by lipids may signify 
distinct temporal activation of the PRKs or that they get activated in different 
compartments, the membranes of which are enriched in different lipids. 









Like other kinases, PRKs are involved in a number of autoregulatory mechanisms. Kitagawa 
et al. (1996) first reported evidence of this when they showed that a peptide with sequence 
corresponding to the amino acids 39-53 of PRK1 (part of the HR1a domain), and with an 
isoleucine mutated to a serine, could be phosphorylated by wild type PRK1. The wild type 
peptide did not get phosphorylated. This suggests that HR1a contains a pseudosubstrate 
region which can bind to the kinase domain and keep the PRK in an autoinhibited state. This 
inhibition is thought to be relieved when RhoA binds to HR1a, freeing up the kinase domain. 
Observations consistent with this regulation of PRK1 have been made in cells (Manser et al., 
2008). 
Yoshinaga et al. (1999) also reported that a region of PRK1 and PRK2 which overlaps with 
the C2 domain is involved in autoinhibition. This autoinhibition was found to be relieved by 
arachidonic acid, highlighting the need of the PRKs to be recruited to a membrane in order 
to be successfully activated. 
Consistent with the autoinhibition of PRK1, the N-terminus of PRK2 has recently been 
shown to both inhibit its catalytic domain as well as its interaction with PDK1 (Bauer et al., 
2012). Specifically, PRK2 activity appears to be dependent on the concentration-dependent 
oligomerisation of the molecule. Cross-linking experiments with His-tagged purified full 
length PRK2 stabilised dimers and tetramers, while similar experiments with FLAG-PRK2 
purified from HEK 293T cells stabilised only dimer, suggesting that dimer and not tetramer is 
the physiological oligomer which forms in vivo. Using deletion mutants, the authors were 
able to define this region of intermolecular PRK2-PRK2 interactions as amino acids 464-500, 
which is located between the C2 domain and the catalytic domain. 
Kinases often autophosphorylate, resulting in the activation or inhibition of their catalytic 
activity. The PRKs have also been shown to autophosphorylate in response to lipids and 
several phosphorylation sites have been identified throughout the molecule (Peng et al., 
1996; Oishi et al., 1999; Yoshinaga et al., 1999). Autophosphorylation was shown to activate 
the catalytic activity of the PRKs.  
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1.4.5 Role in cellular signalling and physiological roles 
 
Table 1.2 lists some of the key PRK substrates which have been identified. The cellular 
processes in which PRKs are involved will be discussed below. 
PRK Substrate Cell process/Function 
PRK1 α-actinin Cytoskeletal regulation 
PRK1 vimentin Cytoskeletal regulation 
PRK1 Tau Alzheimer’s disease 
PRK1 GSK-3β Glucose metabolism 
PRK1 α Crystallin B Molecular chaperone 
PRK1, PRK2 HDAC5 (Thr292), HDAC7, HDAC9 Chromatin remodelling 
PRK1 H3 Thr11 Androgen receptor signalling 
PRK1 ARHGAP15 RhoGAP 
PRK1, PRK2 Cdc25 Cell cycle 
PRK1, PRK2 Pyrin Immune response 
PRK1 EGFR Cell signalling 
PRK1, PRK3 Phospholipase D1 Cell signalling 
PRK2 Cortactin Cytoskeletal  rearrangement 




1.4.5.1 Cytoskeletal regulation and cell adhesion 
The PRKs are widely involved in cytoskeletal regulation. Mukai et al. (1997) were the first to 
suggest this when they performed a yeast two-hybrid screen which identified α-actinin, an 
actin-binding protein , as an interacting partner of PRK1. In addition, overexpression of PRK1 
in fibroblasts resulted in actin reorganisation, while PRK2 only had a small effect (Lim et al., 
2004). PRK1 has been shown to disrupt neurofilament assembly and axonal transport 
(Manser et al., 2008). Furthermore, PRK1 was found to bind and phosphorylate the 
intermediate filament protein vimentin, leading to the disruption of vimentin filaments in 
vitro (Matsuzawa et al., 1997). Knock-down of PRK3 has also been shown to lead to 
vimentin disruption in an orthotopic mouse prostate tumour model (Unsal-Kacmaz et al., 
2012). The actin cross-linking protein α-actinin is another substrate of PRK1 and its affinity 
for PRK1 is increased in the presence of PIP2, a lipid which is involved in actin reorganisation 
(Mukai et al., 1997). 
Table 1.2 Key substrates of the PRKs. The PRK isoform, substrate and corresponding cellular 
process/function are listed. 
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The PRKs are also implicated in stress fibre formation. In particular, PRK1 was shown to be 
involved in insulin-dependent signalling to the actin cytoskeleton. Expression of PDK1 and 
PRK1 in 3T3-L1 and Rat1 cells led to insulin-induced actin cytoskeletal reorganisation and 
specifically to a reduction in the number of stress fibres as well as membrane ruffling. This 
process was prevented when the expressed PRK1 or PDK1 were catalytically inactive (Dong 
et al., 2000). Particularly, expression of a kinase-dead mutant of PRK2 led to almost 
complete loss of actin stress fibres, while expression of wild type PRK2 caused a slight 
reduction in the number of stress fibres while also leading into formation of larger fibres 
(Vincent & Settleman, 1997). Microinjection of dominant-negative PRK2 completely 
disrupted actin stress fibres (Lu & Settleman, 1999). Put together, the above studies suggest 
that both PRK1 and PRK2 may have a role in the disruption of actin stress fibres and the 
cellular reorganisation of F-actin. 
PRK3 also appears to hold multiple roles in cytoskeletal organisation. RNAi-mediated 
knockdown of PRK3 expression in human umbilical endothelial cells (HUVECs) compromised 
these cells’ ability to migrate (Aleku et al., 2008) and also reduced their ability to form stress 
fibres downstream of TNF-α signalling (Möpert et al., 2012). The latter study also linked 
PRK3 to cell adhesion, as PRK3-depleted HUVECs showed irregular VE-catenin and β-catenin 
distribution, proteins which are part of adherens junctions. Furthermore, PRK3-depletion 
also led to a decrease in expression levels of the ICAM-1 glycoprotein and a decrease in the 
phosphorylation of Pyk2 tyrosine kinase, both of which are involved in cell adhesion, 
suggesting that PRK3 either has a direct role in cell adhesion or its loss leads to actin 
cytoskeletal changes which in turn affect cell adhesion. A more recent study has implicated 
PRK3 in the glycosylation of ICAM-1 and integrins β1 and α5 through the regulation of N-
acetylglucosaminyltransferase III and glycosyltransferase, suggesting that PRK3 may indeed 
have a direct role in cell adhesion (Mukai et al., 2016). 
Bourguignon et al. (2007) examined astrocyte activation and migration and determined that 
these processes are dependent on Rac1-dependent PRK2 activation and specifically the 
phosphorylation of cortactin. Cortactin is a cytoskeletal protein which cross-links F-actin and 
its phosphorylation by PRK2 inhibits this process, leading to important cytoskeletal 
rearrangements which are key to astrocyte migration. Expression of the PRK2 HR1 region 
acted as a dominant negative, reducing cortactin phosphorylation and preventing 
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cytoskeletal rearrangements, thus confirming that Rac1 activates PRK2 activity by binding to 
the HR1 domains. 
Thrombin is a serine protease which causes endothelial cell permeability. Gavard & Gutkind 
(2008) showed that thrombin-dependent activation of endothelial cell protease-activated 
receptor 1 (PAR1) activates the heterotrimeric G proteins Gα12/13 and Gα11/q. These G 
proteins then activate RhoA which in turn activates ROCK to stimulate actomyosin 
contractility. PRK1 was also shown to be activated leading to the disruption of cell-cell 
adhesion, resulting in the ROCK/PRK1 synergistic stimulation of vascular leakage. 
Calautti et al. (2002) investigated the activation of Fyn tyrosine kinase in differentiated 
keratinocytes. They found that increased Fyn tyrosine kinase activity was linked to increased 
RhoA expression. They also discovered that PRK2 induces downstream, Fyn/Src-dependent 
tyrosine phosphorylation of β-catenin, γ-catenin and p120ctn, which promote keratinocyte 
cell-cell adhesion. PRK2 therefore directly or indirectly activates Fyn and Src tyrosine 
kinases. The role of PRK2 in cell adhesion has been further demonstrated in C2C12 
myoblasts (Lee et al., 2016). In this study, PRK2 was found to interact directly via its C-
terminal region with Cdo, a cell-surface protein, PKB/Akt and the adaptor protein APPL1, 
leading to PKB/Akt activation which promotes the differentiation of myoblasts. This is in 
contrast to PRK1 which has been shown to be a negative regulator of PKB/Akt downstream 
of B-cell antigen receptors (Yasui et al., 2012). 
In neurons affected with Alzheimer’s disease, PRK1 has been linked to neurofibrillary tangles 
and their key component, the protein tau (Kawamata et al., 1998). In particular, PRK1 
phosphorylates the tau protein which is thought to induce key conformational changes 
(Isagawa et al., 2000). GSK-3β also phosphorylates the tau protein. However it was shown 
that phosphorylation of GSK-3β by PRK1 reduced GSK-3β-dependent phosphorylation of 
tau. PRK1 is also activated in neurons under hypoxia and its loss has been linked to 
decreased cell viability and disrupted actin cytoskeletal organisation (Thauerer et al., 2014). 




1.4.5.2 Androgen receptor signalling, chromatin remodelling and transcriptional regulation 
Metzger et al. (2003) implicated PRK1 and PRK2 in androgen receptor (AR) signalling. They 
showed that PRK1 binds to the transactivation domain of the AR in vitro and also confirmed 
the interaction to occur in vivo by co-immunoprecipitation experiments. PRK1 and the AR 
bind together to the androgen response elements of AR-regulated genes. A subsequent 
study by Metzger et al. (2008) showed that PRK1 phosphorylates Thr 11 of histone H3 which 
is an epigenetic marker linked to the expression of genes regulated by the androgen 
receptor. H3 Thr11 phosphorylation recruits the demethylase JMJD2C which subsequently 
leads to demethylation of H3 Lys9 (methylated H3 Lys9 is associated with a repressive 
chromatin state). Mechanistically this explains the critical role of PRK1 in AR signalling and 
implicates it in prostate cancer. 
Additionally, kinase assays have shown that both PRK1 and PRK2 bind and phosphorylate 
Thr292 of HDAC5 (KM ~ 20 μM) which is within its nuclear localisation signal (NLS) (Harrison 
et al., 2010). HDAC7 and HDAC9 are also phosphorylated by the PRKs in a similar manner. 
This phosphorylation is thought to prevent nuclear import by allowing the binding of 14-3-3 
proteins to HDACs, therefore highlighting a direct effect the PRKs have on chromatin 
structure and as a result transcriptional regulation. 
Rho family-dependent PRK2 activity was also shown to be sufficient for the transcriptional 
activation of the c-fos serum response element (Qulliam et al., 1996). PRK1 was also shown 
to interact with a neurone-specific helix-loop-helix transcription factor, NDRF2, by yeast 
two-hybrid and co-IPs and to amplify NDRF2-mediated transcription (Shibata et al., 1999). 
This further supports the notion that the PRKs may regulate transcription of currently 
undetermined genes. 
 
1.4.5.3 Cell cycle 
The PRKs are also implicated in the cell cycle (Schmidt et al., 2007). PRK2, and to a lesser 
extent PRK1 (suggesting partial redundancy in function), were detected in the cytosol of 
HeLa cells during interphase but at the cleavage furrow during telophase and at the 
midbody during cytokinesis. Furthermore, siRNA-depletion of PRK2 led to failed abscission 
of mother and daughter cells, suggesting a role of the PRKs in the cytoskeletal 
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reorganisation which occurs at cytokinesis. In addition to the role of PRK2 in mitotic exit, it 
was also shown to be important in the G2 to M-phase transition. Cells with depleted PRK2 
exhibited delayed mitotic entry and this phenotype was shown to correlate with reduced 
phospho-histone3 levels and delayed cyclin A/B1 degradation, which are known mitotic 
phase markers. Moreover, reduced phosphorylation of Cdc25 phosphatase was detected in 
PRK2-depleted cells, suggesting that Cdc25 is a substrate of PRK2 and is regulated by it. 
PRK2, as well as PRK1, are substrates of active Cyclin-Dependent Kinase (CDK) 1, suggesting 
a positive feedback loop which further activates the PRKs via Cdc25. In summary, PRK2 (and 
PRK1) are involved in both mitotic entry and exit. In contrast to the above, a previous study 
had shown that addition of active PRK1 into a Xenopus laevis embryo by microinjection 
caused cleavage arrest and delayed mitotic entry (Misaki et al., 2001) and this was linked to 
the in vitro phosphorylation of Cdc25 by PRK1. This suggests that the PRKs may have 
opposite effects in the cells of different species, at least with respect to PRK1. 
The link between the PRKs and CDKs/cyclins extends to the cyclinD1-CDK6 complex, which 
was found to phosphorylate PRK1 and modulate vascular smooth muscle cell division and 
migration which is important in blood vessel wall remodelling (Singh et al., 2012). While this 
suggests that PRK1 is activated downstream of cyclinD1, a more recent study suggests that 
it is also located upstream of it (Wang et al., 2017). In this study, RhoA was shown to 
transcriptionally regulate cyclinD1 expression via PRK1 in human embryonic stem cells 
leading to cell proliferation. Put together, the evidence from these two studies suggests a 
possible feedback loop between PRK1 and cyclinD1. 
 
1.4.5.4 Immune response 
The PRKs have recently been implicated in signalling involving the pyrin inflammasome (Park 
et al., 2016). Pyrin is a protein encoded by the MEFV gene and it is involved in the formation 
of a protein complex known as the pyrin inflammasome. This inflammasome forms as part 
of the immune system’s response to bacterial infection and one of its roles is to induce 
interleukin (IL) release from macrophages to combat infection. In this study, siRNA depletion 
in bone marrow-derived macrophages of PRK1 and PRK2 (but not of ROCK1 or ROCK2) led to 
inflammasome-dependent IL-1β release, suggesting that these two PRKs inhibit pyrin 
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inflammasome activation. In addition, the study showed that mouse pyrin binds directly to 
the PRK kinase domain, leading to phosphorylation of two serines. These phosphoserines 
recruit 14-3-3 scaffold proteins to inhibit inflammasome activation. Toxins such as the C3 
toxin from Clostridium botulinum and TcdB from Clostridium difficile lead to the constitutive 
activation of RhoA and thus to PRK-mediated pyrin inflammasome inhibition. This study 
shows that inhibiting any component of the RhoA/PRK1 pathway is sufficient for pyrin 
inflammasome activation. The MEFV gene is mutated in patients with the autoinflammatory 
diseases Familial Mediterranean Fever and hyperimmunoglobulinemia D syndrome (HIDS). 
The authors knocked in a mutant form of human pyrin in mice (the mutation is in the B30.2 
domain of pyrin which is exclusive to humans) and observed decreased binding to the PRKs, 
suggesting that the B30.2 has a role in the binding of PRK1 to pyrin. Finally, they observed 
spontaneous activation of the pyrin inflammasome pathway in peripheral blood 
mononuclear cells (PBMCs) from patients with HIDS, a result of a loss-of-function mutation 
in the MVK gene, which leads to the abolishment of RhoA geranyl-geranylation and as a 
result reduced PRK1 activation. Unsurprisingly, pyrin inflammasome activation in PBMCs 
was blocked with arachidonic acid. To summarise, PRK1 downstream of RhoA has a novel 
role in the downregulation of pyrin inflammasome formation, which implicates it in the 
innate immune response. 
PRK1 has also recently been implicated in lymphocyte trafficking (Mashud et al., 2017). 
Mouse lymphocytes with PRK1 T778A (in activation loop), an inactive PRK1 mutant, 
displayed reduced migration from secondary lymphoid organs to the blood and lymph, 
leading to a decreased number of lymphocytes in peripheral blood. This may be due to a 
severely decreased migratory response to sphingosine 1-phosphate which activates the 
S1PR GPCR, suggesting that PRK1 is implicated in a signalling pathway downstream of the 
receptor. 
 
1.4.5.5 Thromboxane signalling 
The Thromboxane receptors TPα and TPβ are GPCR receptors which are activated by 
thromboxane A2 (TXA2) produced by the arachidonic acid pathway. These GPCRs have been 
implicated in activation of RhoA via the Gq heterotrimeric G protein (Wikström et al., 2008). 
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Turner et al. (2011) showed that PRK1 interacts with both TPα and TPβ and that this 
interaction is important for TPα- and TPβ-induced cell migration. All 3 PRKs were found to 
interact with the TP receptors in HEK293 cells but in PC-3 cells (an adenocarcinoma, 
prostate cancer cell line), only PRK1 and PRK2 were shown to interact (O’Sullivan et al., 
2015). Furthermore, there was differential association of the PRKs with the TP proteins, e.g. 
PRK1 and PRK3 constitutively formed a complex with both TPα and TPβ, while PRK2 
constitutively associated with TPβ and only transiently associated with TPα (in an agonist-
dependent manner). This interaction led to activation of PRK1 and PRK2 via phosphorylation 
of their turn motif in a PI3-K/PDK1-dependent mechanism. Activation of PRK1 and PRK2 in 
thromboxane signalling was found to be crucial for TXA2-induced chromatin remodelling 
through phosphorylation of H3T11 but also enhanced recruitment of the androgen receptor 
which can also lead to H3T11 phosphorylation (O’Sullivan et al., 2017). Finally, PRK1 and 
PRK2 were found to promote the migration and cellular proliferation of prostate cancer 
cells. To summarise, TP receptor activation leads to activation of Gq and subsequently RhoA, 
which is thought to recruit the PRKs which in turn can interact with the TP receptor to 
mediate downstream signalling. In this way, PRK1 and PRK2 are implicated in TP-mediated, 
androgen-induced cellular responses which are deregulated in cancer. 
 
1.4.5.6 The role of PRK3 in angiogenesis 
PRK3 is unique from the other PRKs in that it has a physiological role in angiogenesis (Mukai 
et al., 2016). Ex vivo aortic ring and in vivo corneal pocket assays of PRK3 knockout mice 
showed decreased micro-vessel sprouting, while MEFs from these mice displayed reduced 
migration which could not be rescued even in the presence of growth factors. Surprisingly, 
PRK3 did not affect tumour angiogenesis, despite the observed reduction in lung metastasis 
of melanoma cells injected in the tail of the PRK3 knockout mice. 
 
1.4.5.7 Apoptosis 
The PRKs are activated during apoptosis by caspase cleavage. Cell extracts from COS-7 cells 
expressing FLAG-PRK1 were incubated with caspase-3 which resulted in the cleavage of 
PRK1 at more than one site (Takahashi et al., 1998). PRK2 is also activated by cleavage 
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(Cryns et al., 1997, Takahashi et al., 1998) and the cleaved PRK2 has been shown to interact 
with PKB/Akt. The constitutively active PRK1 fragment has been suggested not to have a 
direct role in apoptotic events, but rather it may be involved in a different role, such as a 
mild change in morphology observed in microglia (Ueyama et al., 2001). Furthermore, 
glutamate can induce caspase cleavage of PRK1 in neurons to generate the constitutively 
active kinase, which is linked to neurofilament organisation disruption (Manser et al., 2008). 
 
1.4.5.8 Glucose metabolism 
PRK1 has an additional role in the regulation of glucose metabolism. The study by Dong et 
al. (2000) which identified the interaction of PRK1 with PDK1 (see section 1.4.3) also 
observed actin cytoskeletal reorganisation and membrane ruffling in 3T3-L1 fibroblasts and 
also in a Rat1 stable cell line expressing the insulin receptor (Rat1-IR) when the cells were 
treated with insulin or had PRK1 or PDK1 expressed. The inability of cells with non-
phosphorylatable PRK1 or kinase-dead PDK1 to show equivalent cytoskeletal and membrane 
changes suggests that activation of PRK1 via PDK1 phosphorylation is vital for the signal 
transduction from the insulin receptor to the actin cytoskeleton. 
In addition, the effect of PRK1 on insulin-stimulated glucose transport was shown to be 
dependent on both active RhoA and phosphoinositide-3-kinase (PI3-K) (both upstream of 
PRK1), as suggested by a study on rat adipocytes stimulated with GTPγS or insulin (Standaert 
et al., 1998). To some extent this should be unsurprising, as both RhoA and 
phosphoinositides produced by PI3-K-catalysed reactions are known to activate PRK1 (see 
section 1.4.3). Transient expression of constitutively active RhoA and wild type PRK1 also 
increased the levels of GLUT4 glucose transporters translocated to the membrane. This 
translocation was abolished in the case of dominant negative RhoA or PRK1. 
PRK1 has further been implicated in glucose metabolism and specifically glycogen synthesis. 
It has been shown that PRK1 can phosphorylate and inhibit glycogen synthase kinase, GSK-




1.4.5.9 Interactions with other signalling proteins 
The PRK3 proline-rich region was used as bait against a HEK293 cDNA library in a yeast two-
hybrid assay and Graf2, an SH3-containing protein also with a RhoGAP domain for RhoA and 
Cdc42, was identified as an interacting partner (Shibata et al., 2001). In vitro experiments 
with recombinant proteins also showed that PRK3 interacts with both Graf and Graf2. The 
significance of these findings is that PRK3 may be unique amongst the PRK isoforms by 
recruiting a RhoGAP protein, bringing it into proximity with Rho GTPases to terminate 
signalling. 
The PRK2 proline-rich region was instead found to interact with the SH3 domain of the NCK 
adaptor protein and also weakly with the SH3 of phospholipase Cγ (Quilliam et al., 1996), as 
well as one of the SH3 domains of NCKβ (also known as Grb4) (Braverman & Quilliam, 1999). 
NCK interacts with receptor tyrosine kinases via its SH2 domain while NCKβ causes cellular 
transformation through the v-Abl tyrosine kinase (a proto-oncogene). PRK2 therefore may 
act as a direct mediator in signalling downstream of activated receptor tyrosine kinases. The 
interaction of NCK with other Rho family effectors such as WASP also highlights possible 
cross-talk between Rho effector pathways. 
PRK2 also binds to MEKK2, a mitogen-activated protein kinase (MAPK) kinase kinase (Sun et 
al., 2000). The binding region is located just N-terminal of the catalytic domain (residues 
637-660). In contrast, PRK1 did not bind to MEKK2 (residues in the binding region are poorly 
conserved). MEKK2 was found to activate PRK2 directly, suggesting that signalling 
downstream of a MAPK pathway can activate a specific PRK isoform, PRK2. 
Oishi et al. (2001) investigated the co-localisation of the PRK family with phospholipase D1 
and showed that PRK1 and PRK3 interact with this protein by co-immunoprecipitations from 
COS-7 cells. They then confirmed the interaction in vitro and showed that PRK1 binds to the 
internal region (residues 298-598) of phospholipase D1, while PRK3 binds to both the N-
terminal (residues 1-228) and the internal regions. This differential binding of the PRKs may 
in turn explain the higher affinity of phospholipase D1 for PRK3 (due to cooperative binding 
to two of its regions) but it may also explain the differential activation of the phospholipase 
D1 catalytic activity by the PRKs (greater activation for PRK1 than PRK3). Phospholipase D1 
is a regulator of several cell processes, including differentiation, GLUT4 vesicle trafficking, 
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cytoskeletal reorganisation and cell growth (Banno, 2002), therefore the PRKs can be 
considered as upstream regulators of these processes. 
H2O2-mediated activation of PRK1 by phosphorylation of its kinase loop threonine has been 
linked to the survival of cardiac myocytes, direct phosphorylation of α crystallin B (a 
molecular chaperone) and increased cardiac proteasome activity, events suggesting 
protection of heart during ischaemia (Takagi et al., 2010). Hypotonic swelling of cardiac 
myocytes also activates PRK1 and may involve signalling between Src, RhoA, PRK1 and ERK 
which leads to survival (Kajimoto et al., 2011). 
The mammalian target of rapamycin (mTOR), a protein complex with diverse signalling 
roles, including regulation of the cytoskeleton (Jacinto et al., 2004), has recently been 
shown to be critical for the phosphorylation of the turn-motif of PRK1, which leads to its 
activation (Yang et al., 2017). This further implicates the PRKs as effectors downstream of 
PI3K in cellular signalling. 
Several other substrates of PRK1 have been identified, notably ARHGAP15 (a Rho GAP), the 
Ret kinase (a proto-oncogene) and exonuclease 1 (implicated in DNA repair), suggesting the 
existence of many cellular roles of the PRKs which remain uncharacterised (Collazos et al., 
2011). More recently, kinase-interacting substrate screening has identified several other 
possible candidate substrates for PRK1, including ROCK2, which could suggest cross-talk 
between RhoA effector-mediated pathways, and Cdc42EP4 (a Cdc42 and TC10 effector 
protein with a role in cytoskeletal organisation), suggesting cross-talk between effectors of 
distinct Rho subfamilies (Amano et al., 2015). The best PRK1 and PRK3 substrate recognition 
consensus motif appears to be Lys-Arg-Arg-Lys-Pro-Ser-Phe-Arg-Asn-Pro and is similar to the 
consensus phosphorylation motif of PKC (Shiga et al., 2010; Collazos et al., 2011). 
 
1.4.5.10 Development 
Out of the three PRKs, PRK2 has specifically been linked to development. While PRK1 and 
PRK3 were shown to be dispensable during mouse embryogenesis, PRK2 was instead found 
to be essential, as indicated by PRK2 knock-out embryos which showed severe 
cardiovascular abnormalities, a collapsed mesenchyme and a neural crest migration defect, 
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suggesting a role for PRK2 in mesenchymal growth and neural crest migration in vivo 
(Quétier et al., 2016). This is also supported by PRK2 knock-out embryos, which show 
insufficient axial turning and neural tube closure (Danno et al., 2017), effects which were 
unobserved in the case of PRK1 and PRK3 knock-out embryos. Mouse embryonic fibroblasts 
from PRK2 knockout embryos displayed abnormalities in terms of cell proliferation, 
consistent with PRK2’s role in the cell cycle. Out of the three PRKs, PRK2 is therefore the 
isoform which has a distinct role in development. This view is further strengthened by 
evidence of PRK2 regulating apical junction formation in bronchial endothelial cells (Wallace 
et al., 2011). In particular, PRK2 is activated by RhoA and recruited to primordial junctions in 
a RhoA-dependent manner. A dominant negative (kinase-dead) isoform of PRK2 was unable 
to lead to the maturation of primordial to apical junctions, as was a ΔC2 mutant, suggesting 
that localisation via the C2 domain and also the catalytic activity are both indispensable for 
epithelial morphogenesis. 
Recently, PRK1 has been identified as a key player in cerebellar development (zur Nedden et 
al., 2018). PRK1 knockout mice had problems with axonal outgrowth and also with forming 
synapses in Purkinje cells, suggesting that PRK1 is required for these developmental events. 
PRK1 may exert these effects by regulating Akt activity, at least under this particular 
biological context. A more recent study in Drosophila indicated that the Drosophila 
melanogaster isoform of PRK1, Pkn, affects the spatiotemporal regulation of myosin, leading 
to its relocalisation, an event which is thought to promote the asymmetric division of neural 
stem cells. A mutation in the Drosophila Pkn gene, termed the delorean mutation, has also 
been linked to wing morphogenesis in the context of the Jun-terminal kinase pathway (Sass 
& Ostrow, 2014), while Pkn activity has also been linked to negative regulation of actin-
myosin contraction in other developmental processes (Ferreira et al., 2014). 
 
1.4.6 Cellular localisation and tissue-specific expression 
 
1.4.6.1 Cellular localisation 
PRK1 and PRK2 have been detected in the cytosol (Gross et al., 2001; Schmidt et al., 2007; 
Unsal-Kacmaz et al., 2012) while rat PRK1 has also been detected at the plasma membrane 
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(Zhu et al., 2004). The PRKs are all thought to be activated by RhoA and PDK1 which are 
bound to the plasma membrane, so they most likely all localise to that compartment via 
their C2-like domain. 
PRK1 was shown to co-localise with RhoB in the endosomes of Swiss 3T3 cells both by 
immunofluorescence and subcellular fractionation (Mellor et al., 1998), suggesting that 
RhoB targets PRK1 to this compartment. This co-localisation required active RhoB and is 
dependent on the HR1 region of PRK1 as indicated by RhoB Q63L (active mutant) and HR1 
deletion mutants, respectively. The ΔHR1 mutant failed to localise to the endosomes. This is 
consistent with RhoB interacting with HR1 domains in a GTP-dependent manner. In another 
study, co-expression of PRK1 with RhoB showed that RhoB regulates epidermal growth 
factor receptor (EGFR) trafficking through endosomes via PRK1 (Gampel et al., 1999). This 
was disrupted when a kinase-dead mutant of PRK1 (K644M) was used, indicating that RhoB-
mediated localisation in endosomes has a functional role. This may be to trap EGFR in late 
endosomes, preventing their trafficking to lysosomes and their eventual degradation which 
would therefore prolong EGFR signalling (Sandilands & Frame, 2008). 
The PRKs have been detected in several other cellular compartments. PRK1 (Metzger et al., 
2003), PRK2 (Gross et al., 2001) and PRK3 (Oishi et al., 1999; Unsal-Kacmaz et al., 2012) have 
all been detected in the nucleus, suggesting that they contain an NLS or are imported into 
the nucleus in complex with another protein. PRK1 has also been detected at the cell 
midbody and cleavage furrow of dividing cells, as has PRK2 (Schmidt et al., 2007). 
Additionally, PRK2 has been detected on membranes in lamellipodia (Gross et al., 2001) and 
in apical junctions (Wallace et al., 2011). In contrast, PRK3 has also been detected in the 
perinuclear Golgi apparatus (Oishi et al., 1999; Unsal-Kacmaz et al., 2012). 
The diversity in the cellular locations of the PRKs is not unexpected based on their diverse 
cellular functions. Moreover, the differential localisation of the PRKs may partly explain their 
lack of functional redundancy. Finally, it is important to keep in mind that the studies 
mentioned above investigated PRK localisation in specific cell types or under specific 
conditions, e.g. when RhoB is active. This suggests that the PRKs may localise to other 
compartments which are currently unknown, but more importantly that there is dynamic 
trafficking of the PRKs between the various compartments. This trafficking may be mediated 
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by the Rho GTPases themselves, e.g. RhoB/PRK1 in endosomes (Mellor et al., 1998); 
RhoA/PRK3 in perinuclear regions and RhoC/PRK3 in the nucleus (Unsal-Kacmaz et al., 
2012). Another example would be the Rac1- and PDK1-dependent localisation of PRK1 on 
the surface of vesicles under hyperosmotic stress (Torbett et al., 2003). 
 
1.4.6.2 Tissue-specific expression 
PRK1 and PRK2 show ubiquitous tissue expression (Kitagawa et al., 1995; Qulliam et al., 
1996; Vincent & Settleman, 1997), whereas PRK3 was initially undetected in normal tissues 
with northern blotting, but was instead detected in metastatic cancers (Oishi et al., 1999). 
More recently, a study using qPCR which is more sensitive was able to detect PRK3 mRNA in 
adult mouse tissues (Mukai et al., 2016), suggesting that PRK3 is present in normal cells and 
that it does indeed have a physiological role. Interestingly, PRK3 mRNA levels were more 
than threefold higher in testes than in other tissues such as lung, kidney, spleen and heart. 
Brain and skeletal muscle tissues contained the lowest levels of PRK3 mRNA. This is in 
contrast to PRK1, which is highly expressed in brain tissue, where it is estimated that it 
consists of 0.01% of total brain protein (Kitagawa et al., 1995). Therefore, PRK isoform-
specific activity is also regulated at the level of differential tissue expression. 
 
1.4.7 Role in disease 
 
The PRKs are involved in diseases such as cancer or those caused by pathogens. The lack of 
redundancy between the PRKs is highlighted once again by their differential involvement in 
these pathologies, suggesting that to some extent they are involved in distinct molecular 
events and pathways. The PRKs possess astonishingly diverse cellular roles; this may explain 





The first indication that a PRK may be involved in cancer came from Gao et al. (2000). A 
yeast two-hybrid screen identified PRK1 as an interacting partner of the E6 oncoprotein of 
human papilloma virus (HPV). The E6 oncoprotein is known to inactivate the p53 tumour 
suppressor by targeting it for ubiquitination and proteosomal degradation. PRK1 was 
confirmed to interact with the E6 oncoprotein in vivo and to also phosphorylate it, which 
may lead to E6-induced cell immortalisation. 
PRK1 is overexpressed in human prostate cancer and specifically co-expressed with the 
androgen receptor in vivo (Metzger et al., 2003). As discussed previously, PRK1 promotes 
the transcription of androgen receptor-regulated genes by phosphorylating histone H3 
Thr11. This is considered to be an epigenetic marker of prostate cancer (Metzger et al., 
2008). The importance of PRK1 in prostate cancer is further emphasized by the inhibition of 
PRK1 leading to abrogated cellular proliferation of AR-induced tumour cells. Furthermore, 
PRK1 and PRK2, activated downstream of thromboxane receptors, have been shown to both 
mimic and enhance androgen-dependent chromatin remodelling, also in the context of 
prostate cancer (O’Sullivan et al., 2017). PRK1 therefore appears to be a key driver of 
prostate cancer. PRK1 mRNA was also found to be abundant in several other tumourigenic 
tissues, and in particular ovarian cancer, suggesting that PRK1 may govern similar molecular 
events in a wide range of cancers (Galgano et al., 2009). 
In contrast, migration, matrigel invasion and scratch wound assays showed that PRK2, and 
to a lesser extent PRK1, are vital for cell migration and invasion of a bladder tumour cell line 
and their roles in migration are also non-redundant (Lachmann et al., 2011). However 
conflicting evidence showed that PRK2 may inhibit tumour growth in a mouse xenograft 
model (Cheng et al., 2018). In this study, PRK2 in colon cancer cells was found to interact 
with and phosphorylate DUSP6 phosphatase, which inhibited the phosphorylation of Erk1/2. 
Erk1/2 were therefore no longer able to phosphorylate the CREB/Elk1 transcription factors 
thereby inhibiting the transcription of interleukins 4 and 10, which explains decreased levels 
of tumour-associated macrophages (TAMs) in human colon cancer. This anti-tumourigenic 
role of PRK2 may however be cell type-specific. 
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The role of PRK3 in cancer and specifically metastasis has seen increasing characterisation 
(Leenders et al. 2004). PRK3 was found to be necessary for the migration of PC-3 cells, a 
prostate cancer cell line, while PRK3 inhibition abrogated lymph node metastasis in an 
orthotopic mouse prostate tumour model. Contrastingly, O’Sullivan et al. (2015; 2017) 
found that PRK1 and PRK2, but not PRK3, were important for migration in PC-3 cells. The 
importance of PRK1 and PRK2 in prostate cancer cell migration has also been demonstrated 
by another recent study (Yang et al., 2017). 
Unsal-Kacmaz et al. (2012) confirmed the above findings of the role of PRK3 in primary 
tumour growth and lymph node metastasis in mice and interestingly identified RhoC as the 
preferred binding partner of PRK3 during metastasis. This is in contrast to PRK3 showing 
higher affinity for RhoB than RhoA or RhoC in vitro (Hutchinson et al., 2013). The study also 
showed that PRK3 and RhoC are over-expressed in breast cancer cell lines and that PRK3 is 
critical for migration of these cells in a RhoC-dependent manner. This highlights that PRK3 is 
the key driver of neoplastic growth of both prostate and breast cancer cells. Additionally, 
PRK3 is vital for melanoma metastasis in mice and has been implicated in the glycosylation 
of the adhesion molecule ICAM-1, which is involved in signalling between tumour cells 
during metastasis (Mukai et al., 2016). PRK3 therefore drives metastasis, a hallmark of 
cancer. 
An attempt at targeting PRK1 has been made recently, involving the design of small 
molecule inhibitors which bind to the protein’s kinase domain (Slynko et al., 2016). 
Additionally, the low expression of PRK3 in most tissues, in contrast to its high expression in 
cancer, makes it an excellent therapeutic target. An attempt has been made to inactivate 
PRK3 using an siRNA/lipoplex complex known as Atu027, which showed efficacy in mouse 
prostate cancer and mouse pancreatic cancer models (Aleku et al., 2008) and very low 
toxicity in patients (Strumberg et al., 2012). This is currently in Phase II clinical trials. 
 
1.4.7.2 Pathogens 
Salmonella bacteria hijack PRK1 to activate an E3 ubiquitin ligase, SspH1. The crystal 
structure of the PRK1 HR1b domain in complex with SspH1 (Figure 1.15A) indicates that the 
HR1b domain interacts with the leucine-rich repeat (LRR) of this protein, which then 
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sterically displaces the catalytic domain bound to the LRR, causing its activation (Keszei et 
al., 2014). Out of the HR1b residues involved in the interaction, 77% of them are in the 
domain’s C-terminal helix, while only 4 or 5 of these residues are conserved in HR1a or 
HR1c, respectively, explaining the specificity of SspH1 for HR1b. The interacting residues are 
involved in a range of interactions including salt bridges, hydrogen bonds and hydrophobic 
interactions (Figure 1.15B). 
The CagA toxin of Helicobacter pylori, known for disrupting cell adhesion and apical-
basolateral cell polarity was found to co-immunoprecipitate with PRK2 (Mishra et al., 2015). 
CagA was also responsible for the recruitment of PRK2 from the cytosol to the plasma 
membrane of AGS cells infected with Helicobacter pylori. Surprisingly, while CagA inhibited 
PRK2 activity, increased cell motility and cell invasive behaviour of cells infected with CagA 
were observed. This implicates PRK2 directly in the pathology resulting from this toxin. 
Other pathogens also depend on PRK2. These include the HCV virus, where PRK2 
phosphorylates its RNA-dependent RNA polymerase so that it can replicate (Kim et al. 2012; 
Han et al., 2014). Another example is the interaction of PRK2 with the leucine-rich repeat 
domains of the YopM proteins of Yersinia pseudotuberculosis and Yersinia enterocolitica; 
this interaction is necessary for full virulence (McPhee et al., 2010; Hofling et al., 2014). 






























Figure 1.15 Structure of PRK1 HR1b in complex with the Salmonella protein SspH1. (A) Crystal structure 
of PRK1 HR1b (green) interacting with leucine-rich repeats of the Salmonella protein SspH1 (purple) (Keszei 
et al., 2014) (PDB:4NKG). This interaction is important in the pathogenesis of Salmonella. (B) Key types of 
interactions are highlighted. Out of the 13 PRK1 HR1b residues involved in the interaction, 10 are found in 







1.4.8 HR1 domains as Rho family effector domains 
 
1.4.8.1 Which HR1 domains bind to which Rho proteins 
A feature of the PRKs is that they include three GTPase effector domains. This grants them 
the ability to potentially interact with a multitude of Rho GTPases. PRK1 was firstly 
identified as an effector of RhoA (Watanabe et al., 1996). The HR1a domain was shown to 
bind to RhoA (Flynn et al., 1998) and this was later determined to be an interaction of nM 
affinity (Owen et al., 2003). The crystal structure of the RhoA/HR1a complex was solved by 
Maesaki et al. (1999), revealing two possible contact sites for RhoA, although only one of 
them is relevant in solution (Hutchinson et al., 2011). 
RhoA, RhoB and RhoC can all interact with the HR1a domain of PRK1, PRK2 and PRK3, 
indicating that PRKs are effectors of the entire Rho subfamily (Hutchinson et al., 2013). 
These interactions also indicate that to some extent the interactions between HR1 domains 
and G proteins can be predicted based on conserved key residues. Differences between the 
affinities of these interactions do exist. PRK2 HR1a and PRK3 HR1a, as well as their 
respective HR1ab di-domains, bind to the three Rho GTPases with weaker affinities than 
their PRK1 counterparts. In addition, while the C-termini of the Rho proteins did not affect 
their affinity for PRK1 and PRK2 HR1 domains, the affinity of PRK3 HR1a and HR1ab for full 
length rather than truncated RhoB was higher. Also of interest was the affinity of RhoB for 
PRK1 HR1ab which was higher than that of the isolated HR1a domain. This was observed 
uniquely in the case of RhoB and not with RhoA or RhoC, suggesting possible cooperative 
binding of PRK1 HR1a and HR1b to RhoB. Significant differences in helicity and melting 
temperature were also noted between these HR1 domains, suggesting that distinct thermal 
stabilities, and as a result structural rigidity, may explain the accessibility of interacting 
residues by Rho GTPases and thus define the affinity of these interactions. Therefore Rho 
GTPase interactions with HR1 domains may involve use of conserved residues, the C-
terminus of the GTPase, co-operative binding by two HR1 domains as well as protein 
stability and rigidity. 
RhoA also binds to HR1b weakly (~6x more weakly than to HR1a (Owen et al., 2003; 
Blumenstein & Ahmadian, 2004; Flynn et al., 1998). Whether this interaction competes with 
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the RhoA/HR1a interaction or uses a different binding site has not been determined. The 
HR1ab di-domain binds to RhoA as tightly as HR1a (Owen et al., 2003) indicating that there 
is no cooperative binding between the domains. The binding of RhoB and RhoC to HR1b 
alone has not been investigated. 
Rac1 was found to interact with PRK2 (Vincent & Settleman, 1997). Subsequent work 
showed that Rac1 binds to both HR1a and HR1b (Owen et al., 2003). The affinity of Rac1 for 
HR1b however is more than twofold higher than its affinity for HR1a. The affinity of Rac1 for 
the HR1ab di-domain is identical to the affinity for just the HR1b domain, suggesting that 
only one of the two HR1 domains may interact with a Rac1 molecule at the same time. The 
interaction of Rac1 with PRK3 has not been formally investigated, however the conservation 
of the key interacting residues between the HR1b domains indicates that PRK3 HR1b most 
probably does interact with Rac1 (Figure 1.16). The simultaneous binding of two Rac1 
molecules to HR1a and HR1b or of RhoA and Rac1 to HR1a and HR1b, respectively, have not 
been investigated yet but remain a possibility. 
No interacting partners are known for the HR1c domain of any of the PRK isoforms. HR1c 
may not interact with a GTPase or simply interacting partners have not been identified yet. 
The only study to investigate HR1c binding to GTPases came from Flynn et al. (1998) who 
demonstrated with a pull-down that RhoA does not bind to HR1c. The binding of HR1 
domains to the rest of the Rho family proteins has not been investigated to date. 
 
1.4.8.2 HR1 domain similarity and identity 
The HR1 region is the Rho GTPase-interacting region of the PRKs. Each PRK has three HR1 
domains, so there are a total of nine HR1 domains across all three PRKs. Each of these HR1 
domains can potentially interact with one or more Rho GTPases. 
Figure 1.16 shows a sequence alignment between the three HR1a, the three HR1b and three 
HR1c domains of PRK1, PRK2 and PRK3. Table 1.3 provides information on sequence identity 
and similarity between all nine HR1 domains. HR1 domains show ~60% sequence similarity 
and ~25% sequence identity. This divergence may explain their differential biophysical and 
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Table 1.3 Sequence identity and similarity between the HR1 domains. The numbers at the top indicate 
the percentage sequence similarity (calculated as total of fully conserved or highly similar residues) while 




























Figure 1.16 Sequence alignments of the HR1 domains of the three PRKs. There is conservation between 
the three HR1a domains, between the three HR1b domains and between the three HR1c domains. 
Asterisks highlight identical residues at all positions, colons highlight conservation of a strong group and 
periods highlight conservation of a weak group. The cylinders represent α-helices based on the published 
structures of PRK1 HR1a (Maesaki et al., 1999) (PDB:1CXZ) and PRK1 HR1b (Modha et al., 2008) 
(PDB:2RMK). No structure of an HR1c domain is currently available so the cylinders represent α-helices 
based on secondary structure prediction using jpred. Interacting residues are highlighted yellow for the 
RhoA/HR1a interaction and green for the Rac1/HR1b interaction. 
PRK1_HR1a      PG-VQQQLELERERLRREIRKELKLKEGAENLRRATTDLGRS 69 
PRK2_HR1a      DTMVQQKLDDIKDRIKREIRKELKIKEGAENLRKVTTD-KKS 78 
PRK3_HR1a      PGPSQWPPEDEKEVIRRAIQKELKIKEGVENLRRVATD-RRH 49 
                   *   :  :: ::* *:****:***.****:.:**  :  
  
  
PRK1_HR1a      LGPVELLLRGSSRRLDLLHQQLQELHAHVVLPDPAAT 106 
PRK2_HR1a      LAYVDNILKKSNKKLEELHHKLQELNAHIVVSDPED- 114 
PRK3_HR1a      LGHVQQLLRSSNRRLEQLHGELRELHARILL------ 80 
               *. *: :*: *.::*: ** :*:**.*::::       
  
  
PRK1_HR1b      -ATNLSRVAGLEKQLAIELKVKQGAENMIQTYSNGSTK 158 
PRK2_HR1b      CSTSNNRLKALQKQLDIELKVKQGAENMIQMYSNGSSK 168 
PRK3_HR1b      EQLRARHLEALRRQLHVELKVKQGAENMTHTCASGTPK 137 
                     :: .*.:** :*********** :  :.*: * 
  
  
PRK1_HR1b      DRKLLLTAQQMLQDSKTKIDIIRMQLRRALQAGQLENQAAP- 199 
PRK2_HR1b      DRKLHGTAQQLLQDSKTKIEVIRMQILQAVQTNELAFDNAKP 210 
PRK3_HR1b      ERKLLAAAQQMLRDSQLKVALLRMKISSLEASGS-------- 171 
               :***  :***:*:**: *: ::**::     : .         
  
  
PRK1_HR1c      DTQGSPDLGAVELRIEELRHHFRVEHAVAEGAKNVLRLLSAAKAPDR 247 
PRK2_HR1c      --NAKPVISPLELRMEELRHHFRIEFAVAEGAKNVMKLLGSGKVTDR 251 
PRK3_HR1c      --SGSPEPGP-ELLAEELQHRLHVEAAVAEGAKNVVKLLSSRRTQDR 212 
                 ...*  .  **  ***:*::::* *********::**.: :. ** 
  
  
PRK1_HR1c      KAVSEAQEKLTESNQKLGLLREALERRLGELPADHPKGRLLREELAAASS- 297 
PRK2_HR1c      KALSEAQARFNESSQKLDLLKYSLEQRLNEVPKNHPKSRIIIEELSLVAAS 302 
PRK3_HR1c      KALAEAQAQLQESSQKLDLLRLALEQLLEQLPPAHPLRSRVTRELRAAVPG 263 




1.4.8.3 Structural studies 
The advent of the structural understanding of G protein/HR1 interactions came with the 
crystal structure of RhoA in complex with PRK1 HR1a (Maesaki et al., 1999). HR1a was 
shown to form an antiparallel coiled coil structure, as predicted. Interestingly, HR1a was 
also shown to have a short N-terminal helix consisting of 5 amino acids which was not part 
of the interaction with RhoA. The structure identified two RhoA contact sites (I and II) for 
HR1a (Figure 17A). Contact site I buried a surface area of 2080 Å2 and involved a series of 
salt bridges and an extensive hydrogen bond network between HR1a and RhoA α1, β2/β3 
and α5 but no contacts with either of the switches. Contact site II buried a surface area of 
1640 Å2 and comprised mainly hydrophobic contacts between residues in the first long helix 
of HR1a and residues which were part of the switch regions in RhoA (Figures 1.17B and 
1.17C). The authors believed that contact I was the physiological site based on the greater 
surface area that the interaction buried. However, Flynn et al. (1998) had shown that HR1a 
interacts with RhoA in a nucleotide-dependent manner, suggesting that contact II might be 
the true interaction site. Subsequent analysis of contact I and contact II RhoA mutants 
showed that contact I mutants did not affect HR1a binding, while some contact II mutants 
did (Hutchinson et al., 2011). This indicated that contact site II is the most physiologically 
relevant. This should be unsurprising as it is the site which involves the switch regions and 
the interaction of RhoA with PRK1 has been shown to be nucleotide-dependent. This 
contact site also matches that used by other effectors such as ROCK when it binds to RhoA 
(Dvorsky et al., 2004). A key question left unclear by this structural study is whether free 
HR1a forms a coiled coil in solution or is partially or fully unstructured and whether the N-
terminal helix is an artefact of crystal packing in the complex structure. 
The solution NMR structure of HR1b was solved and showed that HR1b also forms an 
antiparallel coiled coil (Owen et al., 2003). Unlike HR1a, HR1b does not have an N-terminal 
helix. The solution NMR structure of Rac1 in complex with HR1b (Modha et al., 2008) shows 
that HR1b interacts with Rac1 at a site which is equivalent to the contact II site of RhoA 
(Figure 1.18A), burying a surface area of ~1500 Å2. This suggests that HR1 domains may all 
use this particular contact site of G proteins. Both helices of HR1b make extensive contacts 
with switch II and less so with switch I. The Rac1 switches make several contacts with HR1b 
around the mid-section and inter-helical loop of the domain and far away from the N- and 
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C-termini (Figures 1.18B and 1.18C). The interface mainly comprises hydrophobic 
interactions, e.g. Leu267Rac1 is buried in a hydrophobic pocket of HR1b which is formed by 
Val141HR1b (helix 1), Ala145HR1b (helix 1) and Met169HR1b (helix 2). Hydrogen-bonding and 
salt bridge interactions are also employed but are less prevalent. The structure also 
highlights a key difference between the way Rac1 interacts with HR1b and the way RhoA 
interacts with HR1a. Rac1 has a triple-proline motif in its C-terminus which is followed by a 
polybasic region consisting of four arginines and two lysines. The prolines form a polyproline 
helix which forces the polybasic region into an extended conformation to avoid charge 
clashes. As a result, the polybasic region folds back and interacts with both the core G 
domain of Rac1 and with HR1b. 
Currently, there are no reported structures of the PRK1 HR1c domain or of any of the PRK2 
or PRK3 HR1 domains. The HR1c domain is predicted to have a unique C-terminal helix 
(Figure 1.16). It is unknown if this helix truly forms in solution and what structural and 
functional importance it may have. Furthermore, the structures of the entire HR1 region or 
of the full length PRK have not been investigated, thereby leaving possible inter-domain, 
intramolecular interactions a mystery. An additional unknown is highlighted by the higher 
affinity of RhoB for the HR1ab di-domain (Hutchinson et al., 2013). This would suggest 
cooperative binding of RhoB by both HR1a and HR1b, although the structural basis of this 





































Figure 1.17 Structure of PRK1 HR1a interacting with RhoA. (A) Crystal structure of RhoA interacting with 
the HR1a domain of PRK1, which forms an antiparallel coiled-coil (Maesaki et al., 1999) (PDB:1CXZ). Two 
different contacts, I and II, were identified in the crystals. (B) Most of the key residues in the contact II 

































Figure 1.18 Structure of PRK1 HR1b interacting with Rac1. (A) Solution structure of Rac1 interacting with 
the HR1b domain of PRK1 (also an antiparallel coiled-coil) (Modha et al., 2008) (PDB:2RMK). The contact 
interface between the two domains mirrors contact II of RhoA-HR1a (Figure 1.17A). (B) Most of the key 
residues in the contact interface are highlighted. (C) Surface plots indicating the Rac1 and HR1b surfaces 






1.5 PRKs - The uncertain and the unknown 
 
1.5.1 The uncertain 
 
1.5.1.1 Specificity and differential affinities of the G protein/HR1 domain interactions 
While a range of Rho GTPases are known to interact with various HR1 domains, the 
specificity of these interactions remains undetermined and cannot be attributed to GTPase- 
and HR1-specific sequence motifs. This makes predicting novel GTPase/HR1 interactions a 
challenging task. In some cases the interaction seems likely, e.g. Rac1-interacting residues in 
PRK1 HR1b are conserved in PRK2 HR1b and PRK3 HR1b. The rigidity of coiled coils may also 
be a contributing factor to these interactions (Hutchinson et al., 2013). 
Surprisingly, it has been demonstrated that while RhoA interacts with HR1a and HR1ab with 
comparable affinities, RhoB interacts more tightly with the HR1ab di-domain (Hutchinson et 
al., 2013). This suggests that both HR1a and HR1b could interact with RhoB at the same 
time. The most probable way this could happen is if both contact sites are used on RhoB, 
e.g. HR1a binds to contact II while HR1b binds to contact I. This cooperative binding has not 
been investigated yet but stands as another variable when one studies these interactions. 
 
1.5.1.2 Activation of the PRKs 
RhoA and PDK1 can both activate PRK1 via direct interactions. It remains uncertain as to 
whether there is a temporal order of these activation events or whether they can interact 
concomitantly. An additional undefined detail is whether RhoA is released upon PRK1 
activation. Yoshinaga et al. (1999) identified three autophosphorylation sites in PRK1; one is 
a threonine in HR1a which makes a Van der Waals contact with a tryptophan residue in 
RhoA as indicated by the RhoA/HR1a structure. It is possible that activation of PRK1 leads to 
its autophosphorylation, with the phosphothreonine disrupting the interaction leading to 
RhoA dissociation. 
Following activation at the cell membrane, the PRKs relocate to multiple cellular 
compartments, including the endosomes and the nucleus. It is possible that PRKs are guided 
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to the right compartment by a compartment-specific GTPase, e.g. RhoB localises PRK1 to 
the endosomes. Nuclear localisation may require a nuclear localisation signal if the PRKs do 
not enter the nucleus in complex with another protein, but no NLS signals have been 
identified yet. 
 
1.5.1.3 Autoregulation of the PRKs 
The pseudosubstrate region in the HR1a domain of PRK1 has been linked to the 
autoregulation of PRK1 catalytic activity (Kitagawa et al., 1996). This infers an intramolecular 
interaction which keeps PRK1 in an autoinhibited state. No attempt has been made at 
solving the structure of the full length protein in this state and neither has it been 
investigated as to whether the HR1a domain undergoes a conformational change for this to 
occur, e.g. the coiled coil structure is disrupted to allow residues 39-53 to bind to the 
catalytic domain. Furthermore, PRK2 is autoregulated by inhibition resulting from 
oligomerisation (Bauer et al., 2012). The dimerisation region is not part of a predicted 
structured domain but may be structured in solution, however this has not been 
investigated to date. Additional PRK oligomerisation sites, the effect of PTMs such as 
phosphorylation on oligomerisation, as well as heterodimerisation between PRK isoforms 
have not been investigated either. 
 
1.5.2 The unknown 
 
1.5.2.1 The HR1c domain 
A lot about the PRKs currently remains unknown. Firstly, the role of the HR1c domain. No 
published studies provide structural characterisation of this domain from any of the three 
PRKs. Additionally, any GTPase interaction partners of this domain, if any, also remain 
unknown. The overall structure of the full-length PRK has not been investigated either, 
preventing any insight into intra-molecular interactions which may help understand the 
physiological role of this kinase. PRKs localise by their C2-like domain to the plasma 
membrane to be activated by RhoA and PDK1. Lipids such as arachidonic acid at the plasma 
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membrane also activate PRKs. It is possible that in the context of the membrane the PRK 
undergoes conformational changes which are essential for its activation. Overall, the lack of 
structural insight has been the Damocles’ sword in understanding PRK (auto-)regulation. 
 
1.5.2.2 The HR1abc tri-domain 
A key question that is often overlooked is whether the three HR1 domains exist 
independently in solution or not. It is assumed that within HR1abc the three HR1 domains 
each form an antiparallel coiled coil. This may not be the case however as the HR1 domains 
could be forming dissimilar structures, e.g. the HR1 domains may form a single, very long 
coiled coil consisting of 3 HR1 helices interacting with the remaining 3. 
 
1.5.2.3 Binding of G proteins to the HR1abc tri-domain 
If the three PRK HR1 domains exist independently in solution, then it can be assumed that 
they can interact freely with their cognate G proteins. If the three HR1 domains interact 
with each other, it is possible that these intramolecular interactions hold the HR1abc tri-
domain in a “closed conformation” which may open up, e.g. when RhoA binds. The 
intramolecular interactions may also compete with the G protein interactions, resulting in a 
lower affinity of the HR1abc tri-domain for G proteins than that of single HR1 domains. 
Another key question which remains unanswered is whether two G proteins can bind to 
HR1abc at the same time or whether this is sterically impossible. Structural insight into this 
will be key to unravelling the knot of Rho GTPase signalling and understanding convergence 











This PhD project primarily aimed to provide a key missing piece of the PRK puzzle, which is 
that of the biophysical and structural understanding of the HR1 domains. Specifically, the 
project aimed to investigate the often over-looked HR1c domain, as well as provide 
structural insight of the three HR1 domains in the context of the HR1abc tri-domain. 
Additionally, the project aimed to discover novel G protein interacting partners for the HR1 
domains and in particular for HR1c, and illuminate potential supercomplexes involving the 
PRKs and more than one G protein. The project’s initial aims were as follows: 
 
1) To biophysically characterise the HR1c domain as well as the HR1abc tri-domain 
2) To solve the NMR solution structure of the HR1c domain and compare it to the structures 
of other HR1 domains and in particular see if the additional, predicted C-terminal helix truly 
forms in solution 
3) To investigate interactions, if any, between the HR1 domains and, if the three HR1 
domains are not independent, structurally characterise the HR1abc tri-domain 
4) To investigate G protein binding to HR1c and to HR1abc, including obtaining a measure of 
the affinity of such interactions, as well as whether two G proteins can bind to the HR1abc 
tri-domain at the same time. 
 
Chapter 3 answers question 1) by providing a comprehensive biophysical characterisation of 
PRK1 and PRK3 HR1 domains. The data obtained here provide part of the answer to 
question 3) and thus guide the experiments done in subsequent chapters. Chapter 4 
addresses question 2) and, in addition to the solution structure of the HR1c domain, 
provides a useful tool to be used in the next chapter. Question 3) is addressed in Chapter 5, 
70 
 
where inter-domain interactions between the HR1 domains are investigated. This chapter 
also connects the two previous chapters together and establishes a coherent model. 
Chapter 6 then adds on to this model by investigating G protein binding to HR1 domains, 
thereby answering question 4) and providing a holistic understanding of HR1abc structure 
and function. 
 
1.6.2 Experimental techniques 
 
To address the aims outlined above, several biochemical and biophysical techniques were 
used. These techniques include chromatography, circular dichroism (CD), analytical 
ultracentrifugation (AUC), nuclear magnetic resonance (NMR), X-ray crystallography, 
isothermal titration calorimetry (ITC), chemical cross-linking, scintillation proximity assays 
(SPAs) and pull-downs. For each technique, sufficient information required to understand 













General chemicals were purchased from Sigma-Aldrich, Thermo Fischer, Formedium, 
Invitrogen, GE Healthcare and New England BioLabs. UltraPureTM Low Melting Point Agarose 
was purchased from Life Technologies. 15N-NH4Cl was purchased from Sigma-Aldrich and 13C 
glucose was purchased from Cambridge Isotope Laboratories. BioRad reagent was 
purchased from Bio-Rad. Cross-linking agents EDC, DMS and DMP (Thermo Fischer) were a 
kind gift from Prof. Dame Jean Thomas.  
 
2.1.2 Commercial kits and other materials 
 
2.1.2.1 DNA purification 
The GenElute Plasmid Miniprep kit was purchased from Sigma-Aldrich and used for plasmid 
purification from E.coli. The QIAquick Gel Extraction kit was purchased from QIAGEN and 
used for gel extraction of DNA from agarose gels. 
 
2.1.2.2 TOPO cloning 
The TOPO TA Cloning Kit containing pCR2.1 TOPO vector and One Shot TOP10F’ chemically 
competent E.coli used in TOPO cloning were purchased from Invitrogen. 
 
2.1.2.3 Site-directed mutagenesis 
The QuikChange Lightning Multi Site-Directed Mutagenesis kit and ultracompetent XL10 
Gold E.coli used for DNA mutagenesis were purchased from Agilent technologies. 
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2.1.2.4 PD10 columns 
PD10 columns were purchased from GE Healthcare. 
 
2.1.2.5 Bead slurries 
Glutathione agarose used in protein affinity purification was purchased from Sigma-Aldrich. 
Alkaline phosphatase agarose was purchased from Sigma-Aldrich for use in nucleotide 
exchange reactions. 
 
2.1.3 Commercial enzymes 
 
Restriction enzymes (BamHI and EcoRI) and T4 DNA ligase were purchased from Roche. Calf-
intestinal alkaline phosphatase was purchased from Sigma-Aldrich and used in the 




Oligonucleotides for PCR were purchased from Sigma-Aldrich (see section 2.1.9). 
 
2.1.5 Microbiological media 
2TY 1.6% Tryptone, 1% Yeast extract, 0.5% NaCl 




Ampicillin: 100 μg/ml 
Chloramphenicol: 20 μg/ml 
Kanamycin: 25 μg/ml 
Tetracycline: 10 μg/ml 
MOPS 
10x MOPS: 400 mM K-MOPS pH 7.4, 40 mM Tricine pH 7.4, 5.28 mM 
MgCl2, 2.76 mM K2SO4, 500 mM NaCl, 100 μM FeSO4, 5 μM CaCl2 
100x micronutrients: 0.4 mM H3BO3, 80 μM MnCl2, 30 μM CoCl2, 10 μM 
CuSO4, 10 μM ZnSO4, 3 μM NH4(MoO2)2 
MOPS (per litre): 100 ml 10x MOPS, 1 ml 100x micronutrients, 1.32 mM 
KH2PO4 pH 7.4, 0.4% (w/v) glucose, 20 mM NH4Cl, 5% (v/v) Celtone 
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(Cambridge Isotopes Ltd) 
M9 
47 mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 4 μM ZnSO4, 1 μM MnSO4, 
0.7 μM H3BO4, 0.7 μM CuSO4, 0.4% (w/v) glucose, 2 μM FeCl3, 2 μM 





2.1.6.1 Cloning and transformation buffers 
Agarose gel buffers 
50x TAE buffer 2 M Tris base, 5% acetic acid, 50 mM EDTA pH 8.0 
5x STOP buffer 50% sucrose (w/v), 50 mM EDTA pH 7.5, 0.1% bromophenol blue 
Transformation buffers 
TF1 10 mM CaCl2, 10 mM MOPS-KOH, pH 6.8 
TF2 75 mM CaCl2, 10 mM MOPS-KOH, pH 6.8 
TF3 75 mM CaCl2, 5% glycerol, 1 mM EDTA, 50 mM MOPS-KOH, pH 7.5 
 
 
2.1.6.2 Protein purification buffers  
Buffer Components 
MTPBS 20 mM sodium phosphate pH 7.3, 150 mM NaCl 
MTPBS (High salt) 20 mM sodium phosphate pH 7.3, 500 mM NaCl 
Thrombin cleavage buffer 20 mM Tris-HCl pH 8.4, 150 mM NaCl, 2.5 mM CaCl2 
Buffer A1 50 mM Tris-HCl pH 7.5, 0.05% NaN3 
Buffer A2 50 mM Tris-HCl pH 7.5, 5 mM DTT, 0.05% NaN3 
Buffer B1 50 mM Tris-HCl pH 7.5, 2 M NaCl, 0.05% NaN3 
Buffer B2 50 mM Tris-HCl pH 7.5, 2 M NaCl, 5 mM DTT, 0.05% NaN3 
Buffer S1 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% NaN3 
Buffer S2 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT, 0.05% NaN3 
Buffer S3 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 5mM 
Table 2.1 Microbiological media. 
Table 2.2 Cloning and transformation buffers. 
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DTT, 0.05% NaN3 
Buffer G 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM reduced glutathione, 0.05% NaN3 
TNMD 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM DTT 
TNMD250 
50 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM 
MgCl2, 5 mM DTT 
Buffer S4 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM DTT, 0.05% NaN3 
 
2.1.6.3 Biochemical and biophysical analysis buffers 
Buffer Components 
CD buffers 
CD buffer 1 50 mM sodium phosphate pH 7.5, 150 mM sodium fluoride 
CD buffer 2 50 mM sodium phosphate pH 7.5, 150 mM sodium fluoride, 1 mM DTT 
CD buffer 3 50 mM sodium phosphate pH 7.5, 500 mM sodium fluoride, 1 mM DTT 
Nucleotide exchange and HPLC buffers 
Nucleotide exchange reaction mix 
5.29 mM GMPPNP, 217 μM (NH4)2SO4, 20.6 
mM Tris-HCl pH 7.5, 59.7 mM NaCl, 1.99 
MgCl2, 1.99 mM DTT 
HPLC buffer 0.6 M ammonium phosphate pH 4.0 
SPA exchange buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl 
SPA buffers 
SPA reaction mix 
5 mg/ml Protein A SPA fluoromicrospheres 
(GE Healthcare), 30 mM Tris-HCl pH 7.5, 0.17 
mg/ml BSA, 0.9 mM MgCl2, 1.7 mM DTT, 
18.7 μg/ml anti-GST antibody (Life 
Technologies A5800) or 10 μg/ml anti-His 
(Sigma-Aldrich H1029) 
SPA dilution buffer 50 mM Tris-HCl pH 7.5, 0.2 mg/mL BSA, 2 mM DTT, 1 mM MgCl2 
ITC buffers 
ITC buffer 1 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT 
ITC buffer 2 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM DTT 
Cross-linking buffers 
EDC buffer 100 mM MES pH 5.0, 150 mM NaCl, 5 mM DTT 
DM buffer 100 mM sodium phosphate pH 8.0, 150 mM 
NaCl, 5 mM DTT 
Table 2.3 Protein purification buffers. 
Table 2.4 Biochemical and biophysical analysis buffers. 
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For all other biochemical and biophysical analyses, the buffers used were identical to the 
final purification buffer of each protein, unless stated otherwise. 
 
2.1.6.4 SDS-PAGE buffers 
Laemmli gels for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Resolving 
gel 
Component Volume (ml) 
1.5 mM Tris-HCl pH 8.8 1.5 
Acrylamide:Bis-Acrylamide (29:1, 30% (w/v)) 2.4-3.6 (12-18%) 
MilliQ H2O 0.8-2.0 
10% (w/v) SDS 0.06 




Component Volume (ml) 
0.5 mM Tris-HCl pH 6.8 0.5 
Acrylamide:Bis-Acrylamide (29:1, 30% (w/v)) 0.25 
MilliQ H2O 1.2 
10% (w/v) SDS 0.02 






3.3% (w/v) SDS, 6 M Urea, 33.3 mM Tris-HCl pH 7.4, 66.7 mM β-
mercaptoethanol, 0.1% bromophenol blue 
Running 






Vector Fusion tag 
Protease 







pCR 2.1 TOPO - - Invitrogen Ampicillin/ Kanamycin TOP10 F’ N/A 






Table 2.5 SDS-PAGE buffers. 
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The generated constructs are listed in Table 2.7. Expression vectors already available in the 
lab are in italic. Other constructs used as templates in PCR or for mutagenesis (e.g. 
pGEXHISP constructs) were already available in the lab from the Part III Master’s Project 
(Sophocleous, 2014) or had been cloned previously by Catherine Hutchinson, so they are 
not listed here. All sequences are from Homo sapiens. Expression vectors were always 
cloned with BamHI and EcoRI restriction sites. 
 
Vector Construct Construct limits 
pCR 2.1 TOPO 
PRK1 HR1abc 1-297 
PRK1 HR1bc 122-297 
RhoA Δ4 F25N Q63L 1-194 
RhoD Δ4 Q75L 1-211 
pGEX-6P-1 
PRK1 HR1a 1-106 
PRK1 HR1ab 1-199 
RhoA Δ4 F25N Q63L 1-194 
RhoD Δ4 Q75L 1-211 
pGEX-HISP(STOP) 
PRK1 HR1b 122-199 
PRK1 HR1c 201-297 
PRK1 HR1bc 122-297 
PRK1 HR1abc 1-297 
PRK2 HR1c 207-302 
PRK2 HR1bc 132-302 
PRK2 HR1abc 1-302 
PRK3 HR1a 1-80 
PRK3 HR1b 100-171 
PRK3 HR1c 169-263 
PRK3 HR1ab 1-171 
Table 2.6 DNA plasmid vectors. N stands for N-terminal and C for C-terminal. 
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PRK3 HR1bc 100-263 
PRK3 HR1abc 1-263 
pGEX-2T 
RhoA Δ12 F25N Q63L 1-186 




The amino acid sequences of all purified proteins, as well as vector tags are listed in 
Appendix 1. 
 
2.1.8 Bacterial strains 
 
Table 2.8 lists the E.coli strains used, their antibiotic resistance and their genotype. 






1 recA1 gyrA96 
relA1 lac [F´ proAB 
lacIqZΔM15 
Tn10 (TetR) 
Deficient in DNA 
recombinase, DNA 
endonuclease and DNA 
gyrase and also contains 
lac/Z mini-gene for 
blue-white selection. 
TOP10 F’ Invitrogen Tetracycline 






Deficient in DNA 
recombinase. The F’ 
episome contains the 
lacIq repressor for 
inducible expression 









supE44 thi-1 recA1 
gyrA96 relA1 





efficiency. Deficient in 
DNA endonuclease, 
DNA recombinase and 
DNA gyrase. 
BL21 Invitrogen None F
- ompT hsdS(rB- 
mB-) 
Deficient in ompT and 
proteases 








F- ompT hsdS(rB- 
mB-) gal dcm (DE3) 
plysSRARE2 (CamR) 
Based on BL21. 
Contains DE3 lysogen 
which encodes T7 
polymerase and also 
contains pRARE2 
plasmid from which rare 
tRNAs for 5 amino acids 








F- ompT hsdS(rB- 
mB-) gal dcm (DE3) 
Contains 
uncharacterised 
mutations which help 
with the expression and 






Conventional cloning and mutagenic primers are listed in Table 2.9. 
Conventional cloning primers 













RhoA F’ CGCGGATCCATGGCTGCCATCCGG 
RhoA R’ CGCGAATTCTCATCACCCAGATTTTTTCTTCCC 
RhoD F’ CGCGGATCCATGACGGCGGCCCAG 
RhoD R’ CGCGAATTCTCATCAAAAGCCCTGGGTAATCCG 
Mutagenic primers 






















































2.2.1 Molecular cloning 
 
2.2.1.1 Agarose gel electrophoresis 
Agarose gels (0.7-1.5%) were made in TAE buffer with 0.5 μg/ml ethidium bromide. DNA 
samples were made up in 5x STOP buffer and 10-15 μl were loaded onto the gel. The gels 
were run in TAE buffer with 0.5 μg/ml ethidium bromide at 100 V, 100 mA for 1 h 30 min 
and were then visualised under UV light. 
Table 2.9 Table of DNA primers. BamHI restriction sites are highlighted in cyan, EcoRI restriction sites are 
highlighted in green, 5’ CGC overhangs are highlighted in yellow and stop codons are in black. 
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2.2.1.2 Polymerase Chain Reaction (PCR) 
For each reaction, 200 μM dNTPs, 10 μl 10xTAQ Buffer (Roche), 100 pmol forward primer, 
100 pmol reverse primer (Table 5) and 50 ng template DNA were combined and the volume 
adjusted to 99 μl with sterile AnalaRTM water. 1 μl Taq Polymerase (Roche) was added after 
step 2 of the PCR program (Table 2.10). PCR products were visualised on a 1.5% agarose gel 
(100 V, 80 min) and verified according to size. 
 
Step Process Temperature (oC) Time (min) Cycles 
1 Denature 95 6 1 
2 Anneal 55 2 1 
3 Pause and add 1 μl Taq Polymerase 72 - - 
4 Extend 72 2 
25 5 Denature 95 2 
6 Anneal 55 2 
7 Extend 72 10 1 
8 HOLD 4 HOLD - 
 
 
2.2.1.3 TOPO cloning 
The PCR product was cloned into a pCR2.1-TOPO vector using a TOPO Cloning Kit (Life 
Technologies) and the resulting product was used to transform TOP10F’ cells according to 
the manufacturer’s instructions. The cells were plated on agar containing kanamycin, 
tetracycline, 500 μM IPTG (isopropyl β-D-1-thiogalactopyranoside) and 80 μg/ml X-Gal (5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside). White colonies, suggesting successful 
incorporation of PCR product into the pCR2.1-TOPO vector, were then patched onto new 
agar plates. 
 
2.2.1.4 Restriction digest of plasmid DNA 
Overnight cultures (5 ml) were inoculated from white colonies. Bacterial plasmid DNA was 
purified using the GenElute Plasmid Miniprep Kit (Sigma-Aldrich) according to the 
manufacturer’s instructions. 
Table 2.10 PCR cycling program. 
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DNA concentration was estimated by UV absorbance at 260 nm and calculated by 
= × 50 /  
where C is the concentration of DNA in μg/ml. 
1 μl BamHI (10 units) and 1 μl EcoRI (10 units) restriction enzymes and 2 μl Buffer B (Roche) 
were added to 16 μl DNA. Restriction digests were carried out for 2-4 hours at 37 oC and 
quenched by addition of 5 μl 5x STOP buffer. “Uncut” samples were prepared by adding 2.5 
μl 5x STOP buffer to 10 μl DNA. Restriction digest products were visualised on a 1.5% 
agarose gel (100 V, 80 min) to confirm the presence of the correct insert in the vector and 
the insert sequence was confirmed by sequencing (Sequencing Facility, Department of 
Biochemistry). 
 
2.2.1.5 Competent cells 
10 ml 2TY with the appropriate antibiotic was inoculated with the relevant E.coli and 
incubated at 37 oC overnight shaking at 180 rpm. 0.75 ml of overnight culture was added to 
20 ml 2TY and shaken at 37 oC to an A600 of 0.4-0.6, spun at 8300 x g for 10 min and the 
supernatant discarded. The pellet was resuspended in 10 ml of ice cold TF1 and spun at 
7000 x g for 10 min. The supernatant was discarded and the pellet was resuspended in 1 ml 
of ice cold TF2 and left on ice for 3-24 h. 
 
2.2.1.6 Bacterial transformation 
Transformation of XL1-Blue MRF+ (hereafter XL1) competent cells was carried out by mixing 
200 μl cells, 20 μl of the ligation reaction and 180 μl TF3. Transformation of BL21, C41 and 
Rosetta2(DE3) competent cells was carried out by mixing 100 μl cells, 1 μl DNA and 99 μl 
TF3 buffer. The cells were incubated on ice for 45 min, followed by heat shock at 42 oC for 
10 min and a further incubation on ice for 2 min. 1 ml 2TY was then added and the cells 
were incubated at 37 oC for 30 min. 200 μl XL1 cells or 100 μl BL21, C41 or Rosetta2(DE3) 
cells were then spread on plates containing the appropriate antibiotic. The rest of the cells 
were pelleted at 16060 x g for 5 min and the supernatant discarded. The pellet was 
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resuspended in 200 μl 2TY and spread on a separate plate containing the appropriate 
antibiotic. Table 2.6 indicates which bacterial strain was used for which vector. 
 
2.2.1.7 Preparation of linearised expression vector by alkaline phosphatase treatment 
Plasmid DNA (pGEXHISP or pGEX6P) from 5 ml of overnight culture was purified and 5 μg 
were mixed with 10 μl Buffer B, 5 μl BamHI (50 units) and 5 μl EcoRI (50 units) (Roche) and 
the volume adjusted to 100 μl with sterile AnalaRTM water. The restriction digest was 
incubated for 4-6 h at 37 oC. Uncut and cut vector samples were visualised on a 0.7% 
agarose gel (100 V, 80 min) to confirm that the vectors had been digested. 71.4 μM Tris-HCl 
pH 8.0, 7.14 μM MgCl2 and 1 unit calf-intestinal alkaline phosphatase were combined and 
the volume adjusted to 210 μl with sterile AnalaRTM water. The reaction mixture was 
incubated at 37 oC for 20 min followed by warming to 65 oC for 20 min. The volume was 
adjusted to 360 μl with sterile AnalaRTM water. 300 μl phenol was added to the reaction 
mixture which was vortexed for 30 sec. The mixture was spun at 16060 x g for 1 min and the 
aqueous layer containing the DNA was removed. The process was repeated by adding 300 μl 
phenol to the DNA which was then separated from phenol. The volume of the reaction was 
then adjusted to 610 μl by adding 300 μl chloroform and the mixture was vortexed for 30 
sec. The mixture was spun at 16060 x g for 1 min and the aqueous layer containing the DNA 
was removed. The process was repeated by adding 300 μl chloroform to the DNA which was 
then separated from chloroform. 300 μl ether were then added to the aqueous layer and 
the mixture was vortexed for 30 sec. The mixture was spun at 16060 x g for 1 min and the 
top ether layer was removed. Residual ether was allowed to evaporate in a fume cupboard 
for 30 min. DNA was quantified as described in section 2.2.1.4. 
 
2.2.1.8 Ligations 
Plasmid DNA from 20 ml of overnight culture was purified and 5 μg were mixed with 10 μl 
Buffer B, 5 μl BamHI (50 units) and 5 μl EcoRI (50 units) (Roche) and the volume adjusted to 
100 μl with sterile AnalaRTM water. The restriction digest was incubated for 4-6 h at 37 oC 
and quenched by addition of 25 μl 5x STOP buffer. The products were visualised on a 1.5% 
UltraPureTM Low Melting Point Agarose (Life Technologies) gel (100 V, 80 min) and the insert 
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fragment purified using the QIAquick Gel Extraction Kit (QIAGEN) according to the 
manufacturer’s instructions. 
16 μl insert, 1 μl alkaline phosphatase-treated, linearised expression vector (pGEXHISP or 
pGEX6P), 2 μl 10xT4 ligase buffer and 1 μl T4 ligase (Roche) were incubated at 16 oC for 16 h. 
XL1 competent cells were transformed with the ligation products and spread on agar plates 
containing ampicillin and tetracycline. Successful ligation reactions were identified by 
restriction digest of plasmid DNA from transformed XL1 colonies and confirmation of an 
insert of the correct size in the expression vector (as described in section 2.2.1.4). 
 
2.2.1.9 Sequencing 
DNA sequencing was performed by the DNA sequencing facility at the Department of 
Biochemistry, University of Cambridge. The sequencing files were viewed with Chromas Lite 
v2.1.1. 
 
2.2.2 Site-directed mutagenesis 
 
Site-directed mutagenesis was performed using the Agilent QuikChange Kit according to the 




Laemmli gels of the appropriate percentage were poured in 1 mm gel cassettes (Thermo 
Fischer) according to Table 2.5. Gel samples were prepared in 2x SDS Loading Buffer, boiled 
for 5 min, spun at 16060 x g for 5 min and 10-15 μl loaded onto the gel alongside unstained 
broad range protein markers (New England Biolabs; markers used are indicated on each gel 
separately). Gels were run at 200 V, 45-55 mA (per gel) for 1 h 10 min, stained with 
InstantBlue (Expedeon) overnight and washed in water overnight. 
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2.2.4 Expression trials 
 
10 ml 2TY with the appropriate antibiotic(s) was inoculated from a plate and incubated at 37 
oC overnight shaking at 180 rpm. 10 ml 2TY with the appropriate antibiotic(s) was inoculated 
with 1 ml of overnight culture and shaken at 180 rpm, 37 oC. Three such cultures were 
grown to an A600 of 0.8. Two of the cultures were induced by adding 0.1 mM IPTG. One of 
the induced cultures was shaken at 180 rpm, 37 oC for 5 h. The uninduced and other 
induced cultures were shaken at 180 rpm, 20 oC for 16 h. 
The total resuspension volume of MilliQ H2O and 2x SDS Loading Buffer used was 
normalised to A600 x  μl. Uninduced and induced samples were prepared. 1 ml of each 
culture was centrifuged at 16060 x g for 5 min, the supernatant discarded and the pellets 
resuspended in half a volume MilliQ H2O. Half a volume 2x SDS Loading Buffer was then 
added. Samples were also prepared by pelleting 2 ml of E.coli culture, discarding the 
supernatant and resuspending in a total volume MilliQ H2O. 1 μl DNase (at 10 mg/ml) and 2 
μl lysozyme (at 20 mg/ml) were added and the samples were left standing at room 
temperature for 20 min. The samples were sonicated (2x 30 sec, with 30 sec rest between 
each pulse) with 50% amplitude on a Sonic Dismembrator Model 120 (Thermo Fischer) and 
then centrifuged at 16060 x g for 5 min. 100 μl of the supernatant were transferred to a 
separate tube and 100 μl 2x SDS Loading Buffer was added to produce a soluble sample. The 
remaining supernatant was discarded and the pellet resuspended in a total volume MilliQ 
H2O and a total volume 2x SDS Loading Buffer. All samples were boiled at 100 oC for 5 min, 
centrifuged at 16060 x g for 5 min and 15 μL loaded onto a gel. Gels were run at 200 V for 70 
min. 
 
2.2.5 Protein expression 
 
8 x or 12 x 50 ml of 2TY with the appropriate antibiotic(s) was inoculated from a plate and 
incubated at 37 oC overnight shaking at 180 rpm. 8 x or 12 x 500 ml 2TY with the appropriate 
antibiotic(s) was inoculated with the overnight cultures. The bacterial cultures were grown 
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at 37 oC to an A600 of 0.8, cooled in cold water baths and induced by adding 0.1 mM IPTG. 
The cultures were then incubated at 20 oC for 20 h shaking at 180 rpm. 
Bacterial cultures were centrifuged at 8671 x g for 15 min. Cell pellets were re-suspended in 
ice cold MTPBS (High salt) or TNMD250 (in which a SIGMAFASTTM Protease Inhibitor Cocktail 
Tablet, EDTA-Free (Sigma-Aldrich) had previously been dissolved), and 1 mM PMSF was then 
added. The cells were lysed by passing five times through an Avestin EmulsiFlex-C5 
Emulsifier (ATA Scientific). 
An additional 1 mM PMSF was added to the cell lysate which was then centrifuged at 40000 
x g for 30 min. The supernatant was added to 2 x (for 4 L preps) or 3 x (for 6 L preps) 7.5 ml 
of glutathione agarose bead slurry (Sigma-Aldrich), which had previously been equilibrated 
in MTPBS (High salt) or TNMD250 and was then left rotating at 4 oC for 2 h. 
 
2.2.6 Protein purification 
 
2.2.6.1 Glutathione agarose purification and proteolytic removal of N-terminal tag 
The bead slurry was spun at 1000 x g for 10 min, the supernatant removed and a gel sample 
taken (10 μl of 1 in 2 dilution in 2x SDS Loading Buffer). The beads were then washed 3 
times in MTPBS (High salt) or TNMD250 and finally resuspended in an equal volume of 
MTPBS (High Salt) or TNMD250. A gel sample of each wash supernatant was taken (10 μl of 1 
in 2 dilution in 2x SDS Loading Buffer) and 10 μl were loaded on a gel. Gels were run at 200 
V for 70 min. Additional MTPBS (High salt) buffer was then added up to 20 ml, followed by 
the addition of 1 mM DTT and 1 mM EDTA pH 7.4 (not for G proteins). 100 μl of HRV 3C 
protease at 4.8 mg/ml were then added and the tubes were incubated on a rotating wheel 
at 4 oC for 16 h. In the case of proteins with a thrombin cleavage site rather than a 3C 
protease cleavage site, the beads were washed 3x in thrombin cleavage buffer as above and 




2.2.6.2 Size-exclusion chromatography 
Size exclusion columns were equilibrated with 2.5 column volumes (CV) of the appropriate 
purification buffer on a Fast Protein Liquid Chromatography (FPLC) ÄKTA Purifier system (GE 
Healthcare). The sample was manually loaded using a 2 ml loop, which had previously been 
washed with 6 ml of purification buffer. The sample was injected on the column and eluted 
in 1.5 CV at a flow rate of 1 ml/min. 2 ml fractions were collected and subsequently 
analysed by SDS-PAGE. The size exclusion columns used are listed in Table 2.11. 
 





Superdex75 16/60 120 GE Healthcare 1 2 
Superdex200 16/60 120 GE Healthcare 1 2 
Heparin 20 GE Healthcare 1 1 
ResourceQ 6 GE Healthcare 1 1 
Glutathione sepharose 10 GE Healthcare 2 - 
 
 
2.2.6.3 Ion exchange chromatography 
Cation exchange chromatography was performed on a Heparin column while anion 
exchange chromatography was performed on a ResourceQ column. The columns were 
regenerated and equilibrated with an ABA wash, consisting of 3 CV of Buffer A1/2 followed 
by 3 CV of Buffer B1/2 and subsequently 3 CV of Buffer A1/2. The columns were then 
equilibrated with 3 CV of 1% Buffer B1 (ResourceQ column) or 10% Buffer B2 (Heparin 
column). The NaCl concentration was lowered by diluting the sample in Buffer A1/2. The 
sample was loaded using a 50 ml SuperLoop (GE Healthcare) in 1% Buffer B1 (PRK1 HR1a) or 
10% Buffer B2 (PRK3 HR1ab and PRK3 HR1abc) at a flow rate of 1 ml/min. The column was 
washed to baseline with 1% Buffer B1 or 10% Buffer B2 at a flow rate of 1 ml/min. The 
protein was eluted with a Buffer B1/2 gradient (starting at 1% Buffer B1 or 10% Buffer B2 
and ending at 50% Buffer B1/2) across 3 CV at a flow rate of 1 ml/min. 1 ml fractions were 
collected and analysed by SDS-PAGE. 
 
Table 2.11 Chromatography columns. 
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2.2.6.4 Glutathione sepharose affinity purification 
The column was equilibrated with 3 CV Buffer S1/2/3. The sample was loaded using a 5 ml 
loop at a flow rate of 1 ml/min. The flow-through was collected and the column was washed 
to baseline with Buffer S1/2/3 at a flow rate of 1 ml/min. The flow-through and wash 
containing unbound protein were pooled. The column was washed (and regenerated) with 
Buffer G at a flow rate of 1 ml/min to elute GST. 
 
2.2.6.5 Purification buffers 
The relevant purification and biophysical analysis buffers for each protein are listed in Table 
2.12. 
Protein Buffers 
PRK1 HR1a MTPBS (High salt), Buffer A1, Buffer B1, Buffer S1, CD buffer 1 
PRK1 HR1b MTPBS (High salt), Buffer S1, CD buffer 1 
PRK1 HR1c MTPBS (High salt), Buffer S1, CD buffer 1 
PRK1 HR1ab MTPBS (High salt), Buffer S2, CD buffer 2 
PRK1 HR1abc MTPBS (High salt), Buffer S2, CD buffer 2 
PRK3 HR1a MTPBS (High salt), Buffer S1, CD buffer 1 
PRK3 HR1b MTPBS (High salt), Buffer S3, CD buffer 3 
PRK3 HR1c MTPBS (High salt), Buffer S1, CD buffer 1 
PRK3 HR1ab MTPBS (High salt), Buffer A2, Buffer B2, Buffer S3, CD buffer 3 
PRK3 HR1abc MTPBS (High salt), Buffer A2, Buffer B2, Buffer S3, CD buffer 3 
RhoA Δ4 F25N Q63L, RhoA Δ12 F25N Q63L, 
Cdc42 Δ7 Q61L TNMD, TNMD250, Buffer S4 
 
 
2.2.6.6 Protein concentrating 
For all intermediate steps of purifications, proteins were purified in an Amicon stirred 
concentrator cell (Millipore) with a YM-10 membrane (or YM-3 for single HR1 domains). The 
final concentrating was done in an Amicon Ultra-4 Centrifugal Filter Unit (Millipore) with an 
Ultracel-10 or Ultracel-3 membrane. 
 
Table 2.12 Purification and biophysical analysis buffers for each protein. 
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2.2.7 Determination of protein concentration 
 
2.2.7.1 Absorbance 
The theoretical extinction coefficient of proteins at 280 nm was predicted from the number 
of tryptophan and tyrosine residues in the sequence using Pepstats. For GTPases, the 
extinction coefficient of the guanine nucleotide, 7720 M-1cm-1, was also taken into account. 
Three μl of protein were taken up in a glass capillary (Shimadzu) of 0.05 cm pathlength and 
the absorbance at 280 nm was measured within a linear range of 0.1-1.0 in a UV-1800 UV-
VIS spectrophotometer (Shimadzu). The concentration was determined according to the 
Beer-Lambert Law, 
=  
where  is the absorbance at 280 nm,  is the theoretical extinction coefficient in M-1cm-1,  
is the concentration in M and  is the pathlength of the capillary in cm. 
 
2.2.7.2 Bradford assay 
For proteins with few or no aromatic residues or proteins unstable at room temperature, 
the concentration was estimated using a Bradford reagent-based assay. 800 μl of SMQ were 
added to 200 μl BioRad reagent in a 1 ml cuvette. 2 μl of protein were then added and the 
contents of the cuvette were mixed by inversion. The absorbance reading at 595 nm was 
recorded after 3 min using a spectrophotometer. The absorbance reading of a blank sample 
(800 μl of SMQ and 200 μl BioRad reagent) was then subtracted from the absorbance of the 
protein sample. The recordings were taken in duplicates (within 5% of each other) and 
averaged. The subtracted, averaged reading was used to estimate the amount of protein, in 
μg, present in the cuvette based on an equation derived from the standard curve of a 
Bradford assay with IgG. Samples that gave spectrophotometer values larger than 1.0 




2.2.7.3 Amino Acid Analysis 
Amino acid analysis was performed by the Protein and Nucleic Acid Chemistry facility at the 
Department of Biochemistry, University of Cambridge. 
 
2.2.8 Mass spectrometry 
 
MALDI-TOF was performed by the Protein and Nucleic Acid Chemistry facility at the 
Department of Biochemistry, University of Cambridge, and by the Proteomics facility at the 
Cambridge Centre for Proteomics, University of Cambridge. 
 
2.2.9 Nucleotide exchange 
 
2.2.9.1 GMPPNP exchange 
The alkaline phosphatase agarose bead slurry was equilibrated with 10 mM Tris-HCl pH 7.5, 
0.1 mM ZnCl2. 
For the nucleotide exchange, 500 μl GTPase (up to 1 mM), 333 μl 20 mM GMPPNP (Sigma-
Aldrich), 333 μl 50% alkaline phosphatase agarose bead slurry and 91 μl 3 M (NH4)2SO4 in 10 
mM Tris-HCl pH 7.5 were mixed to a total volume of 1257 μl. The mixture was then split into 
two separate exchange reactions, which were left rotating at 37 oC for 4 h 30 min. After the 
exchange, 2x~600 μl (the supernatant) were spun down at 16060 x g for 5 min at 4 oC and 
then purified on a Superdex75 16/60 column, as described in section 2.2.6.2 to buffer 
exchange the protein and remove any aggregated protein and the excess GMPPNP. 
 
2.2.9.2 HPLC analysis 
50 μg of protein were mixed with 2 μl of 0.9 M perchlorate, shaken and made up to 100 μl 
with 0.6 M NH4H2PO4 pH 4.0. The precipitated protein was pelleted at 16060 x g for 5 min 
and 100 μl of the supernatant were injected on a PartiSphere SAX column (125 mm x 4.6 
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mm) (Whatman) on a GP50 Gradient Pump HPLC system (Dionex). The column was run 
isocratically with 0.6 M NH4H2PO4 pH 4.0 for 15 min at 1.5 ml/min. One hundred μl of 0.1 
mM GDP, GTP and GMPPNP standards (Sigma-Aldrich) were individually run and compared 
to the guanosine nucleotide released by the exchanged protein. 
 
2.2.9.3 [3H-GTP] exchange 
[8,5’-3H]GTP (0.15 miCi) (GE Healthcare) in 75% EtOH was dried by centrifugal evaporation. 
At least 0.7 mg of GTPase were added to the dry radionucleotide and the volume was made 
up to 145 μl in SPA exchange buffer. 16 μl of 3 M (NH4)2SO4 were then added and the 
reaction was incubated at 37 oC for 3 h. The reaction was quenched by adding 3 μl of 1 M 
MgCl2. Excess radionucleotide was then removed using 2.5 ml G25 Sephadex spin columns 
(GE Healthcare) previously equilibrated in Buffer S4. 
The concentration was determined using a Bradford assay and corrected using a correction 
factor obtained from amino acid analysis. 
 
2.2.10 Circular dichroism 
 
2.2.10.1 Sample preparation 
Proteins were buffer exchanged into their respective CD buffer using a PD10 column and 
then were concentrated to 1 mg/ml. The proteins were further diluted with CD buffer to a 
concentration of 0.2 mg/ml prior to recording the experiments. 
 
2.2.10.2 Data recording 
The proteins were loaded in a 0.1 mm pathlength quartz cuvette which was placed in an 
AVIV 410 instrument (Aviv Biomedical). The ellipticity in millidegrees was measured at 18 oC 
between 185 nm and 260 nm at 1 nm intervals with a 1 s averaging time/point. Four scans 
were recorded in total and averaged. The same was repeated for each of the different CD 
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buffers. The buffer control data was then subtracted from the experimental data, which was 
followed by smoothing the plots. 




where MRE is the calculated mean residue ellipticity in degrees cm2 dmol-1 residue-1, θ is the 
recorded ellipticity in millidegrees, l is the pathlength in cm, C is the protein concentration in 
mg/ml and MRW is the mean residue weight of each protein, calculated by 
= − 1 
where Mr is the molecular mass of the protein in Da and n is the number of residues. 
For thermal melts, ellipticity at 222 nm was monitored at an increasing temperature 
between 18 oC and 80 oC at 2 oC increments with a 30 sec equilibration time. Subsequently, 
refolding was monitored in a similar way by cooling the sample back to 18 oC. 
 
2.2.10.3 Data analysis 
The data were analysed using the DICHROWEB server and percentage helicity was estimated 
using the SELCON3 programme and reference set 3 (Sreerama & Woody, 1993; Whitmore & 
Wallace, 2008). 
 
2.2.11 Analytical ultracentrifugation 
 
The protein and reference sectors of standard double-sector Epon centrepieces with 
sapphire windows were filled with 400 μl of protein and 400 μl of matching buffer, 
respectively. The AUC cell centrepieces were loaded into an An60Ti four-hole rotor and 
placed in an Optima XL-I centrifuge (Beckman Coulter). For temperature sensitive protein 
samples, the AUC cells were first cooled down to 4 oC prior to sample loading. Experiments 
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were carried out at 4 oC and at a rotor speed of 40000 rpm. Interference optics data were 
recorded in the continuous mode without averaging and with radial increments of 0.003 cm. 
Scans were recorded at 1 min 30 sec intervals until no further sedimentation was observed. 
The systematic noise was then subtracted. 
Estimates for the solvent density, solvent viscosity and the protein partial specific volume 
were calculated using the program SEDNTERP (Laue et al., 1992). A total of 200 scans were 
analysed and the data were fit to a continuous c(s) distribution (with a Marquardt-
Levenberg algorithm) using SEDFIT v14.1 (Schuck, 2000). A range of s-values from 0-10 was 
chosen first when fitting the data to confirm absence of very large species. Subsequently, a 
shorter range, e.g. 0-5 was chosen to allow for greater resolution in the c(s) distribution. 
For the PRK1 HR1a/RhoA Δ4 F25N Q63L experiment, the proteins were mixed and incubated 
on ice for 30 min before being loaded into the AUC cells. 
Appendix 3 lists all the AUC experiments performed, the parameters estimated by 
SEDNTERP, the number of scans recorded and the parameters determined. 
 
2.2.12 NMR Spectroscopy 
 
2.2.12.1 Expression of isotopically-labelled proteins 
For small scale expression trials, 10 ml 2TY with the appropriate antibiotic(s) were 
inoculated and grown overnight at 37 oC shaking at 180 rpm. The overnight culture was then 
resuspended in either 10 ml MOPS or M9 minimal medium and 1 ml was then added to 10 
ml MOPS or M9 minimal medium (x3 for Uninduced, Induced at 37 oC and Induced at 20 oC). 
For large scale protein expression, 20 ml 2TY cultures with the appropriate antibiotics were 
grown overnight at 37 oC. The cultures were pelleted and resuspended in 10 ml MOPS or M9 
and then added to 500 ml of MOPS or M9 minimal medium with the appropriate antibiotic. 
15N-NH4Cl was also added to a final concentration of 1 mg/ml as well as 0.4% unlabelled 
glucose (for 15N-labelled proteins) or 0.3% labelled glucose (for 15N/13C-labelled proteins). 
The cultures were then induced, grown and processed as for unlabelled proteins. 
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2.2.12.2 NMR experiments 
NMR spectra were recorded as follows. 
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2.2.12.3 NMR data processing 
NMR data were processed using Azara (Wayne Boucher, University of Cambridge) with the 
help of Dr. Helen Mott. 
 
2.2.12.4 NMR spectra analysis 
NMR spectra were analysed using CCPN Analysis v2.3 (Vranken et al., 2005). 
Table 2.13 NMR experiments. 
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2.2.12.5 Structure calculations 
Structure calculations were performed using ARIA 2.3.1 (Rieping et al., 2007) interfaced to 
CNS 1.3 (Brünger et al., 1998). The predicted dihedral angles from TALOS and the intensities 
of peaks in 15N-separated NOESY/13C-separated NOESY spectra were used to derive dihedral 
angle and distance restraints, respectively. Chemical shift tolerances were set at 0.04 ppm 
for the indirect dimension (proton 1), 0.02 ppm for the direct dimension (proton 2) and 0.5 
ppm for the heteronuclear dimensions. Structures were calculated iteratively for a total of 8 
iterations. During iteration 8, 100 structures were calculated and of these the 50 with the 
lowest energy were refined in water. The final ensemble of structures consisted of the 35 
lowest energy structures. 
 
2.2.12.6 Chemical shift mapping 
Chemical shift changes were calculated using the following equation 
= + (0.15 )  
where  is the combined shift change and  and   are the chemical shift changes in 
the 1H and 15N dimensions, respectively. Residues which could not be reliably assigned due 
to overlap were excluded from the analysis. 
 
2.2.13 Crystallisation trials 
 
Purified PRK1 HR1abc protein was concentrated to 10 mg/ml. One to one (100 nl + 100 nl) 
and two to one (200 nl + 100 nl) protein to buffer drops were set up in seven different 96-
well sitting drop crystallisation plates: Classics Lite Suite (QIAGEN), JCSG+ (QIAGEN), PACT 
(Molecular Dimensions), Wizard I&II (Molecular Dimensions), Wizard III&IV (Molecular 




Custom crystallisation plates were set up using the DRAGONFLY (TTPLabtech) and are listed 
in the table below. Crystallisation trials were set up as before. 
Plate 1 PEG3350 (10-35 mM), NaF (10-300 μM) 
Plate 2 PEG3350 (10-35 mM), KI (10-300 μM) 
Plate 3 PEG4000 (10-35 mM), (NH4)2SO4 (10-300 μM) 
Plate 4 PEG4000 (10-30 mM), MgSO4 (10-250 μM) 
Plate 5 PEG3350 (10-35 mM), Na2SO4 (10-300 μM) 
 
 
For the RhoA Δ12 F25N Q63L/PRK1 HR1abc co-crystallisation trials, the proteins were mixed 
at a 1:1 ratio with a final concentration of 250 mM for each protein and were incubated on 
ice for 30 min before setting up the commercial crystallisation plates as with PRK1 HR1abc. 
 
2.2.14 Isothermal Titration Calorimetry 
 
Proteins were all buffer exchanged using PD10 columns into the same batch of ITC buffer. 
ITC experiments were carried out on an iTC200 microcalorimeter (MicroCal) (GE Healthcare). 
The cell was filled with 200 μl of buffer or protein and the syringe was filled with 100 μl of 
protein. The concentration of protein placed in the syringe was ten-fold that of the 
concentration of protein in the cell. Protein into protein, as well as buffer into buffer and 
protein into buffer control experiments were recorded. Each experiment was performed at 
25 oC and comprised a total of 19 injections over 50 min; the first injection was of 0.4 μl and 
the remaining 18 injections of 2 μl. Protein into buffer control data were subtracted from 
protein into protein data, which were then fit with Origin using a one-site binding model to 









2.2.15.1 Cross-linking with EDC 
Proteins were buffer exchanged into EDC buffer using a PD10 column. Cross-linking 
reactions were set up at room temperature or at 4 oC according to the table. 10 μl samples 
were taken, 10 μl 2x SDS Loading Buffer was added and 10 μl were analysed by SDS-PAGE. 
SDS-PAGE trials 
Protein [Protein] (mM) [EDC] (mM) Volume (μl) 
Intervals at which samples 
were taken 
PRK1 HR1a 1.5 10, 20, 40 50 30 min, 5 h, overnight (4 oC) 
PRK1 HR1ab 1.5 10, 20, 40 50 30 min, 5 h, overnight (4 oC) 
PRK1 HR1abc 0.7 10, 20, 40 50 30 min, 5 h, overnight (4 oC) 
PRK1 HR1ab + 
PRK1 HR1c 
1.5 (HR1ab) 




2.2.15.2 Cross-linking with DMS/DMP 
Proteins were buffer exchanged into DM buffer using a PD10 column. Cross-linking reactions 
were set up at room temperature or at 4 oC according to the table. 10 μl samples were 
taken, 10 μl 2x SDS Loading Buffer was added and 10 μl were analysed by SDS-PAGE. 
SDS-PAGE trials 
Protein [Protein] (mM) 
[DMS]/[DMP] 
(mM) Volume (μl) 
Intervals at which samples 
were taken 
PRK1 HR1a 1.5 10, 15, 20 50 30 min, 5 h, overnight (4 oC) 
PRK1 HR1ab 1.5 10, 15, 20 50 30 min, 5 h, overnight (4 oC) 
PRK1 HR1abc 0.7 10, 15, 20 50 30 min, 5 h, overnight (4 oC) 
PRK1 HR1ab 
+ PRK1 HR1c 
1.5 (HR1ab) 






Table 2.15 Cross-linking reactions with EDC. 





Two litres of E.coli culture expressing the appropriate protein were spun down, lysed and 
purified as detailed in section 2.2.5. The supernatant was added to 4 ml of 50% glutathione 
agarose bead slurry to saturate the beads with the GST-tagged GTPase. Ten μl of the 
purified, glutathione agarose-immobilised GST-tagged GTPase were also taken to assess 
nucleotide state by HPLC as described in section 2.2.9.2. 
The beads were then washed in TNMD buffer to reduce the NaCl concentration to 150 mM. 
200 μl of 50% bead slurry was aliquoted in 1.5 ml Eppendorf tubes and HR1 effector 
proteins were added to a final concentration of 200 μM. The tubes were then rotated on a 
wheel at 4 oC for 30 min to facilitate mixing and binding. The reactions were then spun at 
1000 x g for 10 min, the supernatant was removed and a gel sample was taken. TNMD 
buffer to equal volume (200 μl) was added to the beads to wash off unbound effector 
protein. The beads were spun at 1000 x g for 10 min and a gel sample of the wash was 
taken. The beads were washed for a total of seven times and were finally resuspended in 
50% slurry (200 μl) with TNMD buffer. A gel sample of the beads (pull-down sample) was 
taken. Ten μl of each sample (a 1 in 2 dilution in 2x SDS Loading Buffer) were then analysed 
by SDS-PAGE. 
 
2.2.17 Scintillation Proximity Assay 
 
Scintillation proximity assays (SPAs) were set up as competition assays. 30 nM GST-ACK or 
200 nM PRK1 HR1a-His6 and equimolar Cdc42 Δ7 Q61L·[3H]GTP or RhoA Δ7 F25N 
Q63L·[3H]GTP, respectively, were added to SPA reaction mix so that GTPase/effector 
complexes were bound to SPA fluoromicrospheres via anti-GST or anti-His antibodies. 
Twelve-fold serial dilutions of competitor protein (PRK3 HR1c or PRK1 HR1abc) were set up 
and 25 μl were added to 175 μl of SPA reaction mix to give the final competitor 
concentrations shown in each experiment. Control experiments with untagged ACK and 
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GST-PRK1 HR1a as competitors were also performed. GST-ACK, PRK1 HR1a-His6, untagged 
ACK and GST-PRK1 HR1a were a kind gift from Dr. Darerca Owen. 
The plates were incubated on a shaking platform for 45 min at 18 oC and then spun at 1000 
x g for 2 min to pellet the beads. Each well was counted for 5 minutes in a MicroBeta Trilux 
scintillation counter (PerkinElmer). Non-linear regression analysis was performed using 
GraFit5 according to the following equation: 
SPA Signal =
[ [( P + ) −  ( P +  + ) − 4 ]]
( − − 4 )
 
 
where Smax is the maximum SPA signal, Kd is the dissociation constant between the tagged 
effector and the GTPase, S0 is the total concentration of labelled GTPase, Ki is the 
equilibrium dissociation constant between the GTPase and the untagged effector, E0 is the 
total concentration of tagged effector protein and P is (E0 + S0 + Kd). 
 
2.2.18 Computational methods 
 
The software and software version used are listed in Table 2.17. 
Software Task 
PyMOL v1.3 Structure analysis and structure images 
Clustal Omega Sequence alignment 
Pepstats Protein pI estimation 
ÄKTA Purifier with Unicorn 5 (GE Healthcare) Protein chromatography 
Jpred (Drozdetskiy et al., 2015) Secondary structure prediction 
Dichroweb server CD data analysis 
SEDNTERP (Laue et al., 1992) AUC parameter estimation 
SEDFIT v14.1 (Schuck, 2000) AUC data analysis 
GUSSI AUC profile overlay 
HYDROPRO Frictional ratio prediction 
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CCPN Analysis v2.4 (Vranken et al., 2005) NMR spectra assignment 
Azara (Wayne Boucher, University of 
Cambridge) NMR data processing 
ChemDraw v17.1 Drawing figures 
ARIA v2.3.1 Structure calculations 
Origin ITC data analysis 
NACCESS (Hubbard & Thornton, 1993) Determination of solvent accessibility 
HADDOCK Protein docking 
Dionex with Chromeleon v6.50 (Thermo 
Fischer) HPLC analysis 
Chromas Lite v2.1.1 Analysis of DNA sequences 
Microsoft Office 10 Drawing figures 






Table 2.17 Software. 
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Chapter 3 Purification of PRK1 and PRK3 HR1 constructs and 




The starting point of this work was to design and clone PRK1-PRK3 HR1 constructs. The 
proteins would be expressed as fusions with an N-terminal GST tag to aid solubility and 
purification. Optimal conditions for expression and solubility were identified in small scale 
expression trials and then the purification of each protein was separately optimised to yield 
protein with high purity for biophysical and structural analysis. 
 
3.2 Protein purification 
 
3.2.1 Construct cloning 
 
Existing but also new constructs were designed by predicting secondary structures in jpred 
(Drozdetskiy et al., 2015) and choosing appropriate construct limits. To express N-terminal 
GST fusions of PRK1 HR1a and PRK1 HR1ab, pGEX6P constructs were used which were 
already available in the lab. 
PRK1 HR1c, PRK2 HR1c, PRK2 HR1bc, PRK2 HR1abc, PRK3 HR1c, PRK3 HR1bc and PRK3 
HR1abc were cloned into pGEXHISP during a Master’s project in this lab (Sophocleous, 
2014), while pGEXHISP constructs of PRK1 HR1b, PRK3 HR1a, PRK3 HR1b and PRK3 HR1ab 
were already available in the lab. To express GST fusions of these HR1 constructs, a stop 




PRK1 HR1bc and PRK1 HR1abc constructs were obtained by sub-cloning into pCR2.1(TOPO) 
vector, followed by BamHI/EcoRI ligation into pGEXHISP and then introducing a stop codon 
in the pGEXHISP vector in the same way as the other HR1 constructs. 
All the GST fusions carry an HRV 3C protease cleavage site between GST and the HR1 
construct to allow removal of the tag after the initial affinity purification step. 
 
3.2.2 Expression trials 
 
To assess the expression and solubility of the cloned fusion proteins, expression trials were 
carried out in BL21 and Rosetta2 strains. Expression at two temperatures was tested; 5 h at 
37 oC or 20 h at 20 oC (both vectors). 
In the expression trials, all but one PRK1 domain tested showed increased solubility at 20 oC 
than at 37 oC (most likely because they can more slowly fold and thus do not go into 
inclusion bodies), and expression was increased in the Rosetta2 strain (Figures 3.1A-D; 3.1F). 
The increased expression in Rosetta2 cells should be of no surprise as PRK1 contains 32 rare 
codons; 14 in HR1a, 1 in the linker between HR1a and HR1b, 3 in HR1b and 14 in HR1c. GST-
PRK1 HR1bc was totally insoluble at both temperatures in both strains (Figure 3.1E). 
The PRK2 HR1 domains tested showed poor solubility at both 37 oC and 20 oC (Figures 3.2A-
C) and significant breakdown. At this stage it was decided that PRK2 domains would not be 
further studied. 
Four out of six PRK3 HR1 domains were soluble at 37 oC and showed improved solubility 
when expressed at 20 oC (Figures 3.3A-C; 3.3F). GST-PRK3 HR1ab was only soluble at 20 oC 
(Figure 3.3D). GST-PRK3 HR1bc was soluble at 20 oC (with some breakdown) but this di-
domain construct was not further studied as a result of the lack of solubility of its PRK1 
homolog (Figure 3.3E). GST breakdown could be observed for most PRK3 constructs. There 






























Figure 3.1 SDS-PAGE Analysis of PRK1 construct expression trials. Solubility of fusion protein was assessed 
by identifying band of approximate molecular weight in soluble or pellet fractions. Un for Uninduced 
sample, In for Induced (Total), S for Induced (Soluble) and P for Induced (Pellet). 20 and 37 denote the 
temperature at which the expression was carried out at. Laemmli gels were 12%. (A) GST-PRK1 HR1a (B) 































Figure 3.2 SDS-PAGE Analysis of PRK2 construct expression trials. Solubility of fusion protein was assessed 
by identifying band of approximate molecular weight in soluble or pellet fractions. Un for Uninduced 
sample, In for Induced (Total), S for Induced (Soluble) and P for Induced (Pellet). 20 and 37 denote the 
temperature at which the expression was carried out at. Laemmli gels were 12%. (A) GST-PRK2 HR1c (B) 




























  Figure 3.3 SDS-PAGE Analysis of PRK3 construct expression trials. Solubility of fusion protein was assessed 
by identifying band of approximate molecular weight in soluble or pellet fractions. Un for Uninduced 
sample, In for Induced (Total), S for Induced (Soluble) and P for Induced (Pellet). 20 and 37 denote the 
temperature at which the expression was carried out at. Laemmli gels were 12%. (A) GST-PRK3 HR1a (B) 






Table 3.1 summarises the expression trial results. 
Construct 
BL21 Rosetta2 
37 oC 20 oC 37 oC 20 oC 
PRK1 HR1a (1-106)     
PRK1 HR1b (122-199)     
PRK1 HR1c (201-297)     
PRK1 HR1ab (1-199)     
PRK1 HR1bc (122-297)     
PRK1 HR1abc (1-297)     
PRK2 HR1c (207-302)     
PRK2 HR1bc (132-302)     
PRK2 HR1abc (1-302)     
PRK3 HR1a (1-80)     
PRK3 HR1b (100-171)     
PRK3 HR1c (169-263)     
PRK3 HR1ab (1-171)     
PRK3 HR1bc (100-263)     







Table 3.1 Summary of expression trials. The boxes shaded in yellow represent the best expression 
conditions carried forward in large scale expression. The number of s represents the amount of soluble 
protein and a  represents complete lack of soluble protein. 
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3.2.3 Purification of GST HR1 fusions using glutathione agarose beads 
 
The best expression conditions for each of the constructs identified from the expression 
trials were used for large scale expression and purification (4-6 L E. coli culture). GST fusions 
of all HR1 domain constructs were firstly purified using glutathione agarose beads. An 
example purification of GST-PRK1 HR1c is shown in Figure 3.4A.  
 
3.2.4 Removal of GST tag by proteolytic cleavage 
 
The N-terminal GST was removed by the addition of HRV 3C protease. Cleaved PRK1 HR1c 
eluted from the beads is shown in Figure 3.4B. ‘High salt’ MTPBS pH 7.3 was used during the 
glutathione agarose purification and post-cleavage washes to reduce non-specific binding of 
contaminants to the protein and protein precipitation. The supernatant and washes post-
cleavage were then pooled and 5 mM EDTA was added to reduce any potential protein 











Figure 3.4 SDS-PAGE analysis of recombinant PRK1 HR1c protein expression and purification. Samples 
were taken at each step and analysed by SDS-PAGE. (A) GST-PRK1 HR1c immobilised on glutathione 
agarose beads. Gel was 12%. SN for supernatant, W1-3 for the 3 washes, Beads for 50% bead slurry and 
Pellet for insoluble fraction. (B) PRK1 HR1c washes post-cleavage. Gel was 18%. SN for supernatant and 




3.2.5 Further purification of PRK1 HR1b, PRK1 HR1c, PRK1 HR1abc and PRK3 HR1c by gel 
filtration 
 
PRK1 HR1b was concentrated and loaded onto a Superdex 75 column. A single peak 
corresponding to PRK1 HR1b was observed (Figure 3.5A). Fractions were analysed by SDS-
PAGE and C11-D2 were pooled and concentrated (Figure 3.5B) and the concentration was 
estimated using absorbance at 280 nm and a Bradford assay. HR1b contains only four 











PRK1 HR1c was also loaded onto a Superdex 75 column. HR1c lacks aromatic residues, so 
absorbance was alternatively monitored at a wavelength of 230 nm (peptide bond). A single 
peak corresponding to PRK1 HR1c was observed (Figure 3.6A). Fractions were analysed by 
SDS-PAGE and C8-C11 were pooled and concentrated (Figure 3.6B) and the concentration 
was estimated using a Bradford assay. 
 
 
Figure 3.5 Further purification of PRK1 HR1b and corresponding SDS-PAGE analysis. (A) Gel filtration 
chromatogram of PRK1 HR1b on an S75 column. Blue line indicates A280. (B) SDS-PAGE analysis of 
chromatogram in (A) on an 18% Laemmli gel. ‘Pre’ for sample loaded on the column. The double arrows 













PRK1 HR1abc was concentrated and the protein was loaded onto a Superdex 200 column. 
Absorbance was monitored at 280 nm. More than two peaks corresponding to HR1abc were 
observed (Figure 3.7A). Fractions were analysed by SDS-PAGE and C2-C12 were pooled 
(Figure 3.7B). Fractions D1-D8, which contained GST contamination, were pooled separately 
and loaded a second time on the Superdex 200 column (Figure 3.7C). Fractions C3-C12 
(Figure 3.7D) were pooled together with fractions C1-C12 from the first run, concentrated, 
and the concentration was estimated using a Bradford assay. 
PRK3 HR1c was also purified by two rounds of gel filtration. The protein was loaded onto a 
Superdex 75 column (Figure 3.8A). PRK3 HR1c also lacks aromatic residues, so absorbance 
was again monitored at a wavelength of 230 nm. One peak corresponding to HR1c was 
observed, with elution volume of 54 ml. This was in contrast to PRK1 HR1c which had an 
elution volume of 64 ml, indicating that PRK3 HR1c may be oligomerising in solution. 
Fractions were analysed by SDS-PAGE and C8-C10 were pooled (Figure 3.8B). Fractions C3-
C7, which contained GST contamination, were pooled separately and loaded onto a second 
time on the Superdex 75 column (Figure 3.8C). Fractions C3-C10 (Figure 3.8D) were pooled 
together with fractions C8-C10 from the first run, concentrated, and the concentration was 
estimated using a Bradford assay. 
 
Figure 3.6 Further purification of PRK1 HR1c and corresponding SDS-PAGE analysis. (A) Gel filtration 
chromatogram of PRK1 HR1b on an S75 column. Blue line indicates A230. (B) SDS-PAGE analysis of 
chromatogram in (A) on an 18% Laemmli gel. ‘Pre’ for sample loaded on the column. The double arrows 





















Figure 3.7 Further purification of PRK1 HR1abc and corresponding SDS-PAGE analysis. (A) Gel filtration 
chromatogram of PRK1 HR1abc on an S200 column. Blue line indicates A280. (B) SDS-PAGE analysis of 
chromatogram in (A) on 12% Laemmli gels. (C) Second round gel filtration chromatogram of PRK1 HR1abc 
on an S200 column. Blue line indicates A280. (D) SDS-PAGE analysis of chromatogram in (C) on a 12% 






























Figure 3.8 Further purification of PRK3 HR1c and corresponding SDS-PAGE analysis. (A) Gel filtration 
chromatogram of PRK3 HR1c on an S75 column. Blue line indicates A230. (B) SDS-PAGE analysis of 
chromatogram in (A) on an 18% Laemmli gel. (C) Second round gel filtration chromatogram of PRK3 HR1c 
on S75 column. Blue line indicates A230. (D) SDS-PAGE analysis of chromatogram in (C) on an 18% Laemmli 






3.2.6 Further purification of PRK1 HR1ab, PRK3 HR1a and PRK3 HR1b on a glutathione 
sepharose column followed by gel filtration 
 
Since PRK1 HR1ab and GST have similar molecular weights and cannot be resolved by SDS-
PAGE, it was difficult to tell whether there was any GST contamination. A single gel filtration 
purification step at this stage may not have been sufficient to separate GST dimers from 
potential HR1ab oligomers. Therefore, PRK1 HR1ab was concentrated and the protein 
loaded onto a glutathione sepharose column. This showed that there was some GST 
contamination that was removed (Figure 3.9A). The flow-through and wash were 
concentrated and loaded onto a Superdex 200 column. Two main peaks were observed 
(Figure 3.9B). Fractions were analysed by SDS-PAGE and C7-D6 were pooled and 
concentrated (Figure 3.9C) and the concentration was estimated by both measuring the 
absorbance as well as by a Bradford assay. 
PRK3 HR1a and PRK3 HR1b were purified in the same way, with the initial glutathione 
sepharose column purifying the proteins from their main impurity, GST (Figures 3.10A and 
3.11A). The flow-through and wash were concentrated in each case and loaded onto a 
Superdex 75 column with absorbance being monitored at 280 nm for PRK3 HR1a and 230 
nm for PRK3 HR1b, which lacks aromatic amino acids (Figures 3.10B and 3.11B). For PRK3 
HR1a, fractions C10-D2 were pooled and concentrated following SDS-PAGE analysis (Figure 
3.10C) and the concentration was estimated by measuring the absorbance at 280 nm and 
with a Bradford assay. For PRK3 HR1b, fractions C11-D3 were pooled and concentrated 































Figure 3.9 Further purification of PRK1 HR1ab and corresponding SDS-PAGE analysis. (A) SDS-PAGE 
analysis of purification on a glutathione sepharose column on a 15% Laemmli gel. (B) Gel filtration 
chromatogram of PRK1 HR1ab on an S200 column. Blue line indicates A280. (C) SDS-PAGE analysis of 
chromatogram in (B) on a 15% Laemmli gel. ‘Pre’ for sample loaded on the column, FT for flow-through, 
Wash for wash with buffer A back to baseline and Elute for the column eluate after buffer B wash. The 



























Figure 3.10 Further purification of PRK3 HR1a and corresponding SDS-PAGE analysis. (A) SDS-PAGE 
analysis of purification on a glutathione sepharose column on an 18% Laemmli gel. (B) Gel filtration 
chromatogram of PRK3 HR1a on an S75 column. Blue line indicates A280. (C) SDS-PAGE analysis of 
chromatogram in (B) on an 18% Laemmli gel. ‘Pre’ for sample loaded on the column, FT stands for flow-
through, Wash for wash with buffer A back to baseline and Elute for the column eluate after buffer B wash. 




























Figure 3.11 Further purification of PRK3 HR1b and corresponding SDS-PAGE analysis. (A) SDS-PAGE 
analysis of purification on a glutathione sepharose column on an 18% Laemmli gel. (B) Gel filtration 
chromatogram of PRK3 HR1b on an S75 column. Blue line indicates A230. (C) SDS-PAGE analysis of 
chromatogram in (B) on an 18% Laemmli gel. ‘Pre’ for sample loaded on the column, FT for flow-through, 
Wash for wash with buffer A back to baseline and Elute for the column eluate after buffer B wash. The 





3.2.7 Further purification of PRK1 HR1a on a glutathione sepharose column followed by 
anion exchange chromatography and gel filtration 
 
It was shown previously that loading the protein on a gel filtration column did not 
adequately purify the protein (Catherine Hutchinson, unpublished), suggesting that PRK1 
HR1a may oligomerise. The protein was concentrated to 5 ml and loaded onto a glutathione 
sepharose column. This allowed purification of HR1a from the bulk of the main impurity, 
GST (Figure 3.12A). This purification step preceded the ion exchange step to increase the 
binding capacity of HR1a to the column (as GST is also known to bind). The flow-through and 
wash were pooled to a total of 33.5 ml. 6.7 ml aliquots were diluted to 50 ml with Buffer A1, 
reducing the [NaCl] to 20 mM. The protein was then loaded onto a ResourceQ column 
(Figure 3.12B) and the fractions analysed by SDS-PAGE (Figure 3.12C). Fractions B10-C4 
were, concentrated, and loaded onto a Superdex 200 column. A single peak spanning 15 
fractions, and corresponding to PRK1 HR1a, was observed (Figure 3.12D). Fractions C10-D3 
and D7-D12 were pooled and concentrated (Figure 3.12E) and the protein concentration 




























Figure 3.12 Further purification of PRK1 HR1a and corresponding SDS-PAGE analysis. (A) SDS-PAGE 
analysis of purification on a glutathione sepharose column on an 18% Laemmli gel. (B) Anion exchange 
chromatogram of PRK1 HR1a on a ResourceQ column. Blue line indicates A280. Green line indicates 
increasing buffer B gradient. (C) SDS-PAGE analysis of chromatogram in (B) on an 18% Laemmli gel. (D) Gel 
filtration chromatogram of PRK1 HR1a on an S200 column. Blue line indicates A280. (E) SDS-PAGE analysis of 
chromatogram in (D) on an 18% Laemmli gel. The double arrows indicate the fractions pooled. ‘Pre’ for 
sample loaded on the column, FT for flow-through, Wash for wash with buffer A back to baseline, Elute for 







3.2.8 Further purification of PRK3 HR1ab and PRK3 HR1abc by cation exchange 
chromatograpy and gel filtration 
 
PRK3 HR1ab has a theoretical isoelectric point of 11.0 and a predicted charge of +9.4 at pH 
7.5. To purify the protein from GST and other higher molecular weight contaminants, ion 
exchange chromatography was employed. The protein was concentrated to 100 ml. 20 ml at 
a time were diluted up to 50 ml with Buffer A containing no NaCl, thereby diluting the [NaCl] 
to 200 mM. Some precipitation was observed at this stage, indicating that the protein is 
stable only in conditions of high ionic strength. The protein was then loaded onto a Heparin 
column (Figure 3.13A) and fractions were analysed by SDS-PAGE (Figure 3.13B). Fractions 
C7-D7 were pooled, concentrated to 2 ml and loaded onto a Superdex 200 column (Figure 
3.13C). A single peak corresponding to PRK3 HR1ab was observed following SDS-PAGE 
analysis of the obtained fractions (Figure 3.13D). Fractions D3-D10 were pooled, 
concentrated and the concentration was estimated using a Bradford assay. 
The purification of PRK3 HR1abc had to undergo extensive optimisation in order to obtain a 
protein sample of high yield and purity (both from contaminants such as GST and also from 
nucleic acids). PRK3 HR1abc is a highly positively charged protein, with a theoretical 
isoelectric point of 10.8 and predicted charge of +12 at pH 7.5. Previous attempts at 
purifying a His-tagged version of this protein showed that it is impossible to sufficiently 
purify the protein solely by gel filtration. In addition, absorbance at 260 nm suggested that 
there was nucleic acid contamination. Ion exchange chromatography was therefore 
employed as a way of removing nucleic acid contamination, which is crucial for identifying 
the accurate molecular weight of different species in analytical ultracentrifugation 
experiments, and also purifying the protein from contaminating species such as GST. The 
conditions for loading onto the ion exchange column were optimised from several large 
scale expressions and were found to be 0.22 mg/ml protein, 200 mM NaCl in 50 ml. This 
achieved the following: (a) 200 mM NaCl was sufficiently low for the protein to stick to the 
heparin ligand, (b) diluting the NaCl led to some protein precipitation, which was minimised 
when the final protein concentration was 0.22 mg/ml or lower (c) the Heparin column was 
not saturated, i.e. maximising usage of the column capacity and minimising the number of 
separate aliquots that needed to be purified on the column. Collectively, this meant that the 
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protein was purified from several, usually around 6, separate method runs. Specifically, 
PRK3 HR1abc washes were concentrated to 120 ml. 20 ml aliquots were diluted to 50 ml 
with Buffer A2, reducing the [NaCl] to 200 mM. The protein was then loaded onto a Heparin 
column (Figure 3.14A). Fractions were analysed by SDS-PAGE and C8-D12 were pooled 
(Figure 3.14B). This was done six times in total, once per 20 ml aliquot. The protein was then 
concentrated to 2 ml and loaded onto a Superdex 200 column (Figure 3.14C). Two peaks 
were observed, indicating that this tri-domain is also oligomerising. Fractions were analysed 
by SDS-PAGE and C7-D5 were pooled and concentrated (Figure 3.14D). The concentration 
was estimated by a Bradford assay. The protein is stable at 4 oC but precipitates as it warms 
up. Therefore care was taken to ensure the protein was under cold conditions during all 
stages of purification. Interestingly, the precipitation appeared to be reversible; placing the 
protein back on ice caused the protein to go back into solution in a few seconds. An 





































  Figure 3.13 Further purification of PRK3 HR1ab and corresponding SDS-PAGE analysis. (A) Cation 
exchange chromatogram of PRK3 HR1ab on a Heparin column. Blue line indicates A280. Green line indicates 
increasing buffer B gradient. (B) SDS-PAGE analysis of chromatogram in (A) on a 15% Laemmli gel. (C) Gel 
filtration chromatogram of PRK3 HR1ab on an S75 column. Blue line indicates A280. (D) SDS-PAGE analysis 
of chromatogram in (C) on a 15% Laemmli gel. The double arrows indicate the fractions pooled. ‘Pre’ for 






























Figure 3.14 Further purification of PRK3 HR1abc and corresponding SDS-PAGE analysis. (A) Cation 
exchange chromatogram of PRK3 HR1ab on a Heparin column. Blue line indicates A280. Green line indicates 
increasing buffer B gradient. (B) SDS-PAGE analysis of chromatogram in (A) on a 12% Laemmli gel. (C) Gel 
filtration chromatogram of PRK3 HR1abc on an S75 column. Blue line indicates A280. (D) SDS-PAGE analysis 
of chromatogram in (C) on a 12% Laemmli gel. The double arrows indicate the fractions pooled. ‘Pre’ for 






3.2.9 Yields of purified proteins 
 
The accurate concentration of each protein was determined and purity to 95% was checked 
by amino acid analysis. A correction factor, which translates a protein concentration 
estimated by absorbance at 280 nm or with a Bradford assay to the true concentration, was 
used in subsequent purifications of each protein. The yields of each of the purified proteins 
are summarised in table 3.2. 
PRK1 HR1c and PRK3 HR1c, which had not been previously purified, were confirmed by 
MALDI Mass Spectrometry to be intact and not breaking down at the end of the purification 
procedure (see Appendix 2). 
 Protein Volume of E. coli culture (L) 





HR1a 4 1 1.7 
HR1b 4 0.675 6.5 
HR1c 4 1 3.02 
HR1ab 4 1.5 1.2 
HR1abc 6 1 0.65 
PRK3 
HR1a 4 1 0.52 
HR1b 4 1 0.45 
HR1c 4 1 0.800 
HR1ab 4 1 0.057 






Table 3.2 Final yields of purified proteins obtained. Amino acid analysis was used to accurately determine 
the protein concentration. 
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To determine whether the purified HR1 proteins are structured, their secondary structures 
were investigated by circular dichroism. The predicted α-helical structure of these domains 
makes them ideal candidates for circular dichroism experiments. In addition, the thermal 
stability of the HR1c domains was studied to allow comparison with the published data on 




Circular dichroism (CD) is an excellent method for obtaining an estimate of the total amount 
of secondary structure present in a population of protein molecules in solution. This 
includes α-helices, β-sheets, polyproline helices and random coils (Greenfield, 2006). CD is 
defined as the differential absorption of left-handed and right-handed circularly polarised 
light. Chiral molecules can absorb left-handed and right-handed circularly polarised light to a 
different extent and this can give rise to a CD signal. 
The oscillating electric field of a beam of polarised light can be described in terms of two 
vectors which rotate circularly, one clockwise to the left (L) and the other counterclockwise 
to the right (R). If these two components are absorbed equally or not absorbed at all by the 
sample, then their recombination will regenerate the radiation polarised in the starting 
plane (Kelly et al., 2005). If L and R have different magnitudes, as a result of being absorbed 
to different extents by the sample, then elliptical polarisation is generated, which gives rise 
to the CD signal. This difference in absorbance, ΔA, between the L and R circularly polarised 

















= −  
CD spectra are often expressed in ellipticity 
=  
where  is the ellipticity in degrees and  and  are the minor and major axes, respectively, 
of the ellipse arising from the L and R components.  
This is directly proportional to ΔA. 
= 32.98  
In the common CD experiment, the ellipticity is recorded during a wavelength scan in the far 
UV region of proteins, e.g. 185 nm to 240 nm. The chromophore in proteins is the peptide 
bond. At a wavelength of 210-220 nm, there is a π  π* energy transition from free 
Figure 3.15 Circular dichroism principles. (A) The CD effect. Left (L) and right (R) circularly polarised 
components combine to generate plane polarised radiation. Left panel: The magnitude of the two 
components is the same. The resulting plane polarised radiation is not elliptically polarised. Right panel: 
The magnitude of the two components is different resulting in elliptically (dashed line) plane polarised 
radiation. Figure adapted from Kelly et al. (2005). (B) Overlaid representative CD spectra of proteins with 







electrons in carbonyl oxygens. In addition, there is a stronger π  π* energy transition 
involving the carbonyl π-electrons. These transitions depend on the peptide φ and ψ torsion 
angles and therefore differ between the different secondary structures that can be present 
in proteins (Kelly et al., 2005) (Figure 3.15B). In particular, in the case of an α-helical protein, 
the π  π* transitions lead to a positive signal at 190 nm and negative signals at 208 nm 
and 222 nm (Kelly et al., 2005; Ranjbar & Gill, 2009). 
Online tools such as DICHROWEB exist, which facilitate the analysis of recorded CD spectra 
and fit the data according to reference datasets of proteins with specific secondary 
structures, e.g. fully α-helical. This analysis can lead to an estimate of the total secondary 
structure in solution, which can be informative of the secondary structure of the molecule, 
assuming a single population of species. This has additional advantages in studies which 
investigate secondary structure changes upon ligand binding. 
The thermal stability of proteins can also be assessed by CD (Ranjbar & Gill, 2009). A 
wavelength at which a particular secondary structure feature of the protein leads to a 
strong signal is chosen, e.g. 222 nm for α-helical proteins. Then the ellipticity at that 
wavelength is monitored with increasing temperature, giving rise to a sigmoidal curve, the 
mid-point of which is the melting temperature, Tm. This use of CD has many applications, for 
example in the screening of the stability of proteins in conditions of different buffer, pH, 




All HR1 constructs purified contain secondary structure (Figures 3.16-3.17) and have a % 
helicity ranging between 44-94%. For most HR1 domains, % helicity is similar to that 
predicted by the jpred server. Any considerable differences between predicted and 
recorded helicities are likely to be due to the high rmsd of the particular data reconstruction 
on DICHROWEB. 
The two HR1c domains were more structured than predicted, possibly because they form 
additional helical structure which is not predicted by jpred. 
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PRK3 HR1ab was 89% helical and more helical than either PRK3 HR1a or PRK3 HR1b were as 
separate domains, suggesting an interaction between these two domains. Surprisingly, PRK3 
HR1ab in this study had more than double the helicity than His-tagged PRK3 HR1ab studied 
in Hutchinson et al. (2013), suggesting that the fusion tag prevents the correct folding of the 
PRK3 di-domain. 
The two HR1abc proteins were slightly more helical than predicted, suggesting that the 
three HR1 domains are not independent from each other and may form additional 
secondary structure. 
The results are summarised in Table 3.3. 
 
Construct jpred Structure 
CD 
Helix 1 Helix 2 Total rmsd 
PRK1 HR1a 0.536 0.652 0.38 0.22 0.60 0.014 
PRK1 HR1b 0.759 0.795 0.49 0.27 0.76 0.010 
PRK1 HR1c 0.701  0.61 0.33 0.94 0.008 
PRK1 HR1ab 0.605  0.27 0.17 0.44 0.019 
PRK1 HR1abc 0.607  0.57 0.24 0.81 0.007 
PRK3 HR1a 0.465  0.29 0.19 0.48 0.019 
PRK3 HR1b 0.772  0.50 0.25 0.75 0.012 
PRK3 HR1c 0.725  0.59 0.29 0.88 0.009 
PRK3 HR1ab 0.661  0.58 0.31 0.89 0.008 




The thermal stability of HR1c domains has never been investigated. To test the thermal 
stability of the HR1c domains from PRK1 and PRK3, thermal melts were recorded by 
monitoring ellipticity at 222 nm with increasing temperature (Figure 3.18). The Tm of PRK1 
HR1c domain is approximately 53 oC, while that of PRK3 HR1c is approximately 58 oC. 
Interestingly, while the Tm of PRK3 HR1c is higher than that of its PRK1 counterpart, 
Table 3.3 Summary of CD data. The determined helicity from the fit data on DICHROWEB was compared to 
the predicted helicity from jpred and also the actual helical content from known structures in the case of 
PRK1 HR1a and PRK1 HR1b. 
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secondary structure loss was observed earlier and was only complete at 80 oC. 
Contrastingly, the melting curve of PRK1 HR1c is much sharper, with most of the secondary 
structure lost by 65 oC. This is indicative of helical elements in PRK3 HR1c which differ 
significantly in their stability, whereas they are more uniform in the case of PRK1 HR1c. It’s 
possible that any differences are due to different oligomeric states of the PRK1 and PRK3 
HR1c domains, as suggested by gel filtration (see section 3.2.5). The broad temperature 
range over which PRK3 HR1c secondary structure was lost is unlikely to be due to a mixed 
population of structured and unstructured molecules because the wavelength scan on this 
protein indicated a very high percentage helicity. Furthermore, when the proteins were 
cooled down back to 20 oC, the secondary structure was almost completely restored in the 
case of both proteins. Both HR1c domains have a predicted C-terminal helix which is shorter 
than the main two helices of the domain and is exclusive to the HR1c domains. As only a 
single Tm was apparent from the data, this would suggest that this additional helix may not 
be independent of the other two helices. 
The Tm values of the HR1c domains are higher than those of PRK1 HR1a, PRK2 HR1b, PRK3 
HR1a and PRK3 HR1b and very similar to those of PRK1 HR1b and PRK2 HR1a (Hutchinson et 
al., 2013). The existence of two broad groups of HR1 domains, those with higher and those 


































Figure 3.16 PRK1 construct circular dichroism wavelength scans. (A)-(E) The scans were recorded with 0.2 
mg/ml protein. The experimental data is overlaid with the reconstructed data from the DICHROWEB 




































Figure 3.17 PRK3 construct circular dichroism wavelength scans. (A)-(E) The scans were recorded with 0.2 
mg/ml protein. The experimental data is overlaid with the reconstructed data from the DICHROWEB 

































Figure 3.18 Thermal stability comparison between PRK1 HR1c and PRK3 HR1c. (A)-(C) The thermal melt 
scans was recorded by recording the ellipticity at 222 nm with increasing temperature with 0.2 mg/ml 
protein. Both the melt and the cooling down (refold) are shown. (A) PRK1 HR1c melt and refold (B) PRK3 











Interacting proteins often exist in reversible equilibria between free and bound states. Some 
proteins can reversibly self-associate and this can be summarised with a system in 
equilibrium: 
+  ⇌   
The association rate of the reaction can be described as 
= [ ] [ ]  
= [ ]  
where  is the association rate constant and [ ]  is the concentration of monomeric 
molecule A. 
Similarly, we can write an expression for the dissociation rate 
= [ ]  
where  is the dissociation rate constant and [ ]  is the concentration of the 
complex. 
At equilibrium, the association and dissociation rates are equal such that 
[ ] = [ ]  
The equilibrium constant, Keq, which describes a self-associating system in equilibrium, can 



















The total protein concentration can also be defined as 
[ ] = [ ] + 2[ ]  
Very often systems exist in reversible equilibria which involve more than two species. These 
are called linked equilibria (reviewed in Pollard, 2010) and the linked triangle below 






It is important to note that each of these reactions can be described by a separate 
dissociation constant, and in turn different association and dissociation rates for the 
forward and reverse reactions, respectively. The complexity of characterising such a system 
becomes exponentially difficult with an increasing number of different species in solution. 
However, the first step when characterising the oligomeric state of a macromolecule is to 
determine the number of species in solution and their identity. This should ideally be done 
at a range of concentrations, as with increasing concentration the proportion of higher 
molecular weight species should increase. 
In this work, the oligomeric state of the HR1 domains was investigated by analytical 
ultracentrifugation (AUC). In contrast to analytical gel filtration and native SDS-PAGE, AUC 
can accurately determine the molecular weight of the species in solution and also provide 
information on their shape (Balbo & Schuck, 2005). In the 1990s analytical 








to be the “gold standard” in analysing self-association. It is a first principles technique that 
studies molecules in solution and therefore it has an advantage over other techniques (e.g. 
bio-layer interferometry) in that molecules are not tethered on surfaces. AUC can give an 
estimate of the amount of each species present in solution and its molecular weight. It is a 
powerful method of studying heterogeneous protein interactions and it is also extremely 
sensitive to sample purity which makes it very useful in industry. 
In AUC, a sample and reference are loaded in two separate sectors of a cell (Figure 3.19A). 
The cell is then loaded in a rotor, which is spun at high speeds and the sedimentation 
process which occurs is monitored by an optics component that is present in the 
ultracentrifuge (Figure 3.19B). Centrifugation causes sedimenting species to yield sigmoidal 
concentration profiles whose inflexion points are referred to as sedimenting “boundaries” 
(Figure 3.19C). For solutions containing two or more species of adequately different size, an 
equal number of boundaries may be observed. 
A sedimenting particle (in this case a protein with its solvation shell), of mass m, experiences 
three forces (Figure 3.19D) (Ralston, 1993). Firstly, it experiences the gravitational force, , 
which is equal to the mass times the centrifugal acceleration, ω2r: 
= =  
where m is the mass of the particle in grams, ω is the angular velocity in radians per second, 
r is the distance of the particle from the rotation axis, M is the solute molar weight in g/mol 
and NA is Avogadro’s number. 
Secondly, it experiences a buoyant force, . According to Archimedes’ principle, 
= −  
where m0 is the mass of the displaced solvent. 
From Archimedes’ principle,  
= ̅ = ̅  
































Figure 3.19 Analytical ultracentrifugation setup and principles. (A) Schematic of an AUC cell. The 
reference and sample sectors are equally filled with matching buffer and protein, respectively. (B) A xenon 
flash lamp creates a beam of light which passes through the sectors of an AUC cell placed in a revolving 
rotor and terminates at the detector. (C) Sedimentation gives rise to a sigmoidal boundary which can be 
analysed to derive the sedimentation coefficient, S, and the diffusion coefficient, D. Figure adapted from 
Ralston (1993). (D) Forces acting upon a sedimenting particle. These are the gravitational force, Fs, the 






Substituting (3.14) in (3.13) gives 
= − ̅  
Thirdly, the sedimenting particle experiences the frictional force, , which is equal to the 
frictional coefficient, f, times the sedimenting velocity of the particle, . 
= −  
Shortly after the beginning of an experiment the three forces come into equilibrium, such 
that 
+ + = 0 
Substituting (3.12), (3.15) and (3.16) in (3.17) gives 
− ̅ − = 0 
Collecting the common terms results in 
(1 − ̅ )− = 0 
Rearranging gives 
(1− ̅ )
= =  
= =  
where s is the sedimentation coefficient and is equal to the velocity divided by the 
acceleration (which is the centrifugal field strength, ω2r).  
The sedimentation coefficient can be directly related to a sedimenting boundary 
=  =  











Furthermore, it can be deduced by integration of (3.22) that 
=  
where rm is the radial position of the meniscus in the cell. 
The sedimentation coefficient depends on the solvent density, viscosity and also on the 
partial specific volume of the solute. It is often useful, for comparative purposes, to convert 
the s-value from a particular experiment to the corresponding s-value of the species in 
standard conditions, where the solvent is water and the temperature is 20 oC (Lebowitz et 
al., 2002). The sedimentation coefficient in these standard conditions, s20,w, can be 
calculated as follows 
, =
(1− ̅ ) ,




where η stands for the solvent viscosity, w stands for water, b for the protein buffer and 4 
for 4 oC. 
The second measurable quantity from the data is the diffusion coefficient, D. This can be 
measured from the spreading of a sedimenting boundary. Einstein’s rule relates D to the 
frictional coefficient, f. The two quantities are inversely proportional. 
=  
where R is the gas constant and T is the absolute temperature in Kelvin. 
Rearranging this gives an expression for the frictional coefficient 
= =  
where k is the Boltzmann constant, equal to 1.38 x 10-23 J K-1. 
 








(1 − ̅ )
=  
(1 − ̅ )
 
Dividing both sides by D gives 
=  
(1 − ̅ )
 
which is known as the Svedberg equation that describes a system made up of two 
components (solute and solvent). This equation relates the sedimentation coefficient, the 
diffusion coefficient and the buoyant mass of the particle, (1− ̅ ), and is the basis of the 
analysis of sedimentation profiles. 
Sedimentation is also dependent on sample viscosity. In particular, the Stokes equation 
relates the frictional coefficient, f, to the viscosity, η, of the sample and the hydrodynamic 
radius of the solute (also known as Stokes radius, R0), which is related to the asymmetry and 
solvation of the molecule.  
= 6  




When data are analysed, the fitted frictional coefficient f is divided by the frictional 
coefficient of a hydrodynamically equivalent sphere, f0, which yields the frictional ratio, . 
This is a measure of the shape of the molecule. A more elongated molecule, with a higher 
hydrodynamic radius, will therefore also result in a higher frictional coefficient and, in turn, 
in a higher frictional ratio. Globular proteins tend to have frictional ratios 1-1.2 and more 
elongated proteins tend to have frictional ratios higher than 1.2. 
Lamm was the first to describe the sedimentation of a boundary with a mathematical term. 
The Lamm equation (Lamm, 1929) describes the evolution of the concentration distribution, 











where c is the concentration,  is the diffusion coefficient,  is the sedimentation 
coefficient,  is the radius from the centre of rotation,  is the rotor angular velocity and  is 
time. 
Solving this equation can determine s, D and M according to the Svedberg equation. 
Programs such as SEDFIT provide numerical solutions to the Lamm equation and thus the 
rapid modelling of non-interacting species based on the recorded SV data. This method can 
account for sample heterogeneity and yields a differential sedimentation coefficient 
distribution, c(s) 
( , ) ≅ ( ) ( , , , )  
where ( , ) is the acquired experimental data, ( ) is the continuous distribution of -
values (and is proportional to protein concentration) and ( , , , ) is a Lamm Equation 
solution which is dependent on ( ). 
In the ( ) model, the data are fit by assuming a single frictional ratio represents all 
different species in solution. While in certain cases this may have no significant impact on 
data interpretation, e.g. in a mixture of globular proteins with frictional ratios ranging from 
1.2-1.4, this could be problematic if macromolecules with significantly different frictional 
ratios are present in solution. From equation (3.20), if the frictional ratio is, for example, 
underestimated, then the molecular weight corresponding to a measured -value will be 
underestimated too. It is possible, if further information is available on the species present, 
to fit the data using a ,  model, where both the s-value and the frictional ratio are 
varied. This method can be used to provide a better understanding of the heterogeneity of a 
solution and can be aided by prior knowledge of species present and their possible frictional 
ratios. The ( , ) distribution may also be used to examine protein conformational 
changes, such as the apoE3 protein having a more extended conformation in a submicellar 
environment (Chou et al., 2011). However, it is subject to problems, primarily the frequent 
lack of prior knowledge on the shape of the various species. Integration of the c(s) 




For non-interacting species or for species in slow chemical exchange, the true -values of 
each of the sedimenting species are measured. The ( ) model however does not account 
for species which are reversibly interacting on the time-scale of the experiment, i.e. in 
intermediate-to-fast chemical exchange. For fast exchanging equilibria, e.g. monomer-dimer 
equilibrium, a single sedimenting boundary may be observed. This gives rise to a weighted-
average -value, which describes the entirety of the interacting population and whose -
value lies in between the true -values of monomer and dimer. The value of this weighted 
average -value changes with concentration, e.g. at a higher concentration more dimer 
would be expected, so the observed peak in the ( ) distribution would shift to a greater -
value, corresponding to a higher proportion of dimer. If the exchange is intermediate, 
distinct peaks can be observed for each species present, but their -values may also shift 
with changing concentration. 
A lower temperature slows down the chemical exchange between monomer and other 
oligomeric species and the reaction becomes kinetically limiting, allowing two separate 
sedimenting boundaries to form due to lack of local equilibria. Therefore, separate species, 
can be observed in the ( ) distribution. The species may also have weighted-average -
values which vary with concentration. High concentrations, as well as low diffusion 
coefficients, e.g. if proteins are elongated, can give rise to sharp sedimenting boundaries 
(Schachman, 1959 & Cann et al., 1970). This can allow individual peaks for each species to 
be observed despite the exchange occurring on the timescale of the experiment (Mavaddat 
et al., 2000). 
 
3.4.2 Sedimentation velocity vs. sedimentation equilibrium 
 
The two AUC methods provide different yet complementary information on a solution of 
sedimenting macromolecules (Cole et al., 2008). SV is a hydrodynamic method, providing 
information on the number of species present, their molecular weight, their shape and also 
kinetic information on interactions between them. SE is a thermodynamic method which 
can provide accurate information on the number of species present, their molecular weight 
142 
 
independent of their shape, their stoichiometry and also information on solution non-
ideality. 
While it may be presumed that reversible interactions which occur on the timescale of the 
sedimentation cannot be studied by SV, this method may be the only possibility if the 
sample is unstable or fails to reach equilibrium in a SE experiment (Cole et al., 2008). 
Furthermore, SE lacks the excellent resolution of SV and requires a stricter sample 
homogeneity and purity. A greater number of species also makes it progressively difficult to 
fit SE concentration gradients. Finally, SE experiments last much longer than SV experiments 
and are thus disfavoured if the protein is unstable. 
 
3.4.3 Absorbance vs. interference optics 
 
The choice of detecting system largely depends on the species under study (reviewed in 
Balbo & Schuck, 2005). Absorbance optics has the advantage of being selective to proteins 
(in the presence of non-absorbing components) and it is also not as sensitive to buffer 
mismatch between the reference and sample cells. In addition, lower protein 
concentrations are required than when using interference optics. However, common 
problems arise if a particular buffer component absorbs very strongly or if the protein under 
study has no aromatic residues and therefore an extinction coefficient of zero at 280 nm. An 
additional problem is that a very high concentration can lead to deviations from the linearity 
between sample concentration and absorbance. 
 
In contrast, interference optics exhibit unlimited linearity and can be used with proteins 
which lack aromatic amino acids, such as some of the HR1 domains. Strongly absorbing 
buffer components are also not important. Common problems include the need to use 
higher protein concentrations and also the need for very good buffer and meniscus 
matching to prevent noise in the data from the protein-buffer data subtraction. The 
recording time for each scan is however much faster than when absorbance optics are used. 
143 
 
3.4.4 Experimental conditions used 
 
In this study, a rotor speed of 40000 rpm (An60Ti rotor) was chosen as the appropriate SV 
speed for proteins with size of 10-30 kDa which may form oligomers of much larger size. At 
higher speeds, e.g. 50000 or 60000 rpm, which are routinely used, there is the risk that high 
molecular weight species sediment very quickly and are poorly resolved when the data are 
fit. The temperature at which the experiments were conducted was chosen to be 4 oC, in an 
attempt to slow down the exchange between the various species in solution, allowing the 
accurate determination of the various oligomeric species present. In addition, two of the 
proteins are only stable at 4 oC. The experiments performed, the species observed, their 
corresponding s-values and molecular weights, and the fitted frictional ratios observed are 
outlined in table A3.1 (see Appendix 3). 
The program SEDNTERP was used to calculate the buffer density, buffer viscosity and 







3.4.5 PRK1 HR1a 
 
For PRK1 HR1a, a sedimentation velocity experiment was performed at three concentrations 
(doubling dilution); 100 μM, 200 μM and 400 μM (Figure 3.20). The data were fit with a 
continuous c(s) distribution, and two species were observed. At 100 μM, 59.6% monomer 
(14.9 kDa) and 40.4% dimer (34.6 kDa) were observed, with respective s-values of 0.974 and 
1.64. At 200 μM, 41.4% monomer (15.6 kDa) and 58.6% dimer (34.4 kDa) were observed, 
with s-values 1.04 and 1.77. At 400 μM, 26.5% monomer (19.4 kDa) and 73.5% dimer (37.5 
kDa) were observed, with s-values 1.15 and 1.79. These results indicate that dimerisation is 
concentration-dependent and that the Kd of dimerisation is approximately 150 μM. The 
masses had to be scaled according to monomer-dimer, i.e. assume the smaller species is the 
monomer and identify the larger species as the dimer based on the 1:2 ratio of the MW 
estimated when fitting the data. 
The fitted frictional ratio, , was overestimated (leading to overestimated calculation of 
MW) and it is predicted, using the program HYDROPRO (Ortega et al., 2011), that it should 
be less than the average value of 1.3 found here. 
The s-value of the monomer is very similar to the s-value of the HR1b monomer (see section 
3.4.6), and the mass ratio of the two species is very close to 2, so it seems reasonable that 
the two species are monomer and dimer. There is also monomer-dimer exchange which is 
indicated by the shifting s-values of the monomer peak, suggesting that dimerisation is 

























Figure 3.20 PRK1 HR1a sedimentation velocity experiments. (A)-(C) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK1 HR1a at (A) 100 μM (B) 200 μM (C) 400 μM 





3.4.6 PRK1 HR1b 
 
PRK1 HR1b sedimentation velocity experiments were performed at three concentrations of 
a doubling dilution, 200 μM, 400 μM and 800 μM (Figure 3.21). The data were fit with a 
continuous c(s) distribution, and a major species was observed at an average s-value of 0.73. 
The fitted frictional ratio is 1.42, which agrees with the known structure of HR1b i.e. that of 
an elongated coiled coil. The molecular weight from the fitted data is 10.3 kDa, which is very 
close to the actual molecular weight of 9.1 kDa. HR1b is monomeric as expected, agreeing 
with the NMR data recorded in our lab on this protein. A species at an s-value of 2 was also 
observed but this reflected only 3% of the population of molecules. This is not an oligomer 































Figure 3.21 PRK1 HR1b sedimentation velocity experiments. (A)-(C) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK1 HR1b at (A) 200 μM (B) 400 μM (C) 800 μM 






3.4.7 PRK1 HR1c 
 
A sedimentation velocity experiment was performed for PRK1 HR1c at two concentrations, 
400 μM and 800 μM (Figure 3.22). The data were fit with a continuous c(s) distribution, and 
a single species, the monomer (13.2 kDa) was observed, with an average s-value of 0.77, 
which is very similar to that of PRK1 HR1b. No higher order oligomers were observed at the 
concentrations chosen. The fitted frictional ratio, an average of 1.59 from the two 
experiments, indicates an elongated protein, which is consistent with HR1c being expected 
to be structured as an elongated coiled coil. However this frictional ratio also suggests that 
HR1c is slightly more elongated than HR1a and HR1b. This is unlikely to be due to 
differences in rigidity, as HR1b and HR1c have similar melting temperatures, but may be due 











































Figure 3.22 PRK1 HR1c sedimentation velocity experiments. (A)-(B) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK1 HR1c at (A) 400 μM (B) 800 μM (C) Overlay 





3.4.8 PRK1 HR1ab 
 
For PRK1 HR1ab, a sedimentation velocity experiment was performed at three 
concentrations (doubling dilution); 100 μM, 200 μM and 400 μM (Figure 3.23). The data 
were fit with a continuous c(s) distribution, and two species were observed. At 100 μM, 
56.6% monomer (18.7 kDa) and 43.4% dimer (44.7 kDa) were observed. At 200 μM, 39.1% 
monomer (22.5 kDa) and 60.9% dimer (51.0 kDa) were observed. At 400 μM, 22.5% 
monomer (28.5 kDa) and 77.5% dimer (61.9 kDa) were observed. At this highest 
concentration the frictional ratio is slightly overestimated as a result of solution non-
ideality, which in turn leads to the calculated molecular weights being overestimated too. 
Collectively, these results indicate that dimerisation is concentration-dependent and that 
the Kd of dimerisation is approximately 150 μM. Monomer-dimer exchange is indicated by 
the shifting s-values of the dimer peak. However, the s-value doesn’t shift as much as in 
HR1a, suggesting that the monomer-dimer exchange happens on a slower time-scale. Both 
the Kd of dimerisation, as well as the monomer-dimer exchange, are consistent with the 
PRK1 HR1a data, suggesting that HR1a may have a role as an oligomerisation domain in 
PRK1. No higher order oligomers were observed at the concentrations chosen, suggesting 
that the oligomerisation stops at dimer, as in PRK1 HR1a. Additionally, the frictional ratio is 


























Figure 3.23 PRK1 HR1ab sedimentation velocity experiments. (A)-(C) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK1 HR1ab at (A) 100 μM (B) 200 μM (C) 400 μM 






3.4.9 PRK1 HR1abc 
 
To study the PRK1 HR1abc tri-domain, sedimentation velocity experiments were set up at a 
range of concentrations (Figure 3.24). The data were fit with a c(s) distribution, and three 
species were observed. At 100 μM, these species have s-values of 1.36, 2.02 and 2.74. These 
were best fit to a monomer-dimer-trimer system, which masses of 30.6 kDa, 55.5 kDa and 
87.6 kDa, respectively. The abundances were 47.8% monomer, 23% dimer and 29% trimer. 
The molecular weight of PRK1 HR1abc is 33.1 kDa, so this indicates that the fitted global 
frictional ratio, 1.57, matches the true frictional ratio of each of the species, which do not 
become more globular upon oligomerisation. The dimer, and to a lesser extent the trimer, 
have slightly lower molecular weight than expected as a result of boundary broadening 
caused by dynamic exchange between the species. At 400 μM, there was 9.1% monomer 
(31.0 kDa), 18.2% dimer (45.8 kDa) and 72.7% trimer (83.6 kDa). The respective s-values 
were 1.30, 1.69 and 2.53. At 450 μM, there was 10.8% monomer (38.7 kDa), 15.5% dimer 
(59.9 kDa) and 73.7% trimer (102 kDa). The respective s-values were 1.30, 1.77 and 2.51. At 
500 μM, there was 10.7% monomer (43.2 kDa), 10.8% dimer (60.9 kDa) and 78.5% trimer 
(104 kDa). The respective s-values were 1.38, 1.75 and 2.52. The shifting s-values of all 3 
species from low to high concentrations are indicative of dynamic exchange between 
monomer-dimer-trimer. The increase in the trimer population at a higher concentration 
indicates that oligomerisation is concentration-dependent and the species exist with linked 
































































Figure 3.24 PRK1 HR1abc sedimentation velocity experiments. (A)-(D) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK1 HR1a at (A) 100 μM (B) 400 μM (C) 450 μM 




3.4.10 PRK3 HR1a 
 
Sedimentation velocity experiments were set up at three different concentrations (Figure 
3.25). The data were fit with a c(s) distribution and two species were observed, which best 
fit to a monomer-dimer model. At 100 μM, 89.9% monomer (12.0 kDa) and 10.1% dimer 
(31.8 kDa) were observed, with s-values 0.782 and 1.49. At 200 μM, 78.1% monomer (11.7 
kDa) and 21.9% dimer (24.0 kDa) were observed, with s-values 0.713 and 1.15, while at 400 
μM, 71.9% monomer (11.3 kDa) and 28.1% dimer (22.3 kDa) were observed, with s-values 
0.729 and 1.15. No higher molecular weight species were detected. The Kd of dimerisation is 
approximated to 1 mM, which is more than 6 times higher than the Kd of dimerisation of 
PRK1 HR1a. The fitted frictional ratio indicates an elongated protein, as predicted, and is 
also larger than the frictional ratio of PRK1 HR1a, possibly due to PRK1 HR1a being slightly 
more globular due to the presence of its N-terminal helix, which is absent from PRK3 HR1a. 



























Figure 3.25 PRK3 HR1a sedimentation velocity experiments. (A)-(C) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK3 HR1a at (A) 100 μM (B) 200 μM (C) 400 μM 






3.4.11 PRK3 HR1b 
 
PRK3 HR1b oligomerisation was also investigated with a sedimentation velocity experiment 
(Figure 3.26). The data were fit with a c(s) distribution and two species were observed, 
which best fit to a monomer-dimer system. At 200 μM, 90.3% monomer (11.8 kDa) and 
9.7% dimer (25.2 kDa) were observed, with corresponding s-values of 0.716 and 1.19. At 400 
μM, 85.1% monomer (12.7 kDa) and 14.9% (28.8 kDa) dimer were observed, with s-values of 
0.727 and 1.26, respectively. No further oligomerisation was detected. The Kd of 
dimerisation is approximated to 2 mM, which is the highest dimerisation Kd of any of the 

































Figure 3.26 PRK3 HR1b sedimentation velocity experiments. (A)-(B) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK3 HR1b at (A) 200 μM (B) 400 μM (C) Overlay 





3.4.12 PRK3 HR1c 
 
The self-association of PRK3 HR1c was analysed by sedimentation velocity experiments 
conducted at a range of concentrations with a doubling dilution (Figure 3.27). The data were 
fit with a c(s) distribution, and three species were observed, which were best fit to a 
monomer-dimer-tetramer model. At 100 μM, there was 49.1% monomer (12.7 kDa), 44.7% 
dimer (20.5 kDa) and 6.2% tetramer (48.6 kDa). The respective s-values were 0.666, 0.949 
and 1.68. At 200 μM, there was 36.4% monomer (10.9 kDa), 56.8% dimer (23.2 kDa) and 
6.8% tetramer (46.9 kDa). The respective s-values were 0.606, 1.02 and 1.63. At 400 μM, 
there was 34.7% monomer (14.2 kDa), 49.9% dimer (25.9 kDa) and 15.4% tetramer (41.4 
kDa). The respective s-values were 0.731, 1.10 and 1.51. Therefore the data suggests that 
PRK3 HR1c exists in a linked equilibrium of monomer-dimer-tetramer. This is in contrast to 
PRK1 HR1c which is monomeric. The shifting s-values of all 3 species are indicative of 
dynamic exchange between monomer-dimer-tetramer. The Kd between monomer and 
dimer is estimated to be ~150 μM, which is very similar to the dimerisation Kd of PRK1 HR1a 
and PRK1 HR1ab. The increase in the tetramer population at a higher concentration also 
indicates that oligomerisation is concentration-dependent. At the concentrations chosen, no 
higher order oligomers were observed. 
The frictional ratio is the highest than any of the single HR1 domains studied here and 
slightly higher than the frictional ratio of PRK1 HR1c. This could account for one HR1c being 
monomeric and the other being oligomeric, however PRK1 HR1a, which has the lowest 
frictional ratio, dimerises with similar affinity. Therefore the frictional ratio cannot be used 


























Figure 3.27 PRK3 HR1c sedimentation velocity experiments. (A)-(C) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK3 HR1c at (A) 100 μM (B) 200 μM (C) 400 μM 







3.4.13 PRK3 HR1ab 
 
A sedimentation velocity experiment was performed with the PRK3 HR1ab di-domain 
(Figure 3.28). The data were fit with a c(s) distribution and two species were observed, 
which best represent a monomer-dimer system. At 50 μM PRK3 HR1ab, 91.4% monomer 
and 8.6% dimer were observed, with s-values 1.08 and 1.55. No further oligomers were 
observed. The Kd of dimerisation is estimated to be approximately 500 μM, indicating a 
twice as strong dimerisation as the single PRK3 HR1a domain and a four times as strong 
dimerisation as in the case of PRK3 HR1b, suggesting that in the di-domain the dimerisation 
may involve both of these single domain oligomerisation interfaces. However, in 

























Figure 3.28 PRK3 HR1ab sedimentation velocity experiment. Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profile of PRK3 HR1ab at 50 μM. 
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3.4.14 PRK3 HR1abc 
 
Sedimentation velocity experiments were set up at a range of PRK3 HR1abc concentrations 
and the sedimentation was monitored with interference (Figure 3.29). The data were fit 
with a c(s) distribution, and four species were observed. At 50 μM, these species have s-
values of 1.42, 2.10, 2.78 and 4.04. These were best fit to a monomer-dimer-trimer-larger 
oligomer system, with masses of 20.8 kDa, 37.3 kDa, 58.1 kDa and 98.7 kDa, respectively. 
The molecular weight of PRK3 HR1abc is 33 kDa, so this indicates that the fitted frictional 
ratio, 1.07, is an underestimate assuming that the smallest species at s-value 1.42 is the 
monomer. In practice, this is a logical conclusion as a frictional ratio of 1.07 would indicate 
species which are almost a perfect sphere. The fitted frictional ratio,  , was 
underestimated due to (a) the dominance of the buffer peak at S=0 (a result of slight buffer 
mismatch) and also (b) monomer, dimer, etc. exchange, which leads to a broadening of the 
boundary leading to an overestimate of the diffusion rate. Therefore the masses had to be 
scaled according to monomer, dimer, trimer and larger oligomer. The mass ratios of the 
three smallest species are very close to 1-2-3, so this seems reasonable. The identity of the 
larger oligomer is impossible to predict from this data (could be pentamer or hexamer). The 
monomer-dimer exchange is also indicated by the shifting s-values of the different species 
determined at higher concentrations. At 50 μM there was 13.5% monomer (20.8 kDa), 
22.4% dimer (37.3 kDa), 55.8% trimer (58.1 kDa) and 8.3% larger oligomer (98.7 kDa). The 
respective s-values were 1.42, 2.10, 2.78 and 4.04. At 100 μM, there was 12.9% monomer 
(24.9 kDa), 29.1% dimer (48.8 kDa), 49.5% trimer (66.2 kDa) and 18.5% larger oligomer (113 
kDa). The respective s-values were 1.51, 2.34, 2.89 and 4.13. At 200 μM, there was 5.1% 
monomer (21.1 kDa), 14.1% dimer (38.8 kDa), 54.5% trimer (60.4 kDa) and 26.3% larger 
oligomer (111 kDa), with respective s-values were 1.47, 2.23, 3.01 and 4.51. The shifting s-
values of all four species are indicative of dynamic exchange between monomer-dimer-
trimer-larger oligomer. The increase in the trimer and larger oligomer populations at higher 
concentrations indicates that oligomerisation is concentration-dependent and that the 
species exist under linked equilibria between them. At the concentrations chosen, no higher 






























Figure 3.29 PRK3 HR1abc sedimentation velocity experiments. (A)-(C) Top panel represents the measured 
interference fringe distribution (blue to red from start to finish) and the corresponding fringe pattern. The 
middle panel represents the residuals of the fit, indicating how closely the experimental data match the 
fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality in 
solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-value 
(S)). Peaks represent protein species. % abundance was calculated by integrating the area under each 
peak. The fit rmsd is indicated. Sedimentation profiles of PRK3 HR1abc at (A) 50 μM (B) 100 μM (C) 200 μM 






3.5 Discussion and conclusions 
 
The purification of PRK1 and PRK3 HR1 constructs was presented in this chapter. Gel 
filtration results led to the analysis of the self-association of these proteins by SV-AUC. PRK1 
HR1a and PRK3 HR1c appear to be dimerisation domains for their respective PRKs. While in 
PRK1 the other two HR1 domains, HR1b and HR1c are monomeric and do not self-associate, 
PRK3 HR1a and PRK3 HR1b are weakly oligomerising, in addition to the HR1c domain. In 
addition to the inter-molecular interactions thought to be driven by these oligomerising HR1 
domains, intra-molecular interactions in the context of the HR1abc tri-domains are also 
indicated by the more complex oligomerisation patterns. The oligomeric species of PRK1 
and PRK3 HR1abc tri-domains detected in solution also suggest possible differential roles 
fulfilled by the different oligomeric states of the PRK N-terminal regulatory region. These 
roles may vary between PRK1 and PRK3, both by means of different oligomeric species 
formed but also possible structural differences between them. Nonetheless, this is the first 
time that HR1 domains are shown to be able to self-associate. In contrast, other HR1 
domains, e.g. the HR1 domain from TOCA1, is monomeric (Watson, 2017; unpublished 
data). 
All HR1 constructs purified and used in subsequent experiments are shown to be structured. 
This includes the two HR1c and two HR1abc domains from PRK1 and PRK3, which have 
never been purified from any construct previously in the lab. The thermal stability of the 
two HR1c domains was also tested, and while the Tm was similar for both proteins, the 
shape of the melting curve denotes structural differences between them. 
 
3.5.1 Conclusions about PRK1 oligomerisation 
 
As shown above, HR1b and HR1c are monomeric, while HR1a exists in an equilibrium of 
monomer-dimer. HR1ab also exists in a monomer-dimer equilibrium, with the Kd of 
dimerisation being similar to the HR1a dimerisation Kd, although the exchange between 
them may be slower, suggesting a possible interaction of HR1a with HR1b which is 
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independent of the HR1a-HR1a interaction. Therefore HR1a appears to act as an 
oligomerisation domain in PRK1. Unexpectedly, the HR1abc experiments suggest that the 
tri-domain exists in linked equilibria between monomer, dimer and trimer, which also 
appear to be dynamically exchanging between the different oligomeric states. This suggests 
both intra-molecular and inter-molecular interactions in the context of the tri-domain, 
mediated by HR1c, e.g. between HR1a and HR1c, or HR1b and HR1c and inter-molecular 
interactions, such as the HR1a-mediated dimerisation. The precise oligomerisation steps 
however, e.g. if monomer becomes dimer and then trimer or if monomer can form trimer 
directly, cannot be deduced from this data but are investigated further in chapter 5. 
 
3.5.2 Conclusions about PRK3 oligomerisation 
 
As shown above, HR1a, HR1b and HR1ab are all dimerising with very weak affinities, while 
HR1c exists in a dynamic equilibrium of monomer-dimer-tetramer and oligomerises more 
strongly. Therefore HR1c appears to act as the key oligomerisation domain in PRK3, while 
the other two HR1 domains may be important in stabilising the dimerisation in the full 
length protein. Furthermore, the HR1abc tri-domain exists in linked equilibria between 
monomer, dimer, trimer and a larger oligomer, which also appear to be dynamically 
exchanging between the different oligomeric states. This suggests both intra- and inter-
molecular interactions in the context of the tri-domain, e.g. between HR1c and either HR1a 
or HR1b or both, and inter-molecular interactions, such as the HR1c-mediated dimerisation. 
 
3.5.3 PRK1 and PRK3 oligomerisation comparison 
 
4 species were observed in the case of PRK3 HR1abc while only 3 species were observed for 
PRK1 HR1abc. The largest oligomeric species is bigger than trimer, so it is exclusive to PRK3 
HR1abc. Furthermore, the oligomerisation of PRK3 HR1abc involves higher affinity 
interactions, as indicated by the largest species already being the major species at low 
concentrations. While the PRK1 and PRK3 HR1abc tri-domains share oligomerisation 
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propensity, the particular number and nature of oligomeric species formed, the shape of 
these oligomers (as indicated by the fitted frictional ratios), as well as the strength of the 
interactions driving them (higher proportion of oligomeric species for PRK3 HR1abc when at 
the same concentration as PRK1 HR1abc), appear to be different. This may partly have to do 
with HR1a mediating the oligomerisation in PRK1 and HR1c mediating the oligomerisation in 
PRK3, although interestingly the dimerisation Kd of both PRK1 HR1a and PRK3 HR1c (the 
drivers of oligomerisation in their respective PRK) is similar. 
The weak affinities recorded here may suggest that these interactions are not 
physiologically relevant, as these proteins will never be at such high concentrations in the 
cell to drive oligomerisation. However proteins often tend to be localised to a particular cell 
compartment, so their effective concentration is much higher. The PRKs do localise to the 
plasma membrane via their C2-like domain. It is therefore possible that recruitment to the 
membrane stimulates oligomerisation. 
Furthermore, HR1a-mediated dimerisation would bring the other HR1 domains into 
proximity, therefore increasing their effective molarity even further and potentially driving 
HR1abc trimer formation. 
A comparison of the stability of HR1 domains based on CD data from this chapter and 
Hutchinson et al. (2013) suggests that PRK1 HR1b and HR1c may be monomeric as a result 
of a higher melting temperature, in contrast to PRK1 HR1a which has a melting temperature 
that is lower by 6 oC and forms dimers (Figure 3.30). Rigidity does not seem to correlate with 
dimerisation when PRK1 HR1a and PRK3 HR1a are compared. Instead, PRK1 HR1a is the 
more rigid domain out of the two yet dimerises with 6 times higher the affinity. This may 
suggest that the unique N-terminal helix of PRK1 HR1a may be driving dimerisation. A look 
at the theoretical isoelectric point (pI) of each domain also does not establish a trend of 
dimerisation, in this case based on surface charge. Intra- and inter-molecular interactions in 


















3.5.4 Importance of oligomerisation 
 
This is the first time it has been shown that these HR1 domains are involved in such intra- 
and inter-molecular interactions and it is speculated that they are important in regulating 
PRK catalytic activity through dimerisation. The self-association of these domains may also 
serve to augment or abrogate the interactions of these domains with the Rho family of G 
proteins, which may in its own right affect the activation of the PRKs that are known to be 
activated directly by RhoA and Rac1 (Amano et al., 1996; Lu & Settleman, 1999). Altered 
affinities for Rho G proteins may also affect the localisation of the PRKs and thus have an 
effect on the physiological role these proteins have in cells. Moreover, it has been shown 
previously that in the case of PRK2 there is oligomerisation mediated by a region C-terminal 
to the C2 domain (Bauer et al., 2012), so it is also possible that there are multiple 
oligomerisation sites in the PRKs. 
Figure 3.30 Comparison of biophysical properties of HR1 domains. The oligomeric state, dimerisation 




Weak, transient protein-protein interactions are widespread in cell signalling pathways and 
are key for their regulation, e.g. the SLAM glycoprotein dimerises with a Kd of 200 μM to 1 
mM, which is thought to be important in transient cell-cell contacts made by leukocytes 
(Mavaddat et al., 2000). 
However, a lot remains unknown. Firstly, the structure of HR1c. Secondly, the structure of 
HR1abc which would show the interactions happening between the HR1 domains, both the 
intra-molecular and inter-molecular ones, and particularly the regions of the HR1 domains 
required for these interactions. Thirdly, the oligomerisation scheme, including Kd values and 
particularly association and dissociation rates (i.e. kinetic parameters), between HR1 
domain interactions in the context of their different oligomeric states. Finally, the 
dimerisation interface of HR1a and the effect oligomerisation may have on GTPase binding. 











PRK HR1 domains share ~30% sequence identity and ~60% sequence similarity. The 
structures of PRK1 HR1a and HR1b are known, and these proteins form antiparallel coiled 
coils. All other HR1 domains are also predicted to be coiled coils. Despite their similar 
structures, HR1 domains have different thermal stabilities, which may partly explain why 
they differentially interact with G proteins (Hutchinson et al., 2013). Some of the HR1 
domains are either known or predicted to have additional structural components. In 
particular, PRK1 HR1a has an N-terminal helix consisting of 5 amino acids folded in one 
helical turn whose role remains unknown (whether HR1a is truly structured in solution has 
not been proved yet; the only evidence is from a crystal structure in complex with RhoA 
(Maesaki et al., 1999)). Similarly, HR1c domains from all three PRKs are predicted to have a 
C-terminal helix which is much shorter than the two main helices. Whether this C-terminal 
helix truly exists in solution also remains unknown. It has been shown that PRK1 HR1c does 
not interact with RhoA and no other GTPase interacting partners are known (Flynn et al., 
1998). 
PRK1 HR1c has been successfully purified and initial structural studies by CD suggest that it 
is folded. The protein is also stable at room temperature and AUC shows that it is 
monomeric even at high concentrations. All of the above facilitate studies by Nuclear 
Magnetic Resonance (NMR) spectroscopy, which requires a monodisperse sample that is 
stable for the long duration of the experiments. The structure of the HR1c domain was 
investigated by NMR as described in this chapter. The structure will provide a means of 
understanding why the HR1c may exhibit differential stability, oligomerisation or binding to 
G proteins. In addition, the assigned NMR spectra of HR1c will provide a powerful tool for 
investigating possible interactions between the HR1 domains or with G proteins. An 
introduction to the basic NMR theory required to understand what the NMR signal is, and 
also how magnetisation is generated and transferred in the NMR experiments recorded, will 
be provided. This is to enable the basic understanding of what each of the different 
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experiments recorded shows. The peak assignment process in the different NMR spectra 
will also be briefly explained, as well as how this information enables structure calculations. 
 
4.2 Nuclear Magnetic Resonance 
 
4.2.1 The NMR signal 
 
Nuclear Magnetic Resonance (NMR) is a widely used technique in the study of protein 
structure, with ~10% of the structures in the PDB being NMR solution structures. It is 
considered to be complementary to X-ray crystallography, and some proteins which fail to 
pack into ordered crystals have been found to generate well dispersed NMR spectra (Snyder 
et al., 2005). NMR also has widespread uses in the study of protein-protein interactions, as 
the interacting interface can be determined even without the existence of a structure. 
Similarly, NMR is often used to study small molecules such as peptides or ligands, 
particularly those with therapeutic potential, and their interactions with macromolecules. 
NMR can provide a fingerprint for each spin-active nucleus and therefore provides excellent 
atomic resolution when studying macromolecules. A key advantage of NMR over other 
techniques is the ability to study protein dynamics and in particular protein conformations 
which are not detectable, e.g. very short-lived conformations which would unlikely be 
selected for in X-ray crystallography. While biological macromolecules are abundant in 1H 
nuclei, the natural abundance of 15N and 13C is very low. At the μM and low mM 
concentrations used, the low abundance means that the signal from those nuclei will be 
very weak and lost in the noise. Consequently, biological macromolecules such as proteins 
have to be labelled with 15N and 13C, e.g. by growing the expression host in culture where 
the only sources of N and C are 15N and 13C, respectively. 
When the NMR sample is placed in an NMR magnet, the magnetic moment of each nucleus 
interacts with the applied magnetic field, B0. The energy of this interaction is dependent on 
the angle, θ, between the moment and the field direction. While there is an energetic 
advantage if the magnetic moments of all individual nuclei in our sample align with the 
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applied field, i.e. when θ=0, the thermal motion of the nuclei results in random magnetic 
moments which disrupts this alignment. However the disruption is not absolute, and a small 
excess of nuclei align with the applied magnetic field (Figures 4.1A-B). This overall net 
magnetisation of the entire NMR sample can be represented with a bulk magnetisation 
vector pointing along the z-axis on a set of axes and is referred to as the equilibrium 
magnetisation (Figure 4.1C). 
If the equilibrium magnetisation is somehow tipped away from the z-axis (Figure 4.1D), 
there is precession about the field at frequency ω0 in rads-1, 
= −  
where γ is the gyromagnetic ratio of the nucleus under study and  is the strength of the 
magnetic field. This frequency is termed the Larmor frequency. In NMR experiments, it is 
this magnetisation vector precession that we detect. This is done by winding the detector 
coil round the x-axis. The precessing magnetisation will then ‘cut’ the coil as it cuts into the 
xy plane. The induced current results in free induction decay (FID), which is the NMR signal 
we record (Figure 4.1E). Fourier transformation of this signal produces the familiar signals or 
peaks in NMR spectra, at frequency ω0. 
NMR experiments require the magnetisation to move away from the z-axis and, for 
example, towards the x-axis. This is not possible as the magnetic field cannot be swiftly 
altered. The solution to this problem is to apply a small magnetic field, B1, along the x-axis 
which oscillates at the Larmor frequency (Figure 4.2). When radiofrequency power (or 
pulse) is provided, an oscillating magnetic field along the x-axis is generated, which is 
enough to make the magnetisation precess in the yz plane. If we set the size of this 
oscillating field to 2B1, then we can depict two counter-rotating magnetic fields, each of size 
B1, the x-components of which initially shrink towards zero as they move away from the x-
axis but subsequently increase towards –x. This is impossible in the ‘laboratory frame’ as the 
magnetic field cannot be swiftly altered. Instead, the rotating frame is employed, where the 
coordinate system (the axes) are rotated at the same rate as B1. Essentially, the B1 then 
appears to be static and not oscillating, but the effect is the same as if it would have 



























Figure 4.1 The NMR signal. (A) In an NMR sample, the magnetic moments of all nuclei are of random 
orientation. As a result, there is no net magnetisation. (B) The applied magnetic field, B0, causes more 
moments to align with it. The net magnetisation is now aligned with the B0 field. (C) The net magnetisation 
vector can be represented as being aligned on the z-axis of a xyz axis system. (D) When the magnetisation 
is tilted away from the z-axis, it precesses in the xy plane, about the z-axis. This means that it interacts at 
regular intervals with the receiver coil aligned on the x-axis. (E) This interaction gives the free induction 






























Figure 4.2 The rotating frame and the effective field. (A) Two counter-rotating fields, B+1 and B
-
1 in a fixed 
axis system known as the laboratory frame. (B) The sum of the B+1 and B
-
1 fields give a net magnetic field 
which oscillates about the x-axis. (C) In the rotating frame, the axis system is rotating at -ωtx about the z-
axis. The B-1 field appears to be static on the x-axis. (D) The effective field, Beff, is the sum of the reduced 







If the rotating frame frequency is ωRF, then the apparent Larmor frequency, also known as 
the offset (Ω), is the difference between the true Larmor frequency and the frequency of 
the rotating frame.  
= −  
Equation 4.1 describes how the Larmor frequency and the applied magnetic field are 
related. Substituting this equation and an analogous equation for the frequency of the 
rotating frame into equation 4.2 gives the relationship between the offset and the apparent 
magnetic field of the RF, ΔB. 
= −  
The ΔB and B1 magnetic fields add up to give the effective field, Beff. It is this Beff 
magnetisation vector which precesses and ‘cuts’ the detector coil to give the NMR signal. 
According to the above equation, if the Ω≈0, then ΔB is also ≈0, which means the Beff aligns 
with the x-axis, i.e. the B1 field has an effect.  
NMR spectrometers can provide sufficient RF power to create pulses which cover the entire 
range of chemical shifts of a particular nucleus. In the basic pulse-acquire experiment 
(Figure 4.3), the equilibrium magnetisation is firstly allowed to align along the z-axis. The 
magnetisation then moves onto the –y axis following a 90o pulse on the x-axis. The 
magnetisation then precesses in the xy plane at frequency equal to the Ω. The chemical 
shift, δ, is often expressed in parts per million (ppm) rather than Hz, 
=
−
× 10  
where ωrv is the receiver or “operating” chemical shift of the spectrometer, e.g. 500 MHz. 
A very commonly used pulse sequence is the spin echo. In this pulse sequence, a 180o pulse 
is added at the end of the basic pulse-acquire experiment, separating the sequence into two 
delays (2τ; τ=delay) and the signal is thus not acquired until after the second of the two 
delays. The effect that this has is that the magnetisation ends up along the same axis, 
independent of the length of the delay (τ) or the Ω. The magnetisation vector ends up 






evolution during the first delay is effectively negated by the second delay. We will see later 

























Figure 4.3 Pulse-acquire experiment. (A) The RF line contains pulses such as the 90o pulse on x shown 
here. The acquisition line shows the recorded signal. (B) The acquired FID is processed using a Fourier 
Transform to give a spectrum. This spectrum contains peaks which represent spin active nuclei and their 
position in the spectrum is at their Larmor frequency. This is typically expressed in chemical shift, δ, in 
units of ppm. (C) Before the 90o pulse, bulk magnetisation rests on the z-axis. (D) The 90o pulse on x rotates 
the magnetisation vector from the z-axis to the –y-axis. (E) The magnetisation precesses in the xy plane, 







The above description of the basic NMR experiment only uses the vector model and a small 
number of equations. However as we move to more complicated experiments, involving 
two or more spins, we need to use the product operator approach to describe what is 
happening (Cavanagh et al., 1998; Keeler, 2005). The elegance of this approach comes from 
the fact that by just following a few simple, quantum mechanical rules, even the most 
complex NMR experiments can be studied.  
The energy of interaction between the spin and the magnetic field can be represented with 
the Hamiltonian operator 
 = −  
where  is the Hamiltonian operator of the spin in question, γ is the gyromagnetic ratio of 
the nucleus under study,  is the strength of the magnetic field and  is an operator which 
denotes the nuclear spin angular momentum of spin  and in particular its z-component that 
interacts  with the applied  magnetic field.  
Substituting equation 4.3 for the offset of the spin we get 
 = − =  
During a period of free precession of a two-spin system, the offset and the -coupling 
evolve, and the Hamiltonian is expressed as 
 = , + , +  
where  is the second spin,   is the scalar coupling between the two spins and  is the 
chemical shift in Hz ( = = ), both in units of Hz. 
In the rotating frame, equation 4.7 can be re-written by substituting for the offset of the 
proton, ΩI, and the offset of the heteronuclear spin, ΩS. 
 = + +2  
The scalar or -coupling between two spins is a quantum mechanical property of two nuclei 
which have chemical bond connectivity and results in an observable doublet for each spin, 







resulting in two microenvironments and as a result two slightly different chemical shifts. The 
chemical shift difference between the nuclei, in Hz, is the value of . 
The -coupling is a key feature of many NMR experiments, where it is used to transfer 
magnetisation from one spin to another. 
At each stage in the experiment, different kinds of magnetisation can be detected based on 
which axis the magnetisation of either spin is aligned on, e.g. 2  indicates the proton 
magnetisation being on the z-axis and the heteronuclear spin magnetisation being on the x-
axis. The different types of magnetisation are listed below. 
 
Type of magnetisation Operators 
z-magnetisation on a single spin ,  
in-phase magnetisation , , ,  
anti-phase magnetisation 2 , 2 , 2 , 2  
multiple-quantum coherence 2 , 2 , 2 , 2  
non-equilibrium population 2  
 
In product operator terms, -coupling is used to change in-phase magnetisation to anti-
phase magnetisation, during a time τ, e.g.  and  terms evolve into the anti-phase 2  
and 2  terms. For a specific value of τ there can be complete conversion of the in-phase 
to the anti-phase magnetisation. This is a key feature of the Heteronuclear Single Quantum 
Coherence (HSQC) experiment which will be discussed in section 4.2.2. 
 
We can determine the effect of pulses on magnetisation by following a simple rule. 
cos ×  +  sin ×   
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The new operator can be determined by the diagrammatic representation of the x-, y- and 
z- axes representing the ,  and  operators, respectively. Positive rotation about an axis 
changes the original operator into the new operator. 
It is also important to note that rotating a magnetisation vector about its own axis, e.g.  
about the x-axis, has no effect. Similarly, the above rule can be applied to the effect of 
chemical shift, but instead of cos θ and sin θ we now have cos Ωt and sin Ωt. In this case, 
Figure 4.4A illustrates which the new operator will be. 
The spin echo pulse sequence is a building block of the Insensitive Nuclei Enhanced by 
Polarisation Transfer (INEPT) sequence, which in turn is a building block of many 2D NMR 
experiments, including the HSQC (Cavanagh et al., 1998; Rule & Hitchens, 2006). The role of 
the INEPT pulse sequence is very important. The strength of NMR signals depends on the 
strength of the applied magnetic field and also on the gyromagnetic ratio of the nucleus 
under study. The stronger the applied magnetic field is, or the larger the gyromagnetic ratio 
of the nucleus, the greater the equilibrium magnetisation and therefore the higher the 
signal strength, i.e. higher sensitivity. The INEPT experiment is used to transfer 
magnetisation from a nucleus with a large gyromagnetic ratio, e.g. 1H, to a nucleus with a 
smaller gyromagnetic ratio, e.g. 15N (10 times as small as 1H) or 13C (4 times as small as 1H). 
This has a dramatic effect on the enhancement of the NMR signals. 
Rather than providing an in-detail description of the spin echo and INEPT pulse sequences, 
the use of these sequences will be illustrated in the next section which explains the basic, 
yet very important NMR experiment, the HSQC. 
In this discussion spin I is always 1H while spin S is the heteronuclear spin, i.e. 15N or 13C. The 
experiments always begin on the proton and then transfer magnetisation to the 
heteronuclear spin. This is because the gyromagnetic ratio of the proton is bigger. This leads 





4.2.2 The HSQC pulse sequence 
 
Figure 4.4 illustrates the HSQC pulse sequence . 
At the start of the experiment, there is equilibrium magnetisation, which is aligned with the 
z-axis and is represented by the  operator. The first building block of the HSQC pulse 
sequence is the INEPT which achieves polarisation transfer. The first 90o x-pulse on the 
proton generates transverse magnetisation 
−  
During the 2τ period, the proton chemical shift is refocused due to the 180o pulse. The 180o 




this simplifies the magnetisation to 
−2  
The 90o y-pulse on I changes the magnetisation to 2  and a 90o x-pulse on S at the same 
time changes this to −2 , which can be summarised by 
−2 − 2  
indicating longitudinal I magnetisation and transverse S magnetisation, i.e. magnetisation 
transfer has occurred, leading to a signal from the S, the magnitude of which is dependent 
upon the equilibrium magnetisation of I (usually proton). 
During the t1 period, the chemical shift of spin I is refocused (the J coupling between the 
two spins is also refocused) but the chemical shift of spin S evolves and thereby gets 
encoded.  
 The heteronuclear chemical shift evolves during the t1 period to give 








= 2 cos( )−2 sin( ) 
 
The final building block in the HSQC is a reverse INEPT which achieves polarisation transfer 
back to the proton. An x-pulse is applied to both the proton and the heteronuclear spin. 
2 cos( ) 2 cos( ) 
2 sin( ) −2 sin( ) 
Adding up the two terms gives 
2 cos( ) − 2 sin( ) 
The −2 sin( ) term is double quantum magnetisation which cannot be detected. 
In the final step, the J-coupling evolves to give 
2 cos( ) → cos( ) 
This step is important to convert anti-phase to in-phase magnetisation, which will result in 
two NMR peaks separated by the -coupling. 
This allows decoupling to be applied during detection to give a single resonance line for 
each pair of I and S spins. The final signal is expressed as 
( , ) = cos( )  
A Fourier transformation is then used to give the final signal that is observed as a peak in a 
spectrum. 
Finally, it is important that mention that NMR experiments on biological macromolecules 
are often recorded with water as the solvent. It is therefore imperative that we somehow 
remove the signal of the water protons, which are at a concentration of 111.2 M. This is 
done by including elements in the pulse sequence, such as the WATERGATE and water flip-
back elements. An in-detail description of how these elements work can be found elsewhere 









Three-dimensional experiments use HSQC-based pulse sequences to transfer magnetisation 
from the 1H to the 15N to the 13C. The pulse sequences of these experiments will not be 
























b −  
c −2  
d −2  
e 2 cos( )−2 sin( ) 
f 2 cos( ) − 2 sin( ) 
g cos( ) 
Figure 4.4 Product operator approach and the HSQC pulse sequence. (A) Diagrams for determination of 
the effect of J-coupling evolution on different types of magnetisation. (B) The HSQC pulse sequence. The 





4.2.3 Other through-bond experiments 
 
The HSQC is the basis of several other three-dimensional (3D) experiments which are 
important in the assignment of backbone NH chemical shifts. Four commonly recorded 
triple resonance experiments are the HNCA, the HNCACB, the HN(CO)CA and the 
HN(CO)CACB (Cavanagh et al., 1998; Rule & Hitchens, 2006). These give correlations 
between the amide 1H and 15N and the backbone 13Cα and 13Cβ. Figure 4.11 shows how the 
HSQC is the basis of these experiments and how the peaks are further resolved in the 13C 
dimension. Figure 4.10 summarises the pathway of magnetisation transfer in each of these 
experiments. 
An additional through-bond experiment which is useful in assigning the side-chain chemical 
shifts is the HCCH-TOCSY. This provides a total correlation spectrum which shows which 
protons are connected via a chemical bond. This can be linked to the 13C-HSQC spectrum 
which can help the assignment process. 
 
4.2.4 The NOE 
 
The Nuclear Overhauser Effect (NOE) is a property of dipolar relaxation between two 
nuclear spins. This means that two atoms which may be far away in the protein primary 
sequence, but up to 5 Å close in space, will give rise to an NMR signal as a result of 
successful magnetisation transfer through space from one spin to the other. The strength of 
this NOE signal is inversely proportional to r6, where r is the distance between the two 
nuclei. The intensities of peaks in Nuclear Overhauser Effect Spectroscopy (NOESY) spectra 





4.3 NMR studies on PRK1 HR1c 
 
4.3.1 2D-NOESY and 2D-TOCSY of unlabelled PRK1 HR1c 
 
Two-dimensional (2D) NMR experiments such as the 2D NOESY and 2D TOCSY (Cavanagh et 
al., 1998; Rule & Hitchens, 2006) are a rapid way of obtaining preliminary information on 
the secondary structure of proteins, as well as information on their overall fold. The 2D 
NOESY experiment uses the NOE to report on protons which are close in space. Depending 
on the secondary structure of the protein in question, a different region of the spectrum is 
populated with peaks. For example, in an α-helix the amide protons of sequential residues 
are arranged close to each other. This gives rise to strong NOEs between these protons at 
chemical shifts of 7-9 ppm. In contrast, β-sheet amide protons are located close to the Hα of 
the preceding residue and the resulting NOEs populate an alternative region of the NOESY 
spectrum. The 2D TOCSY experiment transfers magnetisation through chemical bonds via 
the 3J 1H-1H couplings and shows cross-peaks between an amide proton and side chain 
protons (Hα, Hβ, Hγ, etc.). Both of these spectra can also provide information on the 
feasibility of pursuing structural work by NMR. If the peaks are uniformly strong and sharp, 
then the protein is likely to be monomeric (or a small dimer). This also practically means 
that the double and triple resonance experiments which are crucial in structural studies will 
have good resolution and minimal peak overlap. Conversely, if the peaks are broadened, 
then there is indication of exchange processes such as protein oligomerisation, which would 
be a significant impediment when recording other NMR experiments as the resolution of 
recorded spectra would be poor. 
The starting point of this work was to record 1H homonuclear 2D NOESY and 2D TOCSY 
spectra on an unlabelled PRK1 HR1c NMR sample (Figure 4.5). Uniformly strong and sharp 
peaks were observed which suggested that other NMR experiments to be recorded on 
labelled protein would also be of comparable quality. In addition, NOE peaks were observed 
indicative of backbone NH-NH NOEs in an α-helical protein. This indicates that the protein is 
structured and in particular α-helical and it is in agreement with the CD results recorded 
previously (Chapter 3). Furthermore, the absence of broadened peaks is indicative of the 
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lack of oligomerisation or non-specific protein aggregation, which is consistent with the AUC 


























Figure 4.5 2D NOESY and 2D TOCSY spectra of PRK1 HR1c. NMR spectra of 1.6 mM PRK1 HR1c in 20 mM 
sodium phosphate pH 7.3, 150 mM NaCl and 10% D2O were recorded on a Bruker DRX500 at 25 
oC. The 
amide region which contains NH-NH NOEs is highlighted in the 2D NOESY while the NH-Hα etc. fingerprint 




4.3.2 Purification of 15N-labelled NMR sample 
 
To record the double and triple resonance experiments on backbone amides and also side 
chain groups (CH) needed for the structural studies of HR1c, the protein would have to 
include 15N and 13C nuclei, which are the spin active forms of N and C but are of very low 
natural abundance (0.368% for 15N and 1.07% for 13C (Rosman & Taylor, 1998)). To 
isotopically enrich the protein with 15N and 13C, 15NH4Cl and 13C glucose are supplied to a 
bacterial culture as the only sources of nitrogen and carbon, respectively. These cultures can 
be grown in either MOPS or M9 minimal medium. Sometimes the expression can be 
significantly lower in one of the two media, so the expression of the protein in both of these 
media, and how it compares to expression in 2TY medium, was assessed by small scale 
expression. The protein expressed equally well in both media and M9 was chosen as the 
minimal medium in which to express the labelled protein (Figure 4.6). The protein was 
purified as shown previously (Chapter 3) (Figure 4.7) and 10% D2O was added giving an NMR 












Figure 4.6 SDS-PAGE Analysis of 15N PRK1 HR1c expression trials in minimal medium. Solubility of fusion 
protein was assessed by identifying band of approximate molecular weight in soluble or pellet fractions. 
Un for Uninduced sample, In for Induced (Total), S for Induced (Soluble) and P for Induced (Pellet). 20 and 
37 denote the temperature at which the expression was carried out at. Laemmli gels were 12%. (A) 2TY (B) 
MOPS (C) M9 
























Figure 4.7 Purification of 15N PRK1 HR1c and corresponding SDS-PAGE analysis. (A) GST-PRK1 HR1c 
immobilised on glutathione agarose beads. Gel was 12%. SN for supernatant, W1-3 for the 3 washes, Beads 
for 50% bead slurry and Pellet for insoluble fraction. (B) PRK1 HR1c washes post-cleavage. Gel was 18%. SN 
for supernatant and W1-4 for the 4 washes post-cleavage. (C) Gel filtration chromatogram of PRK1 HR1b 
on an S75 column. Blue line indicates A230. (D) SDS-PAGE analysis of chromatogram in (C) on an 18% 







4.3.3 15N-HSQC and 13C-HSQC experiments 
 
The fundamental NMR experiment recorded in protein studies is the HSQC. The 15N-HSQC 
and the 13C-HSQC provide through-bond correlations between proton and nitrogen or 
proton and carbon chemical shifts, respectively. Typically, the 15N-HSQC has a much smaller 
number of expected peaks than the 13C-HSQC does and therefore there is less overlap. The 
15N-HSQC spectrum comprises peaks corresponding to all NH groups in the protein. These 
peaks include backbone NH groups (prolines lack NH groups) and side-chain NH2 groups of 
asparagine and glutamine residues. There are two peaks for each of the side-chain NH2 
groups, one for each of the protons. These have different 1H chemical shifts but an identical 
15N chemical shift and they are located in the top right region of the spectrum, so they are 
very easily identified. Arginine side-chain NH groups are often visible but may be weak as a 
result of exchange broadening. Instead of appearing at very small 15N chemical shifts, they 
are instead aliased to larger 15N chemical shifts. Additionally, while the side-chain NH group 
of tryptophan is observable, the NH group of the histidine and the NH3+ group of the lysine 
side-chains are often not. The N-terminal NH3+ group was not visible due to broadening 
caused by exchange with the water solvent. 
The purified PRK1 HR1c protein has 104 amino acids; 7 amino acids, GPLGSHM come from 
the vector sequence and include a remainder of the 3C protease cleavage site (GPL) as well 
as residues encoded by the restriction sites used during cloning (GSHM).The remaining 97 
amino acids correspond to the HR1c domain (residues 201-297 of the full length PRK1). A 
15N-HSQC spectrum was recorded on the purified sample (Figure 4.8). HR1c contains 5 
proline residues, so the expected number of peaks corresponding to backbone amide 
groups is 98. The 15N-HSQC spectrum was expected to contain a total of 108 peaks; 98 
backbone NH groups and 10 corresponding to the 5 pairs of asparagine and glutamine side-
chain NH2 groups. Instead, only 95 peaks were observed, suggesting that there may be some 
peak overlap. Nevertheless, the spectrum is well-dispersed (δΗ = 7.0-10.4 ppm and δN = 104-
126 ppm) which suggests that the protein is structured and also that pursuing the structure 
is amenable by NMR. The sharpness of the peaks is also consistent with the protein being 
monomeric. The 10 asparagine and glutamine NH2 peaks were easily identified for reasons 
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explained above at δH = 6.4-7.6 ppm and δN = 109-114 ppm. 9 out of 10 arginine side-chain 
(HεNε) peaks were also observed. 
To record experiments that would enable the assignment of backbone and side-chain 
chemical shifts, 15N, 13C-labelled protein was purified in the same way as the 15N-labelled 
protein and concentrated to yield a sample with final concentration of 1.2 mM. The 
recorded 13C-HSQC experiment can be seen in Figure 4.9. This spectrum contains a peak for 
each CH group in the protein and it is noticeably more crowded than the 15N-HSQC. The 
important regions of the spectrum have been annotated to show the different categories of 
CH groups. This spectrum was used to aid side-chain assignments in conjunction with the 



















Figure 4.8 15N-HSQC spectrum of PRK1 HR1c. A 15N-HSQC of 1.6 mM PRK1 HR1c in 20 mM sodium 
phosphate pH 7.3, 150 mM NaCl and 10% D2O was recorded on a Bruker DRX500 at 25 
oC. Asparagine and 
glutamine side-chain NH2 groups, arginine side-chain NεHε groups (aliased in the N dimension and negative, 























Figure 4.9 13C-HSQC spectrum of PRK1 HR1c. A 13C HSQC of 1.2 mM PRK1 HR1c in 20 mM sodium 
phosphate pH 7.3, 150 mM NaCl and 10% D2O was recorded on a Bruker DRX500 at 25 
oC. The various 
aliphatic and aromatic CH group regions are highlighted. 
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4.3.4 Three-dimensional experiments for backbone NH group assignment 
 
Assigning the chemical shifts of backbone and side-chain protons is an obligatory 
requirement in protein structural studies. Dihedral angle restraints can be derived from the 
backbone chemical shifts, while the assignments can be used to derive proton distance 
restraints from NOESY experiments. Together these restraints form the basis of structure 
calculations. The assignment process begins by assigning the backbone NH shifts using a 
series of triple resonance experiments. The side-chains are then assigned by recording 
additional three-dimensional experiments. 
To assign the backbone NH shifts, four three-dimensional experiments were recorded, the 
HNCA (Kay et al., 1990), the HNCACB, the HN(CO)CA and the HN(CO)CACB (Figure 4.10). The 
HNCA gives an intra-residue correlation between the 1H and 15N shifts of the backbone 
amide and the 13C shift of the alpha carbon atom, Cα. In addition, some magnetisation can 
be transferred by the two-bond coupling to the Cα of the preceding residue, giving rise to an 
additional, but weaker peak in the spectrum which can aid the assignment process. The 
HNCACB experiment provides the same correlations that the HNCA does, but in addition it 
gives correlations between the 1H and 15N shifts and both the intra-residue Cβ and also that 
of the preceding residue. The HN(CO)CA experiment gives a single correlation between the 
backbone 1H and 15N and the Cα of the preceding residue, and is therefore useful when 
comparing with the HNCA experiment to identify the Cα shift of the preceding residue 
unambiguously. Finally, the HN(CO)CACB experiment complements the HN(CO)CA, providing 
the same information but in addition a correlation between the 1H and 15N of residue  and 
the Cα and Cβ of residue , and it is used in conjunction with the HNCACB. Together, these 
four experiments establish connectivity between the residues and in this way, we can “walk 
the backbone”, which allows assignment of the backbone chemical shifts. 
Sequential assignment was aided by knowledge of the 13C chemical shifts of all amino acids 
found in databases such as the Biological Magnetic Resonance Bank. For example, the 13Cα 
chemical shift of alanine is approximately expected to be around 51 ppm, while the 13Cβ 
chemical shift is expected to be close to a characteristic shift of 19 ppm. Starting points in 
sequential assignment included residues such as leucine and aspartate with characteristic 
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13Cβ (~40 ppm) as well as glycine, which has no Cβ, so only two peaks appear in the HNCACB 
spectrum and one in the HN(CO)CACB spectrum. Importantly, the chemical shifts can be 
affected by different secondary structures. For example, in an α-helical context, carbon 
chemical shifts are shifted up-field compared to those carbons in a random coil. This is a 
result of the carbonyl groups in an α-helix having an effect on the electronegative properties 
of these atoms (Spera & Bax, 1991). Likewise, side-chain proton chemical shifts are shifted 
down-field compared to those protons in a random coil. 
As prolines lack backbone NH groups, they don’t give rise to any peaks in the HNCA and 
HNCACB experiments. However, in the HN(CO)CA and HN(CO)CACB experiments 
magnetisation can be transferred from the NH of the succeeding-to-the-proline residue, so 
the Cα and Cβ shifts of prolines can be assigned in this way. This becomes very helpful for 
predicting dihedral angle restraints of prolines but also assists side-chain assignments 
(Section 4.3.6). 
The assignment process consisted of three steps (Figure 4.11). Firstly, a peak in the 15N-
HSQC was chosen and used to navigate to the corresponding 15N strip in the 
HNCA/HNCACB/HN(CO)CA/HN(CO)CACB spectra. The chemical shift of the Cα of the  
residue was distinguished from the chemical shift of the Cα of the  residue by comparing 
the HNCA and the HN(CO)CA spectra. Secondly, the Cα chemical shift of the  residue was 
used to search for a 15N strip in the HNCA spectrum which contains a peak of matching 
chemical shift. Thirdly, there was navigation back to the 15N-HSQC to find the corresponding 
peak of the  residue. In this way, a sequential link was established between the two 
amide peaks in the HSQC. “Forward walking” of the backbone was also performed. A Cα 
peak (residue ) was selected in the HNCA strip and the corresponding HN(CO)CA strip of 
residue  was located by finding a peak with a matching chemical shift. The Cβ chemical 
shift was used alongside Cα for shift matching by comparing HNCACB and HN(CO)CACB 






























Figure 4.10 Triple resonance experiment magnetisation transfer pathways. Magnetisation transfer 
pathways of (A) HNCA (B) HNCACB (C) HN(CO)CA and (D) HN(CO)CACB. The chemical shift of the coloured 
nuclei is recorded in these experiments. The arrows indicate the through-bond magnetisation transfer 
using one- or two-bond J-couplings. The carbonyl carbon is used in the magnetisation transfer but its 






























Figure 4.11 Backbone NH assignment using triple resonance experiments. A peak in the 15N-HSQC was 
used to navigate to the corresponding 15N strip in the HNCA/HNCACB/HN(CO)CA/HN(CO)CACB spectra. The 
chemical shift of the Cα of the i  residue was distinguished from the chemical shift of the Cα of the i 
residue by comparing the HNCA and the HN(CO)CA spectra. Secondly, the Cα chemical shift of the i  
residue was then used to locate an 15N strip in the HNCA spectrum which contains a peak of matching 
chemical shift. Thirdly, there was navigation back to the 15N-HSQC to find the corresponding peak of the 
i  residue. In this way, a sequential link was established between the two amide peaks in the HSQC. 
“Forward walking” of the backbone was also possible. A Cα peak (residue i) was selected in the HNCA strip 
and the corresponding HN(CO)CA strip of residue i  was located by finding a peak with a matching 
chemical shift. There was subsequent navigation in the 15N-HSQC to link the i and i  residues. The Cβ 
chemical shifts were determined in the same way by comparing the HNCACB and HN(CO)CACB 
experiments. The figure shows the 15N strips of five sequential residues. HNCA in blue, HNCACB in teal and 




4.3.5 15N-separated TOCSY and 15N-separated NOESY for backbone assignment 
 
To aid the assignment of backbone amide chemical shifts, two further experiments were 
recorded on the 15N PRK1 HR1c sample, the 15N-separated TOCSY and the 15N-separated 
NOESY. These are both three-dimensional experiments based on the HSQC and 
homonuclear 1H-1H couplings. They provide correlations between the backbone NH atoms 
and the side-chain protons (Figures 4.12A-B). In theory, correlations between all side-chain 
protons should be visible in the 15N-separated TOCSY spectrum. However, this was often not 
the case, as a result of the small J-coupling (4-6 Hz) in helical proteins, which results in 
inefficient magnetisation transfer. These two spectra were used in parallel to help 
distinguish between intra-residue and inter-residue NOEs, as the 15N-separated TOCSY 
















Figure 4.12 15N-separated NOESY and 15N-separated TOCSY experiments. (A) Magnetisation transfer 
pathway of 15N-separated TOCSY. In this experiment, magnetisation is transferred through bond using the 
J-coupling. (B) Magnetisation transfer pathway of 15N-separated NOESY. In this experiment, magnetisation 




The 15N-separated NOESY spectrum contains cross peaks for the NH-NH NOEs present in α-
helices. These NOEs can be used as an alternative to the triple resonance experiments to 
assign the NH peaks in the 15N-HSQC (Figure 4.13A). A peak was located in the 15N-HSQC and 
used to navigate to the corresponding 15N strip in the 15N-separated NOESY/15N-separated 
TOCSY window. The NH-NH NOE was selected and used to navigate to the orthogonal plane 
of these spectra and identify a return NOE peak. A return peak was located and used to 
navigate to a new strip in the 15N-separated NOESY/15N-separated TOCSY window and finally 
back to the 15N-HSQC to establish connectivity between two peaks. This method was used to 
confirm the backbone assignments from the triple resonance experiments but to also assign 
the 10 backbone amides that could not be assigned using that set of experiments, e.g. 
Glu291 and Ala244. Since the HR1c domain is predicted to be α-helical, NOEs between  
to ,  protons were also observed. Figure 4.13B shows an example of aligned 
15N strips 
of five consecutive residues and the NH-NH NOEs connecting them. 
All backbone amides were assigned using a combination of the two approaches described 
above with the exception of a His amide found in the N-terminus of the protein and 
corresponding to vector sequence. 
The 15N-separated NOESY spectrum provided the first out of two sets of distance restraints 































Figure 4.13 15N-separated NOESY spectrum of PRK1 HR1c. A 15N-separated NOESY of 1.6 mM PRK1 HR1c 
in 20 mM sodium phosphate pH 7.3, 150 mM NaCl and 10% D2O was recorded on a Bruker DRX500 at 25 
oC. 15N-separated NOESY in navy and 15N-separated TOCSY in red. (A) An NOE peak was used to navigate to 
the orthogonal plane of the spectrum to locate a matching NOE pattern and then navigate back to a new 
15N strip. (B) Aligned 15N strips of five consecutive residues. The NH-NH NOEs between them are linked 





4.3.6 HCCH-TOCSY and 13C-separated NOESY 
 
The HCCH-TOCSY was recorded on the double-labelled sample. Similar to the 15N-separated 
TOCSY, it provides through-bond correlations between side-chain protons bound to a 13C, so 
it is used to assign side-chain 1H and 13C chemical shifts (Figure 4.14A). Peaks picked in this 
spectrum were used to pick the 13C HSQC spectrum. Conversely, unassigned regions in the 
13C HSQC spectrum were also used to navigate to the HCCH-TOCSY spectrum to help assign 
missing resonances. 
Similarly, the 13C-separated NOESY experiment (Figure 4.14B) was used to assign NOEs in 
side-chain protons. Through comparison with the HCCH-TOCSY, intra-residue and inter-
residue NOEs were able to be distinguished. This experiment was particularly useful when 
assigning intra-residue protons, as the HCCH-TOCSY is sometimes significantly overlapped. 
















Figure 4.14 Magnetisation transfer pathways of HCCH-TOCSY and 13C-separated NOESY. (A) 
Magnetisation transfer pathway of HCCH-TOCSY. In this experiment, magnetisation is transferred through 
bond using the J-coupling. (B) Magnetisation transfer pathway of 13C-separated NOESY. In this experiment, 




4.3.7 Assignment of aliphatic side-chains 
 
The 1H, 15N, 13Cα cross-peak of a residue, e.g. Asp281 (Figure 4.15) was located in the HNCA 
spectrum. It was then used to navigate to the corresponding CH strip in the HCCH-TOCSY 
spectrum. The same procedure was repeated for the 1H, 15N, 13Cβ cross-peak in the HNCACB 
spectrum. Peaks in the HCCH-TOCSY and corresponding to magnetisation transferred from 
the 1Hα to the 1Hβ were selected and assigned. The 15N-separated TOCSY spectrum was used 
to aid the assignment procedure, particularly if the Hα and other side-chain protons had 
already been assigned in that spectrum. Figure 4.15 shows an example of the assignment 
procedure of a short aliphatic side-chain, Asp281. 
If the amino acid had additional CH groups in the side-chain, the TOCSY peaks were selected 
and were used to navigate to the orthogonal plane of the spectrum (Figure 4.16). From that 
view, a TOCSY pattern matching with the 1Hα and the 1Hβ was found at a 13C chemical shift 
characteristic of that particular CH group, e.g. Leu271 HγCγ. Then there was navigation from 
the orthogonal plane back to the normal plane at the HγCγ strip. The TOCSY and NOESY 
peaks from that proton, e.g. Hγ, to the other intra-residue protons, e.g. Hα and Hβ, were then 



































Figure 4.15 Assignment of CH groups in a short aliphatic side-chain. (A) Displayed formula of Asp. The key 
J-couplings are highlighted. (B) The Asp281 Cα and Cβ peaks in the HNCA and HNCACB were used to 
navigate to the corresponding 13C strips in the HCCH-TOCSY spectrum. The corresponding 15N strip in the 
15N-separated TOCSY and 15N-separated NOESY spectra was used in parallel to assign the side-chain proton 






























Figure 4.16 Assignment of CH groups in a longer aliphatic side-chain. (A) Displayed formula of Leu. (B) The 
Leu271 HαCα and HβCβ peaks were assigned as shown in Figure 4.16. To assign the Cδ1 chemical shift, the Hα 
Hδ1Cα peak was used to navigate to the orthogonal plane of the HCCH-TOCSY spectrum. A matching pattern 
was located and then there was navigation back to the Hδ1Cδ1 strip. The same procedure was repeat for the 
Leu HγCγ and the Hδ2Cδ2. (C) HCCH-TOCSY strips of Leu271 HαCα, Hβ1/Hβ2Cβ, HγCγ, Hδ1Cδ1 and Hδ2Cδ2. HCCH-






4.3.8 NH2 group assignment 
 
There are two asparagines and three glutamines in PRK1 HR1c. As a result there are ten 
peaks in the 15N-HSQC which correspond to the side-chain NH2 groups. In asparagine, the 
NH2 protons are close in space to the Hβ protons (Figure 17A). Similarly, in glutamine, the 
NH2 protons are close in space to the Hγ protons (Figure 17B). The NH2 peaks in the 15N-
HSQC were used to navigate to the corresponding 15N strip in the 15N-separated NOESY 
spectrum. NOEs from the NH2 protons to the nearest intra-residue CH group (HβCβ for Asn 
and HγCγ for Gln) protons were used to assign the NH2 side-chain chemical shifts (Figure 
4.17C). The 13C-separated NOESY experiment was also used to find return NOEs from the Hα 
and Hβ atoms to the side-chain NH2 protons to confirm the assignments. 
 
4.3.9 Assignment of Phe222 
 
PRK1 HR1c has a single phenylalanine residue, F222, which is in the first α-helix. The Hα and 
Hβ chemical shifts were assigned firstly as explained above. The 15N-separated NOESY and 
13C-separated NOESY spectra were used to help assign the Hδ, Hε and Hζ protons (Figure 
4.18). The Hδ and Hε are expected to have very similar chemical shifts, which makes their 
assignment difficult. Hδ and Hε NOEs were assigned on the basis that the Hδ is closer to the 
Hβ, so the NOE between these two protons should be stronger than that between the Hε 
and the Hβ (and also by using the NH strip where there is an NOE from the NH to the Hδ). 

































Figure 4.17 Assignment of side-chain NH2 groups. (A-B) Displayed formulae of (A) Asn and (B) Gln. The 
arrows highlight the strongest NOE between the side-chain NH2 protons and an intra-residue CH group. (C) 
Assignment of Asn234. NOEs to the nearest CH group protons were used to assign the side-chain NH2 
proton chemical shifts and were confirmed by return peaks in the 13C-separated NOESY in the 
corresponding CH strip in the HCCH-TOCSY/13C-separated NOESY window. These NOEs are indicated with 
black circles. 15N-separated NOESY in navy, 15N-separated TOCSY in red, HCCH-TOCSY in black and 13C-


































Figure 4.18 Assignment of Phe222 side-chain protons using CH-CH NOEs. (A) Chemical formula of 
phenylalanine. The arrows indicate intra-residue NOEs between the Hβ and the Hδ or between the Hβ and 
Hε protons. (B) Aligned CH strips of the Hα, Hβ1, Hβ2, Hδ, Hε and Hζ protons in the 
13C-separated NOESY (in 
skyblue) and NH strip in 15N-separated NOESY (navy). The strength of the Hδ and Hε NOEs to the Hβ protons 





4.3.10 Assignment of prolines 
 
The Cα and Cβ chemical shifts were assigned using the triple resonance experiments as 
explained above. These were used to navigate to the correct Cα and Cβ planes in the HCCH-
TOCSY. In addition, the 15N-separated NOESY was used to assign the Hδ protons on the basis 
of an NOE from the NH of the preceding residue to the proline Hδ protons. Furthermore, the 
Hδ protons of proline are near the Hα of residue , giving rise to strong NOE peaks 
between them (Figure 4.19). This was used as the basis to help assign the proline Hδ 
chemical shifts. 
 
4.3.11 Medium and long range NOEs 
 
Medium range NOEs were seen between   etc. and  or side-chain protons, e.g. 
Thr258 Hα and Asn261 NH/Hβ/Hδ (Figure 4.20). 
Long range NOEs were identified by systematically going through strips of the 3D NOESY 
spectra and picking peaks which were identified neither as intra-residue NOEs nor as NOEs 
to neighbouring amino acid protons. If an already assigned proton had a very similar 
chemical shift, then the NOE was assigned to be to that proton (only if it was the only 
proton with that chemical shift). The identity of the interacting proton in these long range 
NOEs was confirmed by checking for a return NOE peak. This was done by selecting the NOE 
peak and then navigating to the orthogonal plane of the spectrum to locate the cross-peak. 
 
4.3.12 Ambiguous and unambiguous NOEs 
 
There is often ambiguity arising when assigning NOE peaks. This arises when an NOE peak is 
actually many NOE peaks which are overlapped as a result of the protons experiencing a 
similar chemical environment or because of poor spectral dispersion. The volume of the 
NOE peak is therefore dependent on all of these contributing pairs of protons. Such peaks 
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were often left with one or more dimensions unassigned. Particular care was taken when 
assigning long range NOEs, as any wrong assignments could have a deleterious effect on 
calculated structures. NOE assignment ambiguity was resolved during structure calculations 



































Figure 4.19 Assignment of proline side-chains. (A) Displayed formula of a His-Pro di-peptide. The arrows 
highlight the inter-residue NOEs between the proline Hδ protons and the adjacent NH and Hα protons of 
residue i-1 (His282). (B) The His282 Hα and Pro283 Hδ1/Hδ2 strips in the HCCH-TOCSY/
13C-separated NOESY 
spectra and the His282 NH strip in the 15N-separated NOESY spectrum were used to assign the chemical 
shifts of proline side-chain Hδ1 and Hδ2 protons by identifying NOEs between them and the His282 NH and 
Hα protons. These NOEs are indicated with black circles. 
15N-separated NOESY in navy, 15N-separated 






























Figure 4.20 Assignment of α-helical i to i+3 NOEs. The Asn261 backbone NH and side-chain NH2 (Hδ1/Hδ2) 
strips in the 15N-separated NOESY and the Thr258 HαCα and Asn261 Hβ1/Hβ2Cβ strips in the 
13C-separated 
NOESY were used to assign α-helical i to i+3 NOEs. These NOEs are indicated with black circles. 15N-
separated NOESY in navy, 15N-separated TOCSY in red and 13C-separated NOESY in skyblue. 
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4.4 Structure calculations using ARIA 
 
4.4.1 Dihedral angles 
 
A key restraint in structural calculations is the set of dihedral or torsion angles, φ and ψ of 
the protein polypeptide backbone. While NMR methods are available to measure the 
dihedral angles of peptides, this is not feasible when work is done on larger proteins. TALOS 
(Torsion Angle Likeliness Obtained from Shift and Sequence Similarity), and its newer 
versions named TALOS+ and TALOS-N can predict protein local geometry from chemical 
shifts (Shen & Bax, 2013), as chemical shifts are inherently related to the local protein 
structure. 
TALOS-N takes the input chemical shifts and creates dihedral angle restraint lists by 
comparing to two protein structure databases. The first database comprises 580 proteins for 
which both backbone chemical shifts (15N, 13C, 13Cα, 13Cβ, 1Hα and 1HN) are available in the 
BMRB (Markley et al., 2008) and atomic coordinates are available from high-resolution X-ray 
structures in the PDB (Berman et al., 2012). The second database utilised by TALOS-N 
contains 9523 high-resolution X-ray structures for which chemical shift assignments are not 
experimentally available but rather predicted using the SPARTA+ program (Shen & Bax, 
2010). SPARTA+ performs the reciprocal of TALOS-N, i.e. determines chemical shifts from 
local geometry. Specifically, a φ/ψ distribution code is assigned to every residue of each 
protein in this database, linking the backbone conformation of each residue to the 
Ramachandran plot. An artificial neural network then links the φ/ψ distribution code to 
chemical shift. This highlights why the database uses a large number of high-resolution 
structures. Put together, the two databases utilised by TALOS-N establish a link between 
chemical shift and local geometry. 
TALOS-N utilises an artificial neural network (based on the first database) to predict φ/ψ 
distributions for each residue of the protein in question from submitted NMR chemical 
shifts, the residue type and adjacent residues. The protein is then split into heptapeptides 
and the second, larger database is used as a reference to identify heptapeptides with 
matching φ/ψ distributions and preferably heptapeptides with a matching central residue. 
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The top 1000 heptapeptides are chosen. The SPARTA+ predicted chemical shifts of these 
1000 peptides are then scored and further compared with the query protein experimental 
chemical shifts. The 25 top matches are found and the φ/ψ distribution of their middle 
residue is averaged. This φ/ψ distribution average is used as the prediction of the φ/ψ 
distribution of the protein heptapeptide. 
In brief, NMR chemical shifts are submitted to TALOS-N which goes on to predict φ/ψ 
distributions for every residue based on the first, smaller database of protein structures. The 
protein is then divided into heptapeptides and the top φ/ψ distribution matches are 
selected from the second, larger database of protein structures. The matching 
heptapeptides are further refined on the basis of their predicted chemical shifts (by 
SPARTA+) with the experimental chemical shifts of the query protein. The chemical shifts of 
these top 25 matches are then used to calculate an average φ/ψ distribution which is used 
as the predicted φ/ψ distribution for the query protein. The predicted φ/ψ distribution 
combines data from both databases and is therefore less prone to error if only the smaller 
database were used to predict φ/ψ angles directly. Additionally, TALOS-N is an 
improvement over the original TALOS and TALOS+ as it uses heptapeptides (and not 
tripeptides) which are more representative of local protein structure. Predicted dihedral 
angles for each residue provided by TALOS-N can therefore be used as restraints in structure 
calculations. 
In addition to dihedral angle predictions, TALOS-N also classifies these predictions. 
Specifically, if the φ/ψ angles of the central residues of each of the 25 top matched 
heptapeptides cluster in the same region of the Ramachandran plot, then the prediction is 
classified as “strong”. In contrast, if more than 10 but less than 25 φ/ψ angle values cluster 
in the same region, the prediction is classified as “generous”, while if there is no clear 
clustering the prediction is classified as “warning”, i.e. the prediction is ambiguous. Residues 
may also be classified as “dynamic” if they are predicted to have a dynamic conformation. 
PRK1 HR1c chemical shifts (see Appendix 4) were submitted to TALOS-N to obtain dihedral 
angle predictions. Residues 208-241 and 243-294 were classified as strong predictions and 
207 as a generous prediction. 195-197, 202-206 and 295-296 were classified as dynamic 
while 198-201 and 242 were classified as ambiguous. 
211 
 
4.4.2 Distance restraints 
 
The other important structure calculation restraints which come from our data are distance 
restraints. These are based on the strength of NOE peaks selected in NOESY spectra. The 
greater the volume (or intensity) of the peak, the closer two protons are in space. The NOE 
is useful for any protons which are up to 5 Å away. As explained in section 4.3.12, there is 
often peak overlap in NOESY spectra and sometimes the identity of all the protons 
contributing to a particular NOE peak is unknown. ARIA (Ambiguous Restraints for Iterative 
Assignment) is a structure calculation method which gets around this problem and 
facilitates structure calculations. The ambiguity in the NOE assignments is resolved during 
the structure calculation. The method will be discussed here briefly.  
As stated above, the volume of an NOE peak between two spins, Vij, is proportional to the 
distance between them, dij 
∝  
but this relationship is also subject to protein concentration, dynamics and spin diffusion 
(Nilges, 1996). As a result, the constant of proportionality relating distance to the NOE is 
unknown. ARIA gets around this problem by performing distance calibration during the 
structure calculations (Linge et al., 2001) and for this reason this constant can be written as 
the calibration factor, Ccal. In the first iteration of the structure calculations, iteration zero, 
this factor is derived from a structure which has extended geometry with randomised 
torsion angles and side-chains with idealised geometries. As a result, Ccal is subject only to 
distances between intra-residue spins. With subsequent iterations, Ccal is derived from the 
lowest energy calculated structures and refined after every single iteration. Since the 
distance is calibrated with each subsequent iteration, we can write 
= ( )  





ARIA gets around ambiguous assignments by describing the effective distance, D, which 
describes the summation of distances (di) between the proton pairs of all possible 
assignments which total Nδ, where δ is the chemical shift tolerance 
≡  
We can then state that the ambiguous NOE strength will be proportional to the inverse sixth 
power of the effective distance 
∝ ≡  
The ARIA method uses 8 consecutive iterations in the structure calculation. With 
subsequent iterations there is an increasing number of ambiguous NOEs which are assigned. 
The final iteration involves refinement of the structure in water.  
 
4.4.3 Initial structure calculations 
 
A total of 2500 distance restraints were submitted to ARIA for the first structure calculation, 
with approximately 50% of these being unambiguous. The structure calculation ran for a 
total of 8 iterations, with 20 structures calculated during each iteration. The 10 lowest 
energy structures were refined in water and used to produce a list of restraint violations. 
 
4.4.4 Manual refinement 
 
Restraint violations were manually inspected and key problems, e.g. swapped assignments 
of Arg247 and Arg274, were obvious and corrected immediately. Furthermore, many 
violations were the product of very weak NOEs, e.g. due to spin diffusion, being used in the 





manual refinement of the key violations were then performed and the next structure 
calculation was set up. 
With each new structure, the number of violations decreased, e.g. from 600 to 500 and so 
on. In addition, as the key violations were sorted out, other smaller violations also 
disappeared. 
Structures calculated initially suffered from wrongly assigned ambiguous NOEs. This caused 
helix 1 of PRK1 HR1c bending from its N-terminus upwards. With each subsequent structure 
calculation, the ensemble of structures improved and could then also be used to derive 
distance information to unambiguously assign more NOEs. 
A total of 100 structures were calculated in the final iteration of the last structure 
calculation. The 50 lowest energy structures were refined in water and the structure 
ensemble consisted of the 45 lowest energy structures (section 4.4.5). 
The average structure was calculated from the structure ensemble and the rmsd of each of 
the 45 structures from the average was then determined. This was used to identify the 
structure with the lowest rmsd, i.e. the one that is closest to the average structure. Table 
4.1 includes the key structure statistics of both the ensemble of structures and the structure 
closest to the mean. For the structure ensemble, the backbone rmsd of the ordered regions 
was 0.552 while the sidechain rmsd was 0.989. The statistics also include information on 





Experimental restraints   
Completeness of chemical shift assignment (%):   
C  70.8  
H  98.4  
N  65.8  
NOE-based distance restraints:   
Total non-degenerate  2085  
Unambiguous  1534  
Ambiguous  551  
   
Violations   
NOE distance violations ≥ 0.5 Å 1.9 ± 1.59  
Torsion angles ≥ 5 ᵒ 0.66 ± 0.710  
   
Average Van der Waal energy (kcal/mol) -177 ± 16.9  
 
 A B 
Coordinate precision for well-ordered regions   
RMSD of backbone atoms (Å) 0.552 ± 0.174 0.255 
RMSD of all heavy atoms (Å) 0.989 ± 0.146 0.793 
   
Ramachandran analysis for all residues   
Residues in most favoured regions (%): 92.9 95.6 
Residues in additionally allowed regions (%): 6.3 3.3 
Residues in generously allowed regions (%): 0.5 0 
Residues in disallowed regions (%): 0.3 1.1 
   
Ramachandran analysis for ordered regions   
Residues in most favoured regions (%): 98.4 95.6 
Residues in additionally allowed regions (%): 1.5 3.3 
Residues in generously allowed regions 0.1 0 
Residues in disallowed regions (%): 0 1.1 
   
Sidechain analysis for ordered regions   
Rotomeric sidechains (%): 97.1 97.1 
Non-rotomeric sidechains (%): 2.9 2.9 
   
RMS deviations for all residues   
from experimental restraints:   
NOE distances (Å)  0.0524 ± 0.0148 0.0351 
Dihedral angles (ᵒ)  0.875 ± 0.105 0.911 
   
from idealised geometry:   
Bond lengths (Å)  0.00446 ± 0.000269 0.00410 
Angles (ᵒ)  0.615 ± 0.0223 0.580 
Impropers (ᵒ)  1.38 ± 0.128 1.23 
   
 
Column A contains information on the ensemble of 45 structures. 
Column B contains information for the structure that is closest to the mean. 
  Table 4.1 Experimental restraints and structural statistics. 
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4.4.5 The structure 
 
The PRK1 HR1c domain consists of three α-helices (Figure 4.21). The first two helices form 
an antiparallel coiled coil structure which resembles the structure of other HR1 domains. 
Helix 1 spans 34 residues (Leu208-Ala241) while helix 2 spans 31 residues (Arg247-Glu277). 
Helix 3 is a C-terminal helix which spans 12 residues (Lys284-Ala295) in a total of 3.6 α-
helical turns. Two inter-helical loops exist, connecting helices 1 and 2 and helices 2 and 3, 
respectively. The first inter-helical loop comprises Ala242-Asp246 while the second inter-
helical loop comprises Leu278-Pro283. The N-terminal region of the protein is unstructured 
and this is in agreement with the TALOS-N secondary structure prediction. Overall, the 
secondary structure in the structure matched the prediction from TALOS-N. 
Helix 2 is fairly straight while helix 1 twists around it (slight left-handed twist). Helix 3 forms 
contacts with both the N-terminal part of helix 1 and the C-terminal part of helix 2 to form a 
triple helix, while it slightly twists around the other two helices. 
The structure is dependent on short (intra-residue), medium (i to i+3) and long range NOEs. 
The antiparallel coiled coil between helices 1 and 2 is formed by multiple, hydrophobic 
inter-helical contacts between side-chains of Ile215, Leu218, Phe222, His226, Ala229, 
Ala232, Leu236, Leu239 (helix 1) and side-chains of Val250, Ala253, Leu257, Asn261, 
Leu264, Leu267, Leu271 and Leu275 (Figure 4.22). At the same time, helix 3 is also involved 
in hydrophobic interactions with helices 1 and 2. For example, the Hδ of Leu288 (helix 3) 




























Figure 4.21 The NMR solution structure of PRK1 HR1c. (A) The ensemble of the 45 lowest energy 
structures of PRK1 HR1c. The backbone traces are overlaid. (B) Cartoon representation of the lowest 
energy structure. (C) End-on view of the protein in cartoon representation. Helix 1 wraps around helix 2 

































Figure 4.22 Inter-helical contacts in the coiled coil. (A) Helical wheel plot of the PRK1 HR1c coiled coil. 
Residues involved in inter-helical contacts are highlighted in blue. (B) Cartoon representation of the PRK1 
HR1c coiled coil (in blue). Residues involved inter-helical contacts are highlighted in yellow and the side-
chains are shown as sticks. The inter-helical contacts are also shown on each individual helix, highlighting 





The triple coiled coil region consists of interactions between all three helices. Out of the 
three helices, helix 2 contributes more side-chains to these interactions than helices 1 or 3 
do. The most extensive interactions involve the phenyl ring of Phe222 (helix 1) (Figure 4.23), 
which is buried between the methyl groups of Leu264, Leu267 and Leu271 (helix 2). 
Importantly the overall twist of helix 1 appears to favour docking of the phenyl ring in the 
hydrophobic pocket made by these three helix 2 leucines. The phenyl ring also makes 
hydrophobic contacts with the side-chain methyl group of Leu292 (helix 3) and with the Hβ 
of Ala295 (helix 3), promoting the positioning of helix 3 alongside helices 1 and 2. In 
addition, hydrophobic contacts are formed between Ile215 (helix 1), Leu271 (helix 2) and 



















Figure 4.23 The key long-range NOEs in the triple helical region. A cartoon representation of the triple 
helical region of PRK1 HR1c in blue. Residues involved in NOEs to Phe222 are shown as sticks and are 
coloured in yellow. Dotted yellow lines indicate the key NOEs. Phe222 (helix 1) is buried in a hydrophobic 
pocket made by Leu264, Leu267 and Leu271 (helix 2). Leu292 and Ala295 (helix 3) and His226 (helix 1) also 
















Important NOEs were also observed in the two inter-helical loops (Figure 4.24). The turn in 
the first inter-helical loop is mediated by the contact between the side-chain methyl group 
of Ala242 and the Pro245 side-chain. The remaining side-chains are solvent exposed. In the 
second inter-helical loop, the side-chain methyl of Leu278 (just after the end of helix 2) 
makes a Van der Waals contact with the Hα Gly285 (helix 3), helping to position helix 3 
against helix 2. The turn made by this inter-helical loop is dependent on contacts between 







Figure 4.24 The loop region NOEs. A cartoon representation of the inter-helical loops in PRK1 HR1c. PRK1 
HR1c is in blue while residues with key NOEs are coloured in yellow. Dotted yellow lines indicate the key 
NOEs. (A) Loop between helices 1 and 2. The side-chain methyl group of Ala242 contacts the side-chain of 
Pro245. (B) Loop between helices 2 and 3. The Hδ of Leu278 contacts the Hα of Gly285 (helix 3), while 




4.4.6 Comparison with other HR1 domain structures 
 
Structures of other HR1 domains have been solved and the HR1 domains all form anti-
parallel coiled coils. These HR1 domains are PRK1 HR1a (Maesaki et al., 1999; PDB:1CXZ), 
PRK1 HR1b (Owen et al., 2003; PDB:1URF), TOCA1 HR1 (Watson et al., 2016; PDB:5FRG) and 
CIP4 HR1 (Kobashigawa et al., 2009; PDB:2KE4). The structure of PRK1 HR1a is from a crystal 
structure in complex with RhoA (the GTPase may have an effect on the structure of the 
HR1a domain), while all other HR1 domain structures are NMR solution structures just like 
that of PRK1 HR1c presented here. 
All HR1 domains have two main α-helices which form an antiparallel coiled coil (Figure 4.25). 
The length of these helices however varies between the different HR1 domains. The length 
of helix 1 (38 residues in HR1a, TOCA1 and CIP4, 30 residues in HR1b and 34 residues in 
HR1c) is less variable than the length of helix 2 (25, 32, 31, 29 and 35 residues for HR1a, 
HR1b, HR1c, TOCA1 and CIP4, respectively). For HR1a, HR1c, TOCA1 and CIP4, helix 1 is 
longer than helix 2, with the difference in the number of residues between the two helices 
ranging from 3 to 13. In contrast, helix 2 of HR1b is longer than helix 1, although only by 2 
residues. The difference in length of helices 1 and 2 is greatest in HR1a and TOCA1 while it is 
much smaller in the case of HR1b, HR1c and CIP4. The length of the inter-helical loop also 
differs between the HR1 domains. While the inter-helical loop of all three PRK1 HR1 
domains comprises 5 residues, the loop of TOCA1 and CIP4 comprises of 10 and 9 residues, 
respectively. In addition, while the inter-helical loop of the PRK1 HR1 domains is 
unstructured, short 310 helices form in the loop of TOCA1 and CIP4. These subtle differences 
in structure, including the length and twist of helices as well as differences in inter-helical 
loops may explain the differential affinity of these HR1 domains for Rho GTPases. 
In all 5 HR1 domains, helix 2 is fairly straight while helix 1 twists (left handed-twist) around 
helix 2 to form the coiled coil structure. As the helices have variable length and are aligned 
at different angles with respect to each other, the resulting twist is not the same in the 5 
HR1 domains. This results in an inter-helical distance of approximately 10 Å at both coiled 
coil ends of HR1c, TOCA1 and CIP4. Contrastingly, in HR1a and HR1b the distance ranges 
from 10 to 12 Å. 
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HR1a and HR1c are special in that they have additional α-helices. HR1a has an N-terminal 
helix which comprises 5 residues and forms hydrophobic contacts with both of the main 
helices. The extra helix in HR1c is C-terminal and not N-terminal, but like the N-terminal 
HR1a helix, it also packs against the main two helices. A key difference between these two 
additional helices is their orientation. The C-terminal HR1c helix is slightly tilted with respect 
to the main two helices, while the N-terminal HR1a helix is much more tilted. The N-
terminal helix of HR1a has not been shown to actually exist in solution and may be an 
artefact of crystal packing. In contrast, the C-terminal helix of HR1c exists in solution. It is 
possible that it has a role as a stabilising helix in the interaction of the other two helices with 
a GTPase, similar to the stabilising helix of mDia1 which helps the protein’s two main helices 
interact with RhoC (Rose et al., 2005). Whether this helix is truly fixed to the other two 
helices in solution or whether it can freely move around was investigated in the next section 



































Figure 4.25 Structural comparison of HR1 domains. PRK1 HR1a (PDB:1CXZ) is in orange, PRK1 HR1b 
(PDB:1URF) is in green, PRK1 HR1c is in blue, TOCA1 HR1 (PDB:5FRG) is in red and CIP4 HR1 (PDB:2KE4) is 
in purple. (A) Structures of HR1 domains in cartoon representation. (B) The helices of each structure are 
represented by cylinders. The number of residues of each helix and the inter-helical distance at either end 





4.5 Relaxation analysis of the HR1c structure 
 
Relaxation is the process by which the bulk magnetisation of spins returns to equilibrium, 
i.e. it re-aligns with the z-axis. The rate of relaxation is dependent on the environment of the 
relevant nuclei as well as the motion of the entire molecule. Therefore, relaxation analysis is 
invaluable in providing such information. 15N relaxation experiments (T1, T2 and 
heteronuclear steady-state NOE experiments) are useful as they can provide information on 
ps-ns time-scale dynamics of backbone amides. To understand what these experiments 




4.5.1.1 Transverse and longitudinal relaxation 
Transverse relaxation is the process by which magnetisation in the xy-plane decays away to 
zero. Conversely, longitudinal relaxation is the re-appearance of the z-magnetisation to its 
equilibrium value. The rates of longitudinal and transverse relaxation,  (or ) and  (or 







where  and  are the longitudinal and transverse time constants, respectively. 
 
4.5.1.2 Relaxation mechanisms 
Two main relaxation mechanisms exist for spin-half nuclei, chemical shift anisotropy and the 
dipolar mechanism, and they will both be briefly discussed here. 
As discussed earlier in this Chapter, the magnetic moment of each nucleus interacts with the 





chemical shift, δ. The size of this small magnetic field and consequently the size of δ are 
dependent on each molecule’s orientation with respect to B0 (and also depends on the γ of 
each nucleus), i.e. δ is anisotropic. As the molecules tumble in solution, there is variation in 
their small magnetic field and it is this variation which can lead to relaxation. 
The second relaxation mechanism is the dipolar one, also known as dipole-dipole relaxation, 
which describes how spins can often experience the magnetic moment of a nearby spin. The 
local field experienced due to this nearby spin is inversely proportional to the cubic distance 
between the two spins (i.e. only occurs for neighbouring spins, typically <5 Å). The field is 
also dependent on the γ of both local field-generating and local field-experiencing spins 
(higher for 1H), as well as the orientation of the vector connecting the two spins with 
respect to B0. 
 
4.5.1.3 The correlation and the spectral density functions and T1 and T2 experiments 
In an NMR sample, the local magnetic field experienced by a spin, Blocal, is not constant but 
rather it randomly varies with time. The correlation function, ( , ) describes how Blocal 
varies between time  and time + , 
( , ) = ( ) × ( + ) 
with the vinculum indicating that this is strictly representative of a population ensemble of 
spins.  
The molecule’s rotational diffusion is described by the correlation function 
( ) = ×
| |
 
where  is the rotational correlation time (the average time it takes for a molecule to 


















For changes in local magnetic fields to cause relaxation, they must be oscillating near the 
Larmor frequency. It is therefore useful to Fourier transform the correlation function to 
obtain a frequency function, which is known as the spectral density function, ( ) 




1 +  
( ) =
2
1 +  
The Fourier transform changes the exponential decay function ( ) into the Lorentzian 
lineshape ( ). Figure 4.27 shows a plot of the spectral density function at three different 


























Figure 4.26 Correlation function plot. Plots of the correlation function at doubling values of the correlation 















The higher the value of , the lower the frequencies to which ( ) effectively spreads. An 
important point to note is that by integration the area under ( ) is , i.e. it is 
independent of . This practically means that with decreasing , the maximum value of 
( ) (at = 0; ), also decreases. This is important as the rate of longitudinal relaxation 






and is shown as a plot of ( ) against  in Figure 4.28. The maximum of this function is 


























Figure 4.27 Spectral density function plots. Plots of J(ω) at doubling values of the correlation time, τc. 














The reduced spectral density ( ) is the simplified version of ( ) which is independent of 
local fields and is written as 
( ) =
2
1 +  
such that        ( ) = ( ) 





In the fast motion limit,  is very small (e.g. in the case for small molecules), ≪ 1, 
therefore ( ) = 2 , i.e. the reduced spectral density function is independent of . 
In the slow motion limit, (e.g. in the case of small proteins), ≫ 1, therefore 
( ) = . 
The rate constant for longitudinal relaxation, , is given by 
Figure 4.28 Spectral density function at Larmor frequency. Plot of ( ) against the rotational 












= ( ) 
i.e.  is dependent on the reduced spectral density function. 









i.e. it depends on both (0) (the maximum value of the reduced spectral density function 
when = 0) and ( ). Importantly, the non-secular term is equal to , i.e. the 
longitudinal rate constant, , contributes to the transverse rate relaxation, . 
At fast motion, ( ) = 2  and (0) = 2  so the relaxation rate constants can be re-
written as 
= 2  
= 2  
This means that for small molecules, = , i.e. magnetisation disappears from the xy-
plane and re-appears on the z-axis at the same rate.  





This means that for large molecules ≫ , i.e. magnetisation disappears from the xy-
plane long before it re-appears on the z-axis. 
Finally, the  ratio, can be used to report on the apparent correlation time for backbone 
amides. Low values are indicative of local, highly dynamic motions on the ps-ns time-scale, 










In practice, for 15N T1 and T2 experiments, 15N-HSQC experiments are recorded with a series 
of increasing delays during which relaxation occurs. Peak intensities can then be fitted to an 
exponential decay 
( ) =  
where ( ) is peak intensity at delay ,  is peak intensity when the delay is zero and R is 
the rate of relaxation.  
 
4.5.1.2 The steady-state NOE experiment 
In steady-state NOE relaxation analysis (Keeler, 2005), a weak field is used to irradiate and 
therefore saturate a particular spin, i.e. z-magnetisation becomes equal to zero, e.g. when 
magnetisation of spin two is saturated, = 0. 
Irradiating spin two long enough leads to a steady state (ss) where magnetisation of spin 
one is constant and does not change with time, which can be written as 
= 0 
The Solomon equation for spin  magnetisation is expressed as 
= − ( ) − − −  
where ( ) is the rate of self-relaxation of spin one,  is the magnetisation of spin one,  
is the spin one magnetisation at equilibrium,  is the magnetisation of spin two,  is the 
spin two magnetisation at equilibrium and  is the rate of cross-relaxation. 
At steady state conditions, = 0 such that 
= 0 = − ( ) , − − −  
0 = − ( ) , − − −  








, = ( ) +  
which shows that cross-relaxation and the longitudinal relaxation rate of spin one both 
control the steady state NOE.  
The NOE enhancement by this experiment, , is determined by 
=
( ) + −
= ( ) 
on the assumption that = . 
 
4.5.1.3 The heteronuclear steady-state NOE experiment 
In the heteronuclear steady-state NOE experiment, spin one is the proton ( ) and spin two is 
the heteronucleus ( ), e.g. 15N. The 1H is saturated and changes to the 15N signal are 
observed. The experiment consists of a single re-focused INEPT where the magnetisation at 
the start is on the 15N and is subsequently transferred onto the 1H. 
The steady-state value of z-magnetisation on the heteronuclear spin, , , is given by 
, = ( ) +  
where ( ) is the rate of self-relaxation,  is the spin  magnetisation at equilibrium,  is 
the spin  magnetisation at equilibrium and  is the rate of cross-relaxation. 
The ratio of the equilibrium spin populations of the two spins is the same as the ratio of the 
gyromagnetic ratios of those spins 
=  
where = 267 ×  10     (for 1H) and = −27 × 10     (for 15N). 








which when substituted in the expression of ,  gives 
, = ( ) +  
Therefore the NOE enhancement by the heteronuclear steady-state NOE experiment, , , 
is given by 
, = ( ) 




= 2  
Therefore from the Solomon equations, we can get simplified expressions for ( )  and , 
( ) =  





(  represents the distance between the two spins,  is a constant termed the permeability 
of vacuum with value 4 × 10   and ħ is Planck’s constant). 
Substituting the ( ) and  expressions into the expression for ,  simplifies it to 
, = 2  
for fast motion (in small organic molecules). 
As  (1H) is positive and (15N) is negative, ,  will be negative for spins in fast motion. 











negative 15N signals, while for less dynamic backbone amides the ,  will be approximately 
zero.  
In practice, in heteronuclear steady-state NOE relaxation analysis, separate spectra are 
recorded with and without proton saturation (saturated and reference spectra, 
respectively). Heteronuclear NOE values are established by calculating the ratio of peak 
intensities 
=  
where  represents peak intensity. 
 
4.5.2 15N-relaxation experiments on PRK1 HR1c 
 
A heteronuclear steady-state NOE experiment was recorded on PRK1 HR1c and intensity 
ratios were calculated (Figure 4.29A). Negative values were obtained for N-terminal 
residues as well as the two C-terminal residues, which are unstructured and are therefore 
highly dynamic. A smaller intensity ratio was also seen with Ala242 and to a much greater 
extent Lys243 and Asp246, which are in the inter-helical loop. Similarly smaller intensity 
ratios were seen for residues in the second inter-helical loop (Ala280-His282). In contrast, 
the intensity ratios for the residues in all three helices were positive, suggesting that helix 3 
is truly fixed on the other two helices and is not swinging around in solution. 
T1 and T2 constant times were also obtained (Figures 4.29B-C). For helices 1 and 2, T1 values 
of most residues were greater than 0.8 s. In contrast, for helix 3 residues, T1 values ranged 
from 0.703-0.836 s, while T1 values for residues in unstructured regions were typically lower 
(~0.6 s). T2 values of most residues in all three helices and both inter-helical loops were 
~0.05 s, while for the unstructured N-terminus and the last two C-terminal residues, they 
were greater, with the greatest T2 value being ~15 times larger than the smallest T2 value. 
An interesting observation was made when then  ratio was plotted. The average ratio 




average ratio across helix 3 was 13.4, suggesting that this helix has a different orientation 
with respect to the principal diffusion axis of the molecule (the coiled coil), i.e. it is not 








































































































































































































































































































































































































































Figure 4.29 15N relaxation measurements for PRK1 HR1c. Experiments were recorded with a 1.6 mM PRK1 
HR1c sample in MTPBS pH 7.3 and 10% D2O recorded on a Bruker DRX500 at 25 
oC. Values were obtained 
from peak intensities from the relevant 15N-HSQC spectra. (A) 1H-15N heteronuclear NOE intensity ratios 
(saturated to reference experiment) for each residue. (B) T1 constant values for each residue. (C) T2 
constant values for each residue. (D) T1/T2 ratio for each residue. The grey bars indicate the mean T1/T2 





























































































































4.6 Investigating the structure of PRK3 HR1c 
 
4.6.1 Sequence alignment of the two HR1c domains 
 
The HR1c domains from PRK1 and PRK3 have high sequence identity and sequence similarity 
(Figure 4.30), yet it has been shown in Chapter 3 that they have considerable differences in 
terms of their oligomerisation and stability. PRK1 HR1c is monomeric in solution and has a 
melting temperature which is 5 oC higher than that of PRK3 HR1c, which oligomerises in 
solution. The solution structure of PRK1 HR1c confirmed secondary structure predictions 
and showed that both the two main helices but also the C-terminal helix actually exist. The 
differences between these two domains however suggest that PRK3 HR1c may structurally 
differ. Leu292PRK1 (helix 3) is conserved as Leu257PRK3, suggesting that the C-terminal helix 
may be packed against the other two helices of PRK3 HR1c. While Phe222PRK1 is strongly 
conserved as Leu187PRK3, this may prevent formation of the triple coiled coil, as the phenyl 
ring is crucial for several interactions with helix 2 and helix 3 side-chains. 
Interestingly, a leucine, a glutamate and an alanine in the C-terminal helix of PRK1 are 
replaced by three arginine residues in PRK3 which are on the same side of the helix, 
spanning two consecutive helical turns. These residues are solvent exposed in the PRK1 
HR1c structure but in PRK3 HR1c they may be involved in electrostatic interactions, which 
could possibly drive PRK3 HR1c oligomerisation. The C-terminal helix in PRK3 HR1c is the 
least conserved helix which might explain the significant difference in the oligomeric state of 










PRK1      DTQGSPDLGAVELRIEELRHHFRVEHAVAEGAKNVLRLLSAAKAP    245 
PRK3      --SGSPEPGP-ELLAEELQHRLHVEAAVAEGAKNVVKLLSSRRTQ    210 
            .***: *  **  ***:*:::** *********::***: ::  
 
 
PRK1      DRKAVSEAQEKLTESNQKLGLLREALERRLGELPADHPKGRLLREELAAASS-  297 
PRK3      DRKALAEAQAQLQESSQKLDLLRLALEQLLEQLPPAHPLRSRVTRELRAAVPG  263 




4.6.2 Investigating the structure of PRK3 HR1c by NMR 
 
To explore the possibility of studying the structure of PRK3 HR1c by NMR, the quality of 
NMR spectra of this protein was assessed by recording 2D-NOESY and 2D-TOCSY spectra on 
unlabelled protein. In contrast to the strong, sharp peaks seen in the 2D-NOESY and 2D-
TOCSY of PRK1 HR1c, weak peaks were observed in the case of PRK3 HR1c (Figure 4.31). This 
is a result of protein oligomerisation where there is dynamic exchange between the 
different oligomeric states, leading to broadening of the NMR signals. This is consistent with 
the AUC findings from Chapter 3. The structure of PRK3 HR1c was therefore not investigated 







Figure 4.30 Sequence alignment of PRK1 HR1c and PRK3 HR1c. Sequences were aligned with Clustal 
Omega. Asterisks highlight identical residues at all positions, colons highlight conservation of a strong 
group and periods highlight conservation of a weak group. The cylinders represent α-helices based on the 





























Figure 4.31 2D NOESY and 2D TOCSY spectra of PRK3 HR1c. NMR spectra of 0.7 mM PRK3 HR1c in 20 mM 
sodium phosphate pH 7.3, 150 mM NaCl and 10% D2O were recorded on a Bruker DRX500 at 25 
oC. The 
amide region which contains NH-NH NOEs is highlighted in the 2D NOESY while the NH-Hα etc. fingerprint 





This chapter details a solution NMR approach in determining the structure of PRK1 HR1c. 
The structure shows that HR1c consists of three helices. The two longest helices form an 
antiparallel coiled coil which is analogous to that of HR1a and HR1b. In addition, the third 
helix packs against the other two helices to form a triple helix. This C-terminal helix is absent 
in both HR1a and HR1b so it is a unique feature of the HR1c domain. The functional role of 
this helix remains unknown but it may have a role in the interactions of this HR1 domain 
with Rho GTPases. 
Similarly to HR1a and HR1b, HR1c is likely to also be a type D anti-parallel coiled coil effector 
of GTPases. Type D effectors are the most popular type of helical GTPase effector and 
include effectors of Rho, Rab and Arf GTPases (reviewed in Mott & Owen, 2015). Effectors of 
this type interact with the GTPase via a longer N-terminal helix and a shorter C-terminal 
helix. While the majority of helical GTPase effectors use a single pair of helices to bind to the 
GTPase, there are some exceptions. For example, mDia1 (another type D effector) forms 
two helices which interact with the switch regions of RhoC in a GTP-dependent manner 
(Rose et al., 2005). A third helix packs against these helices and stabilises their orientation, 
promoting GTPase binding. This stabilising helix also contributes two residues to the 
interaction with switch 2 of RhoC. The C-terminal helix of HR1c, which also packs against the 
two main helices, may therefore have a similar role in GTPase binding. 
The lack of published interacting partners of HR1c may suggest that this domain evolved 
away from the other HR1 domains and does not bind to GTPases. However HR1c may 
instead be involved in inter-domain interactions (either intra-molecular or inter-molecular) 
that are crucial for the formation of the HR1abc trimer (see Chapter 3). The C-terminal helix 
may have a role in mediating these interactions, which could explain why it is unique to the 
HR1c domain. The solution structure of HR1c is a powerful tool in the pursuit of structural 





Chapter 5 Investigating the intra- and inter-molecular interactions 




A key question regarding PRK1 is whether the three HR1 domains interact with each other 
or exist independently in solution. As shown in Chapter 3, HR1b and HR1c are monomeric in 
solution while HR1a and the HR1ab di-domain dimerise, suggesting that PRK1 dimerisation 
is mediated by inter-molecular HR1a-HR1a interactions. The characterisation of HR1abc by 
AUC however indicated that the tri-domain exists as monomer, dimer and trimer in solution. 
The trimer is indicative of further interactions in the context of HR1abc which only occur 
when HR1c is present in the context of HR1a and HR1b. These interactions could occur intra-
molecularly, i.e. between HR1 domains of a single HR1abc protomer, or inter-molecularly, 
i.e. between two or more protomers, driving trimer formation. Such interactions may be 
significant for the regulation of PRK1 activity, e.g. formation of inactive oligomers as seen in 
PRK2 (Bauer et al., 2012) or differential binding of oligomers to GTPases. The aim of this 
Chapter will therefore be to investigate these interactions and to structurally characterise 
HR1abc. 
 
5.2 Investigating the structure of the HR1abc tri-domain 
 
The gold standard to elucidate the intra-molecular and inter-molecular interactions is to 
obtain a structure of HR1abc. The following sections outline attempts to do this by NMR 






5.2.1 Investigating HR1abc by NMR 
 
To determine whether the quality of HR1abc spectra would enable the structural 
characterisation of HR1abc by solution NMR, a 2D NOESY spectrum was recorded on an 
unlabelled sample at 20 oC. The resulting spectrum contained few NH-NH and NH-Hα NOEs 
due to significant NMR signal linewidth broadening. Despite the fact that the spectrum was 
recorded at a concentration of 450 μM, where the trimer is the predominant species in 
solution (73.7% trimer), the spectrum was of poor quality. This is the result of the chemical 
exchange in the intermediate regime between the oligomeric states of HR1abc as observed 
previously in AUC experiments. 
To investigate whether the chemical exchange could sufficiently be decreased, a 2D NOESY 
was recorded at 5 oC. Figure 5.1 shows the overlaid 2D NOESY temperature titration spectra. 
As expected, at the lower temperature there was significantly stronger signal strength, as 
well as improved resolution. A number of new NOEs also appeared, suggesting a reduced 
rate of chemical exchange between the various oligomeric states of HR1abc. However, in 
comparison to other 2D NOESY spectra, such as that of HR1c (Chapter 4), there is still 
significant peak broadening and many NOEs are not visible. As a result, further investigation 




























Figure 5.1 2D NOESY titration spectra of PRK1 HR1abc. Overlaid NMR spectra of 0.45 mM PRK1 HR1abc in 
20 mM sodium phosphate pH 7.3, 150 mM NaCl, 5 mM DTT and 10% D2O were recorded on a Bruker 
DRX500 at 5 oC (blue) and 20 oC (red). 
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5.2.2 Crystallisation trials 
 
5.2.2.1 HR1abc crystallisation trials 
Initial crystallisation trials were set up in crystallisation plates screening a wide range of 
compounds. Drops were set up by mixing PRK1 HR1abc at 10 mg/ml at 1:1 and 1:0.5 ratios 
with the buffer in each well. Some phase separation was seen as early as one week but no 
further changes were observed in the next two months. Phase separation was primarily 
observed in wells with polyethylene glycol 3350 or polyethylene glycol 4000 as one of the 
components (Figure 5.2A). 
A second round of crystallisation trials was then carried out in order to screen around these 
conditions and therefore maximise the probability that a crystal would form. While phase 
separation was observed, as expected, no crystals formed even after one year. This suggests 














Figure 5.2 PRK1 HR1abc crystallisation trials. (A) Example of drop with phase separation as seen in PRK1 
HR1abc crystallisation trials set up with 10 mg/ml PRK1 HR1abc. (B) Example of drop with phase separation 
as seen in PRK1 HR1abc/RhoA Δ12 F25N Q63L co-crystallisation trials set up with 250 μM PRK1 HR1abc and 




5.2.2.2 HR1abc + RhoA Δ12 F25N Q63L crystallisation trials 
Since the crystal structure of HR1a was solved as a complex with RhoA (Maesaki et al., 
1999), it is possible that RhoA stabilised HR1a and promoted crystal formation. Therefore a 
similar approach was also employed with HR1abc. RhoA was purified from E. coli from a 
construct lacking the unstructured C-terminal tail which would hinder ordered crystal 
packing (Δ12). The F25N mutation makes recombinant RhoA soluble with no reported 
functional implications and it has been widely used in biochemical and biophysical studies. 
The Q63L mutation was used to ‘lock’ the GTPase in a constitutively active conformation. 
RhoA Δ12 F25N Q63L was purified and loaded with the non-hydrolysable analogue GMPPNP 
in the same way as RhoA Δ4 (see Chapter 6 for purification details). Crystallisation trials 
were set up using a 1:1 mixture of RhoA:HR1abc at a concentration of 250 mM for each 
protein. Some phase separation was observed during week one, however as with the 
previous crystallisation trials no crystals formed (Figure 5.2B). It therefore appeared that 
obtaining the structure of HR1abc was not amenable by X-ray crystallography. 
It is worth nothing that further screening could have been carried out at different protein 
concentrations, lower temperatures or using other buffers. However given the 













Section 5.2 highlights the experimental obstacles encountered when attempting to 
investigate the structure of the HR1abc tri-domain. In brevity, the reversible intra- and inter-
molecular interactions of HR1abc prevent its structural characterisation by NMR and X-ray 
crystallography. Without a structure it is difficult to know whether the HR1 domains interact 
or are independent of each other but also, if they interact, which contacts they form and 
how. Structural studies of equivalent systems have been published but they are driven by 
mutations that stabilise the protein in a single oligomeric state. Therefore a monodisperse 
sample can be obtained and structurally characterised, e.g. as with amyloid-β oligomers 
(Sandberg et al., 2010). This was not possible with HR1abc as the HR1a dimerisation site and 
inter-HR1 contact sites are not known. In addition, even if the structure of such a 
monomeric mutant protein was available, it may not be physiologically relevant. 
To bypass this problem, it was decided to dissect the sum of intra- and inter-molecular 
interactions by studying interactions between individual HR1 domains or between the 
HR1ab di-domain and HR1c. The aim was to obtain different puzzle pieces which would be 
put together to give us a structural understanding of HR1abc. 
 
5.3.2 Isothermal Titration Calorimetry experiments 
 
Isothermal Titration Calorimetry (ITC) is a biophysical method used to study protein-protein 
interactions. It involves heat changes occurring when two proteins interact. These heat 
changes are produced when a protein in a syringe is gradually injected into another protein 
in a cell. This allows the derivation of parameters such as Kd, entropy change and 
stoichiometry of the interaction. ITC depends on polar or charged residues involved in the 
interaction, so it is not useful in identifying or characterising protein-protein interactions 
which are driven solely by hydrophobic contacts. 
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If the HR1 domains interact via charged or polar residues, then a heat change is expected 
upon such an interaction. ITC was used to not only identify such HR1 inter-domain 
interactions, but also to provide a measure of the affinity between the two domains. While 
these affinities would be of isolated domains in vitro, they would still be helpful, e.g. to 
compare to published affinities of HR1 domains for GTPases. This could help understand if 
GTPases could potentially disrupt these interactions. 
In this case, the HR1ab di-domain was placed in the cell and HR1c was titrated from the 
syringe. Since HR1ab can dimerise, it would be disadvantageous to place it in the syringe, as 
the change from high to low concentration upon injection could lead to release of a heat of 
dilution which would complicate the interpretation and potentially obscure any heat 
changes arising from HR1ab interacting with HR1c. The experiment was repeated at two 
concentrations; 500 μM HR1c into 50 μM HR1ab and 5 mM HR1c into 500 μM HR1ab. No 
heat changes were observed in either case, indicating that either HR1ab does not interact 
with HR1c or that any inter-domain interactions must be solely hydrophobic. 
 
5.3.3 NMR titrations with individual domains 
 
The HR1abc trimer, the formation of which is thought to be driven by intra-molecular and 
inter-molecular interactions, becomes the primary species in solution only at high μM 
concentrations (above 400 μM; see Chapter 3). This suggests that any possible interactions 
between HR1 domains are weak, making them difficult to be detected by techniques such as 
pull-downs using recombinant proteins. This is because the HR1 proteins would need to be 
at concentrations at least ten-fold above the Kd (to ensure binding) and this is not possible. 
If these interactions are solely hydrophobic, then methods such as ITC also fail, as discussed 







NMR is a powerful tool for studying protein-protein interactions. The sensitivity of NMR 
enables the fingerprinting of potentially all of the individual protons in the protein. The 
ability of NMR to detect tiny changes in the chemical environment of protons means that it 
can be employed to study all kinds of protein-protein interactions, including transient, weak 
interactions. Typically, NMR protein-protein interaction studies are carried out as titrations, 
where an unlabelled protein is gradually titrated into a labelled protein and experiments, 
e.g. 15N HSQC, are recorded at each titration point. Interactions are detected in the form of 
chemical shift perturbations (CSPs) which reflect a change in the chemical environment of 
protons. 
Chemical exchange refers to the dynamic interconversion of a proton between two or more 
distinct states or environments (reviewed in Kleckner & Foster, 2010; Williamson, 2013). 
NMR spectra can be affected by chemical exchange and are typically categorised in three 
exchange regimes (Figure 5.3) based on the rate of the chemical exchange, , which is a 
measure of the stochastic exchange events per second (and is temperature-dependent). 
These regimes are slow exchange, intermediate exchange and fast exchange and are 
defined by the value of  relative to the chemical shift difference, . 
For residues undergoing slow exchange ( ≪ | |), two distinct peaks are observable. 
One peak is at the chemical shift of the original, unbound state and the second peak is at 
the chemical shift of the bound state. As the protein population in the bound state increases 
and the population of the free state decreases, the intensity of peaks of the bound state 
increases while the intensity of peaks of the unbound state decreases. 
When ≫ | |, fast exchange occurs. A single peak is observed which is representative 
of both bound and unbound species populations. The peak is a population-weighted 
average and its exact chemical shift depends on the proportion of each of the bound and 
unbound species. Comparing such peaks from experiments with different ligand 
concentrations appears as if the peak is moving in a single direction. Fast exchange is often 
observed for protein-protein interactions with low affinities. 
Intermediate exchange, as the name suggests, results when ≈ | |. In this regime, the 
peak is observed at an average chemical shift of the unbound and bound states. 
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Interconversion between bound and unbound states (ms timescale) during the detection 
step of NMR experiments leads to ‘exchange broadening’, i.e. peaks have broadened 




















Figure 5.3 Chemical exchange regimes in NMR. (A) Examples of slow, intermediate and fast exchange of a 
single resonance in a 1D NMR spectrum. In the slow exchange regime, two peaks are observed, each at the 
chemical shift of the free (ωfree) and bound (ωbound) states. In the fast exchange regime, a single peak is 
observed at a population-weighted average chemical shift of the free and bound states. Δω increases with 
a stronger magnetic field and kex increases with increasing temperature. In the intermediate exchange 
regime, the linewidth is increased as a result of exchange broadening. (B) Examples of slow, intermediate 
and fast exchange in a 2D spectrum. Peaks have the same shape throughout in the limit of fast exchange. 
In slow exchange, the intensity of the bound species peak increases with increasing ligand concentration, 




5.3.3.2 15N HR1c + HR1a 
Unlabelled HR1a was titrated into 15N HR1c and 15N HSQC experiments were recorded. Small 
chemical shift changes were observed and shift changes continued to occur when the 
HR1c:HR1a ratio was increased from 1:2 to 1:6. Small chemical shift changes are indicative 
of a weak interaction between HR1c and HR1a. The chemical shift changes however are also 
small because the backbone amide protons are physically shielded in an α-helix. The shift 
changes were all in the fast exchange regime. 
Two main binding sites were concluded from the data. These were indicated by the greatest 
shift changes across the entire protein (Figure 5.4). The first site, which is the one with the 
greatest shift changes, spans Val224 to Ala232. The exact sequence is VEHAVAEGA, which 
consists of a mixture of hydrophobic and charged residues. The greatest shift change occurs 
to Val228 at the centre of the sequence, which is solvent exposed (side-chain is 60% solvent 
exposed) according to NACCESS (Hubbard & Thornton, 1993). The largest shift changes 
occur with a periodicity of i to i+3, which is indicative of a single surface on the α-helix being 
used in the interaction. As with Val228, Glu225 and Gly231 are also solvent exposed. The 
remaining residues that shift, such as Ala229, probably do not contribute to the interaction 
with HR1a, but instead show chemical shift changes as a result of a propagated effect from 
the interacting residues. 
A second site is also found in helix 1 of HR1c, spanning Val235 to Ala242, and Asp246 in the 
inter-helical loop. Helical i to i+3 periodicity is also observable here, specifically between 
Leu236, Leu239 and Ala242. Ala242 is the first residue of the flexible HR1c inter-helical loop 
(Ala242 to Asp246). The sequence of this second site is VLRLLSAAKAPD. 
Smaller chemical shifts of approximately half the magnitude are observed with some helix 2 
residues, specifically Gln254, Lys256, Thr258 and Ser260. However only Lys256 and Ser260 
are on the same interface as the interacting residues above, therefore it is likely that if helix 
2 of HR1c interacts with HR1a, it will be via these two residues. 
It is important to keep in mind that HR1a also exists in a dynamic equilibrium between 
monomer and dimer as indicated by AUC experiments. This means that HR1a dimerisation 
and the HR1a interaction with HR1c are occurring simultaneously. It cannot be concluded 
from the data whether HR1c preferentially interacts with HR1a monomer or dimer. The 
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concentration of HR1a in these experiments ranges from 60 μM (1:0.25), where HR1a exists 
mainly as monomer, to 1.4 mM (1:6), where ~90% of HR1a is expected to be dimeric. The 
fact that the HR1a shift changes remain small even when a high concentration of HR1a is 
achieved can be explained in one of two ways. Firstly, that HR1c interacts with the HR1a 
dimer equally strongly to the monomer but the interaction with both is weak. Secondly, that 
HR1c interacts only with either the HR1a monomer or the dimer, i.e. the HR1c-HR1a 
interaction blocks or enhances the HR1a-HR1a interaction. Assuming that the HR1abc trimer 
is formed from the HR1abc dimer, it is unlikely that HR1a dimerisation is disrupted by the 
HR1a-HR1c interaction (which may drive trimer formation). Therefore HR1a dimerisation is 
unlikely to compete with the HR1a-HR1c interaction. 
Plotting the normalised intensity changes for each residue reveals that there is an intensity 
drop from the beginning to the end-point of the titration. The intensity changes are not 
selective for any particular region of HR1c but are indicative of linewidth broadening due to 
formation of the HR1a-HR1c complex under intermediate exchange. 
When mapping protein-protein interaction interfaces by NMR, titrations are often carried 
out reciprocally, using either 15N-labelled protein. This was not done in this case as previous 
work in the lab has shown that the HSQC spectrum of 15N HR1a looks broadened (due to the 


































Figure 5.4 Quantitative analysis of 15N HSQC spectra when HR1a was titrated into 15N HR1c. (A) Bar chart 
showing the chemical shift changes for each residue of HR1c. The black line represents the mean combined 
shift change. Mean: 0.0078, standard deviation: 0.0074. (B) Residues which shifted more than the mean 






























































5.3.3.3 15N HR1c + HR1b 
To investigate whether HR1b also interacts with HR1c, HR1b was titrated into 15N-labelled 
HR1c and HSQC experiments were recorded. Small chemical shift changes were observed 
and they were also indicative of fast exchange. The greatest shift changes observed were 
approximately half in magnitude compared to those in the HR1a-HR1c interaction (Figure 
5.5). This suggests that HR1c interacts with HR1b more weakly than it does with HR1a. 
One HR1b binding site appeared to be identical to the first HR1a binding site, i.e. 
VEHAVAEGA, with larger shift changes at i to i+3 intervals. Glu225, Val228 and Gly231 
showed the biggest changes in this binding site, consistent with their solvent accessibility. 
This HR1c binding site is therefore shared by both HR1a and HR1b, suggesting that these 
two domains may compete for binding to the same site or that each one binds to this site in 
a different protomer in the context of an HR1abc oligomer. The second binding site was also 
shared with HR1a as indicated by the Val235, Leu239, A242 and D246 shift changes. A third 
potential binding site was seen in helix two and comprised Gln254, Thr258, Asn261, Leu264, 
Leu267 and Leu271, i.e. residues with helical periodicity, with the largest shift change being 
that of Leu267. While Gln254 and Thr258 also shifted in the HR1a titrations, the remaining 
residues (Asn261, Leu264, Leu267 and Leu271) had only shifted very slightly (section 
5.3.3.2). Another difference with the HR1a titrations is that with HR1b the shift changes 
seen in helix 2 are of approximately the same magnitude as the shifts in helix 1, while in 
HR1a the few helix 2 shift changes were much smaller than the helix 1 shift changes. This 
suggests that both sites could equally be used by HR1c. Finally, non-selective intensity 
changes were also observed as with HR1a. 
Interestingly, the HR1b contact sites are found on opposing sides of the HR1c coiled coil 
(Figure 5.5B). It is possible that one HR1b molecule binds to HR1c using contact sites one 
























































































Figure 5.5 Quantitative analysis of 15N HSQC spectra when HR1b was titrated into 15N HR1c. (A) Bar chart 
showing the chemical shift changes for each residue of HR1c. The black line represents the mean combined 
shift change. Mean: 0.004, standard deviation: 0.0036. (B) Residues which shifted more than the mean 





5.3.3.4 15N HR1c + HR1a + HR1b 
To investigate whether HR1b can interact with HR1c in the presence of HR1a, HR1b 
titrations were carried out on the NMR sample containing HR1c and HR1a in a 1:6 ratio. 
Some small shift changes were observed and were clustered at the first and second contact 
sites and specifically involved Val228 and Val235 (Figure 5.6). The greatest shift change was 
that of Leu267 in helix 2, which is consistent with the observed results in the HR1b 
titrations. None of the other HR1b contact site three residues shifted significantly, 
suggesting that HR1b binding to HR1c in complex with HR1a may not occur identically to 
when HR1b binds to free HR1c. The other explanation however could be that HR1a (as 
dimer) and HR1b, which are both in six-fold excess to HR1c, may preferentially interact with 
each other, i.e. HR1a interacts with HR1b, preventing it interacting with HR1c. Regardless, 
the lack of major shift changes suggests that HR1b does not form many further contacts 
with HR1c in the presence of HR1a. Additionally, reduced intensities on addition of HR1b 
































































































Figure 5.6 Quantitative analysis of 15N HSQC spectra when HR1b was titrated into 15N HR1c + HR1a. (A) 
Bar chart showing the chemical shift changes for each residue of HR1c. The black line represents the mean 
combined shift change. Mean: 0.0046, standard deviation: 0.004. (B) Residues which shifted more than the 















5.3.3.5 15N HR1c + HR1b + HR1a 
To investigate whether HR1a can interact with HR1c in the presence of HR1b, HR1a 
titrations were carried out on the NMR sample containing HR1c and HR1b in a 1:6 ratio. 
Very small chemical shift changes (~0.01) were observed (Figure 5.7). These changes 
primarily involved the VEHAVAEGA binding site (but also the VLRLLSAA site), suggesting that 
HR1a may be displacing HR1b to bind to HR1c. This can also be explained in terms of HR1a 
and HR1b existing in a dynamic, linked equilibrium with HR1c where more HR1a than HR1b 
molecules bind to HR1c at a given time (the changes seen here reflect a population 










































Figure 5.7 Quantitative analysis of 15N HSQC spectra when HR1a was titrated into 15N HR1c + HR1b. (A) 
Bar chart showing the chemical shift changes for each residue of HR1c. The black line represents the mean 
combined shift change. Mean: 0.0034, standard deviation: 0.0034. (B) Residues which shifted more than 







































































5.3.3.6 15N HR1c + HR1ab 
The interactions of HR1a and HR1b with HR1c were also investigated by titrating the di-
domain HR1ab into 15N HR1c. Small shift changes were observed with a magnitude similar to 
HR1b, suggesting that HR1ab, like HR1b, binds more weakly to HR1c than HR1a does (Figure 
5.8). This also suggests that HR1b hinders binding of HR1a to HR1c (possibly because HR1a 
and HR1b interact with each other). At the titration end-point, the concentration of HR1ab 
was approximately six times higher than the Kd of HR1ab dimerisation, i.e. a HR1ab was 
mainly dimeric. This suggests that dimeric HR1ab can interact with HR1c. 
The majority of the observed shift changes were clustered in the same two sites seen in the 
case of HR1a. The first site ranged from Val224 to Ala232 with the greatest shift change 
being that of Gly231, which is consistent with what was observed previously with the single 
HR1a domain. Interestingly Val228 did not shift in a single direction but ‘moved around’, 
possibly due to distinct interactions with both HR1a and HR1b. The second contact site 
ranged from Val235 to Ala242, i.e. the end of helix 1 and part of the inter-helical loop. The 
shift of Ser240 was the greatest however the Leu239 shift was of similar magnitude, which 
was once again consistent with the HR1a titration results. Some additional shift changes 
were seen at a third site which matched the other HR1b interacting interface. These shift 
changes included Thr258, Asn261, Leu264 and Leu267 which were observed previously with 
HR1b. Interestingly Leu271 did not shift much in these HR1ab titrations in contrast to the 
HR1b titrations. Regardless, when the HR1a, HR1b and HR1ab chemical shift mapping data 
are put together, we can conclude that HR1ab can weakly interact with HR1c and that the 
interaction is driven by HR1a with possible cooperative binding by HR1b. 
Line broadening was also observed as indicated by the reduced intensities, suggesting that a 
complex forms between HR1ab and HR1c. The intensities were reduced by as much as 40-
50% in contrast to the smaller percentage changes seen in the experiments above. This 
suggests that when all three HR1 domains are present, and HR1a and HR1b are tethered by 
a linker sequence, they can form a complex that is in intermediate exchange (there could 
also be two ongoing exchange processes; formation of the trimer and HR1a dimerisation). 
This also highlights the effects of tethering the domains. In cells the three HR1 domains are 
covalently linked so the effective molarity is much higher than when they exist as individual 
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domains in vitro. This may explain why the HR1abc trimer is the predominant species at 400 





































































































5.3.4 15N PRK1 HR1ab 
 
5.3.4.1 Purification of 15N HR1ab 
15N-labelled PRK1 HR1ab was expressed in M9 minimal medium and was purified as shown 
previously for the unlabelled protein. An NMR sample was made up at a concentration of 
357 μM. 
 
5.3.4.2 Optimising the 15N HR1ab HSQC 
The 15N HR1ab recorded at a concentration of 357 μM suffered from poor spectral 
dispersion as a result of chemical exchange. Chemical exchange was suspected from the 
AUC results (Chapter 3), therefore it was decided to dilute the sample and record another 
HSQC spectrum. New peaks appeared as the concentration was lowered (Figure 5.9). At first 
glance the 15N HSQC of HR1ab overlays with the 15N HSQC of HR1b (provided by Dr. Helen 
Mott) (Figure 5.11). Most of the peaks which appeared when diluting HR1ab do not 
correspond to peaks in the HR1b spectrum, suggesting that those peaks are of HR1a 
Figure 5.8 Quantitative analysis of 15N HSQC spectra when HR1ab was titrated into 15N HR1c. (A) Bar 
chart showing the chemical shift changes for each residue of HR1c. The black line represents the mean 
combined shift change. Mean: 0.004, standard deviation: 0.0035. (B) Residues which shifted more than the 
mean chemical shift change of all residues are coloured magenta on the structure of HR1c. (C) Ratio of 


























































































backbone amides and their linewidth broadening is due to intermediate exchange between 
the monomeric and dimeric states. Approximately 50 new peaks appeared out of a total of 
~120 peaks missing of HR1a (and inter-domain linker) residues when the concentration 
changed from 357 μM to 15 μM. However, most of the peaks which appeared are very weak 
in comparison to the peaks which correspond to HR1b backbone amides. This suggests that 
there is still considerable intermediate exchange between monomeric and dimeric HR1a, 
even at 15 μM which is ten-fold below the dimerisation Kd of HR1ab. In an attempt to 
further improve the spectrum, an HSQC was recorded at a higher concentration of NaCl, 
which would disrupt any salt bridges that could be involved in HR1a dimerisation. However 
no considerable change was seen (Figure 5.10). 
Some peaks which were only observed in HR1ab and must therefore belong to HR1a (or to 
the 15 amino acid linker between HR1a and HR1b) were strong in the spectra at all the 
different concentrations. One of these was identified as the side-chain NH of Trp13, which is 
located at a distinct 1H/15N shift. In HR1ab, the HR1b peaks do not undergo line broadening 
at high concentrations while HR1a peaks do, suggesting that the two domains exist 
independently in solution. However on closer inspection, some of the HR1b peaks in the 
HR1ab spectrum show small shift changes relative to their position in the HR1b spectrum 
(Figure 5.11A). As HR1b is monomeric, the shift changes must be due to an interaction that 
exists between HR1a and HR1b. Whether HR1b interacts with monomeric or dimeric HR1a 
cannot be concluded from these data however. 
The chemical shift changes were mapped and are shown in Figure 5.11B. One contact site 
was identified, spanning residues Arg185 to Leu193 which are located in helix 2 of HR1b. 
These residues are centred around Gln189 which shows the greatest shift change. 
Additionally, α-helical i to i+3 periodicity is observed between Arg186 and Gln189 which 
show large shift changes, while Leu193 is also on the same side as these two residues (and it 
is the last residue of helix 2). These residues are also solvent exposed (>50%), suggesting 
this is the contact site on HR1b for HR1a. Interestingly, Val128 and Leu131 (start of helix 1) 
are close to this contact site and also show shift changes, so perhaps they are also part of 





























Figure 5.9 15N-HSQC spectrum of PRK1 HR1ab. (A) 15N-HSQC spectra of PRK1 HR1ab in 50 mM Tris-HCl pH 
7.5, 150 mM NaCl, 5 mM DTT and 10% D2O at concentrations ranging from 357 μM to 15 μM (red to blue) 
were recorded on an Avance AV800 at 25 oC. (B) 15N-HSQC spectrum of PRK1 HR1ab at 50 μM 


























Figure 5.10 Effect of NaCl on quality of the 15N-HSQC spectrum of PRK1 HR1ab. 15N-HSQC spectra of 50 
μM PRK1 HR1ab in 50 mM Tris-HCl pH 7.5, 150 mM (green) or 250 mM (purple) NaCl, 5 mM DTT and 10% 
D2O were recorded on an Avance AV800 at 25 


























Figure 5.11 Comparison of PRK1 HR1b and PRK1 HR1ab. (A) 15N-HSQC spectrum of 50 μM PRK1 HR1ab in 
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM DTT and 10% D2O (green) overlaid with PRK1 HR1b spectrum 
(black) provided by Dr. Helen Mott. (B) Bar chart showing the chemical shift changes for each residue of 
HR1ab in comparison with HR1b. The black line represents the mean combined shift change. Mean: 
0.0026, standard deviation: 0.0023. (C) Residues which shifted more than the mean chemical shift change 





























































































































































































































5.3.4.3 15N HR1ab + HR1c 
To investigate the binding of HR1c to HR1ab, titrations were carried out using an NMR 
sample of 15N HR1ab at 50 μM, since at this concentration there is considerable number of 
new peaks appearing in comparison to higher concentrations. No significant shift changes 
were observed. A few shift changes were observed in helix 2, primarily those of Leu163, 
Ala166 and Gln167 but they were very small (Figure 5.12). A few other shift changes were 
not clustered so cannot be considered important in the binding of HR1c. It is possible that 
HR1c is interacting with HR1a residues whose backbone amide peaks are not observable in 
the HSQC (and the results above suggest that HR1a interacts with HR1c more strongly than 
HR1b does). HR1ab is also mainly monomeric at 50 μM, so it is possible that no shift changes 
were observed because HR1c prefers to interact with dimeric HR1ab; the reciprocal titration 
suggested that HR1c binds to dimeric HR1ab and was also characterised by line broadening 
(suggesting the formation of a larger complex). Unlike the reciprocal 15N HR1c + HR1ab 
experiment, intensity changes were minimal suggesting that HR1c does not interact with 
monomeric HR1ab. The significant line-width broadening in HSQC of dimeric HR1ab would 
in theory prevent mapping the binding interface of HR1c on the di-domain, however this has 


























































































Figure 5.12 Quantitative analysis of 15N HSQC spectra when HR1c was titrated into 15N HR1ab. (A) Bar 
chart showing the chemical shift changes for each HR1b residue in HR1ab. The black line represents the 
mean combined shift change. Mean: 0.0036, standard deviation: 0.0024. (B) Residues which shifted more 





5.3.5 Cross-linking experiments 
 
5.3.5.1 Theory 
Weak protein-protein interactions pose a hurdle when they are being investigated, as they 
are reversible and the concentration of purified proteins is often not much higher than the 
Kd of the interaction, meaning that protein samples are often a mixture of bound and 
unbound species. In turn, polydispersity hinders detailed structural investigation. 
Cross-linking agents are becoming increasingly popular as tools that can be used to lock 
proteins in a particular conformation or stabilise a weak, transient protein-protein 
interaction (López-Alonso et al., 2009; Hu et al., 2012; Lepvrier et al., 2014). The aim was 
therefore to investigate whether cross-linking agents could be used to stabilise monomeric 
or oligomeric HR1a, HR1ab and HR1abc, which would provide an understanding of the 
species formed by intra- and inter-molecular interactions and also ideally produce a 
monodisperse sample that would facilitate structural studies. 
 
5.3.5.2 Chemistry of the different cross-linking agents 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is a zero-length, heterobifunctional 
cross-linker, which can conjugate carboxylates (-COOH) to primary amines (-NH2) via an 
amide bond. It is a zero-length cross-linker because it does not become part of the cross-
link. As a result, it is considered to have increased cross-linking specificity over other cross-
linkers, as any initial modification of a carboxylate that does not successfully lead to a 
reaction with a primary amine leads to the regeneration of the carboxylate group (Figure 
5.13). 
Dimethyl suberimidate (DMS) and dimethyl pimelimidate (DMP) are homobifunctional 
cross-linkers with identical lysine-reactive groups at either end. DMS and DMP only differ in 
the length of the spacer arm, with DMP being a methylene group shorter. As their spacer 




















The first step was to perform small scale trials at different cross-linking agent 
concentrations. Three concentrations of each cross-linker were chosen and they were 
tested against HR1a, HR1ab and HR1abc. Following incubation at 30 min or 5 h at room 
temperature or overnight incubation at 4 oC, gel samples were taken and were analysed by 
SDS-PAGE. The concentration of HR1a and HR1ab was 1.5 mM, which is ten-fold above the 
dimerisation Kd of these proteins. The concentration of HR1abc was 0.7 mM; at this 
concentration HR1abc is predominantly trimer in solution. These protein concentrations 
aimed to allow the cross-linking and stabilisation of oligomeric complexes that could be 
further investigated structurally. 
Figure 5.14 shows the HR1a cross-linking trials. At 10 mM, EDC caused the formation of a 25 
kDa species which was identified as an HR1a dimer, while a bigger species of ~35-40 kDa 
was also observed (probably a trimer). The majority of the protein appeared to run as a 
monomer on the gel, suggesting that either it was unmodified or intramolecularly cross-
linked. At 20 mM EDC the concentration of monomer was significantly reduced in 






comparison to 10 mM EDC. The levels of the dimer were also reduced while a range of high 
order oligomeric species formed. At 40 mM EDC, less monomer, less dimer and a greater 
proportion of higher order oligomers formed. Since HR1a is known to only exist as monomer 
and dimer in solution, the oligomers seen here are non-physiological, suggesting that EDC is 
inducing non-specific cross-linking. The dimer seen on the gels may therefore not be a 
stabilised version of the dimer which forms in solution. Obtaining a monodisperse sample of 
the dimer which can be used in biophysical analysis is therefore unobtainable by this 
method. 
In the case of DMS and DMP, monomer and dimer were the main species observed across 
all cross-linking agent concentrations (Figures 5.14B-C). While there was no major difference 


















Figure 5.14 PRK1 HR1a cross-linking trials. Cross-linking was performed at a range of EDC, DMS or DMP 
concentrations. (A) EDC reactions after 5 h at room temperature or overnight at 4 oC. (B) DMS and DMP 
reactions after 5 h at room temperature or overnight at 4 oC. (C) EDC, DMS and DMP reactions after 30 







of the protein remained monomeric, either because it didn’t react with the cross-linking 
agent, or because it was stabilised intra-molecularly. Higher order oligomers formed at low 
levels and were generally lower when DMP was used, suggesting that the ‘longer arm’ DMS 
causes slightly higher levels of non-specific cross-linking. 
Cross-linking of PRK1 HR1ab with EDC produced similar results to HR1a cross-linking with 
EDC. Some dimer was observed at 10 mM EDC although most of the protein remained 
monomeric (Figures 5.15A and 5.15C). At higher concentrations of EDC, the levels of 
monomer and dimer decreased and higher molecular weight species formed, once again, 




















Figure 5.15 PRK1 HR1ab cross-linking trials. Cross-linking was performed at a range of EDC, DMS or DMP 
concentrations. (A) EDC reactions after 5 h at room temperature or overnight at 4 oC. (B) DMS and DMP 
reactions after 5 h at room temperature or overnight at 4 oC. (C) EDC, DMS and DMP reactions after 30 
min. 







Cross-linking of PRK1 HR1abc with EDC resulted in mainly monomer and low levels of dimer 
at 10 mM EDC, while at higher EDC concentrations HR1abc formed higher-order oligomers 
which ran as a smear on the gel or were stuck in the stacking gel wells (Figures 5.16A and 
5.16C). With DMS and more so with DMP, the major species was the monomer so it was 























Figure 5.16 PRK1 HR1abc cross-linking trials. Cross-linking was performed at a range of EDC, DMS or DMP 
concentrations. (A) EDC reactions after 5 h at room temperature or overnight at 4 oC. (B) DMS and DMP 
reactions after 5 h at room temperature or overnight at 4 oC. (C) EDC, DMS and DMP reactions after 30 







The stabilisation of HR1a, HR1ab and HR1abc monomers by these cross-linkers was 
investigated by setting up cross-linking reactions of the best conditions identified above and 
the products analysed by size exclusion chromatography in comparison to a control 
reaction. The elution volume of the monomer remained identical between control and 
cross-linked samples suggesting that monomers seen in the trials above were not stabilised. 
In order to stabilise the interaction between HR1ab and HR1c, cross-linking studies were set 
up (Figure 5.17). While a low level of a species corresponding to the molecular weight of 
HR1abc can be seen in both EDC and DMS reactions (particularly in the EDC reaction), HR1c 
itself is cross-linked by both EDC and DMS. 
The failure of cross-linking reactions to stabilise oligomers doesn’t mean that these 
oligomers don’t form in solution. It simply implies that the appropriate functional groups are 
















Figure 5.17 Cross-linking trials of PRK1 HR1ab and PRK1 HR1c. Cross-linking reactions were set up with 1.5 
mM PRK1 HR1ab mixed with 1.5 mM PRK1 HR1c or with PRK1 HR1c alone (control reaction). (A) EDC 
reactions were performed with 10 mM EDC overnight at 4 oC. (B) DMS were performed with 20 mM DMS 







The interactions between the three PRK1 HR1 domains are weak interactions. Therefore a 
question arises as to whether these weak, transient interactions are truly physiologically 
relevant. However these weak affinities are of individual domains which are independent in 
solution. Physiologically, these domains exist in the context of the HR1abc tri-domain and 
they are covalently linked to each other so that their effective molarity is much higher. 
Therefore the affinity of these domains for each other in vivo is likely to be higher than 
experiments with individual domains suggest. Furthermore, evidence has been presented 
here that all three of the PRK1 HR1 domains interact with each other; HR1a with HR1b, 
HR1a with HR1c and HR1b with HR1c. These interactions may be intra-molecular or inter-
molecular. Therefore the effective molarity is expected to be further enhanced as more of 
these intra- and inter-molecular interactions occur, i.e. there probably is a cooperative 
effect in the formation of the HR1abc trimer. The HR1abc trimer itself is probably driven by 
the HR1a·HR1c and HR1b·HR1c interactions, as HR1ab only forms monomer and dimer, and 
it is the presence of HR1c (which is monomeric by itself) in the context of HR1abc which 
leads to trimer formation. An important piece of the puzzle that is missing however is the 
stoichiometry of these interactions; for example, two HR1a domains may interact with a 
single HR1c domain via each of the two main binding sites on helix 1 or two HR1b domains 
may interact with HR1c, each on one of two opposite surfaces. 
The interaction of HR1a with HR1b may also compete with the interaction of these two 
domains with HR1c. This is suggested by the inability of the HR1ab to interact with HR1c 
while monomeric HR1a may interact (early titration points; see section 5.3.3.2). 
Interestingly none of these contact sites involve residues in helix 3 of HR1c. The function of 
this unique C-terminal helix therefore remains unknown. 
These HR1-HR1 interactions may be weak and transient, however equivalent interactions 
are important in cellular signalling. Their purpose often involves the rapid activation and 
ensuing inactivation of signalling pathways through the formation of reversible protein-
protein interactions. In this case they could allow HR1abc to transiently exchange between 
different oligomeric states, each of which may have a particular functional role. The 
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domains are also covalently linked in full length PRK1 and therefore their effective molarity 
is much higher. This suggests that these interactions may indeed be physiologically relevant. 
Other examples of signalling proteins with intramolecular interactions governed by effective 
molarity include the non-receptor tyrosine kinase src (LaFevre-Bernt, et al., 1998). 
In addition to the interactions between different HR1 domains, HR1a has also been shown 
to dimerise (Chapter 3). The NMR titration data presented in this Chapter suggest that 
dimeric HR1a and HR1ab can weakly interact with HR1c. Assuming that the HR1abc dimer is 
formed by HR1a dimerisation and that HR1abc oligomerisation follows a linear pathway 
from monomer to dimer to trimer, then it is possible that HR1a dimerisation may have a 
role in bringing two PRK1 molecules in proximity to form the dimer, which is then poised to 
interact with an additional protomer, for example via HR1c. The dimerisation itself appears 
to be unaffected by the presence of the other HR1 domains as indicated by the 15N 
HR1ab/HR1c titration where the HR1a peaks still remain significantly broadened. This is also 
suggested by the ability of the HR1a dimer to bind to HR1c as suggested by the 15N 
HR1c/HR1a titration. 
A further unknown concerns the oligomerisation of HR1abc which stops at trimer. If the HR1 
domain interacting interfaces were not all satisfied in the trimer, then it would be expected 
that the trimer would form larger oligomers. This doesn’t happen however, suggesting that 
all these contact sites are used in the HR1abc trimer so an additional protomer cannot 
interact to form a larger oligomer. As discussed in Chapter 3, this may also be indicative of a 
relatively globular species and not one which linearly oligomerises. An additional aspect 
which remains unclear is whether HR1abc can have several conformations, even as a 
monomer, depending on which of the contacts between the HR1 domains form. These 
different conformations may have several implications including the activation of the PRKs; 
stabilising HR1a in a conformation that keeps its autoinhibitory sequence away from the 
PRK1 active site; the preferential binding of a GTPase to a particular HR1 domain. 
It is known that binding of RhoA (and Rac1) to PRK1 activates it. These intra- and inter-
molecular interactions may therefore serve to keep the HR1abc regulatory region of PRK1 in 
a ‘closed’, autoinhibited state. Binding of GTPases, which occur with nM to low μM 
affinities, may therefore ‘open up’ the structure, disrupting these HR1-HR1 interactions and 
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in turn PRK1 oligomers. The effect of GTPase binding on PRK1 oligomerisation is investigated 
in Chapter 6. 
An interesting observation can also be made when looking at the aligned sequence of the 
three PRK1 HR1 domains (Figure 5.18). Many of the residues in HR1c that interact with HR1a 
and HR1b correspond to residues in HR1a and HR1b that interact with RhoA and Rac1, 
respectively. These residues are Glu225HR1c, Val228HR1c, Gly231HR1c and Ala232HR1c, which are 
conserved as Glu49HR1a/Glu138HR1b, Leu52HR1a/Val141HR1b, Gly55HR1a/Gly144HR1b and 
Ala56HR1a/Ala145HR1b in HR1a and HR1b, respectively. Interestingly, they are three of only 
eight residues fully conserved across all three PRK1 HR1 domains, and three out of four 
residues which are both fully conserved and also used to bind to GTPases. The above 
suggests that binding of a GTPase to HR1c may be prevented if HR1a and HR1b compete for 
the same binding site. Conversely, it is possible that binding of a GTPase to HR1c may 
displace HR1a and HR1b, causing further conformational changes in the HR1abc tri-domain, 
with potential functional implications. Even if HR1c has no cognate GTPase binding partner, 
it is intriguing that this same site is used in HR1 domains to bind either to GTPases or to 
other HR1 domains. This may indicate that this region is thermodynamically less rigid and 











PRK1_HR1a MASDAVQSEPRSWSLLEQLGLAGADLAAPGVQQQLELERERLRREIRKELKLKEGAENLR  60 
PRK1_HR1b --------------------------------ATNLSRVAGLEKQLAIELKVKQGAENMI  149 
PRK1_HR1c ------------------------DTQGSPDLGAVELRIEELRHHFRVEHAVAEGAKNVL  236 
                                               .   *.:.:  *  : :**:*:  
 
PRK1_HR1a RATTDL----GRSLGPVELLLRGSSRRLDLLHQQLQELHAHVVLPDPAAT----------- 106 
PRK1_HR1b QTYSNGSTKDRKLLLTAQQMLQDSKTKIDIIRMQLRRALQAGQLENQAAP----------- 199 
PRK1_HR1c RLLSAAKAPDRKAVSEAQEKLTESNQKLGLLREALERRLGELPADHPKGRLLREELAAASS 297 
         :  :       : :  .:  *  *. ::.:::  *..        .  .            
Figure 5.18 Sequence alignment of PRK1 HR1 domains. Asterisks highlight identical residues at all 
positions, colons highlight conservation of a strong group and periods highlight conservation of a weak 
group. Interacting residues in the RhoA-PRK1 HR1a (Maesaki et al., 1999) and Rac1-PRK1 HR1b (Modha et 
al., 2008) structures are highlighted in yellow and green, respectively. 
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6.1.1 Known interactions 
 
PRK1 was first identified as an effector of RhoA (Watanabe et al., 1996) and Rac1 (Vincent & 
Settleman, 1997), but while the N-terminal region of PRK1 was shown to be mediating these 
interactions, the exact HR1 domains binding to these GTPases remained unknown until work 
by Flynn et al. (1998) and Owen et al. (2003). Maesaki et al. (1999) provided the first 
structural characterisation of an HR1 domain, that of HR1a in complex with RhoA. The NMR 
solution structure of Rac1 in complex with HR1b (Modha et al., 2008) and mutational 
analysis of the RhoA/HR1a interface by Hutchinson et al. (2011) provided much needed 
insight into the contact site used in these interactions. A further study by Hutchinson et al. 
(2013) established that the PRKs are effectors of the entire Rho subfamily (RhoA, RhoB and 
RhoC), while more recently a mass spectrometry study from mouse tissues has suggested 
that RhoD may also interact with PRK1 (Paul et al., 2017). 
Table 6.1 summarises the published affinities of PRK1 HR1 domains for Rho GTPases. It is 
worth noting that HR1 domains of TOCA family proteins interact with Cdc42 and TC10 with 
10-100-fold lower affinities (~10 μM) than Rho GTPases, suggesting that features other than 









GTPase HR1 domain Affinity (nM) 
RhoA 
PRK1 HR1a 1501, 1503 
PRK1 HR1b >10002, 18003 
PRK1 HR1ab 1401 
RhoB 
PRK1 HR1a 521 
PRK1 HR1b - 
PRK1 HR1ab 151 
RhoC 
PRK1 HR1a 821 
PRK1 HR1b - 
PRK1 HR1ab 901 
Rac1 
PRK1 HR1a 1692 
PRK1 HR1b 682 







The possibility that there are other GTPases which bind to the HR1 domains but remain 
unknown is very likely. Predicting which GTPases may interact with the PRK HR1 domains, as 
well as how strongly they may interact, is not a straightforward task. This is because binding 
of HR1 domains appears to not only depend on sequence specificity, but rather also on their 
structural stability and rigidity (Hutchinson et al., 2013). Currently, only members of the Rho 
and Rac subfamilies of the Rho family of GTPases are known to bind to PRK effector 
domains, while the diversity of the HR1 domains extends to the Cdc42 subfamily when the 
TOCA, CIP4 and FBP17 proteins are also considered. It is possible that members of other 
subfamilies can interact with the PRK HR1 domains. Such interactions may remain unknown 
because these GTPases and the HR1 domains may interact very weakly and also because the 
other GTPase subfamilies are less well-studied. A recent study employed mass spectrometry 
Table 6.1 Summary of published G protein/PRK1 HR1 domain affinity data. The Kd values of the individual 
HR1a or HR1b domains, as well as the HR1ab di-domain are listed. Hyphens represent binding data that are 
not available. The number in superscript denotes the paper from which the data were obtained. 1 – 
Hutchinson et al., 2011; 2 – Owen et al., 2003; 3 – Blumenstein & Ahmadian, 2004. 
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to identify effectors of six well-studied Rho GTPases, RhoA, RhoB, RhoC, Rac1, Cdc42 and 
RhoD (Paul et al., 2017). Interestingly, PRK1 was pulled down not only by some of its known 
interacting GTPases, but also with RhoD. While the specific HR1 domain interacting with 
RhoD was not the focus of this mass spectrometry study, these results highlight that our 
knowledge of GTPase/effector interactions remains nebulous. 
 
This chapter aims to identify interacting partners of the HR1c domain. In addition, it aims to 
provide preliminary characterisation of GTPase interactions with the HR1abc tri-domain, as 
well as a measure of the affinity of RhoA for the HR1abc tri-domain in an attempt to 
understand whether interactions between the HR1 domains affect binding of GTPases. 
Furthermore, this Chapter aims to investigate if the HR1a dimer can interact with RhoA or 
not. The above investigations aim to provide further understanding of the HR1abc tri-
domain structure and attempt to link GTPase interactions to the discovery of HR1 
oligomerisation presented in Chapter 3. 
 
6.2 Investigating new interaction partners between the Rho family and the 
HR1 domains 
 
6.2.1 Choice of GTPases to test 
 
To test binding to GTPases pull-downs were conducted between GST-tagged GTPases and 
untagged HR1 effectors. In the interest of time, binding of all 23 members of the Rho family 
to the HR1c domain could not be investigated. RhoA was chosen as a positive control when 
optimising the pull-downs as it can interact with HR1a. It also had an additional role as a 
negative control for HR1c pull-downs, as RhoA has been shown not to interact with PRK1 
HR1c (Flynn et al., 1998). RhoD was also chosen, a decision primarily made based on its 
recent identification as an interacting partner of PRK1 (Paul et al., 2017), but also due to its 
localisation in the endosomes of cells, where PRK1 is also known to localise. Until recently, 
PRKs were thought to be exclusive effectors of the Rho and Rac subfamily GTPases. RhoD is 
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not a member of these subfamilies so it was interesting to see if PRK interactions extend to 
other members of the Rho family. 
Additionally, the putative interaction of Cdc42 with PRK3 HR1c, firstly seen in the Part III 
Master’s project (Sophocleous, 2014), was further investigated with the aim of obtaining a 
Kd of this interaction. Cdc42 also interacts with the HR1 domains of TOCA, CIP4 and FBP17 
so a Kd would provide clues as to whether this interaction is of nM affinity like those of 
RhoA/HR1a and Rac1/HR1b or μM affinity like those of the TOCA family HR1 domains for 
Cdc42. 
 
6.2.2 Choosing the best expression conditions 
 
Before performing the pull-downs, the expression and solubility of GST-RhoA and GST-RhoD 
GTPases was assessed with small scale expression (Figure 6.1). Three E. coli strains were 
chosen. These were BL21, Rosetta2 which provides rare codon tRNAs for five amino acids 
and C41, which carries uncharacterised mutations that help with the solubility of ‘toxic’ 
proteins. Both RhoA and RhoD showed increased solubility at 20 oC than at 37 oC. RhoA was 
soluble in all three strains but there was elevated expression in Rosetta2, which was the 
strain chosen for expression. RhoD was completely insoluble in Rosetta2 and mostly 
insoluble in BL21 as well. However some soluble protein was seen in the C41 strain which 



























Figure 6.1 SDS-PAGE Analysis of Rho GTPase expression trials. The fusion proteins were expressed in 
BL21, Rosetta2 and C41 E.coli strains. Solubility of (A) GST-RhoA Δ4 F25N Q63L and (B) GST-RhoD Q75L was 
assessed by identifying a band of appropriate molecular weight in soluble or pellet fractions. Un for 
Uninduced sample, In for Induced (Total), S for Induced (Soluble) and P for Induced (Pellet). 20 and 37 







To investigate the binding of HR1 domains to RhoA and RhoD, 2-way pull-downs were 
performed between N-terminal GST-tagged RhoA and RhoD and untagged PRK1 HR1a, 
HR1b, HR1c and HR1ab effector proteins. Constitutively active variants of the GTPases were 
used to allow GTP-loaded GTPases to be expressed and purified from E.coli and immediately 
used in pull-down, without the need for a prior nucleotide exchange step. 
RhoA pull-downs (Figure 6.2) indicated that HR1a and HR1ab interact with RhoA as 
expected. HR1c did not interact with RhoA, which is consistent with earlier observations 
(Flynn et al., 1998). PRK1 HR1b stains very weakly with Coomassie blue and also interacts 
with RhoA more weakly than HR1a does, so the HR1b pulled down by GST-RhoA can only 
faintly be seen. 
 
RhoD was also confirmed to interact with PRK1 (Figure 6.3). Specifically, the RhoD pull-
downs showed that HR1a and HR1ab interact with RhoD, i.e. HR1a is the specific effector 
domain which interacts with this GTPase. RhoD also appears not to interact with HR1b or 
HR1c, but the result is inconclusive as a result of a limited amount of GST-RhoD immobilised 































Figure 6.2 RhoA interacts with PRK1. 2-way pull-downs between GST-RhoA Δ4 F25N Q63L and (A) PRK1 
HR1abc, (B) PRK1 HR1b, (C) PRK1 HR1c or (D) PRK1 HR1ab. HR1 effector protein was added to GST-RhoA 
immobilised on glutathione agarose beads. Following incubation, unbound protein was washed off. 
Binding was assessed by SDS-PAGE on gels of the appropriate percentage. M for molecular weight markers 
and SN for supernatant after incubation. The pull-down sample represents the proteins bound to the 


























Figure 6.3 RhoD interacts with PRK1. 2-way pull-downs between GST-RhoD Δ4 F25N Q75L and (A) PRK1 
HR1abc, (B) PRK1 HR1b, (C) PRK1 HR1c or (D) PRK1 HR1ab. HR1 effector protein was added to GST-RhoD 
immobilised on glutathione agarose beads. Following incubation, unbound protein was washed off. 
Binding was assessed by SDS-PAGE on gels of the appropriate percentage. M for molecular weight markers 
and SN for supernatant after incubation. The pull-down sample represents the proteins bound to the 






6.2.4 Expression and purification of GTPases 
 
Untagged Rho GTPases were needed for use in experiments which would measure their 
affinity for HR1 domains as well as other biophysical studies (see section 6.3). Proteins were 
purified using glutathione agarose purification, the N-terminal GST tag was cleaved with 
HRV 3C protease (RhoA Δ4 F25N Q63L) or thrombin (Cdc42 Δ7Q61L and RhoA Δ12 F25N 
Q63L (see Chapter 5)) and the proteins were further purified using size-exclusion 
chromatography on a Superdex75 16/60 column. Figure 6.4 shows the purification of RhoA 




















Figure 6.4 Purification of RhoA Δ4 F25N Q63L and corresponding SDS-PAGE analysis. (A) GST-RhoA Δ4 
F25N Q63L immobilised on glutathione agarose beads. Gel was 12%. SN for supernatant, W1-4 for the 4 
washes and Beads for 50% bead slurry. (B) RhoA Δ4 F25N Q63L washes post-cleavage. Gel was 15%. SN for 
supernatant and W1-4 for the 4 washes post-cleavage. (C) Gel filtration chromatogram of RhoA Δ4 F25N 
Q63L on an S75 column. Blue line indicates A280. (D) SDS-PAGE analysis of chromatogram in (C) on a 15% 






6.2.5 Nucleotide exchange 
 
To lock the GTPase in its active, GTP-bound conformation, to allow binding to effectors, a 
slowly hydrolysable analogue, GMPPNP, was mixed with each GTPase in an exchange 
reaction. The protein was subsequently re-purified on a Superdex75 16/60 column to 
remove excess GMPPNP and purify the protein from any aggregates formed during the 
exchange. To check for successful nucleotide exchange, a small amount of protein was 
precipitated to release its nucleotide, the identity of which was confirmed by HPLC by 















Figure 6.5 GMPPNP nucleotide exchange of GTPases. HPLC chromatogram of guanosine nucleotides. GDP, 
GTP and GMPPNP standards were compared to the nucleotide bound to RhoA Δ4 F25N Q63L. GTP in black, 
GDP in magenta and GMPPNP in blue. Nucleotide bound to RhoA Δ4 F25N Q63L before the exchange in 



























6.2.6 Measuring the affinity of Cdc42 for PRK3 HR1c 
 
PRK3 HR1c had previously been shown to interact with Cdc42 (Sophocleous, 2014). To 
measure the affinity of this interaction by competition scintillation proximity assay (SPA), 
Cdc42 Δ7 Q61L was purified and labelled with [3H]GTP. Cdc42/GST-ACK complexes (ACK for 
Activated-Cdc42 Kinase; a Cdc42 effector) were formed and PRK3 HR1c was used to 
compete Cdc42 off GST-ACK, resulting in a decrease in counts. Fitting the data gave a 
measure of the Kd at 8.08 μM (Figure 6.6). This affinity is about 10-100 times weaker than 
that of HR1a and HR1b for their cognate GTPases, suggesting that not all HR1 domains 
interact with Rho GTPases with similar affinities. Additionally, the affinity of Cdc42 for PRK3 
HR1c is similar to the affinity of Cdc42 for the HR1 domains of TOCA/CIP4/FBP17. It is also 
important to note that PRK3 HR1c must be interacting with Cdc42 in a GTP-dependent 
manner as it competes with ACK. The number of counts remaining at the highest 
concentration of PRK3 HR1c was the same as when ACK competes with itself (Figure 6.6C). 
This indicates that HR1c must share the binding site on Cdc42 with ACK, i.e. the nucleotide-
sensitive switch regions. 
The binding of PRK1 HR1c to Cdc42 was also investigated by competition SPAs but it was 
found that it doesn’t interact (not shown). This highlights differential binding of GTPases to 
































Figure 6.6 Competition SPA to measure the affinity of Cdc42 for PRK3 HR1c. (A) Principle of competition 
SPA. (B) Cdc42 Δ7 Q61L·[3H·GTP] was mixed with GST-ACK and immobilised on SPA fluoromicrospheres via 
an anti-GST antibody. The GTPase was competed off with increasing concentrations of PRK3 HR1c, the data 
were fitted to a competition binding isotherm using non-linear regression and the Kd of the Cdc42/PRK3 
HR1c interaction was calculated. (C) ACK was used to compete Cdc42 off GST-ACK as a positive control. 







6.2.7 Sequence alignments 
 
To get an understanding of how RhoD may be interacting with PRK1 HR1a, the amino acid 
sequences of RhoA and RhoD were aligned (Figure 6.7). Out of the 12 interacting residues of 
RhoA with HR1a, 10 are fully conserved in RhoD. The remaining two residues are also 
weakly conserved. It is therefore very likely that HR1a binds to RhoD using contact II. 
Furthermore, none of the RhoA/HR1a contact residues are conserved in RhoD, which 










Figure 6.7 Sequence alignment of RhoA and RhoD. Sequences were aligned with Clustal Omega. Asterisks 
highlight identical residues at all positions, colons highlight conservation of a strong group and periods 
highlight conservation of a weak group. Residues which are involved in the RhoA/PRK1 HR1a interaction 
and are identical between RhoA and RhoD are highlighted in yellow, while non-identical residues are 
highlighted in cyan. RhoA/HR1a contact I residues are highlighted in pink. 
RhoA      ------------MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEV 48 
RhoD      MTAAQAAGEEAPPGVRSVKVVLVGDGGCGKTSLLMVFADGAFPESYTPTVFERYMVNLQV 60 
                       ..   *:*:****.****.**:**:.. *** *.*****.*:.:::* 
 
RhoA      DGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCP 108 
RhoD      KGKPVHLHIWDTAGQDDYDRLRPLFYPDASVLLLCFDVTSPNSFDNIFNRWYPEVNHFCK 120 
         .** *.* :******:******** ***:.*:*:**.: **:*::** ::* ***:***  
 
RhoA      NVPIILVGNKKDLRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVR 168 
RhoD      KVPIIVVGCKTDLCKDKSLVNKLRRNGLEPVTYHRGQEMARSVGAVAYLECSARLHDNVH 180 
          :****:** *.** :*:   .:* :   ***. ..*::**. :**..*:****: :*.*: 
 
RhoA      EVFEMATRAALQARRGK-----KKSGCLVL  193 
RhoD      AVFQEAAEVALSSRGRNFWRRITQGFCVVT  210 




RhoA  MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDT 60 
Rac1  --MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDT 58 
Cdc42 --MQTIKCVVVGDGAVGKTCLLISYTTNKFPSEYVPTVFDNYAVTVMIGGEPYTLGLFDT 58 
            * *:***** ******* ::.: **  *:****:** . : : *:   *.*:** 
 
RhoA  AGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKD 120 
Rac1  AGQEDYDRLRPLSYPQTDVFLICFSLVSPASFENVRAKWYPEVRHHCPNTPIILVGTKLD 118 
Cdc42 AGQEDYDRLRPLSYPQTDVFLVCFSVVSPSSFENVKEKWVPEITHHCPKTPFLLVGTQID 118 
      ***************:***:*:***: ** *:**:  ** **: *.**:.*::***.: * 
 
RhoA  LRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQ 180 
Rac1  LRDDKDTIEKLKEKKLTPITYPQGLAMAKEIGAVKYLECSALTQRGLKTVFDEAIRAVLC 178 
Cdc42 LRDDPSTIEKLAKNKQKPITPETAEKLARDLKAVKYVECSALTQKGLKNVFDEAILAALE 178 
       **:*  * .:* : *  *:.   .  :*. : *. *:**** *: *:: **: *  *.*  
 
RhoA  ARRGKK-KSGCLVL 193 
Rac1  PPPVKKRKRKCLLL 192 
Cdc42 PPEPKK-SRRCVLL 191 




PRK1_HR1a MASDAVQSEPRSWSLLEQLGLAGADLAAPGVQQQLELERERLRREIRKELKLKEGAENLRR 61 
PRK1_HR1b --------------------------------ATNLSRVAGLEKQLAIELKVKQGAENMIQ 150 
PRK3_HR1c ---------------------SGS------PEPGPELLAEELQHRLHVEAAVAEGAKNVVK 202 
                                                   *.:.:  *  : :**:*: : 
 
PRK1_HR1a ATT----DLGRSLGPVELLLRGSSRRLDLLHQQLQELHAHVVLPDPAAT------------ 106 
PRK1_HR1b TYSNGSTKDRKLLLTAQQMLQDSKTKIDIIRMQLRRALQAGQLENQAA-----------P- 199 
PRK3_HR1c LLSSRRTQDRKALAEAQAQLQESSQKLDLLRLALEQLLEQLPPAHPLRSRVTRELRAAVPG 263 







Figure 6.8 highlights the residues in RhoA and Rac1 that are known to interact with PRK1 
HR1a and PRK1 HR1b, respectively, and are also conserved in Cdc42 and PRK3 HR1c, 
suggesting that this is an interaction involving the switches, which is consistent with PRK3 
HR1c competing ACK off Cdc42 in the SPA above. Most interacting residues are fully or 
strongly conserved between the HR1 domains and between the GTPases, which may 
suggest that additional features, such as HR1 rigidity or oligomerisation may influence 
GTPase specificity for HR1 domains. 
  
Figure 6.8 Sequence alignments of Rho family GTPases and their HR1 effector domains. (A)-(B) Sequence 
alignments were performed using Clustal Omega. Asterisks highlight identical residues at all positions, 
colons highlight conservation of a strong group and periods highlight conservation of a weak group. 
Interacting residues in the RhoA-PRK1 HR1a (Maesaki et al., 1999) and Rac1-PRK1 HR1b (Modha et al., 
2008) structures are boxed. Interacting residues which are conserved are highlighted. Yellow for fully 
conserved residues, green for conserved non-polar or hydrophobic residues and cyan for conserved 
charged or polar residues. (A) Sequence alignment of human RhoA, Rac1 and Cdc42. The switch regions 
are in bold. (B) Sequence alignment of PRK1 HR1a, PRK1 HR1b and PRK3 HR1c. 
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6.3 How does oligomerisation affect GTPase binding? 
 
6.3.1 RhoA binds to monomeric HR1a 
 
Previous work in the lab showed that RhoA interacts with the PRK1 HR1a domain (Owen et 
al., 2003; Hutchinson et al., 2011). Scintillation proximity assays used to prove this 
interaction were performed with nM concentrations of HR1a. At such low concentrations, 
which are >1000 times below its dimerisation Kd, HR1a was monomeric. Therefore we know 
that monomeric HR1a can interact with RhoA, forming a 1:1 complex, and that HR1a uses 
the contact II binding interface of RhoA (Hutchinson et al., 2011). 
 
6.3.2 RhoA binds to dimeric HR1a 
 
To test whether RhoA can bind to dimeric HR1a, AUC sedimentation velocity experiments 
were conducted (Figure 6.9). RhoA and HR1a were mixed at equimolar concentrations. The 
concentration chosen was 150 μM, which is the approximate dimerisation Kd of HR1a. At 
this concentration, the individual proportions of monomer and dimer are equal. This 
suggests that if RhoA can bind to both monomeric and dimeric HR1a, the complexes 
expected to be detectable are RhoA + HR1a (1:1 complex), RhoA + 2 x HR1a (1:2 complex) as 
well as unbound RhoA, unbound monomeric HR1a and unbound dimeric HR1a. The 
abundance of each of these five possible species depends on which interactions actually 
occur in solution, as well as their affinity. Figure 6.9A shows the sedimentation profile of 
RhoA which is the control experiment and provides the s-value of unbound RhoA, to help 
identify species present in solution in the experiment when HR1a is added. Figure 6.9B 
shows the sedimentation profile of RhoA mixed with HR1a at equimolar concentrations. 
From the five possible species, only two were detected. The first species was identified to be 
unbound RhoA, as the s-value is identical to that of free RhoA (Figure 6.9C). The interaction 
between the two proteins is confirmed because the abundance of the unbound RhoA 
species goes down despite the total RhoA concentration being equal between the two 
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experiments. The second species is therefore the bound species and the fit suggests a 
molecular weight of 49.6 kDa. As discussed in Chapter 3, the predicted MW is dependent on 
the fitted frictional ratio, which in turn is inversely proportional to the diffusion of the 
sedimenting species. In this case, there are two sedimenting species, so the frictional ratio is 
expected to be a global average representing both species. RhoA has a frictional ratio of 
1.11 and the complex, which is the major species in this experiment, has a frictional ratio of 
1.31, which suggests that this species is less globular than RhoA but slightly more globular 
than the dimerising HR1a (whose frictional ratio is 1.33). It is likely that this is a 1:2 complex 
of RhoA bound to dimeric HR1a. The reason why RhoA must be bound to dimeric HR1a 
rather than two HR1a monomers is that from the mutational analysis done in our lab, only 
one of the two contact sites is used by HR1a when bound to RhoA (Hutchinson et al., 2011). 
This species is unlikely to be the 1:1 complex. If the fitted frictional ratio were to be lower, 
then the predicted MW would also be lower but for the MW to be 33 kDa (that of the 1:1 
complex), the frictional ratio would have to be less than 1, i.e. the species would have to be 
more spherical than a sphere, which is not possible. The identification of the complex as the 
1:2 complex is also supported by the presence of free RhoA which was detected, despite the 
equimolar concentrations used. To sum up, RhoA was found to stabilise the HR1a dimer and 

























Figure 6.9 RhoA Δ4 F25N Q63L sedimentation velocity experiments. (A)-(B) Top panel represents the 
measured interference fringe distribution (blue to red from start to finish) and the corresponding fringe 
pattern. The middle panel represents the residuals of the fit, indicating how closely the experimental data 
match the fitted model. The grey image is a picture of the AUC cell which indicates the level of non-ideality 
in solution. The bottom plot represents the best-fit c(s) sedimentation coefficient distribution (against s-
value (S)). Peaks represent protein species. % abundance was calculated by integrating the area under 
each peak. The fit rmsd is indicated. Sedimentation profiles of (A) 150 μM RhoA Δ4 F25N Q63L (B) RhoA Δ4 






6.3.3 Measuring the affinity of dimeric PRK1 HR1a for RhoA 
 
RhoA may bind to the HR1a dimer directly or via a step-wise mechanism, i.e. RhoA firstly 
binds to a single HR1a domain and subsequently to a second HR1a monomer, as 
summarised in the equation below. 
 
To measure the affinity of RhoA for the HR1a dimer an isothermal titration calorimetry 
experiment (ITC) was conducted. RhoA at 1 mM concentration was placed in the syringe and 
injected into the cell which contained 100 μM PRK1 HR1a (60% monomer and 40% dimer 
according to AUC results in chapter 3). Heat changes were observed and the data were fit to 
a binding isotherm to calculate the Kd of the interaction (Figure 6.10). No step-wise binding 
was observed. 
The Kd was calculated to be 602 nM, while the stoichiometry of the interaction as shown by 
N, was 0.643, suggesting that not all of the titrant is used to saturate binding to the protein 
in the cell. This is consistent with what was observed in AUC, i.e. RhoA forms a 1:2 complex 
with HR1a. The reaction was shown to be exothermic, with an unfavourable, negative 
change in entropy. 
The affinity of RhoA Δ4 shown here is weaker than either RhoA Δ12 or RhoA full-length 




























  Figure 6.10 Measuring the affinity of RhoA Δ4 F25N Q63L for the PRK1 HR1a dimer. 1 mM RhoA Δ4 F25N 
Q63L·GMPPNP in the syringe was injected into 100 μM of PRK1 HR1a in the cell of an ITC instrument. Heat 
changes were recorded and the data were fit to a binding isotherm used to calculate the Kd, ΔH, ΔS and 
stoichiometry of the interaction. 
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6.4 Investigating the binding of RhoA to the HR1abc tri-domain 
 
Previous studies investigating the interactions of HR1 domains with GTPases used isolated 
HR1 domains or the HR1ab di-domain. Currently it is not known whether the HR1abc tri-
domain actually interacts with GTPases, and while very likely, this has never been proven. As 
shown in the previous Chapter, the three PRK1 HR1 domains are not independent of each 
other. As a result, it is possible that these intra- and inter-molecular interactions inhibit 
binding of GTPases or reduce the affinity of such interactions. Conversely, GTPases may 
preferentially bind to the HR1abc trimer similar to how RhoA binds and stabilises the PRK1 
HR1a dimer (section 6.3.2). Additionally, cooperative binding of GTPases by two or more 
HR1 domains of HR1abc may also occur and has been observed in the case of the PRK1 
HR1ab di-domain binding to RhoB more tightly than HR1a does (Hutchinson et al., 2013). 
 
6.4.1 2-way pull-downs between G proteins and HR1abc 
 
To investigate whether HR1abc can interact with GTPases, 2-way pull-downs were carried 
out (Figure 6.11). Specifically, the binding of PRK1 HR1abc and PRK3 HR1abc to RhoA was 
tested. Both HR1abc tri-domains interacted with RhoA, indicating that the presence of all 
three HR1 domains does not interfere with binding. As in vivo studies have shown that 
binding of RhoA to the PRKs is necessary for their activation, it is perhaps unsurprising that 
the HR1abc tri-domain, which is the PRK regulatory region and physiologically more 
relevant, does interact with RhoA. These pull-downs do not indicate however if RhoA 
preferentially binds to a particular oligomeric state of HR1abc. 
The HR1abc tri-domains were added to a final concentration of 100 μM. Most of the 
effector protein remained bound to GST-RhoA and did not dissociate during the washes. 
This suggests that the Kd of the interaction between RhoA and either HR1abc is well below 































Figure 6.11 RhoA interacts with PRK1 HR1abc and PRK3 HR1abc. 2-way pull-downs between GST-RhoA 
Δ12 F25N Q63L and (A) PRK1 HR1abc or (B) PRK3 HR1abc. HR1abc effector protein was added to GST-RhoA 
immobilised on glutathione agarose beads. Following incubation, unbound protein was washed off. 
Binding was assessed by SDS-PAGE on 12% gels. M for molecular weight markers and SN for supernatant 
after incubation. The pull-down sample represents the proteins bound to the glutathione agarose beads at 
the end of the experiment. Green boxes indicate pulled-down effector proteins. (C) The nucleotide state of 






6.4.2 Measuring the affinity of PRK1 HR1abc for RhoA 
 
The affinity of PRK1 HR1abc for RhoA was determined by competition SPAs (Figure 6.12). 
RhoA/PRK1 HR1a complexes were formed and HR1a was competed off with HR1abc and the 
decrease in counts was used to calculate a Kd for the RhoA/HR1abc interaction. The Kd was 
determined to be 21.9 μM which is more than 100 times lower than the affinity of HR1a or 
HR1ab for RhoA. 
The maximum concentration of HR1abc used in the assay was 60 μM. At this concentration 
HR1abc is expected to be mainly monomeric based on the AUC results on this protein (some 
dimer and trimer are still expected in solution). The binding seen here therefore suggests 
that HR1abc monomer does not interact tightly with RhoA. The monomer of the tri-domain 
interacts more weakly with RhoA than HR1a or HR1ab do, suggesting that intra-molecular, 
inter-domain interactions may be abrogating RhoA binding or that there is differential 





























Figure 6.12 Competition SPA to measure the affinity of RhoA for PRK1 HR1abc. (A) RhoA Δ7 F25N 
Q63L·[3H·GTP] was mixed with PRK1 HR1a-His6 and immobilised on SPA fluoromicrospheres via an anti-His 
antibody. The GTPase was competed off with increasing concentrations of PRK1 HR1abc, the data were 
fitted to a competition binding isotherm using non-linear regression and the Kd of the RhoA/PRK1 HR1abc 








The PRKs form an effector alphabet for Rho GTPases. Figure 6.13 summarises all known 













In this chapter it has been shown using a combination of AUC and ITC that RhoA stabilises 
the PRK1 HR1a dimer to form a 1:2 complex. This result highlights the utility of both of these 
methods and challenges the naïve assumptions often made in binding studies where the 
stoichiometry of the interacting species is thought to be 1:1. This is not the first time RhoA 
has been shown to bind to a dimeric effector. Specifically, the ROCK effectors of RhoA bind 
to the GTPase switches via a parallel coiled coil which is formed when two long α-helices 
dimerise (Dvorsky et al., 2004). As the HR1a dimer is stabilised in complex with RhoA, it is 
possible that all four helices make contact with RhoA. A step-wise model may also be 
possible, where initially only one coiled coil interacts with RhoA and subsequently its 
dimerisation Kd is lowered, allowing recruitment of a second HR1a to form the 1:2 complex. 
Other examples of Ras superfamily GTPases binding to dimeric effectors include Rac1 (Rho 
family) binding to a dimer of Arfaptin (Tarricone et al., 2001) and Arf6 binding to a dimer of 
Figure 6.13 Summary of known PRK1 and PRK3 HR1 domain interactions with Rho GTPases. (A) PRK1 





MKLP1 (Makyio et al., 2012). Stabilisation of dimers of effectors by their cognate GTPase has 
been previously studied. Cdc42, another GTPase in the Rho family, has been shown to 
induce dimerisation of its effector IQGAP (LeCour Jr. et al., 2016). This mechanism of dimer 
stabilisation is therefore shared across the family. 
In Chapter 3 it was shown that PRK3 HR1a has a dimerisation Kd of 1 mM, which is 
approximately 6 times higher than the dimerisation Kd of PRK1 HR1a. PRK3 HR1a also 
interacts 100 times more weakly with RhoA than PRK1 HR1a does (Hutchinson et al., 2013). 
It is possible that RhoA does not stabilise the PRK3 HR1a dimer or conversely that low levels 
of PRK3 HR1a dimer are not sufficient to form the 1:2 complex. This suggests, that GTPases 
may have distinct effects on the structure of full-length PRKs depending on their specific 
interactions with HR1 domains. 
RhoA·GTP is required for activation of the PRKs. Mechanistically this has never been 
investigated but it has been speculated that RhoA activates the PRKs by binding to HR1a and 
thereby removing the autoinhibitory effect caused by the pseudosubstrate region in this 
domain (Kitagawa et al., 1996). In this chapter, the characterisation of the RhoA/HR1a 
complex by biophysical methods such AUC and ITC has revealed the stabilisation of the 
HR1a dimer, which is otherwise in a reversible monomer-dimer equilibrium when free in 
solution. RhoA likely also induces formation of HR1abc dimers in the context of the full 
length kinase. This may have a critical role in the activation of the PRK1, e.g. by cross-
phosphorylation as seen in the case of tyrosine kinase receptors or by enhancing the local 
concentration of catalytic domains which are activated by inter-molecular PIF motif 
interactions. These dimers are likely to be different to the inactive dimers seen in PRK2 
(Bauer et al., 2012). 
Recent work in our lab by a Master’s student under my guidance investigated the effect that 
RhoB bladder cancer mutations have on binding to PRK1. RhoB E29Q bound to HR1a and 
HR1ab with comparable affinity, suggesting that HR1b can no longer interact with RhoB. 
Glu29 is located in contact I of RhoB and mutating it to Gln reverts it back to the wild type 
RhoA, which cannot bind to the PRKs using contact I (Hutchinson et al., 2011). This suggests 
that HR1ab may bind cooperatively to RhoB, with HR1a binding to contact II and HR1b 
binding to contact I. The reduced affinity of the mutant RhoB for PRK1 may result in the 
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disruption of RhoB/PRK1 endosomal signalling or the inability of PRK1 to localise to 
endosomes and may explain the tumour suppressor properties of RhoB. 
Rac1 interacts with PRK1 HR1a with a similar affinity to the RhoA/HR1a interaction. Binding 
of Rac1 to dimeric HR1a has never been investigated however. It therefore remains to be 
seen if Rac1 can also stabilise the HR1a dimer or if this effect is exclusive to RhoA. Assuming 
that RhoA activates PRK1 through HR1a-mediated dimerisation, then Rac1 may also bind to 
dimeric HR1a and activate PRK1 in a similar manner (Lu & Settleman, 1999). 
PRK3 HR1c is no more like the TOCA family HR1 domains than other PRK HR1 domains, yet it 
interacts with Cdc42 with near-identical affinity to the TOCA family HR1 domains. The 
melting temperatures of the HR1 domains are also different, suggesting that it is not the 
rigidity of these domains which makes them all interact with Cdc42. Put together, these 
data could be indicative of specificity being defined by sequence and structural 
characteristics of the G protein rather than the HR1 domain. This is further highlighted by 
the oligomeric state of these effector proteins; the TOCA family HR1 domains are 
monomeric while PRK3 HR1c exists in a monomer-dimer-tetramer equilibrium. Whether 
Cdc42 can stabilise the PRK3 HR1c dimer (or tetramer) like RhoA stabilises the PRK1 HR1a 
domain is also possible but has not currently been investigated. If Cdc42 does bind to the 
oligomeric PRK3 HR1c, then this may explain why PRK1 HR1c, which is monomeric, does not 
interact with Cdc42. 
It is also likely that TCL and TC10, which belong to the Cdc42 subfamily, can also interact 
with PRK3 HR1c. It may also be the case that PRK1 HR1c, which cannot interact with Cdc42, 
interacts with either of these two-related proteins. TC10 is involved in signalling of GLUT 
transporters to the membrane and PRK1 is also known to regulate this process. TC10 may 
therefore be acting via PRK1 to control this signalling. 
Interestingly, the SH3 domain of Graf and Graf2 interacts exclusively with the proline-rich 
region of PRK3 (Shibata et al., 2001). Graf and Graf2 contain a RhoGAP domain which can 
stimulate the intrinsic GTP hydrolysis of RhoA and Cdc42. It is possible therefore that PRK3 
recruits these RhoGAPs to revert the GTPases back to their inactive, GDP-bound 
conformation to terminate signalling. The exclusive binding of Graf and Graf2 to PRK3 may 
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therefore be viewed as a feedback mechanism for the equally exclusive binding of PRK3 to 
Cdc42. 
RhoD is considered to be one of the ‘typical’ Rho GTPases yet this view can be challenged as 
RhoD is set apart from other ‘typical’ GTPases due to its fast-cycling nature. It localises to 
early endosomes, where it regulates endosomal trafficking and dynamics via numerous 
effectors, including the hDia2C Diaphanous protein (Gasman et al., 2003), c-Src kinase and 
the Rab5 effector, Rabankyrin. Specifically, RhoD recruits hDia2C from the plasma 
membrane (Gasman et al., 2003), which suggests that a similar event may occur with RhoD 
and PRK1. A physiological role of PRK1 in early endosomes has not been reported yet, 
however RhoD may have a role in guiding PRK1 to late endosomes. At late endosomes, 
RhoB can then bind to PRK1 to regulate epidermal growth factor receptor trafficking 
(Gampel et al., 1999). RhoD may therefore have a role in regulating how many PRK1 
molecules localise to late endosomes, thereby indirectly regulating late endosomal 
signalling.  
More Rho GTPases may interact with the PRKs. For example, eleven out of twelve amino 
acids involved in the RhoA/HR1a interaction are conserved in the three Rnd proteins (Figure 
6.14), suggesting that the Rnd proteins may also interact with PRK1. Screening HR1 domains 
















RhoH   -MLSSIKCVLVGDSAVGKTSLLVRFTSETFPEAYKPTVYENTGVDVFMDGIQISLGLWDTAGNDAFRSIRPLSYQQ 75 
Rnd1   PVVARCKLVLVGDVQCGKTAMLQVLAKDCYPETYVPTVFENYTACLETEEQRVELSLWDTSGSPYYDNVRPLCYSD 84 
Rnd2   GQSGRCKIVVVGDAECGKTALLQVFAKDAYPGSYVPTVFENYTASFEIDKRRIELNMWDTSGSSYYDNVRPLAYPD 78 
Rnd3   NQNVKCKIVVVGDSQCGKTALLHVFAKDCFPENYVPTVFENYTASFEIDTQRIELSLWDTSGSPYYDNVRPLSYPD 94 
RhoD   PGVRSVKVVLVGDGGCGKTSLLMVFADGAFPESYTPTVFERYMVNLQVKGKPVHLHIWDTAGQDDYDRLRPLFYPD 88 
RhoF   PGRKELKIVIVGDGGCGKTSLLMVYSQGSFPEHYAPSVFEKYTASVTVGSKEVTLNLYDTAGQEDYDRLRPLSYQN 90 
RhoA   MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPD 76 
RhoC   MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYIADIEVDGKQVELALWDTAGQEDYDRLRPLSYPD 76 
RhoB   MAAIRKKLVVVGDGACGKTCLLIVFSKDEFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPD 76 
Wrch-2 PPELGIKCVLVGDGAVGKSSLIVSYTCNGYPARYRPTALDTFSVQVLVDGAPVRIELWDTAGQEDFDRLRSLCYPD 102 
Wrch-1 AEGRGVKCVLVGDGAVGKTSLVVSYTTNGYPTEYIPTAFDNFSAVVSVDGRPVRLQLCDTAGQDEFDKLRPLCYTN 120 
TCL    DEKKMLKCVVVGDGAVGKTCLLMSYANDAFPEEYVPTVFDHYAVTVTVGGKQHLLGLYDTAGQEDYNQLRPLSYPN 92 
TC10   PGALMLKCVVVGDGAVGKTCLLMSYANDAFPEEYVPTVFDHYAVSVTVGGKQYLLGLYDTAGQEDYDRLRPLSYPM 80 
Cdc42  --MQTIKCVVVGDGAVGKTCLLISYTTNKFPSEYVPTVFDNYAVTVMIGGEPYTLGLFDTAGQEDYDRLRPLSYPQ 74 
RhoG   --MQSIKCVVVGDGAVGKTCLLICYTTNAFPKEYIPTVFDNYSAQSAVDGRTVNLNLWDTAGQEEYDRLRTLSYPQ 74 
Rac2   --MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDSKPVNLGLWDTAGQEDYDRLRPLSYPQ 74 
Rac1   --MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQ 74 
Rac3   --MQAIKCVVVGDGAVGKTCLLISYTTNAFPGEYIPTVFDNYSANVMVDGKPVNLGLWDTAGQEDYDRLRPLSYPQ 74 
             * *:***   **:.::   :   :*  * *:. :   .          : : **:*.  :  :* * *   
 
RhoH   ADVVLMCYSVANHNSFLNLKNKWIGEIRSNLPCTPVLVVATQTDQREMGP-------H-R 127 
Rnd1   SDAVLLCFDISRPETVDSALKKWRTEILDYCPSTRVLLIGCKTDLRTDLSTLMELSHQ-K 143 
Rnd2   SDAVLICFDISRPETLDSVLKKWQGETQEFCPNAKVVLVGCKLDMRTDLATLRELSKQ-R 137 
Rnd3   SDAVLICFDISRPETLDSVLKKWKGEIQEFCPNTKMLLVGCKSDLRTDVSTLVELSNH-R 153 
RhoD   ASVLLLCFDVTSPNSFDNIFNRWYPEVNHFCKKVPIIVVGCKTDLCKDKSLVNKLRRN-G 147 
RhoF   THLVLICYDVMNPTSYDNVLIKWFPEVTHFCRGIPMVLIGCKTDLRKDKEQLRKLRAA-Q 149 
RhoA   TDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRNDEHTRRELAKM-K 135 
RhoC   TDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRQDEHTRRELAKM-K 135 
RhoB   TDVILMCFSVDSPDSLENIPEKWVPEVKHFCPNVPIILVANKKDLRSDEHVRTELARM-K 135 
Wrch-2 TDVFLACFSVVQPSSFQNITEKWLPEIRTHNPQAPVLLVGTQADLRDDVNVLIQLDQGGR 162 
Wrch-1 TDIFLLCFSVVSPSSFQNVSEKWVPEIRCHCPKAPIILVGTQSDLREDVKVLIELDKC-K 179 
TCL    TDVFLICFSVVNPASYHNVQEEWVPELKDCMPHVPYVLIGTQIDLRDDPKTLARLLYM-K 151 
TC10   TDVFLICFSVVNPASFQNVKEEWVPELKEYAPNVPFLLIGTQIDLRDDPKTLARLNDM-K 139 
Cdc42  TDVFLVCFSVVSPSSFENVKEKWVPEITHHCPKTPFLLVGTQIDLRDDPSTIEKLAKN-K 133 
RhoG   TNVFVICFSIASPPSYENVRHKWHPEVCHHCPDVPILLVGTKKDLRAQPDTLRRLKEQ-G 133 
Rac2   TDVFLICFSLVSPASYENVRAKWFPEVRHHCPSTPIILVGTKLDLRDDKDTIEKLKEK-K 133 
Rac1   TDVFLICFSLVSPASFENVRAKWYPEVRHHCPNTPIILVGTKLDLRDDKDTIEKLKEK-K 133 
Rac3   TDVFLICFSLVSPASFENVRAKWYPEVRHHCPHTPILLVGTKLDLRDDKDTIERLRDK-K 133 
       :  .: *:.:    :  .   .*  *          :::. : *                 
 
RhoH   ASCVNAMEGKKLAQDVRAKGYLECSALSNR-GVQQVFECAVRTAVNQARRRNRRRLFS-- 184 
Rnd1   QAPISYEQGCAIAKQLGAEIYLEGSAFTSEKSIHSIFRTASMLCLNKPSPLPQKSPVRSL 203 
Rnd2   LIPVTHEQGTVLAKQVGAVSYVECSSRSSERSVRDVFHVATVASLGRGHRQLRRTDSRRG 197 
Rnd3   QTPVSYDQGANMAKQIGAATYIECSALQSENSVRDIFHVATLACVNKTNKNVKRNKSQRA 213 
RhoD   LEPVTYHRGQEMARSVGAVAYLECSARLHD-NVHAVFQEAAEVALSSRGRNFWRRITQ-- 204 
RhoF   LEPITYMQGLSACEQIRAALYLECSAKFRE-NVEDVFREAAKVALSALKKAQRQKKRR-- 206 
RhoA   QEPVKPEEGRDMANRIGAFGYMECSAKTKD-GVREVFEMATRAALQARRGKKKS------ 188 
RhoC   QEPVRSEEGRDMANRISAFGYLECSAKTKE-GVREVFEMATRAGLQVRKNKRRR------ 188 
RhoB   QEPVRTDDGRAMAVRIQAYDYLECSAKTKE-GVREVFETATRAALQKRYGSQN------- 187 
Wrch-2 EGPVPQPQAQGLAEKIRACCYLECSALTQK-NLKEVFDSAILSAIEHKARLE-----KKL 216 
Wrch-1 EKPVPEEAAKLCAEEIKAASYIECSALTQK-NLKEVFDAAIVAGIQYSDTQQQPKKSKSR 238 
TCL    EKPLTYEHGVKLAKAIGAQCYLECSALTQK-GLKAVFDEAILTIFHPKKKKKRCSEGH-- 208 
TC10   EKPICVEQGQKLAKEIGACCYVECSALTQK-GLKTVFDEAIIAILTPKKHTVKKRIGS-- 196 
Cdc42  QKPITPETAEKLARDLKAVKYVECSALTQR-GLKNVFDEAILAALEPPETQPKRK----- 187 
RhoG   QAPITPQQGQALAKQIHAVRYLECSALQQD-GVKEVFAEAVRAVLNPTPIKR-GR----- 186 
Rac2   LAPITYPQGLALAKEIDSVKYLECSALTQR-GLKTVFDEAIRAVLCPQPTRQQKR----- 187 
Rac1   LTPITYPQGLAMAKEIGAVKYLECSALTQR-GLKTVFDEAIRAVLCPPPVKKRKR----- 187 
Rac3   LAPITYPQGLAMAREIGSVKYLECSALTQR-GLKTVFDEAIRAVLCPPPVKKPGK----- 187 
          :    .   .  : :  *:* *:     .:. :*  *    .                
 
Figure 6.14 Sequence alignment of Rho GTPases. Sequences were aligned with Clustal Omega. Asterisks 
highlight identical residues at all positions, colons highlight conservation of a strong group and periods 
highlight conservation of a weak group. Residues which are involved in the RhoA/PRK1 HR1a interaction 





Chapter 7 Discussion and future directions 
 
The principal aim of this study was to obtain biochemical, biophysical and structural insight 
into the HR1 domains. This was been successful with PRK1 HR1 domains and to a lesser 
extent with the PRK3 HR1 domains. Chapter 3 provided extensive characterisation of the 
secondary structure of PRK1 and PRK3 HR1a, HR1b, HR1c, HR1ab and HR1abc proteins, as 
well as insight into the secondary structure and stability, for the first time, of HR1c domains. 
Furthermore, work in Chapter 3 revealed that PRK1 HR1a as well as all three PRK3 domains 
can all oligomerise, identifying HR1 domains for the first time as drivers of PRK 
oligomerisation. Chapter 4 presented the NMR solution structure of the PRK1 HR1c domain. 
This domain is structurally more diverse from HR1a and HR1b. While it conserves two 
helices which form a coiled coil, it also has a shorter, C-terminal helix which forms a triple 
coiled coil structure. Chapter 5 explored the inter-molecular interactions between PRK1 HR1 
domains which were indicated by AUC experiments on the HR1abc tri-domain in Chapter 3. 
The key finding was that the three HR1 domains all interact with each other and it is these 
interactions which are thought to drive formation of a higher order complex (as observed 
for the HR1abc trimer). Chapter 6 then expanded this linked equilibrium model by directly 
connecting RhoA to PRK1 oligomerisation while also investigating novel GTPase interactions 
with HR1 domains. 
The aim of this chapter will be to collectively review these findings and understand their 
significance in PRK signalling in the context of a simple, yet coherent model. The chapter 
also aims to highlight key questions which have arisen from this study but remain 









7.1 Structural and biochemical insight into the HR1 domains 
 
7.1.1 Intra- and inter-molecular interactions 
 
HR1 domains are approximately 10 kDa each and despite their sequence identity being very 
low (~30%), they share structural conservation as they fold into coiled coils. The stability of 
HR1 domains however is one of their key differences as indicated by melting temperatures 
ranging from 33.2 to 60.1 oC (Hutchinson et al., 2013; Chapter 3). Out of the three PRK1 
domains, HR1a has the lowest melting temperature, and coincidentally is the only PRK1 HR1 
domain which can oligomerise. Low melting temperature may therefore be important both 
in its dimerisation, but also in its ability to interact with HR1b and HR1c as well as with 5 Rho 
GTPases (RhoA, RhoB, RhoC, Rac1 and RhoD). In contrast, HR1b is thermodynamically more 
rigid and while it shares the contacts HR1a makes with RhoA in its interaction with Rac1, it 
only binds with nM affinity due to additional contacts made with the polybasic region in the 
C-terminus of Rac1 (Owen et al., 2003; Modha et al., 2008). HR1c is also more rigid than 
HR1a, and like HR1b it is monomeric in solution. 
The PRK3 HR1 domains differ greatly from their PRK1 homologs. Firstly, both HR1a and 
HR1b have significantly lower melting temperatures than HR1c (HR1a: 33.2 oC, HR1b: 42.9 
oC; 58 oC), and all three domains can oligomerise. Strangely, the domain with the highest 
melting temperature is the domain with the lowest dimerisation Kd, suggesting that rigidity 
cannot entirely account for HR1 oligomerisation. PRK3 HR1c has high sequence identity to 
PRK1 HR1c, and while PRK1 HR1c is monomeric, PRK3 HR1c forms a monomer-dimer-
tetramer mixture. 
The structure of PRK1 HR1c has been solved by solution NMR, revealing a coiled coil domain 
which has an additional C-terminal helix. This helix packs against the other two helices, 
forming a triple helix. This is an additional difference between HR1c and other HR1 domains, 




PRK1 HR1c still has not had a cognate GTPase identified. However it may have evolved to 
interact intra- and inter-molecularly with HR1a and HR1b, thereby promoting formation of 
HR1abc oligomers. 
Figure 7.1 illustrates a linked equilibrium between HR1abc monomer, dimer and trimer and 
their RhoA-bound states. RhoA stabilises the HR1a dimer but whether it can stabilise the 
HR1abc dimer as well has not been investigated. If other GTPases are brought into this 
linked equilibrium e.g. if Rac1 can interact with HR1abc at the same time as RhoA does, then 
the system gets exponentially complicated. This leads to the question as to why is there a 
need to exist in so many different states, and not just two oligomeric states (one 
catalytically active and one catalytically inactive). The answer may have to do with the 
ability of each of these states to differentially interact with GTPases, leading to swift change 
in cellular localisation which is a property the PRKs are likely to have given their 













Figure 7.1 Model of RhoA binding to PRK1 HR1abc. Model of PRK1 oligomers and RhoA linked equilibria. 




7.1.2 Wider implications for PRK signalling in cells 
 
The findings in this study, in conjunction with published studies, allow us to delineate the 
PRK1 pathway in cells (Figure 7.2). PRK1 in the cytosol is inactive as it needs a series of 
activating factors which are only found in the plasma membrane. When the plasma 
membrane is enriched in particular phospholipids due to upstream signalling, PRK1 gets 
recruited via its C2-like domain which binds to these membrane phospholipids. Some 
activation of PRK1 may occur directly via arachidonic acid, PIP2, PIP3 and cardiolipin (Mukai 
et al., 1994; Morrice et al., 1994; Kitagawa et al., 1995; Peng et al., 1996; Yu et al., 1997; 
Mukai & Ono, 2006; Palmer et al., 1995), but PRK1 remains largely in an autoinhibited state 
(Kitagawa et al., 1996; Yoshinaga et al., 1999). RhoA also attaches to the plasma membrane 
via its geranylgeranylated C-terminus. Rho GEFs can then catalyse nucleotide exchange and 
as a result RhoA·GTP can interact with the HR1a domain of PRK1. RhoA therefore relieves 
PRK1 autoinhibition exerted by the HR1a pseudosubstrate region (Kitagawa, et al. 1996). 
RhoA also promotes dimerisation of PRK1 by stabilising the HR1a dimer (Chapter 6). Rac1, 
which can also activate PRK1 (Lu & Settleman, 1999), may also promote HR1a dimerisation, 
while simultaneous binding to HR1b may promote intra- and inter-molecular HR1 
interactions, which can lead to HR1abc trimer formation. Dimerisation (or oligomerisation) 
may have additional activatory roles, e.g. leads to autophosphorylation of PRK1 which can 
activate its catalytic activity (Yoshinaga et al., 1999). RhoA also enhances the activation of 
PRK1 by PDK1 (also localised to the plasma membrane via its lipid-binding pleckstrin 
homology domain) which phosphorylates the turn motif of the PRK1 kinase domain. A 
ternary complex between RhoA, PRK1 and PDK1 may form to cooperatively enhance these 
three events: removal of autoinhibition, phosphorylation and dimerisation. Following PRK1 
activation, RhoA and PDK1 dissociate via a mechanism which is currently unknown. 
PRK1 dimerisation by the HR1a domain brings all the HR1 domains of two PRK1 protomers 
into proximity. This increase in effective molarity promotes formation of intra- and inter-
molecular HR1 interactions which involve the HR1c domain. Formation of the HR1abc trimer 
may be what causes dissociation of RhoA, as it binds more weakly to RhoA than HR1a does 




downstream signalling in numerous cellular processes, including regulation of the 
cytoskeleton, cell adhesion and regulation of pyrin inflammasome formation. 
Activated PRK1 may then be localised to early endosomes by RhoD which binds to the HR1a 
domain. RhoB binds to PRK1 with greater affinity than other GTPases, suggesting that RhoB 
may then compete with RhoD for binding to PRK1, localising it to late endosomes (Mellor et 
al., 1998). Here, PRK1 regulates the trafficking of epidermal growth factor receptors (EGFR), 
which may prolong EGFR signalling (Gampel et al., 1999). When RhoB is active in the 
endosomes, it is thought to suppress Rac1 activity (Marcos-Ramiro et al., 2016). 
Mechanistically this could involve PRK1, which can bind (at least separately) to both of these 
GTPases. When Rac1 is more active than RhoB, PRK1 may be translocated to the plasma 
membrane again, terminating RhoB/PRK1-dependent signalling in late endosomes. 
PRK1 can also bind to the transactivation domain of the androgen receptor (AR), which may 
localise it to the nucleus. PRK1, in complex with the AR, bind to androgen responsive 
elements of AR-regulated genes. PRK1 phosphorylates Thr11 of histone H3 (Metzger et al., 
2008) while it can also phosphorylate three histone HDACs, events which are both linked to 















Figure 7.2 PRK1 activation and localisation pathways. Structures of PRK1 HR1a (orange), PRK1 HR1b 
(green), PRK1 HR1c (blue), PKC C2-like domain (red), PRK1 kinase domain (yellow), RhoA (marine blue), 
Rac1 (magenta) and PDK1 (purple) are shown in cartoon representation. The structures of RhoD (dark 
green) and RhoB (sky blue) in complex with HR1 domains are models and are also shown in cartoon 
representation. The proteins and HR1 domains relevant at each stage are highlighted in their respective 
colours, while all other domains are shadowed out. (A) Cytosolic PRK1 localises to the membrane via its C2-
like domain in response to lipids. (B) PDK1 and RhoA both activate PRK1; the former via phosphorylation of 
the PRK1 kinase domain and the latter by relieving PRK1 autoinhibition and promoting dimerisation of the 
HR1a domain. Dimerisation enables further oligomerisation and may also enhance autophosphorylation, 
which may further activate PRK1 and release RhoA and PDK1. (C) PRK1 can also be activated by Rac1 which 
binds to the HR1b domain. Rac1 also binds to the HR1a domain which may also activate PRK1 via 
dimerisation. (D) PRK1 translocates to early endosomes, where it interacts with RhoD via its HR1a domain. 
(E) PRK1 then translocates to late endosomes, where it can interact with RhoB which may possibly involve 
HR1a and HR1b interacting with contact II and contact I, respectively. (F) PRK1 may relocate to the plasma 
membrane as a result of antagonistic RhoB/Rac1 signalling. (G) PRK1 also localises to the nucleus, possibly 




7.2 Future work 
 
7.2.1 Characterisation of the dimerisation interface 
 
A key question is about the dimerisation interface of PRK1. Previous attempts in our lab to 
study the HR1a domain by NMR have been unsuccessful due to extensive linewidth 
broadening, which can now be attributed to the chemical exchange between monomer and 
dimer. The 15N HSQC PRK1 HR1ab spectrum at a concentration ten-fold lower than the 
dimerisation Kd of HR1ab resulted in the appearance of many new backbone amide peaks 
from the HR1a domain. However approximately 50-60 more peaks were still missing and it is 
probable that it is these peaks which are involved in dimerisation. Without a way of 
assigning the peaks which have appeared, it is impossible to assign the peaks which remain 
disappeared. Given more time, pH titrations could be carried out in an attempt to see if the 
dimerisation could be stabilised or stopped or if the rate of chemical exchange could be 
significantly lowered. 
Hydrogen/deuterium exchange (H/D exchange) mass spectrometry (MS) is a method which 
has been used to map protein-protein, protein-lipid and other interactions (reviewed in Cao 
et al., 2013). Proteins of interest are incubated with D2O and are therefore labelled via 
exchangeable hydrogens. The reaction is then quenched, the protein is digested and 
peptides are analysed by MS. This could be used to identify the HR1a dimerisation site as 
this site would be less prone to H/D exchange. 
A more laborious approach would involve the systematic alanine scanning of each HR1a 
residue and the characterisation of the oligomeric state of each mutant protein. Similar 
experiments may be used to investigate the dimerisation interfaces of the PRK3 HR1 
domains and in particular PRK3 HR1c, which has a dimerisation affinity similar to that of 
PRK1 HR1a. The oligomerisation of the PRK2 HR1 domains has not been investigated due to 
the difficulty of obtaining soluble protein for HR1c and HR1abc proteins. Co-expressing with 
chaperones may solve this problem and then the oligomeric state of PRK2 domains could be 




Yoshinaga et al. (1999) reported possible autophosphorylation sites on PRK1. One of these is 
Thr63 which is located in helix 1 of HR1a. Thr63 forms a Van der Waals contact with Trp58 
of RhoA as seen in the RhoA/HR1a structure (Maesaki et al., 1999). The distance between 
these two residues is measured to be 3.8 Å. This suggests that if Thr63 is phosphorylated, 
then the negatively charged phosphate would displace RhoA. This may be a regulatory 
mechanism, which may have a role in the dissociation of RhoA from PRK1 once PRK1 is 
activated. A phosphomimic mutant HR1a, e.g. Thr63Glu could be designed and the affinity 
for RhoA could be measured. A decreased affinity would suggest that upon PRK1 activation, 
autophosphorylation occurs which leads to RhoA dissociation. 
 
7.2.2 Characterisation of the HR1abc tri-domain 
 
The HR1abc trimer is likely to involve interactions between HR1 domains of different 
protomers which are not necessarily of 1:1 stoichiometry. Therefore had more time been 
available, AUC experiments of different combinations of HR1 domains would have been 
carried out. The information from these experiments would couple exceptionally well with 
the HR1 mapping data (Chapter 5), e.g. it could indicate if HR1a binds to more than one 
contact site on HR1c at a time, or if several molecules bind to the different sites. 
Small Angle X-ray Scattering (SAXS) is a powerful method for obtaining structural 
information about proteins (Svergun, 2007). While SAXS strictly requires a monodisperse 
sample, size exclusion chromatography (SEC)-SAXS has recently allowed the structural 
characterisation of oligomers in a polydisperse sample (Fekry et al., 2017). This is because 
the data obtained from each species as it elutes from a gel filtration column can be analysed 
separately. Therefore, (SEC)-SAXS could be used to study HR1abc oligomers. 
The binding site of HR1a on HR1c has been determined in Chapter 5. However the reciprocal 
binding site on HR1a has not been determined. A way to investigate if the dimerisation site 
overlaps with the RhoA-interaction site, RhoA could be titrated into 15N HR1c bound HR1a 
and competition HSQC titrations carried out to see if the peaks of interacting residues would 




7.2.3 PRKs as Rho GTPase effectors 
 
7.2.3.1 Identification of novel GTPase interacting partners 
The results presented in this study demonstrate that many more GTPases may interact with 
the PRKs and in particular the HR1c domain but remain unknown. To identify new 
interacting GTPases, co-immunoprecipitations from cells could be carried out. This would 
require mutations to stop RhoA/Rac1 binding (as these two GTPases may bind more 
strongly than any other GTPases bind to PRK1). This could have a structural effect, e.g. loss 
of HR1-HR1 interactions, that may prevent other G proteins from binding to HR1c. Two-way 
pull-downs using purified proteins may therefore be a better option (although more 
laborious). 
Additionally, the interaction of Cdc42 with PRK3 HR1c has only been seen in vitro and may 
therefore not be physiological. This interaction can therefore be confirmed by co-
immunoprecipitations. 
 
7.2.3.2 Differential use of contacts I and II 
Based on alanine scanning of RhoB contact sites done by a student under my guidance, it is 
speculated that RhoB binds to both HR1a and HR1b using contact sites II and I, respectively. 
The binding site of HR1b for RhoB could be determined by carrying out NMR titrations. 
It can be argued that RhoB may bring the HR1a and HR1b domains of two separate 
protomers into proximity, thereby mediating PRK oligomerisation or it may simply bind to 
HR1a and HR1b from a single protomer. It would be interesting to determine the oligomeric 
complexes formed between RhoB and HR1ab and if and how they differ from those of RhoA 
and HR1ab. Therefore AUC and SEC-SAXS experiments could be carried out. These results 
could highlight differences in the supercomplexes formed (as a result of differential use of 
the contact sites). This would explain both in vivo and in vitro evidence that RhoB is the 
cognate GTPase of PRK1 (as well as PRK2 and PRK3), as RhoB binds to PRK1 with higher 
affinity than RhoA and RhoC do (Hutchinson et al., 2013) and it localises with PRK1 in 




7.2.3.3 Simultaneous GTPase protein binding 
Another key question which needs to be answered is whether two or more GTPases can 
simultaneously interact with a single PRK. For this, 3-way pull-downs can be carried out, 
using a GST-tagged GTPase, adding HR1abc and then adding another GTPase that is 
untagged. 
Simultaneous GTPase binding would provide clues as to whether there is signalling 
convergence in cells, e.g. two GTPases (RhoA and Rac1 for example) can activate a PRK at 
the same time. 
 
7.2.3.4 Characterisation of supercomplexes 
RhoA has been shown to interact with the HR1a dimer, while the NMR solution structure of 
Rac1 with HR1b shows that Rac1 binds to monomeric HR1b. The effect of RhoB, RhoC, RhoD 
and Cdc42 on the oligomerisation of HR1 domains has not been investigated. Therefore AUC 
experiments could be performed to determine this. 
As has been described previously, some Rho GTPases can interact with more than one HR1 
domain. RhoA binds to PRK1 HR1a with higher affinity than it does to HR1b, while Rac1 
binds to both HR1a and HR1b with similar affinities. The affinities of RhoA and Rac1 for 
HR1ab suggest that only contact II is used to bind to HR1 domains, so only one of these HR1 
domains may bind at a given time. Assuming that the PRKs can interact simultaneously with 
more than one GTPase, different supercomplexes can potentially form in solution. These 
include two RhoA molecules each binding to HR1a and HR1b; two Rac1 molecules each 
binding to HR1a and HR1b; RhoA binding to HR1a and Rac1 to HR1b. In contrast, RhoB binds 
to HR1ab with higher affinity than both RhoA or Rac1 and it is speculated to bind to HR1b 
via contact I and to HR1a via contact II. This suggests that it could prevent binding of either 
RhoA or Rac1. Furthermore, bigger supercomplexes may form if multiple GTPases can 






























Figure 7.3 Possible supercomplexes between PRK1 HR1 domains and Rho family GTPases. (A) One RhoA 
molecule binds to HR1a while another RhoA molecule binds to HR1b. (B) One Rac1 molecule binds to HR1a 
while another Rac1 molecule binds to HR1b. (C) One Rac1 molecule binds to each of HR1a and HR1b. (D) 
Model of PRK1 oligomers and RhoA linked equilibria. All these interactions may occur with HR1 domains of 




To analyse these supercomplexes, analytical ultracentrifugation can be used to determine 
the molecular weight of the complexes formed and as a result determine the stoichiometry 
of the interacting species. These supercomplexes can then be studied by cryo electron 
microscopy to obtain structural information on how they assemble. However given the likely 
polydispersity of these samples, SEC-SAXS may be a better alternative to study these 
different complexes. 
 
7.2.3.5 Effector handover 
RhoA, RhoB, RhoC, Rac1, RhoD and Cdc42 are the six classical Rho GTPases and they all 
interact with one or more PRKs. Importantly, their cellular localisation differs. Fluorescent 
studies in cells would therefore be key to understanding if each of these GTPases co-
localises with the PRKs to compartments upon particular cellular stimuli. It is also possible 
that the GTPases are involved in an effector handover mechanism as depicted in Figure 7.1. 
For example, RhoA activates PRK1 at the plasma membrane and subsequently RhoD binds 
to PRK1 to take it to early endosomes. PRK1 is then passed on to RhoB in late endosomes 
where Rac1 can ‘recycle’ the effector by bringing it back to the plasma membrane. Such 
antagonistic signalling between RhoB and Rac1 has previously been described (Marcos-
Ramiro et al., 2016), however the molecular mechanism and effectors involved in this 
signalling have not been elucidated. PRK1, a common effector of RhoB and Rac1, may be 
what is driving this. The PRKs may therefore be involved in a tug-of-war between several 
Rho GTPases; the GTPase which wins the tug-of-war may depend on the particular signalling 
pathway. 
 
7.2.4 PRKs on the membrane 
 
The C2-domain of PRKs interacts with membrane lipids and therefore localises the PRKs to 
the plasma membrane, where they can be activated by GTPases, lipids and PDK1. 
Biophysical (AUC) and structural studies (NMR) would reveal whether oligomerisation is 




could be used to immobilise the PRK and then investigate its structure and measure its 
activity in a kinase assay against some of its many substrates. 
 
7.3 Concluding remarks 
 
The PRKs are an example of how little we know in molecular terms about many signalling 
proteins. Careful biochemical, biophysical and structural characterisation of any interacting 
systems is a prerequisite to be able to truly decipher, in molecular terms, how these 
signalling molecules are activated, regulated and more importantly deregulated in disease. 
This includes determining the oligomeric state of proteins, the affinity and stoichiometry of 
interacting domains and the structural characterisation of the complex and in particular of 
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Table A3.1 Summary of AUC results. All experiments were SV experiments carried out at 40000 rpm at 4 oC. 
Sedimentation was monitored by interference. A total of 200 scans, recorded with an interval of 1 min 30 sec, 
were analysed for each different protein concentration. The partial specific volume, buffer density and buffer 
viscosity were estimated using the program SEDNTERP. The frictional ratio and rmsd of each fit, as well as the 
s-value (s20,w in brackets), % abundance and corresponding MW of each species detected are listed. Artefacts 
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